{"PMC5743209": [["IntroductionNeonates and infants are disproportionately susceptible to multiple viral and bacterial pathogens, many of which are encountered via mucosal and barrier sites, including the respiratory and digestive tracts, skin, and other mucosal surfaces.", [["mucosal", "ANATOMY", 145, 152], ["barrier sites", "ANATOMY", 157, 170], ["respiratory", "ANATOMY", 186, 197], ["digestive tracts", "ANATOMY", 202, 218], ["skin", "ANATOMY", 220, 224], ["mucosal", "ANATOMY", 236, 243], ["Neonates", "ORGANISM", 12, 20], ["infants", "ORGANISM", 25, 32], ["mucosal", "TISSUE", 145, 152], ["barrier sites", "MULTI-TISSUE_STRUCTURE", 157, 170], ["digestive tracts", "MULTI-TISSUE_STRUCTURE", 202, 218], ["skin", "ORGAN", 220, 224], ["mucosal surfaces", "TISSUE", 236, 252], ["infants", "SPECIES", 25, 32], ["multiple viral and bacterial pathogens", "PROBLEM", 71, 109], ["mucosal and barrier sites", "TREATMENT", 145, 170], ["the respiratory and digestive tracts", "PROBLEM", 182, 218], ["multiple", "OBSERVATION_MODIFIER", 71, 79], ["viral", "OBSERVATION", 80, 85], ["bacterial pathogens", "OBSERVATION", 90, 109], ["mucosal", "ANATOMY", 145, 152], ["barrier sites", "OBSERVATION", 157, 170], ["respiratory", "ANATOMY", 186, 197], ["digestive tracts", "ANATOMY", 202, 218], ["skin", "ANATOMY", 220, 224], ["mucosal", "ANATOMY", 236, 243], ["surfaces", "ANATOMY_MODIFIER", 244, 252]]], ["The worse outcome of infants to infection, as well as their limited and delayed responses to vaccines, has been primarily attributed to immaturity of the immune system in early life.", [["immune system", "ANATOMY", 154, 167], ["infection", "DISEASE", 32, 41], ["infants", "ORGANISM", 21, 28], ["immune system", "ANATOMICAL_SYSTEM", 154, 167], ["infants", "SPECIES", 21, 28], ["infection", "PROBLEM", 32, 41], ["vaccines", "TREATMENT", 93, 101], ["immaturity of the immune system", "PROBLEM", 136, 167], ["worse", "OBSERVATION_MODIFIER", 4, 9], ["infection", "OBSERVATION", 32, 41], ["immaturity", "OBSERVATION", 136, 146]]], ["Reduced functional responses by T lymphocytes have been specifically implicated due to their role in coordinating many aspects of adaptive immunity.IntroductionA major challenge during the neonatal period is to not only develop immune responses to the diverse pathogens encountered at multiple sites, but also to contain infections while at the same time preventing potentially lethal effects associated with systemic infection and immune responses.", [["T lymphocytes", "ANATOMY", 32, 45], ["sites", "ANATOMY", 294, 299], ["infections", "DISEASE", 321, 331], ["infection", "DISEASE", 418, 427], ["T lymphocytes", "CELL", 32, 45], ["T lymphocytes", "CELL_TYPE", 32, 45], ["IntroductionA major challenge", "TREATMENT", 148, 177], ["immune responses", "PROBLEM", 228, 244], ["the diverse pathogens", "PROBLEM", 248, 269], ["infections", "PROBLEM", 321, 331], ["systemic infection", "PROBLEM", 409, 427], ["infections", "OBSERVATION", 321, 331], ["systemic", "OBSERVATION_MODIFIER", 409, 417], ["infection", "OBSERVATION", 418, 427]]], ["The immediate response to infection with pathogenic and non-pathogenic microorganisms involves components of the innate immune response, which are highly active during infancy, including the production of anti-microbial peptides, direct phagocytosis from neutrophils and monocytes/macrophages, and production of anti-microbial products and pro-inflammatory cytokines (for a review, see [1]).", [["neutrophils", "ANATOMY", 255, 266], ["monocytes", "ANATOMY", 271, 280], ["macrophages", "ANATOMY", 281, 292], ["infection", "DISEASE", 26, 35], ["neutrophils", "CELL", 255, 266], ["monocytes", "CELL", 271, 280], ["macrophages", "CELL", 281, 292], ["neutrophils", "CELL_TYPE", 255, 266], ["monocytes", "CELL_TYPE", 271, 280], ["macrophages", "CELL_TYPE", 281, 292], ["anti-microbial products", "PROTEIN", 312, 335], ["pro-inflammatory cytokines", "PROTEIN", 340, 366], ["infection", "PROBLEM", 26, 35], ["pathogenic and non-pathogenic microorganisms", "PROBLEM", 41, 85], ["anti-microbial peptides", "PROBLEM", 205, 228], ["direct phagocytosis", "PROBLEM", 230, 249], ["neutrophils", "TEST", 255, 266], ["monocytes", "TEST", 271, 280], ["macrophages", "PROBLEM", 281, 292], ["anti-microbial products", "TREATMENT", 312, 335], ["pro-inflammatory cytokines", "TEST", 340, 366], ["infection", "OBSERVATION", 26, 35], ["non-pathogenic", "OBSERVATION_MODIFIER", 56, 70], ["microorganisms", "OBSERVATION", 71, 85], ["immune response", "OBSERVATION", 120, 135], ["highly", "OBSERVATION_MODIFIER", 147, 153], ["active", "OBSERVATION_MODIFIER", 154, 160], ["anti-microbial peptides", "OBSERVATION", 205, 228], ["macrophages", "ANATOMY", 281, 292], ["anti-microbial products", "OBSERVATION", 312, 335]]], ["These innate immune responses are not sufficient to clear most pathogens or to prevent dissemination of infection, and adaptive immune responses characterized by specificity and long-term memory are subsequently triggered.", [["infection", "DISEASE", 104, 113], ["infection", "PROBLEM", 104, 113], ["long-term memory", "PROBLEM", 178, 194], ["infection", "OBSERVATION", 104, 113]]], ["The adaptive immune response is mobilized in early life and required for protecting the neonate, as infants with severe combined immunodeficiency (SCID) who lack lymphocytes suffer from repeated and disseminated infections [2] and ultimately succumb without immune reconstitution.IntroductionThe adaptive immune response is initiated by dendritic cells (DCs) which have taken up antigens in the affected tissues and migrated to the tissue-draining lymph node(s).", [["lymphocytes", "ANATOMY", 162, 173], ["dendritic cells", "ANATOMY", 337, 352], ["DCs", "ANATOMY", 354, 357], ["tissues", "ANATOMY", 404, 411], ["tissue", "ANATOMY", 432, 438], ["lymph node", "ANATOMY", 448, 458], ["immunodeficiency", "DISEASE", 129, 145], ["SCID", "DISEASE", 147, 151], ["infections", "DISEASE", 212, 222], ["neonate", "ORGANISM", 88, 95], ["infants", "ORGANISM", 100, 107], ["lymphocytes", "CELL", 162, 173], ["dendritic cells", "CELL", 337, 352], ["DCs", "CELL", 354, 357], ["tissues", "TISSUE", 404, 411], ["tissue", "TISSUE", 432, 438], ["lymph node", "MULTI-TISSUE_STRUCTURE", 448, 458], ["lymphocytes", "CELL_TYPE", 162, 173], ["dendritic cells", "CELL_TYPE", 337, 352], ["DCs", "CELL_TYPE", 354, 357], ["infants", "SPECIES", 100, 107], ["severe combined immunodeficiency (SCID)", "PROBLEM", 113, 152], ["lack lymphocytes", "PROBLEM", 157, 173], ["disseminated infections", "PROBLEM", 199, 222], ["immune reconstitution", "TREATMENT", 258, 279], ["The adaptive immune response", "TREATMENT", 292, 320], ["mobilized", "OBSERVATION_MODIFIER", 32, 41], ["disseminated", "OBSERVATION_MODIFIER", 199, 211], ["infections", "OBSERVATION", 212, 222], ["without", "UNCERTAINTY", 250, 257], ["immune reconstitution", "OBSERVATION", 258, 279], ["dendritic cells", "OBSERVATION", 337, 352], ["affected tissues", "ANATOMY", 395, 411], ["tissue", "ANATOMY", 432, 438], ["draining", "OBSERVATION_MODIFIER", 439, 447], ["lymph node", "OBSERVATION", 448, 458]]], ["DCs present antigen to T cells in the context of major histocompatibility complex (MHC) molecules and simultaneously provide costimulatory signals (CD80 and CD86) necessary for T cell activation via the cell surface T cell antigen receptor (TCR) and the costimulatory receptor CD28.", [["DCs", "ANATOMY", 0, 3], ["T cells", "ANATOMY", 23, 30], ["T cell", "ANATOMY", 177, 183], ["cell", "ANATOMY", 203, 207], ["DCs", "CELL", 0, 3], ["T cells", "CELL", 23, 30], ["major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 49, 81], ["CD80", "GENE_OR_GENE_PRODUCT", 148, 152], ["CD86", "GENE_OR_GENE_PRODUCT", 157, 161], ["T cell", "CELL", 177, 183], ["cell", "CELL", 203, 207], ["T cell antigen receptor", "GENE_OR_GENE_PRODUCT", 216, 239], ["TCR", "GENE_OR_GENE_PRODUCT", 241, 244], ["CD28", "GENE_OR_GENE_PRODUCT", 277, 281], ["DCs", "CELL_TYPE", 0, 3], ["T cells", "CELL_TYPE", 23, 30], ["major histocompatibility complex (MHC) molecules", "PROTEIN", 49, 97], ["CD80", "PROTEIN", 148, 152], ["CD86", "PROTEIN", 157, 161], ["cell surface T cell antigen receptor", "PROTEIN", 203, 239], ["TCR", "PROTEIN", 241, 244], ["costimulatory receptor", "PROTEIN", 254, 276], ["CD28", "PROTEIN", 277, 281], ["costimulatory signals", "TEST", 125, 146], ["T cell activation", "PROBLEM", 177, 194], ["the cell surface", "TEST", 199, 215], ["the costimulatory receptor CD28", "TREATMENT", 250, 281]]], ["Following these activating signals, T cells begin to rapidly proliferate.", [["T cells", "ANATOMY", 36, 43], ["T cells", "CELL", 36, 43], ["T cells", "CELL_TYPE", 36, 43], ["these activating signals", "TEST", 10, 34], ["T cells", "PROBLEM", 36, 43]]], ["CD4+ T cells, in particular, begin to produce IL-2, which acts in both an autocrine and paracrine manner as a third signal to further enhance proliferation and subsequent differentiation into effector T cells (Teff).", [["CD4+ T cells", "ANATOMY", 0, 12], ["effector T cells", "ANATOMY", 192, 208], ["Teff", "ANATOMY", 210, 214], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["IL-2", "GENE_OR_GENE_PRODUCT", 46, 50], ["effector T cells", "CELL", 192, 208], ["Teff", "CELL", 210, 214], ["CD4", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 5, 12], ["IL", "PROTEIN", 46, 48], ["effector T cells", "CELL_TYPE", 192, 208], ["Teff", "CELL_TYPE", 210, 214], ["T cells", "PROBLEM", 5, 12], ["T cells", "OBSERVATION", 5, 12]]], ["Along with IL-2, the presence of additional cytokines at this time influences the commitment of newly activated T cells to defined functional subsets with particular cytokines promoting certain subsets.", [["T cells", "ANATOMY", 112, 119], ["IL-2", "GENE_OR_GENE_PRODUCT", 11, 15], ["T cells", "CELL", 112, 119], ["IL", "PROTEIN", 11, 13], ["cytokines", "PROTEIN", 44, 53], ["activated T cells", "CELL_TYPE", 102, 119], ["cytokines", "PROTEIN", 166, 175], ["additional cytokines", "PROBLEM", 33, 53], ["newly activated T cells", "PROBLEM", 96, 119], ["cytokines", "OBSERVATION", 44, 53]]], ["Among CD4+ T cells, Th1, Th2, Th17, regulatory T cell (Treg), and follicular helper T cell (Tfh) subsets have been well-described [3, 4].", [["CD4+ T cells", "ANATOMY", 6, 18], ["regulatory T cell", "ANATOMY", 36, 53], ["Treg", "ANATOMY", 55, 59], ["follicular helper T cell", "ANATOMY", 66, 90], ["CD4", "GENE_OR_GENE_PRODUCT", 6, 9], ["Th1", "GENE_OR_GENE_PRODUCT", 20, 23], ["Th2", "GENE_OR_GENE_PRODUCT", 25, 28], ["Th17", "GENE_OR_GENE_PRODUCT", 30, 34], ["regulatory T cell", "CELL", 36, 53], ["Treg", "CELL", 55, 59], ["follicular helper T cell", "CELL", 66, 90], ["Tfh", "GENE_OR_GENE_PRODUCT", 92, 95], ["CD4+ T cells", "CELL_TYPE", 6, 18], ["Th1, Th2, Th17, regulatory T cell", "CELL_TYPE", 20, 53], ["Treg", "CELL_TYPE", 55, 59], ["follicular helper T cell (Tfh) subsets", "CELL_TYPE", 66, 104], ["CD4", "TEST", 6, 9], ["T cells", "TEST", 11, 18], ["Th1", "TEST", 20, 23], ["Th2", "TEST", 25, 28], ["Th17", "TEST", 30, 34], ["regulatory T cell", "TEST", 36, 53], ["T cells", "OBSERVATION", 11, 18], ["Th1", "ANATOMY", 20, 23], ["Th2", "ANATOMY", 25, 28], ["Th17", "ANATOMY", 30, 34], ["T cell", "OBSERVATION", 47, 53], ["follicular", "ANATOMY", 66, 76]]], ["CD8+ T cells appear to be less heterogeneous and differentiate primarily into cytotoxic effectors (CTLs) analogous to Th1-type CD4+ T cells [5].", [["CD8+ T cells", "ANATOMY", 0, 12], ["CTLs", "ANATOMY", 99, 103], ["Th1-type CD4+ T cells", "ANATOMY", 118, 139], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["CTLs", "CELL", 99, 103], ["CD4", "GENE_OR_GENE_PRODUCT", 127, 130], ["CD8", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 5, 12], ["cytotoxic effectors", "CELL_TYPE", 78, 97], ["CTLs", "CELL_TYPE", 99, 103], ["Th1-type CD4+ T cells", "CELL_TYPE", 118, 139], ["CD8", "TEST", 0, 3], ["T cells", "PROBLEM", 5, 12], ["CTLs", "TEST", 99, 103], ["Th1", "TEST", 118, 121], ["T cells", "PROBLEM", 132, 139], ["less heterogeneous", "OBSERVATION_MODIFIER", 26, 44], ["cytotoxic effectors", "OBSERVATION", 78, 97]]], ["Newly activated effector T cells then home to the affected tissues where they exert their effector functions.", [["effector T cells", "ANATOMY", 16, 32], ["tissues", "ANATOMY", 59, 66], ["effector T cells", "CELL", 16, 32], ["tissues", "TISSUE", 59, 66], ["activated effector T cells", "CELL_TYPE", 6, 32], ["Newly activated effector T cells", "PROBLEM", 0, 32], ["effector T cells", "OBSERVATION", 16, 32]]], ["Th1-type T cells, typically generated in the context of viral infections, are robust producers of IFN-\u03b3 and TNF-\u03b1 and are required to clear many types of viral and bacterial infections encountered in early life.IntroductionFollowing the resolution of infection, a fraction of responding effector T cells will be retained long-term as populations of memory T cells, which persist for up to a lifetime of an individual.", [["Th1-type T cells", "ANATOMY", 0, 16], ["effector T cells", "ANATOMY", 287, 303], ["memory T cells", "ANATOMY", 349, 363], ["viral infections", "DISEASE", 56, 72], ["infections", "DISEASE", 174, 184], ["infection", "DISEASE", 251, 260], ["Th1-type T cells", "CELL", 0, 16], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 98, 103], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 108, 113], ["effector T cells", "CELL", 287, 303], ["memory T cells", "CELL", 349, 363], ["Th1-type T cells", "CELL_TYPE", 0, 16], ["IFN", "PROTEIN", 98, 101], ["TNF-\u03b1", "PROTEIN", 108, 113], ["effector T cells", "CELL_TYPE", 287, 303], ["memory T cells", "CELL_TYPE", 349, 363], ["Th1-type T cells", "PROBLEM", 0, 16], ["viral infections", "PROBLEM", 56, 72], ["IFN", "TEST", 98, 101], ["TNF", "TEST", 108, 111], ["viral and bacterial infections", "PROBLEM", 154, 184], ["infection", "PROBLEM", 251, 260], ["responding effector T cells", "PROBLEM", 276, 303], ["memory T cells", "PROBLEM", 349, 363], ["viral", "OBSERVATION_MODIFIER", 56, 61], ["infections", "OBSERVATION", 62, 72], ["viral", "OBSERVATION", 154, 159], ["bacterial", "OBSERVATION_MODIFIER", 164, 173], ["infections", "OBSERVATION", 174, 184], ["infection", "OBSERVATION", 251, 260]]], ["Memory T cells are heterogeneous in their localization and maintenance within circulation, lymphoid tissues, and multiple peripheral tissues and barrier sites, including the skin, lungs, and intestines.", [["Memory T cells", "ANATOMY", 0, 14], ["lymphoid tissues", "ANATOMY", 91, 107], ["peripheral tissues", "ANATOMY", 122, 140], ["barrier sites", "ANATOMY", 145, 158], ["skin", "ANATOMY", 174, 178], ["lungs", "ANATOMY", 180, 185], ["intestines", "ANATOMY", 191, 201], ["Memory T cells", "CELL", 0, 14], ["lymphoid tissues", "TISSUE", 91, 107], ["peripheral tissues", "TISSUE", 122, 140], ["barrier sites", "TISSUE", 145, 158], ["skin", "ORGAN", 174, 178], ["lungs", "ORGAN", 180, 185], ["intestines", "ORGAN", 191, 201], ["Memory T cells", "CELL_TYPE", 0, 14], ["multiple peripheral tissues", "PROBLEM", 113, 140], ["barrier sites", "TREATMENT", 145, 158], ["the skin, lungs, and intestines", "PROBLEM", 170, 201], ["heterogeneous", "OBSERVATION_MODIFIER", 19, 32], ["lymphoid tissues", "OBSERVATION", 91, 107], ["multiple", "OBSERVATION_MODIFIER", 113, 121], ["peripheral tissues", "OBSERVATION", 122, 140], ["barrier sites", "OBSERVATION", 145, 158], ["skin", "ANATOMY", 174, 178], ["lungs", "ANATOMY", 180, 185], ["intestines", "ANATOMY", 191, 201]]], ["It is now understood that a significant fraction of memory T cells in both mice and humans is comprised of non-circulating, tissue-resident memory (TRM) T cells [6\u20138].", [["memory T cells", "ANATOMY", 52, 66], ["tissue-resident memory (TRM) T cells", "ANATOMY", 124, 160], ["memory T cells", "CELL", 52, 66], ["mice", "ORGANISM", 75, 79], ["humans", "ORGANISM", 84, 90], ["tissue-resident memory (TRM) T cells", "CELL", 124, 160], ["memory T cells", "CELL_TYPE", 52, 66], ["non-circulating, tissue-resident memory (TRM) T cells", "CELL_TYPE", 107, 160], ["mice", "SPECIES", 75, 79], ["humans", "SPECIES", 84, 90], ["mice", "SPECIES", 75, 79], ["humans", "SPECIES", 84, 90]]], ["The functional importance of TRM in protection from reinfection has been demonstrated in adult murine models at a number of tissue sites and for several pathogens [6, 9\u201312], and the predominant presence of TRM-phenotype cells in human tissues [13] suggests important roles for maintaining immune protection and homeostasis in humans.IntroductionThe generation, function, and regulation of immune responses by T cells during early life are not well understood, in either mouse models or humans.", [["tissue sites", "ANATOMY", 124, 136], ["TRM-phenotype cells", "ANATOMY", 206, 225], ["tissues", "ANATOMY", 235, 242], ["T cells", "ANATOMY", 409, 416], ["TRM", "CHEMICAL", 29, 32], ["reinfection", "DISEASE", 52, 63], ["murine", "ORGANISM", 95, 101], ["tissue sites", "MULTI-TISSUE_STRUCTURE", 124, 136], ["TRM-phenotype cells", "CELL", 206, 225], ["human", "ORGANISM", 229, 234], ["tissues", "TISSUE", 235, 242], ["humans", "ORGANISM", 326, 332], ["T cells", "CELL", 409, 416], ["mouse", "ORGANISM", 470, 475], ["humans", "ORGANISM", 486, 492], ["TRM-phenotype cells", "CELL_TYPE", 206, 225], ["T cells", "CELL_TYPE", 409, 416], ["murine", "SPECIES", 95, 101], ["human", "SPECIES", 229, 234], ["humans", "SPECIES", 326, 332], ["mouse", "SPECIES", 470, 475], ["humans", "SPECIES", 486, 492], ["human", "SPECIES", 229, 234], ["humans", "SPECIES", 326, 332], ["mouse", "SPECIES", 470, 475], ["humans", "SPECIES", 486, 492], ["TRM in protection", "TREATMENT", 29, 46], ["reinfection", "PROBLEM", 52, 63], ["several pathogens", "PROBLEM", 145, 162], ["phenotype cells in human tissues", "PROBLEM", 210, 242], ["immune protection", "TREATMENT", 289, 306], ["reinfection", "OBSERVATION", 52, 63], ["phenotype cells", "OBSERVATION", 210, 225]]], ["Defining the functional capacities of early-life T cells continues to evolve with findings that infant T cells may have diverse or distinct functions depending on the nature of the infection or stimulus [14].", [["early-life T cells", "ANATOMY", 38, 56], ["T cells", "ANATOMY", 103, 110], ["infection", "DISEASE", 181, 190], ["early-life T cells", "CELL", 38, 56], ["T cells", "CELL", 103, 110], ["early-life T cells", "CELL_TYPE", 38, 56], ["infant T cells", "CELL_TYPE", 96, 110], ["distinct functions", "PROBLEM", 131, 149], ["the infection", "PROBLEM", 177, 190], ["capacities", "OBSERVATION_MODIFIER", 24, 34], ["infection", "OBSERVATION", 181, 190]]], ["Moreover, the ability of early-life infections to promote tissue-localized T cell responses, lasting T cell memory, and TRM responses is only beginning to be characterized.", [["tissue", "ANATOMY", 58, 64], ["T cell", "ANATOMY", 75, 81], ["T cell", "ANATOMY", 101, 107], ["infections", "DISEASE", 36, 46], ["tissue", "TISSUE", 58, 64], ["T cell", "CELL", 75, 81], ["T cell", "CELL", 101, 107], ["early-life infections", "PROBLEM", 25, 46], ["cell", "OBSERVATION", 77, 81]]], ["Neonates and infants have substantial populations of T cells from birth, both in the blood and in peripheral tissues.", [["T cells", "ANATOMY", 53, 60], ["blood", "ANATOMY", 85, 90], ["peripheral tissues", "ANATOMY", 98, 116], ["Neonates", "ORGANISM", 0, 8], ["infants", "ORGANISM", 13, 20], ["T cells", "CELL", 53, 60], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["peripheral tissues", "TISSUE", 98, 116], ["T cells", "CELL_TYPE", 53, 60], ["Neonates", "SPECIES", 0, 8], ["infants", "SPECIES", 13, 20], ["T cells", "PROBLEM", 53, 60], ["substantial", "OBSERVATION_MODIFIER", 26, 37], ["populations", "OBSERVATION_MODIFIER", 38, 49], ["T cells", "OBSERVATION", 53, 60], ["blood", "ANATOMY", 85, 90], ["peripheral tissues", "ANATOMY", 98, 116]]], ["These T cells, however, are predominantly na\u00efve, express distinct patterns of homing receptors compared to adults, and in some cases may generate more regulatory than pro-inflammatory responses.", [["T cells", "ANATOMY", 6, 13], ["T cells", "CELL", 6, 13], ["T cells", "CELL_TYPE", 6, 13], ["homing receptors", "PROTEIN", 78, 94], ["predominantly", "OBSERVATION_MODIFIER", 28, 41], ["na\u00efve", "OBSERVATION", 42, 47]]], ["In order to develop therapies to better treat infections and promote robust, protective responses to vaccines, it is essential to define the mechanisms that control T cell differentiation, function, tissue localization, and maintenance at the earliest life stages.IntroductionThis review will discuss current paradigms in infant T cell immunity and tissue localization and how recent studies have begun to shift our understanding of T cell responses in early life with implications in the design of vaccines and therapeutics to protect this vulnerable population.Burden of infection and immunological challenges in early lifeFollowing birth, neonates transition from a largely sterile environment to one where they are rapidly exposed to novel innocuous antigens and microorganisms and an abundance of potentially pathogenic organisms.", [["T cell", "ANATOMY", 165, 171], ["tissue", "ANATOMY", 199, 205], ["T cell", "ANATOMY", 329, 335], ["tissue", "ANATOMY", 349, 355], ["T cell", "ANATOMY", 433, 439], ["infections", "DISEASE", 46, 56], ["infection", "DISEASE", 573, 582], ["T cell", "CELL", 165, 171], ["tissue", "TISSUE", 199, 205], ["infant T cell", "CELL", 322, 335], ["tissue", "TISSUE", 349, 355], ["T cell", "CELL", 433, 439], ["therapies", "TREATMENT", 20, 29], ["infections", "PROBLEM", 46, 56], ["vaccines", "TREATMENT", 101, 109], ["tissue localization", "TEST", 199, 218], ["tissue localization", "TEST", 349, 368], ["vaccines", "TREATMENT", 499, 507], ["therapeutics", "TREATMENT", 512, 524], ["infection", "PROBLEM", 573, 582], ["immunological challenges", "TREATMENT", 587, 611], ["a largely sterile environment", "TREATMENT", 667, 696], ["novel innocuous antigens", "PROBLEM", 738, 762], ["microorganisms", "PROBLEM", 767, 781], ["potentially pathogenic organisms", "PROBLEM", 802, 834], ["infection", "OBSERVATION", 573, 582]]], ["The majority of the earliest pathogen encounters during early life occur at the interface where our immune system meets the external environment, including skin, gastrointestinal, and respiratory tracts.", [["immune system", "ANATOMY", 100, 113], ["skin", "ANATOMY", 156, 160], ["gastrointestinal", "ANATOMY", 162, 178], ["respiratory tracts", "ANATOMY", 184, 202], ["skin, gastrointestinal, and respiratory tracts", "DISEASE", 156, 202], ["skin", "ORGAN", 156, 160], ["gastrointestinal", "ORGAN", 162, 178], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["skin", "ANATOMY", 156, 160], ["gastrointestinal", "ANATOMY", 162, 178], ["respiratory tracts", "ANATOMY", 184, 202]]], ["As a consequence, the burden of infectious disease in early life occurs at these tissue sites.", [["tissue sites", "ANATOMY", 81, 93], ["infectious disease", "DISEASE", 32, 50], ["tissue sites", "MULTI-TISSUE_STRUCTURE", 81, 93], ["infectious disease", "PROBLEM", 32, 50], ["burden", "OBSERVATION_MODIFIER", 22, 28], ["infectious", "OBSERVATION", 32, 42]]], ["Annually, over 2 million neonates are affected by severe infections with lower respiratory tract infections (LRTIs), malaria, diarrheal illnesses, neonatal sepsis, and meningitis among the most common etiologies in this population [15, 16].", [["lower respiratory tract", "ANATOMY", 73, 96], ["infections", "DISEASE", 57, 67], ["lower respiratory tract infections", "DISEASE", 73, 107], ["LRTIs", "DISEASE", 109, 114], ["malaria", "DISEASE", 117, 124], ["diarrheal illnesses", "DISEASE", 126, 145], ["neonatal sepsis", "DISEASE", 147, 162], ["meningitis", "DISEASE", 168, 178], ["neonates", "ORGANISM", 25, 33], ["tract", "ORGANISM_SUBDIVISION", 91, 96], ["severe infections", "PROBLEM", 50, 67], ["lower respiratory tract infections", "PROBLEM", 73, 107], ["malaria", "PROBLEM", 117, 124], ["diarrheal illnesses", "PROBLEM", 126, 145], ["neonatal sepsis", "PROBLEM", 147, 162], ["meningitis", "PROBLEM", 168, 178], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["infections", "OBSERVATION", 57, 67], ["lower", "ANATOMY_MODIFIER", 73, 78], ["respiratory tract", "ANATOMY", 79, 96], ["infections", "OBSERVATION", 97, 107], ["LRTIs", "OBSERVATION", 109, 114], ["malaria", "OBSERVATION", 117, 124], ["diarrheal illnesses", "OBSERVATION", 126, 145], ["sepsis", "OBSERVATION", 156, 162], ["meningitis", "OBSERVATION", 168, 178], ["most common", "OBSERVATION_MODIFIER", 189, 200]]], ["The systemic spread of infection can result in sepsis, which is the most common cause of death in infants and young children worldwide.", [["infection", "DISEASE", 23, 32], ["sepsis", "DISEASE", 47, 53], ["death", "DISEASE", 89, 94], ["infants", "ORGANISM", 98, 105], ["children", "ORGANISM", 116, 124], ["infants", "SPECIES", 98, 105], ["children", "SPECIES", 116, 124], ["infection", "PROBLEM", 23, 32], ["sepsis", "PROBLEM", 47, 53], ["death", "PROBLEM", 89, 94], ["systemic", "OBSERVATION_MODIFIER", 4, 12], ["spread", "OBSERVATION_MODIFIER", 13, 19], ["infection", "OBSERVATION", 23, 32], ["sepsis", "OBSERVATION", 47, 53], ["most common", "OBSERVATION_MODIFIER", 68, 79]]], ["Failure to effectively control pathogens within the respiratory tract has led it to be the most common cause of pediatric sepsis [17].", [["respiratory tract", "ANATOMY", 52, 69], ["sepsis", "DISEASE", 122, 128], ["respiratory tract", "ORGANISM_SUBDIVISION", 52, 69], ["Failure to effectively control pathogens within the respiratory tract", "PROBLEM", 0, 69], ["pediatric sepsis", "PROBLEM", 112, 128], ["pathogens", "OBSERVATION", 31, 40], ["respiratory tract", "ANATOMY", 52, 69], ["sepsis", "OBSERVATION", 122, 128]]], ["The high susceptibility of infants to disseminated infection indicates that tissue-immune responses are less well-developed and are not always sufficient to contain infection in the neonatal period.Burden of infection and immunological challenges in early lifeViral respiratory tract infections (VRTIs) are ubiquitous among children with nearly all children having experienced infection with respiratory syncytial virus (RSV) within the first 2 years of life [18].", [["tissue", "ANATOMY", 76, 82], ["lifeViral respiratory tract", "ANATOMY", 256, 283], ["infection", "DISEASE", 51, 60], ["infection", "DISEASE", 165, 174], ["infection", "DISEASE", 208, 217], ["lifeViral respiratory tract infections", "DISEASE", 256, 294], ["VRTIs", "DISEASE", 296, 301], ["infection", "DISEASE", 377, 386], ["respiratory syncytial virus", "DISEASE", 392, 419], ["RSV", "DISEASE", 421, 424], ["infants", "ORGANISM", 27, 34], ["tissue", "TISSUE", 76, 82], ["lifeViral respiratory tract", "ORGANISM_SUBDIVISION", 256, 283], ["children", "ORGANISM", 324, 332], ["children", "ORGANISM", 349, 357], ["respiratory syncytial virus", "ORGANISM", 392, 419], ["RSV", "ORGANISM", 421, 424], ["infants", "SPECIES", 27, 34], ["children", "SPECIES", 324, 332], ["children", "SPECIES", 349, 357], ["respiratory syncytial virus", "SPECIES", 392, 419], ["respiratory syncytial virus", "SPECIES", 392, 419], ["RSV", "SPECIES", 421, 424], ["disseminated infection", "PROBLEM", 38, 60], ["infection", "PROBLEM", 165, 174], ["infection", "PROBLEM", 208, 217], ["immunological challenges", "PROBLEM", 222, 246], ["early lifeViral respiratory tract infections", "PROBLEM", 250, 294], ["infection", "PROBLEM", 377, 386], ["respiratory syncytial virus", "PROBLEM", 392, 419], ["high", "OBSERVATION_MODIFIER", 4, 8], ["susceptibility", "OBSERVATION_MODIFIER", 9, 23], ["disseminated", "OBSERVATION_MODIFIER", 38, 50], ["infection", "OBSERVATION", 51, 60], ["infection", "OBSERVATION", 165, 174], ["infection", "OBSERVATION", 208, 217], ["early", "OBSERVATION_MODIFIER", 250, 255], ["lifeViral", "OBSERVATION_MODIFIER", 256, 265], ["respiratory tract", "ANATOMY", 266, 283], ["infection", "OBSERVATION", 377, 386], ["syncytial virus", "OBSERVATION", 404, 419]]], ["Viruses account for the majority of LRTI in children less than 5 years of age [19], with RSV, influenza, and rhinoviruses most prevalent; however, significant morbidity and mortality also result from human metapneumovirus (HMPV), coronavirus, bocavirus, parainfluenza, enterovirus, and adenovirus [20].", [["LRTI", "DISEASE", 36, 40], ["influenza", "DISEASE", 94, 103], ["rhinoviruses", "DISEASE", 109, 121], ["human metapneumovirus (HMPV), coronavirus, bocavirus, parainfluenza, enterovirus, and adenovirus", "DISEASE", 200, 296], ["children", "ORGANISM", 44, 52], ["RSV", "ORGANISM", 89, 92], ["rhinoviruses", "ORGANISM", 109, 121], ["human metapneumovirus", "ORGANISM", 200, 221], ["HMPV", "ORGANISM", 223, 227], ["coronavirus", "ORGANISM", 230, 241], ["bocavirus", "GENE_OR_GENE_PRODUCT", 243, 252], ["parainfluenza", "ORGANISM", 254, 267], ["enterovirus", "ORGANISM", 269, 280], ["adenovirus", "ORGANISM", 286, 296], ["children", "SPECIES", 44, 52], ["human", "SPECIES", 200, 205], ["metapneumovirus", "SPECIES", 206, 221], ["coronavirus", "SPECIES", 230, 241], ["parainfluenza", "SPECIES", 254, 267], ["RSV", "SPECIES", 89, 92], ["human metapneumovirus", "SPECIES", 200, 221], ["HMPV", "SPECIES", 223, 227], ["Viruses", "PROBLEM", 0, 7], ["RSV", "PROBLEM", 89, 92], ["influenza", "PROBLEM", 94, 103], ["rhinoviruses", "PROBLEM", 109, 121], ["significant morbidity", "PROBLEM", 147, 168], ["human metapneumovirus (HMPV)", "PROBLEM", 200, 228], ["coronavirus", "PROBLEM", 230, 241], ["bocavirus", "PROBLEM", 243, 252], ["parainfluenza", "PROBLEM", 254, 267], ["enterovirus", "PROBLEM", 269, 280], ["adenovirus", "PROBLEM", 286, 296], ["influenza", "OBSERVATION", 94, 103]]], ["RSV alone is the second leading cause of death in infants and young children and the most frequent cause of non-neonatal infant mortality [21].", [["RSV", "DISEASE", 0, 3], ["death", "DISEASE", 41, 46], ["RSV", "ORGANISM", 0, 3], ["infants", "ORGANISM", 50, 57], ["children", "ORGANISM", 68, 76], ["infants", "SPECIES", 50, 57], ["children", "SPECIES", 68, 76], ["infant", "SPECIES", 121, 127], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["death", "PROBLEM", 41, 46]]], ["The clinical features of viral LRTI typically begin with mild symptoms progressing in severity to respiratory distress and lung tissue damage [20].", [["respiratory", "ANATOMY", 98, 109], ["lung tissue", "ANATOMY", 123, 134], ["LRTI", "DISEASE", 31, 35], ["respiratory distress", "DISEASE", 98, 118], ["lung tissue damage", "DISEASE", 123, 141], ["lung tissue", "TISSUE", 123, 134], ["viral LRTI", "PROBLEM", 25, 35], ["mild symptoms", "PROBLEM", 57, 70], ["respiratory distress", "PROBLEM", 98, 118], ["lung tissue damage", "PROBLEM", 123, 141], ["viral LRTI", "OBSERVATION", 25, 35], ["mild", "OBSERVATION_MODIFIER", 57, 61], ["respiratory distress", "OBSERVATION", 98, 118], ["lung", "ANATOMY", 123, 127]]], ["Few options for treatment are currently available, with supportive care prevailing [22].", [["treatment", "TREATMENT", 16, 25]]], ["A variety of antiviral therapeutics, including immunoglobulins, siRNA-interference, fusion inhibitors, and small molecules, are currently in development at the clinical trial phase [23].", [["immunoglobulins", "GENE_OR_GENE_PRODUCT", 47, 62], ["immunoglobulins", "PROTEIN", 47, 62], ["antiviral therapeutics", "TREATMENT", 13, 35], ["immunoglobulins", "TREATMENT", 47, 62], ["siRNA", "TREATMENT", 64, 69], ["fusion inhibitors", "TREATMENT", 84, 101], ["small molecules", "PROBLEM", 107, 122], ["antiviral therapeutics", "OBSERVATION", 13, 35], ["small molecules", "OBSERVATION_MODIFIER", 107, 122]]], ["While children with underlying conditions including malnutrition, chronic lung disease, congenital heart disease, and those born extremely prematurely (< 29 weeks gestation) are at increased risk for severe illness, from LRTI [24], the majority of children who require hospitalization have none of these risk factors [25, 26], emphasizing the general vulnerability of infants to these infections.Burden of infection and immunological challenges in early lifeDiarrheal illnesses are the other major clinical manifestation of early-life infections, with 70% of the 700,000 deaths worldwide occurring in the first 2 years of life.", [["lung", "ANATOMY", 74, 78], ["heart", "ANATOMY", 99, 104], ["malnutrition", "DISEASE", 52, 64], ["chronic lung disease", "DISEASE", 66, 86], ["congenital heart disease", "DISEASE", 88, 112], ["illness", "DISEASE", 207, 214], ["LRTI", "DISEASE", 221, 225], ["infections", "DISEASE", 385, 395], ["infection", "DISEASE", 406, 415], ["lifeDiarrheal illnesses", "DISEASE", 454, 477], ["infections", "DISEASE", 535, 545], ["deaths", "DISEASE", 571, 577], ["children", "ORGANISM", 6, 14], ["lung", "ORGAN", 74, 78], ["heart", "ORGAN", 99, 104], ["children", "ORGANISM", 248, 256], ["infants", "ORGANISM", 368, 375], ["children", "SPECIES", 6, 14], ["children", "SPECIES", 248, 256], ["infants", "SPECIES", 368, 375], ["underlying conditions", "PROBLEM", 20, 41], ["malnutrition", "PROBLEM", 52, 64], ["chronic lung disease", "PROBLEM", 66, 86], ["congenital heart disease", "PROBLEM", 88, 112], ["severe illness", "PROBLEM", 200, 214], ["these infections", "PROBLEM", 379, 395], ["infection", "PROBLEM", 406, 415], ["immunological challenges", "PROBLEM", 420, 444], ["early lifeDiarrheal illnesses", "PROBLEM", 448, 477], ["early-life infections", "PROBLEM", 524, 545], ["malnutrition", "OBSERVATION", 52, 64], ["chronic", "OBSERVATION_MODIFIER", 66, 73], ["lung", "ANATOMY", 74, 78], ["disease", "OBSERVATION", 79, 86], ["heart", "ANATOMY", 99, 104], ["disease", "OBSERVATION", 105, 112], ["infections", "OBSERVATION", 385, 395], ["infection", "OBSERVATION", 406, 415], ["early", "OBSERVATION_MODIFIER", 524, 529]]], ["Rotavirus remains the most common cause of severe and fatal diarrhea worldwide [27], although a vaccine is available.", [["Rotavirus", "DISEASE", 0, 9], ["diarrhea", "DISEASE", 60, 68], ["Rotavirus", "ORGANISM", 0, 9], ["Rotavirus", "PROBLEM", 0, 9], ["severe and fatal diarrhea", "PROBLEM", 43, 68], ["a vaccine", "TREATMENT", 94, 103], ["most common", "OBSERVATION_MODIFIER", 22, 33], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["fatal", "OBSERVATION_MODIFIER", 54, 59], ["diarrhea", "OBSERVATION", 60, 68]]], ["Cholera is also a significant cause of diarrhea-related mortality, with peak incidence in children under 5 years of age, during epidemics.", [["Cholera", "DISEASE", 0, 7], ["diarrhea", "DISEASE", 39, 47], ["children", "ORGANISM", 90, 98], ["children", "SPECIES", 90, 98], ["diarrhea", "PROBLEM", 39, 47], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["diarrhea", "OBSERVATION", 39, 47]]], ["Importantly, multiple episodes of diarrheal illness have been associated with nutritional deficits resulting in long-term consequences, including growth stunting and decreased cognitive function [28].", [["diarrheal illness", "DISEASE", 34, 51], ["nutritional deficits", "DISEASE", 78, 98], ["stunting", "DISEASE", 153, 161], ["decreased cognitive function", "DISEASE", 166, 194], ["diarrheal illness", "PROBLEM", 34, 51], ["nutritional deficits", "PROBLEM", 78, 98], ["long-term consequences", "PROBLEM", 112, 134], ["growth stunting", "PROBLEM", 146, 161], ["decreased cognitive function", "PROBLEM", 166, 194], ["multiple", "OBSERVATION_MODIFIER", 13, 21], ["episodes", "OBSERVATION_MODIFIER", 22, 30], ["diarrheal illness", "OBSERVATION", 34, 51], ["long-term consequences", "OBSERVATION_MODIFIER", 112, 134]]], ["The focus of therapy during acute infectious diarrheal illness focuses on hydration status, with therapies including antibiotics reserved for specific etiologies (i.e., cholera).", [["diarrheal illness", "DISEASE", 45, 62], ["cholera", "DISEASE", 169, 176], ["therapy", "TREATMENT", 13, 20], ["acute infectious diarrheal illness", "PROBLEM", 28, 62], ["hydration status", "TREATMENT", 74, 90], ["therapies", "TREATMENT", 97, 106], ["antibiotics", "TREATMENT", 117, 128], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["infectious", "OBSERVATION_MODIFIER", 34, 44]]], ["Prevention is of particular importance in diarrheal illness with a focus on hygiene and vaccination [29].", [["diarrheal illness", "DISEASE", 42, 59], ["diarrheal illness", "PROBLEM", 42, 59]]], ["The prevalence of mucosal infections in early life suggests inefficient mucosal immune responses and a need to enhance immunity in a site-specific fashion.Peripheral seeding and initiation of early-life T cell responsesIn both mice and humans, T cells have distinct phenotypic and distribution patterns in early life which change gradually with age (Table 1).", [["mucosal", "ANATOMY", 18, 25], ["mucosal", "ANATOMY", 72, 79], ["T cell", "ANATOMY", 203, 209], ["T cells", "ANATOMY", 244, 251], ["mucosal infections", "DISEASE", 18, 36], ["mucosal", "ORGANISM_SUBDIVISION", 18, 25], ["mucosal", "ANATOMICAL_SYSTEM", 72, 79], ["T cell", "CELL", 203, 209], ["mice", "ORGANISM", 227, 231], ["humans", "ORGANISM", 236, 242], ["T cells", "CELL", 244, 251], ["T cells", "CELL_TYPE", 244, 251], ["mice", "SPECIES", 227, 231], ["humans", "SPECIES", 236, 242], ["mice", "SPECIES", 227, 231], ["humans", "SPECIES", 236, 242], ["mucosal infections", "PROBLEM", 18, 36], ["inefficient mucosal immune responses", "PROBLEM", 60, 96], ["Peripheral seeding", "TREATMENT", 155, 173], ["early-life T cell responses", "TREATMENT", 192, 219], ["mucosal", "ANATOMY", 18, 25], ["infections", "OBSERVATION", 26, 36], ["inefficient", "OBSERVATION_MODIFIER", 60, 71], ["mucosal immune", "OBSERVATION", 72, 86], ["seeding", "OBSERVATION", 166, 173], ["distinct", "OBSERVATION_MODIFIER", 257, 265], ["phenotypic", "OBSERVATION_MODIFIER", 266, 276], ["distribution", "OBSERVATION_MODIFIER", 281, 293], ["patterns", "OBSERVATION_MODIFIER", 294, 302]]], ["Although mice are born relatively lymphopenic, humans are born with a full complement of peripheral lymphocytes [30\u201332].", [["peripheral lymphocytes", "ANATOMY", 89, 111], ["mice", "ORGANISM", 9, 13], ["humans", "ORGANISM", 47, 53], ["peripheral lymphocytes", "CELL", 89, 111], ["peripheral lymphocytes", "CELL_TYPE", 89, 111], ["mice", "SPECIES", 9, 13], ["humans", "SPECIES", 47, 53], ["mice", "SPECIES", 9, 13], ["humans", "SPECIES", 47, 53], ["lymphopenic", "PROBLEM", 34, 45], ["relatively", "OBSERVATION_MODIFIER", 23, 33], ["lymphopenic", "OBSERVATION", 34, 45]]], ["The majority of T cells in human infants exhibit features of recent thymic emigrants, including high levels of T cell receptor excision circles (TRECs) as transient products of TCR gene rearrangement and expression of CD31 on the cell surface [32, 33] (Table 1).", [["T cells", "ANATOMY", 16, 23], ["thymic emigrants", "ANATOMY", 68, 84], ["T cell", "ANATOMY", 111, 117], ["cell surface", "ANATOMY", 230, 242], ["T cells", "CELL", 16, 23], ["human", "ORGANISM", 27, 32], ["infants", "ORGANISM", 33, 40], ["thymic emigrants", "CELL", 68, 84], ["T cell receptor excision circles", "GENE_OR_GENE_PRODUCT", 111, 143], ["TCR", "GENE_OR_GENE_PRODUCT", 177, 180], ["CD31", "GENE_OR_GENE_PRODUCT", 218, 222], ["cell surface", "CELLULAR_COMPONENT", 230, 242], ["T cells", "CELL_TYPE", 16, 23], ["thymic emigrants", "CELL_TYPE", 68, 84], ["TCR gene", "DNA", 177, 185], ["CD31", "PROTEIN", 218, 222], ["human", "SPECIES", 27, 32], ["infants", "SPECIES", 33, 40], ["human", "SPECIES", 27, 32], ["recent thymic emigrants", "PROBLEM", 61, 84], ["T cell receptor excision circles", "TREATMENT", 111, 143], ["TCR gene rearrangement", "PROBLEM", 177, 199], ["the cell surface", "TEST", 226, 242], ["thymic emigrants", "OBSERVATION", 68, 84]]], ["In both humans and infant mice (> 1 week of age), the majority of T cells present within blood and lymphoid and peripheral tissues in early life exhibit a na\u00efve phenotype with high expression of L-selectin (CD62L) and low expression of the activation marker CD44 for murine na\u00efve T cells, and expression of the CD45RA isoform and the chemokine receptor CCR7 for human na\u00efve T cells [32, 34].", [["T cells", "ANATOMY", 66, 73], ["blood", "ANATOMY", 89, 94], ["lymphoid", "ANATOMY", 99, 107], ["peripheral tissues", "ANATOMY", 112, 130], ["na\u00efve T cells", "ANATOMY", 274, 287], ["na\u00efve T cells", "ANATOMY", 368, 381], ["humans", "ORGANISM", 8, 14], ["infant mice", "ORGANISM", 19, 30], ["T cells", "CELL", 66, 73], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["lymphoid", "CELL", 99, 107], ["peripheral tissues", "TISSUE", 112, 130], ["L-selectin", "GENE_OR_GENE_PRODUCT", 195, 205], ["CD62L", "GENE_OR_GENE_PRODUCT", 207, 212], ["CD44", "GENE_OR_GENE_PRODUCT", 258, 262], ["murine", "ORGANISM", 267, 273], ["na\u00efve T cells", "CELL", 274, 287], ["CD45RA", "GENE_OR_GENE_PRODUCT", 311, 317], ["CCR7", "GENE_OR_GENE_PRODUCT", 353, 357], ["human", "ORGANISM", 362, 367], ["na\u00efve T cells", "CELL", 368, 381], ["T cells", "CELL_TYPE", 66, 73], ["L-selectin", "PROTEIN", 195, 205], ["CD62L", "PROTEIN", 207, 212], ["CD44", "PROTEIN", 258, 262], ["murine na\u00efve T cells", "CELL_TYPE", 267, 287], ["CD45RA isoform", "PROTEIN", 311, 325], ["chemokine receptor", "PROTEIN", 334, 352], ["CCR7", "PROTEIN", 353, 357], ["human na\u00efve T cells", "CELL_TYPE", 362, 381], ["humans", "SPECIES", 8, 14], ["infant", "SPECIES", 19, 25], ["mice", "SPECIES", 26, 30], ["murine", "SPECIES", 267, 273], ["human", "SPECIES", 362, 367], ["humans", "SPECIES", 8, 14], ["mice", "SPECIES", 26, 30], ["human", "SPECIES", 362, 367], ["T cells", "PROBLEM", 66, 73], ["a na\u00efve phenotype", "PROBLEM", 153, 170], ["murine na\u00efve T cells", "PROBLEM", 267, 287], ["the CD45RA isoform", "TREATMENT", 307, 325], ["the chemokine receptor CCR7", "TEST", 330, 357], ["human na\u00efve T cells", "TEST", 362, 381], ["lymphoid", "ANATOMY", 99, 107], ["peripheral tissues", "ANATOMY", 112, 130], ["high expression", "OBSERVATION_MODIFIER", 176, 191], ["low expression", "OBSERVATION_MODIFIER", 218, 232]]], ["In mice, T cells during the first week of post-natal life display increased expression of activation markers, including enhanced levels of CD44, as a result of lymphopenia-induced homeostatic expansion which transitions to a more na\u00efve-like phenotype in the second week of life and beyond [30, 31].", [["T cells", "ANATOMY", 9, 16], ["lymphopenia", "DISEASE", 160, 171], ["mice", "ORGANISM", 3, 7], ["T cells", "CELL", 9, 16], ["CD44", "GENE_OR_GENE_PRODUCT", 139, 143], ["T cells", "CELL_TYPE", 9, 16], ["activation markers", "PROTEIN", 90, 108], ["CD44", "PROTEIN", 139, 143], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["activation markers", "TEST", 90, 108], ["enhanced levels of CD44", "PROBLEM", 120, 143], ["lymphopenia", "PROBLEM", 160, 171], ["homeostatic expansion", "PROBLEM", 180, 201], ["lymphopenia", "OBSERVATION", 160, 171], ["homeostatic expansion", "OBSERVATION", 180, 201]]], ["In humans, this early-life homeostatic expansion does not occur, suggesting that use of mice as models for human early-life T cell immunity should assess responses following this initial period of lymphopenia-induced proliferation.", [["T cell", "ANATOMY", 124, 130], ["lymphopenia", "DISEASE", 197, 208], ["humans", "ORGANISM", 3, 9], ["mice", "ORGANISM", 88, 92], ["human", "ORGANISM", 107, 112], ["T cell", "CELL", 124, 130], ["humans", "SPECIES", 3, 9], ["mice", "SPECIES", 88, 92], ["human", "SPECIES", 107, 112], ["humans", "SPECIES", 3, 9], ["mice", "SPECIES", 88, 92], ["human", "SPECIES", 107, 112], ["human early-life T cell immunity", "TREATMENT", 107, 139], ["lymphopenia", "PROBLEM", 197, 208], ["induced proliferation", "PROBLEM", 209, 230], ["lymphopenia", "OBSERVATION", 197, 208], ["proliferation", "OBSERVATION", 217, 230]]]], "82cec9273215e27cc141926b184323b77f8f01fc": [["INTRODUCTIONIn the year 2003, two different groups reported on the presence of three novel genes closely placed to each other, on human chromosome 19 that coded for interferons (IFNs) with potent antiviral properties.", [["chromosome 19", "ANATOMY", 136, 149], ["human", "ORGANISM", 130, 135], ["chromosome 19", "CELLULAR_COMPONENT", 136, 149], ["interferons", "GENE_OR_GENE_PRODUCT", 165, 176], ["IFNs", "GENE_OR_GENE_PRODUCT", 178, 182], ["human chromosome 19", "DNA", 130, 149], ["interferons", "PROTEIN", 165, 176], ["IFNs", "PROTEIN", 178, 182], ["human", "SPECIES", 130, 135], ["human", "SPECIES", 130, 135], ["interferons (IFNs)", "TREATMENT", 165, 183], ["potent antiviral properties", "TREATMENT", 189, 216]]], ["1, 2 These genes due to their relatedness to the interleukin 10 (IL-10) family were initially christened IL-28A, IL-28B and IL-29, and subsequently changed to IFNL2, IFNL3 and IFNL1.", [["interleukin 10", "GENE_OR_GENE_PRODUCT", 49, 63], ["IL-10", "GENE_OR_GENE_PRODUCT", 65, 70], ["IL-28A", "GENE_OR_GENE_PRODUCT", 105, 111], ["IL-28B", "GENE_OR_GENE_PRODUCT", 113, 119], ["IL-29", "GENE_OR_GENE_PRODUCT", 124, 129], ["IFNL2", "GENE_OR_GENE_PRODUCT", 159, 164], ["IFNL3", "GENE_OR_GENE_PRODUCT", 166, 171], ["IFNL1", "GENE_OR_GENE_PRODUCT", 176, 181], ["interleukin 10 (IL-10) family", "PROTEIN", 49, 78], ["IL", "PROTEIN", 105, 107], ["IL", "PROTEIN", 124, 126], ["IFNL2", "PROTEIN", 159, 164], ["IFNL3", "PROTEIN", 166, 171], ["IFNL1", "PROTEIN", 176, 181], ["IL", "TEST", 113, 115], ["IL", "TEST", 124, 126]]], ["3 The genes encode IFN\u03bb-2, IFNL-\u03bb3 and IFNL-\u03bb1, respectively; together with the newly discovered IFNL-\u03bb4 (or IFNL4) they constitute the type III IFNs or the lambda IFNs (IFNL-\u03bbs).", [["IFN\u03bb-2", "GENE_OR_GENE_PRODUCT", 19, 25], ["IFNL-\u03bb3", "GENE_OR_GENE_PRODUCT", 27, 34], ["IFNL-\u03bb1", "GENE_OR_GENE_PRODUCT", 39, 46], ["IFNL-\u03bb4", "GENE_OR_GENE_PRODUCT", 97, 104], ["IFNL4", "GENE_OR_GENE_PRODUCT", 109, 114], ["type III IFNs", "GENE_OR_GENE_PRODUCT", 136, 149], ["lambda IFNs", "GENE_OR_GENE_PRODUCT", 157, 168], ["IFNL-\u03bbs", "GENE_OR_GENE_PRODUCT", 170, 177], ["IFN\u03bb-2", "DNA", 19, 25], ["IFNL", "PROTEIN", 27, 31], ["\u03bb3", "DNA", 32, 34], ["IFNL", "DNA", 39, 43], ["\u03bb1", "DNA", 44, 46], ["IFNL", "PROTEIN", 97, 101], ["\u03bb4", "PROTEIN", 102, 104], ["IFNL4", "DNA", 109, 114], ["type III IFNs", "PROTEIN", 136, 149], ["lambda IFNs", "PROTEIN", 157, 168], ["IFNL-\u03bbs", "PROTEIN", 170, 177], ["The genes encode IFN\u03bb", "TEST", 2, 23], ["IFNL", "TEST", 27, 31], ["the type III IFNs", "PROBLEM", 132, 149]]], ["IFNL-\u03bb1, 2 and 3 activate antiviral responses through the JAK-STAT (janus kinase-signal transducer and activator of transcription) pathway by utilizing a distinct receptor complex made of a heterodimer formed between IFN-\u03bbR1 and IL-10R2.", [["IFNL-\u03bb1", "GENE_OR_GENE_PRODUCT", 0, 7], ["2", "GENE_OR_GENE_PRODUCT", 9, 10], ["3", "GENE_OR_GENE_PRODUCT", 15, 16], ["JAK-STAT", "GENE_OR_GENE_PRODUCT", 58, 66], ["janus kinase-signal transducer and activator of transcription", "GENE_OR_GENE_PRODUCT", 68, 129], ["IFN-\u03bbR1", "GENE_OR_GENE_PRODUCT", 217, 224], ["IL-10R2", "GENE_OR_GENE_PRODUCT", 229, 236], ["IFNL", "PROTEIN", 0, 4], ["\u03bb1, 2 and 3", "PROTEIN", 5, 16], ["JAK", "PROTEIN", 58, 61], ["STAT", "PROTEIN", 62, 66], ["janus kinase", "PROTEIN", 68, 80], ["receptor complex", "PROTEIN", 163, 179], ["IFN", "PROTEIN", 217, 220], ["IL-10R2", "PROTEIN", 229, 236], ["IFNL", "TEST", 0, 4], ["the JAK", "TEST", 54, 61], ["STAT (janus kinase-signal transducer", "TREATMENT", 62, 98], ["a heterodimer", "TREATMENT", 188, 201], ["IFN", "TEST", 217, 220]]], ["2, 3 Subsequent studies showed that unlike the receptors that bind to type I IFNs, the IFN-\u03bb receptors were expressed on selective cell types mainly of epithelial origin, hepatocytes and some immune cells.", [["cell", "ANATOMY", 131, 135], ["epithelial origin", "ANATOMY", 152, 169], ["hepatocytes", "ANATOMY", 171, 182], ["immune cells", "ANATOMY", 192, 204], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 70, 81], ["IFN-\u03bb receptors", "GENE_OR_GENE_PRODUCT", 87, 102], ["cell", "CELL", 131, 135], ["epithelial", "CELL", 152, 162], ["hepatocytes", "CELL", 171, 182], ["immune cells", "CELL", 192, 204], ["type I IFNs", "PROTEIN", 70, 81], ["IFN-\u03bb receptors", "PROTEIN", 87, 102], ["epithelial origin", "CELL_TYPE", 152, 169], ["hepatocytes", "CELL_TYPE", 171, 182], ["immune cells", "CELL_TYPE", 192, 204], ["Subsequent studies", "TEST", 5, 23], ["type I IFNs", "PROBLEM", 70, 81], ["the IFN-\u03bb receptors", "TREATMENT", 83, 102], ["epithelial origin", "PROBLEM", 152, 169], ["hepatocytes", "PROBLEM", 171, 182], ["some immune cells", "PROBLEM", 187, 204], ["selective cell types", "OBSERVATION", 121, 141], ["epithelial", "ANATOMY_MODIFIER", 152, 162], ["origin", "ANATOMY_MODIFIER", 163, 169], ["hepatocytes", "ANATOMY", 171, 182], ["immune cells", "OBSERVATION", 192, 204]]], ["[3] [4] [5] [6] The discovery of IFN-\u03bbs was seminal in the sense that it showed the presence of an alternate system to the well-known type I IFNs (IFN-\u03b1 and IFN-\u03b2) that the different nucleated cells in the body, especially the ones on epithelial surfaces, can utilize to combat viral infections.", [["nucleated cells", "ANATOMY", 183, 198], ["body", "ANATOMY", 206, 210], ["epithelial surfaces", "ANATOMY", 235, 254], ["viral infections", "DISEASE", 278, 294], ["[3] [4] [5] [6]", "SIMPLE_CHEMICAL", 0, 15], ["IFN-\u03bbs", "GENE_OR_GENE_PRODUCT", 33, 39], ["seminal", "ORGANISM_SUBSTANCE", 44, 51], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 134, 145], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 147, 152], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 157, 162], ["nucleated cells", "CELL", 183, 198], ["body", "ORGANISM_SUBDIVISION", 206, 210], ["epithelial surfaces", "TISSUE", 235, 254], ["IFN", "PROTEIN", 33, 36], ["\u03bbs", "PROTEIN", 37, 39], ["type I IFNs", "PROTEIN", 134, 145], ["IFN", "PROTEIN", 147, 150], ["\u03b1", "PROTEIN", 151, 152], ["IFN-\u03b2", "PROTEIN", 157, 162], ["nucleated cells", "CELL_TYPE", 183, 198], ["IFN", "TEST", 33, 36], ["type I IFNs", "PROBLEM", 134, 145], ["IFN", "TEST", 147, 150], ["the different nucleated cells in the body", "PROBLEM", 169, 210], ["viral infections", "PROBLEM", 278, 294], ["nucleated cells", "OBSERVATION", 183, 198], ["body", "ANATOMY", 206, 210]]], ["Later studies in mice have shown that type III IFNs form a strong barrier at the host-environment interface, which encompasses large regions of epithelial lining to the respiratory, gastrointestinal and urogenital tracts of mammals.", [["epithelial lining", "ANATOMY", 144, 161], ["respiratory", "ANATOMY", 169, 180], ["gastrointestinal", "ANATOMY", 182, 198], ["urogenital tracts", "ANATOMY", 203, 220], ["mice", "ORGANISM", 17, 21], ["type III IFNs", "GENE_OR_GENE_PRODUCT", 38, 51], ["epithelial lining", "TISSUE", 144, 161], ["gastrointestinal", "ORGAN", 182, 198], ["urogenital tracts", "MULTI-TISSUE_STRUCTURE", 203, 220], ["type III IFNs", "PROTEIN", 38, 51], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["Later studies", "TEST", 0, 13], ["type III IFNs", "PROBLEM", 38, 51], ["strong", "OBSERVATION_MODIFIER", 59, 65], ["large", "OBSERVATION_MODIFIER", 127, 132], ["epithelial lining", "OBSERVATION", 144, 161], ["respiratory", "ANATOMY", 169, 180], ["gastrointestinal", "ANATOMY", 182, 198], ["urogenital tracts", "ANATOMY", 203, 220]]], ["[7] [8] [9] [10] A major boost in the area of IFN-\u03bb research came after another discovery in the year 2009.", [["[7] [8] [9] [10] A", "SIMPLE_CHEMICAL", 0, 18], ["IFN", "PROTEIN", 46, 49]]], ["Three independent groups conducted genome-wide association studies (GWASs) involving treatment response to chronic hepatitis C virus (HCV) infections, in three different geographical regions of the world, and reported that single-nucleotide polymorphisms (SNPs) in the IFNL locus (Figure 1 ), had strong association with treatment-induced HCV clearance irrespective of ethnicity and geographical location of the hosts.", [["chronic hepatitis C virus (HCV) infections", "DISEASE", 107, 149], ["chronic hepatitis C virus", "ORGANISM", 107, 132], ["IFNL", "GENE_OR_GENE_PRODUCT", 269, 273], ["Figure 1", "GENE_OR_GENE_PRODUCT", 281, 289], ["HCV", "ORGANISM", 339, 342], ["IFNL locus", "DNA", 269, 279], ["hepatitis C virus", "SPECIES", 115, 132], ["hepatitis C virus", "SPECIES", 115, 132], ["HCV", "SPECIES", 134, 137], ["HCV", "SPECIES", 339, 342], ["chronic hepatitis C virus (HCV) infections", "PROBLEM", 107, 149], ["single-nucleotide polymorphisms (SNPs)", "PROBLEM", 223, 261], ["treatment", "TREATMENT", 321, 330], ["HCV clearance", "PROBLEM", 339, 352], ["chronic", "OBSERVATION_MODIFIER", 107, 114], ["hepatitis", "OBSERVATION", 115, 124], ["HCV", "OBSERVATION", 339, 342]]], ["[11] [12] [13] The search for a 'causative' or a 'functional' SNP at the IFNL locus that could give a biological explanation for the HCV-GWAS results was taken up rigorously by several groups, but none seem to have given a better explanation to the HCV-IFN-\u03bb 'puzzle' than the group from the National Institutes of Health, USA, that discovered the presence of another IFNL upstream to IFNL3, named as IFNL4 (refs 14,15; Figure 1 ; in Figure 1b , the alleles for the respective SNPs are shown as beneficial (B) or non-beneficial (NB) with respect to the studies on HCV (reviewed in ref.", [["SNP", "CHEMICAL", 62, 65], ["IFNL", "GENE_OR_GENE_PRODUCT", 73, 77], ["IFNL", "GENE_OR_GENE_PRODUCT", 368, 372], ["IFNL3", "GENE_OR_GENE_PRODUCT", 385, 390], ["IFNL4", "GENE_OR_GENE_PRODUCT", 401, 406], ["NB", "CANCER", 529, 531], ["HCV", "ORGANISM", 564, 567], ["IFNL locus", "DNA", 73, 83], ["IFN", "PROTEIN", 253, 256], ["IFNL", "PROTEIN", 368, 372], ["IFNL3", "DNA", 385, 390], ["IFNL4", "DNA", 401, 406], ["refs 14,15; Figure 1", "DNA", 408, 428], ["HCV", "SPECIES", 133, 136], ["HCV", "SPECIES", 564, 567], ["a 'functional' SNP", "TREATMENT", 47, 65], ["the HCV", "PROBLEM", 129, 136], ["the respective SNPs", "PROBLEM", 462, 481], ["the studies", "TEST", 549, 560], ["HCV", "PROBLEM", 564, 567]]], ["15 ; the major allele for each of the SNPs depicted in Figure 1b has been shown to be the beneficial one in HCV infections).", [["HCV infections", "DISEASE", 108, 122], ["HCV", "ORGANISM", 108, 111], ["HCV", "SPECIES", 108, 111], ["the SNPs", "PROBLEM", 34, 42], ["HCV infections", "PROBLEM", 108, 122], ["infections", "OBSERVATION", 112, 122]]], ["Functional IFN-\u03bb4 is expressed only in a subset of individuals, due to a frameshiftcausing deletion polymorphism (IFNL4-\u0394G; rs368234815) in the first exon of IFNL4 (Figure 1 ).", [["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 11, 17], ["IFNL4-\u0394G", "GENE_OR_GENE_PRODUCT", 114, 122], ["IFN", "PROTEIN", 11, 14], ["\u03bb4", "PROTEIN", 15, 17], ["frameshiftcausing deletion polymorphism", "DNA", 73, 112], ["IFNL4", "DNA", 114, 119], ["IFNL4", "DNA", 158, 163], ["a frameshiftcausing deletion polymorphism", "PROBLEM", 71, 112]]], ["14 The presence of the alternate allele (IFNL4-TT) renders IFNL4 a pseudogene and this allele is seen i\u00f1 50% of the European population and in most of the east Asian population, but IFNL4 is a functional gene (IFNL4-\u0394G allele) in majority (~95%) of the African population, 16 suggesting that human evolution has played an active role in elimination of a functional IFN-\u03bb4 in the human species.", [["IFNL4-TT", "GENE_OR_GENE_PRODUCT", 41, 49], ["IFNL4", "GENE_OR_GENE_PRODUCT", 59, 64], ["IFNL4", "GENE_OR_GENE_PRODUCT", 182, 187], ["IFNL4-\u0394G", "GENE_OR_GENE_PRODUCT", 210, 218], ["human", "ORGANISM", 292, 297], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 365, 371], ["human", "ORGANISM", 379, 384], ["alternate allele", "DNA", 23, 39], ["IFNL4", "DNA", 41, 46], ["TT", "DNA", 47, 49], ["IFNL4", "DNA", 59, 64], ["allele", "DNA", 87, 93], ["IFNL4", "DNA", 182, 187], ["functional gene", "DNA", 193, 208], ["IFNL4", "DNA", 210, 215], ["\u0394G allele", "DNA", 216, 225], ["IFN", "PROTEIN", 365, 368], ["\u03bb4", "PROTEIN", 369, 371], ["human", "SPECIES", 292, 297], ["human", "SPECIES", 379, 384], ["human", "SPECIES", 292, 297], ["human", "SPECIES", 379, 384], ["the alternate allele (IFNL4-TT)", "TREATMENT", 19, 50], ["a functional IFN", "TEST", 352, 368], ["active", "OBSERVATION_MODIFIER", 322, 328]]], ["17 In fact, the pseudogene shows strong positive selection in human evolution, whereas the functional gene is conserved in other mammalian species except in mice and rats where the gene is completely absent.", [["human", "ORGANISM", 62, 67], ["mice", "ORGANISM", 157, 161], ["rats", "ORGANISM", 166, 170], ["human", "SPECIES", 62, 67], ["mice", "SPECIES", 157, 161], ["rats", "SPECIES", 166, 170], ["human", "SPECIES", 62, 67], ["mice", "SPECIES", 157, 161], ["the pseudogene", "TEST", 12, 26], ["strong positive selection in human evolution", "PROBLEM", 33, 77], ["strong", "OBSERVATION_MODIFIER", 33, 39], ["positive", "OBSERVATION_MODIFIER", 40, 48], ["selection", "OBSERVATION", 49, 58], ["human evolution", "OBSERVATION_MODIFIER", 62, 77], ["mammalian species", "OBSERVATION", 129, 146], ["absent", "OBSERVATION", 200, 206]]], ["17 In this article, I review the literature on genetic association studies that have shown the involvement of the HCV-GWAS SNPs in non-HCV disorders that involve both viral diseases and some non-infectious conditions.", [["non-HCV disorders", "DISEASE", 131, 148], ["viral diseases", "DISEASE", 167, 181], ["HCV", "ORGANISM", 114, 117], ["HCV-GWAS SNPs", "DNA", 114, 127], ["HCV", "SPECIES", 114, 117], ["non-HCV", "SPECIES", 131, 138], ["genetic association studies", "TEST", 47, 74], ["the HCV", "PROBLEM", 110, 117], ["GWAS SNPs", "PROBLEM", 118, 127], ["non-HCV disorders", "PROBLEM", 131, 148], ["both viral diseases", "PROBLEM", 162, 181], ["some non-infectious conditions", "PROBLEM", 186, 216], ["HCV", "OBSERVATION", 114, 117], ["both", "OBSERVATION_MODIFIER", 162, 166], ["viral diseases", "OBSERVATION", 167, 181], ["non-infectious", "OBSERVATION", 191, 205]]], ["I also update the progress on transcriptional studies of the IFNL4 gene and examine whether the functional IFN-\u03bb4-generating SNP is sufficient to explain the molecular mechanism of causality in the diseases it is associated with, and whether the other IFNL locus SNPs (mainly the ones regulating IFN-\u03bb3 expression) may have any functional roles to play in the observed phenotypes.GENETIC ASSOCIATION OF IFNL LOCUS POLYMORPHISMS IS NOT LIMITED TO HCV INFECTIONS: INNATE IMMUNITY IS THE KEYIFNL-\u03bbs and innate immunity against viruses Innate and adaptive immunity are the two indispensable arms of the mammalian immune system.", [["immune system", "ANATOMY", 609, 622], ["SNP", "CHEMICAL", 125, 128], ["IFNL4", "GENE_OR_GENE_PRODUCT", 61, 66], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 107, 113], ["IFNL", "GENE_OR_GENE_PRODUCT", 252, 256], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 296, 302], ["KEYIFNL-\u03bbs", "CELL", 485, 495], ["immune system", "ANATOMICAL_SYSTEM", 609, 622], ["IFNL4 gene", "DNA", 61, 71], ["IFN", "PROTEIN", 107, 110], ["\u03bb4", "PROTEIN", 111, 113], ["IFNL locus SNPs", "DNA", 252, 267], ["IFN", "PROTEIN", 296, 299], ["\u03bb3", "PROTEIN", 300, 302], ["transcriptional studies", "TEST", 30, 53], ["the functional IFN", "TEST", 92, 110], ["SNP", "TREATMENT", 125, 128], ["the diseases", "PROBLEM", 194, 206], ["the other IFNL locus SNPs", "PROBLEM", 242, 267], ["HCV INFECTIONS", "PROBLEM", 446, 460], ["innate immunity", "TREATMENT", 500, 515], ["viruses Innate and adaptive immunity", "TREATMENT", 524, 560], ["diseases", "OBSERVATION", 198, 206], ["mammalian immune", "OBSERVATION", 599, 615]]], ["Although we had a clearer understanding of the principles of functioning of the adaptive immunity arm, a lack of advanced molecular techniques and incomplete understanding of molecular mechanisms made us remain unaware of the intricacies of functioning of the innate immunity arm, for a long time.", [["the adaptive immunity arm", "TREATMENT", 76, 101], ["advanced molecular techniques", "PROBLEM", 113, 142]]], ["18 With the advent of superior molecular biology techniques and the discovery of the pathogenassociated molecular pattern (PAMP) or pattern recognition receptors, 19 we now have better understanding of how nucleated cells can differentially recognize different classes of pathogens and propagate signals to their surroundings, in the process raising the immediate alarm in the host.", [["cells", "ANATOMY", 216, 221], ["PAMP", "GENE_OR_GENE_PRODUCT", 123, 127], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 132, 161], ["nucleated cells", "CELL", 206, 221], ["pathogenassociated molecular pattern", "PROTEIN", 85, 121], ["PAMP", "PROTEIN", 123, 127], ["pattern recognition receptors", "PROTEIN", 132, 161], ["nucleated cells", "CELL_TYPE", 206, 221]]], ["19 Large strides were made in the area of molecular recognition of viral PAMPs and signal transduction that leads to raising of antiviral states within virusinfected cells.", [["cells", "ANATOMY", 166, 171], ["virusinfected cells", "CELL", 152, 171], ["viral PAMPs", "PROTEIN", 67, 78], ["virusinfected cells", "CELL_TYPE", 152, 171], ["Large strides", "PROBLEM", 3, 16], ["viral PAMPs", "PROBLEM", 67, 78], ["signal transduction", "PROBLEM", 83, 102], ["antiviral states within virusinfected cells", "PROBLEM", 128, 171], ["Large", "OBSERVATION_MODIFIER", 3, 8], ["strides", "OBSERVATION", 9, 16], ["viral PAMPs", "OBSERVATION", 67, 78]]], ["10, 20 The epithelial cells, being at the interface between the host and the environment in the respiratory, gastrointestinal and the urogenital tract, are not only prone to a variety of viral infections but are strategically located to respond and propagate alarm signals to the underlying immune cells ( Figure 2) .", [["epithelial cells", "ANATOMY", 11, 27], ["respiratory", "ANATOMY", 96, 107], ["gastrointestinal", "ANATOMY", 109, 125], ["urogenital tract", "ANATOMY", 134, 150], ["immune cells", "ANATOMY", 291, 303], ["infections", "DISEASE", 193, 203], ["epithelial cells", "CELL", 11, 27], ["gastrointestinal", "ORGAN", 109, 125], ["urogenital tract", "ORGAN", 134, 150], ["immune cells", "CELL", 291, 303], ["epithelial cells", "CELL_TYPE", 11, 27], ["immune cells", "CELL_TYPE", 291, 303], ["The epithelial cells", "PROBLEM", 7, 27], ["viral infections", "PROBLEM", 187, 203], ["epithelial cells", "OBSERVATION", 11, 27], ["host", "OBSERVATION_MODIFIER", 64, 68], ["environment", "OBSERVATION_MODIFIER", 77, 88], ["respiratory", "ANATOMY", 96, 107], ["gastrointestinal", "ANATOMY", 109, 125], ["urogenital tract", "ANATOMY", 134, 150], ["viral", "OBSERVATION_MODIFIER", 187, 192], ["infections", "OBSERVATION", 193, 203], ["immune cells", "OBSERVATION", 291, 303]]], ["However, the primary function of the epithelium is to provide a physical barrier between the underlying lamina propria and the lumen of the cavity or the exterior.", [["epithelium", "ANATOMY", 37, 47], ["lamina propria", "ANATOMY", 104, 118], ["lumen", "ANATOMY", 127, 132], ["cavity", "ANATOMY", 140, 146], ["epithelium", "TISSUE", 37, 47], ["lamina propria", "TISSUE", 104, 118], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 127, 132], ["cavity", "ORGAN", 140, 146], ["a physical barrier", "TREATMENT", 62, 80], ["lamina propria", "ANATOMY", 104, 118], ["lumen", "ANATOMY_MODIFIER", 127, 132], ["cavity", "OBSERVATION", 140, 146], ["exterior", "ANATOMY_MODIFIER", 154, 162]]], ["Even though they can sense and respond to PAMPs and damage-associated molecular patterns, 21 the epithelial cells are not professional immune cells and due to their high level of differentiation, may lack the plasticity required to send out amplified and prolonged signals to the lamina propria.", [["epithelial cells", "ANATOMY", 97, 113], ["immune cells", "ANATOMY", 135, 147], ["lamina propria", "ANATOMY", 280, 294], ["epithelial cells", "CELL", 97, 113], ["immune cells", "CELL", 135, 147], ["lamina propria", "TISSUE", 280, 294], ["PAMPs", "PROTEIN", 42, 47], ["epithelial cells", "CELL_TYPE", 97, 113], ["professional immune cells", "CELL_TYPE", 122, 147], ["PAMPs", "TEST", 42, 47], ["damage", "TEST", 52, 58], ["professional immune cells", "PROBLEM", 122, 147], ["epithelial cells", "OBSERVATION", 97, 113], ["immune cells", "OBSERVATION", 135, 147], ["lamina propria", "ANATOMY", 280, 294]]], ["Therefore, a crucial link still remained missing about how an adaptive immune response is shaped within distantly located lymph nodes that have obligatory 'immune-rich environments', by taking cues from signals generated by viral infections at the epithelium ( Figure 2 ).GENETIC ASSOCIATION OF IFNL LOCUS POLYMORPHISMS IS NOT LIMITED TO HCV INFECTIONS: INNATE IMMUNITY IS THE KEYThe discovery of the new class of effector immune cells called the innate lymphoid cells (ILCs) may seem to have provided the answer to this puzzle ( Figure 2 ).", [["lymph nodes", "ANATOMY", 122, 133], ["epithelium", "ANATOMY", 248, 258], ["immune cells", "ANATOMY", 423, 435], ["innate lymphoid cells", "ANATOMY", 447, 468], ["ILCs", "ANATOMY", 470, 474], ["viral infections", "DISEASE", 224, 240], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 122, 133], ["epithelium", "TISSUE", 248, 258], ["immune cells", "CELL", 423, 435], ["innate lymphoid cells", "CELL", 447, 468], ["ILCs", "CELL", 470, 474], ["effector immune cells", "CELL_TYPE", 414, 435], ["innate lymphoid cells", "CELL_TYPE", 447, 468], ["ILCs", "CELL_TYPE", 470, 474], ["viral infections", "PROBLEM", 224, 240], ["effector immune cells", "TREATMENT", 414, 435], ["the innate lymphoid cells", "TREATMENT", 443, 468], ["shaped", "OBSERVATION_MODIFIER", 90, 96], ["lymph nodes", "OBSERVATION", 122, 133], ["viral infections", "OBSERVATION", 224, 240], ["new", "OBSERVATION_MODIFIER", 401, 404], ["effector immune cells", "OBSERVATION", 414, 435], ["innate lymphoid cells", "OBSERVATION", 447, 468]]], ["ILCs are derivatives of common lymphoid precursors along with T and B cells.", [["ILCs", "ANATOMY", 0, 4], ["lymphoid precursors", "ANATOMY", 31, 50], ["T", "ANATOMY", 62, 63], ["B cells", "ANATOMY", 68, 75], ["ILCs", "CELL", 0, 4], ["lymphoid precursors", "CELL", 31, 50], ["T", "CELL", 62, 63], ["B cells", "CELL", 68, 75], ["ILCs", "CELL_TYPE", 0, 4], ["common lymphoid precursors", "CELL_TYPE", 24, 50], ["T and B cells", "CELL_TYPE", 62, 75], ["common lymphoid precursors", "PROBLEM", 24, 50], ["T and B cells", "TREATMENT", 62, 75], ["common lymphoid precursors", "OBSERVATION", 24, 50]]], ["22 These cells are stationed near the epithelial surfaces in larger numbers and respond to signals from the surrounding cells by secreting cytokines and chemokines in large quantities, thereby acting as signal amplifiers in both health and disease.", [["cells", "ANATOMY", 9, 14], ["epithelial surfaces", "ANATOMY", 38, 57], ["cells", "ANATOMY", 120, 125], ["cells", "CELL", 9, 14], ["epithelial surfaces", "TISSUE", 38, 57], ["cells", "CELL", 120, 125], ["cytokines", "PROTEIN", 139, 148], ["chemokines", "PROTEIN", 153, 163], ["secreting cytokines", "TREATMENT", 129, 148], ["disease", "PROBLEM", 240, 247], ["epithelial", "ANATOMY_MODIFIER", 38, 48], ["surfaces", "OBSERVATION_MODIFIER", 49, 57], ["larger", "OBSERVATION_MODIFIER", 61, 67], ["numbers", "OBSERVATION_MODIFIER", 68, 75], ["secreting cytokines", "OBSERVATION", 129, 148], ["large quantities", "OBSERVATION_MODIFIER", 167, 183]]], ["23 The ILCs are considered the innate immunity counterparts to the various Th (T helper) cell (CD4+ (cluster of differentiation)) subsets of the adaptive immune system (Figure 2 ; ref.", [["ILCs", "ANATOMY", 7, 11], ["Th (T helper) cell", "ANATOMY", 75, 93], ["ILCs", "CELL", 7, 11], ["T helper) cell", "CELL", 79, 93], ["CD4", "GENE_OR_GENE_PRODUCT", 95, 98], ["ILCs", "CELL_TYPE", 7, 11], ["Th (T helper) cell", "CELL_TYPE", 75, 93], ["CD4", "PROTEIN", 95, 98], ["CD4", "TEST", 95, 98], ["ILCs", "OBSERVATION", 7, 11]]], ["For example, ILC2s respond to IL-33 generated from influenza virus-infected epithelial cells by secreting IL-5 and IL-13, both known inducers of Th2 immunity.", [["epithelial cells", "ANATOMY", 76, 92], ["influenza virus-infected", "DISEASE", 51, 75], ["ILC2s", "GENE_OR_GENE_PRODUCT", 13, 18], ["IL-33", "GENE_OR_GENE_PRODUCT", 30, 35], ["influenza virus", "ORGANISM", 51, 66], ["epithelial cells", "CELL", 76, 92], ["IL-5", "GENE_OR_GENE_PRODUCT", 106, 110], ["IL-13", "GENE_OR_GENE_PRODUCT", 115, 120], ["Th2", "GENE_OR_GENE_PRODUCT", 145, 148], ["ILC2s", "PROTEIN", 13, 18], ["IL-33", "PROTEIN", 30, 35], ["infected epithelial cells", "CELL_TYPE", 67, 92], ["IL", "PROTEIN", 106, 108], ["IL-13", "PROTEIN", 115, 120], ["influenza virus", "SPECIES", 51, 66], ["ILC2s", "PROBLEM", 13, 18], ["IL", "TEST", 30, 32], ["influenza virus", "PROBLEM", 51, 66], ["infected epithelial cells", "PROBLEM", 67, 92], ["secreting IL", "TEST", 96, 108], ["IL", "TEST", 115, 117], ["ILC2s", "OBSERVATION", 13, 18], ["influenza virus", "OBSERVATION", 51, 66], ["epithelial cells", "OBSERVATION", 76, 92], ["Th2 immunity", "OBSERVATION", 145, 157]]], ["25 The natural killer cells, now classified as ILC1 cells, are considered the Tc (T cytotoxic) cell (CD8+) counterparts.", [["natural killer cells", "ANATOMY", 7, 27], ["ILC1 cells", "ANATOMY", 47, 57], ["T cytotoxic) cell", "ANATOMY", 82, 99], ["CD8+) counterparts", "ANATOMY", 101, 119], ["natural killer cells", "CELL", 7, 27], ["ILC1 cells", "CELL", 47, 57], ["T cytotoxic) cell", "CELL", 82, 99], ["CD8", "GENE_OR_GENE_PRODUCT", 101, 104], ["natural killer cells", "CELL_TYPE", 7, 27], ["ILC1 cells", "CELL_LINE", 47, 57], ["Tc (T cytotoxic) cell (CD8+) counterparts", "CELL_TYPE", 78, 119], ["The natural killer cells", "TREATMENT", 3, 27], ["ILC1 cells", "PROBLEM", 47, 57], ["the Tc", "TEST", 74, 80], ["natural killer cells", "OBSERVATION", 7, 27]]], ["24 Even though most studies so far on ILCs have been on mice, ILCs have also been characterized in a variety of human tissues 26 and are deregulated in many human diseases.", [["ILCs", "ANATOMY", 38, 42], ["ILCs", "ANATOMY", 62, 66], ["tissues", "ANATOMY", 118, 125], ["ILCs", "CELL", 38, 42], ["mice", "ORGANISM", 56, 60], ["ILCs", "CELL", 62, 66], ["human", "ORGANISM", 112, 117], ["tissues", "TISSUE", 118, 125], ["human", "ORGANISM", 157, 162], ["ILCs", "CELL_TYPE", 38, 42], ["ILCs", "CELL_TYPE", 62, 66], ["mice", "SPECIES", 56, 60], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 157, 162], ["mice", "SPECIES", 56, 60], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 157, 162], ["many human diseases", "PROBLEM", 152, 171], ["many human", "OBSERVATION_MODIFIER", 152, 162], ["diseases", "OBSERVATION", 163, 171]]], ["27 With emerging roles of type III IFNs at the epithelium, 8, 10, 28 ILCs and IFN-\u03bbs now seem to be the major players in innate immunity at barrier surfaces.", [["epithelium", "ANATOMY", 47, 57], ["ILCs", "ANATOMY", 69, 73], ["type III IFNs", "GENE_OR_GENE_PRODUCT", 26, 39], ["epithelium", "TISSUE", 47, 57], ["ILCs", "CELL", 69, 73], ["IFN-\u03bbs", "GENE_OR_GENE_PRODUCT", 78, 84], ["barrier surfaces", "MULTI-TISSUE_STRUCTURE", 140, 156], ["type III IFNs", "PROTEIN", 26, 39], ["IFN", "PROTEIN", 78, 81], ["\u03bbs", "PROTEIN", 82, 84], ["type III IFNs at the epithelium", "PROBLEM", 26, 57], ["IFN", "TEST", 78, 81], ["type III", "OBSERVATION_MODIFIER", 26, 34], ["epithelium", "ANATOMY_MODIFIER", 47, 57]]], ["The minor allele (Mi) is the non-beneficial allele (that leads to expression of a functional IFN-\u03bb4 and also lowers expression of IFN-\u03bb3) and the major allele (Ma) is the beneficial allele (that does not produce a functional IFN-\u03bb4 and is associated with higher levels of expression of IFN-\u03bb3) for all SNPs, again with respect to HCV studies.", [["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 93, 99], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 130, 136], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 225, 231], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 286, 292], ["allele", "DNA", 10, 16], ["Mi", "DNA", 18, 20], ["non-beneficial allele", "DNA", 29, 50], ["IFN", "PROTEIN", 93, 96], ["\u03bb4", "PROTEIN", 97, 99], ["IFN", "PROTEIN", 130, 133], ["\u03bb3", "PROTEIN", 134, 136], ["major allele", "DNA", 146, 158], ["Ma", "DNA", 160, 162], ["allele", "DNA", 182, 188], ["IFN", "PROTEIN", 225, 228], ["\u03bb4", "PROTEIN", 229, 231], ["IFN", "PROTEIN", 286, 289], ["\u03bb3", "PROTEIN", 290, 292], ["HCV", "SPECIES", 330, 333], ["The minor allele (Mi", "PROBLEM", 0, 20], ["a functional IFN", "TEST", 80, 96], ["IFN", "TEST", 130, 133], ["IFN", "TEST", 286, 289], ["all SNPs", "PROBLEM", 298, 306], ["HCV studies", "TEST", 330, 341]]], ["15 The information on LD values has been obtained from 1000 Genomes Project reference panel (http://www.1000genomes.org), October 2014 release; some LD (r 2 ) values for YRI (marked with *) were obtained from ref.", [["LD values", "TEST", 22, 31], ["YRI", "PROBLEM", 170, 173]]], ["The MAF values were obtained from dbSNP (National Center for Biotechnology Information).", [["MAF", "DNA", 4, 7], ["The MAF values", "TEST", 0, 14]]], ["In Asian population, MAFs of rs12979860, rs8099917 and rs4803217 are from JPT population; and MAFs of rs368234815, rs8103142 and rs28416813 are from CHB-JPT populations.", [["rs8099917", "GENE_OR_GENE_PRODUCT", 41, 50], ["rs4803217", "GENE_OR_GENE_PRODUCT", 55, 64], ["rs368234815", "GENE_OR_GENE_PRODUCT", 102, 113], ["rs28416813", "GENE_OR_GENE_PRODUCT", 129, 139], ["rs12979860", "TEST", 29, 39], ["rs8099917", "TEST", 41, 50], ["MAFs", "TEST", 94, 98], ["CHB", "TEST", 149, 152]]], ["YRI, Yoruba in Ibadan, Nigeria; CEU, residents with ancestry from northern and western Europe; CHB/JPT, Han Chinese in Beijing, China/Japanese in Tokyo, Japan; -, MAF information not available for the TA repeat polymorphism rs59702201.GENETIC ASSOCIATION OF IFNL LOCUS POLYMORPHISMS IS NOT LIMITED TO HCV INFECTIONS: INNATE IMMUNITY IS THE KEYHow ILCs respond and interact with the epithelial cells during viral infections and how they cross-talk with other immune cells at the barrier surfaces in shaping and maintaining the optimal Th responses, will form the next exciting wave in innate immunity research.GENETIC ASSOCIATION OF IFNL LOCUS POLYMORPHISMS IS NOT LIMITED TO HCV INFECTIONS: INNATE IMMUNITY IS THE KEYSimilarly, research on the production, regulation and functions of IFN-\u03bbs in viral infections has also been exciting in the last decade.", [["ILCs", "ANATOMY", 347, 351], ["epithelial cells", "ANATOMY", 382, 398], ["immune cells", "ANATOMY", 458, 470], ["viral infections", "DISEASE", 406, 422], ["viral infections", "DISEASE", 794, 810], ["KEYHow ILCs", "CELL", 340, 351], ["epithelial cells", "CELL", 382, 398], ["immune cells", "CELL", 458, 470], ["barrier surfaces", "TISSUE", 478, 494], ["IFN-\u03bbs", "GENE_OR_GENE_PRODUCT", 784, 790], ["TA repeat polymorphism rs59702201", "DNA", 201, 234], ["ILCs", "CELL_TYPE", 347, 351], ["epithelial cells", "CELL_TYPE", 382, 398], ["immune cells", "CELL_TYPE", 458, 470], ["IFN", "PROTEIN", 784, 787], ["\u03bbs", "PROTEIN", 788, 790], ["the TA repeat polymorphism", "TEST", 197, 223], ["HCV INFECTIONS", "PROBLEM", 301, 315], ["viral infections", "PROBLEM", 406, 422], ["other immune cells", "TREATMENT", 452, 470], ["the barrier surfaces", "TREATMENT", 474, 494], ["HCV INFECTIONS", "PROBLEM", 675, 689], ["IFN", "TREATMENT", 784, 787], ["viral infections", "PROBLEM", 794, 810], ["viral infections", "OBSERVATION", 794, 810]]], ["Human IFN-\u03bbs are secreted (except IFN-\u03bb4 that is poorly secreted 30 ) in response to the detection of viral RNA intermediates from the cytoplasm of epithelial cells via the toll-like receptor and retinoic acid inducible gene I-like receptor) pathways.", [["cytoplasm", "ANATOMY", 135, 144], ["epithelial cells", "ANATOMY", 148, 164], ["retinoic acid", "CHEMICAL", 196, 209], ["retinoic acid", "CHEMICAL", 196, 209], ["Human", "ORGANISM", 0, 5], ["IFN-\u03bbs", "GENE_OR_GENE_PRODUCT", 6, 12], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 34, 40], ["cytoplasm", "ORGANISM_SUBSTANCE", 135, 144], ["epithelial cells", "CELL", 148, 164], ["toll-like receptor", "GENE_OR_GENE_PRODUCT", 173, 191], ["retinoic acid inducible gene I-like receptor", "GENE_OR_GENE_PRODUCT", 196, 240], ["Human IFN-\u03bbs", "PROTEIN", 0, 12], ["IFN", "PROTEIN", 34, 37], ["\u03bb4", "PROTEIN", 38, 40], ["epithelial cells", "CELL_TYPE", 148, 164], ["toll-like receptor", "PROTEIN", 173, 191], ["retinoic acid inducible gene I-like receptor", "PROTEIN", 196, 240], ["Human", "SPECIES", 0, 5], ["Human IFN", "TEST", 0, 9], ["IFN", "TEST", 34, 37], ["viral RNA intermediates", "PROBLEM", 102, 125], ["epithelial cells", "PROBLEM", 148, 164], ["the toll-like receptor", "TREATMENT", 169, 191], ["retinoic acid inducible gene I", "TREATMENT", 196, 226], ["epithelial cells", "OBSERVATION", 148, 164]]], ["4, 7, 31 IFN-\u03bbs are also known to be secreted by macrophages, plasmacytoid dendritic cells, monocyte-derived dendritic cells and hepatocytes.", [["macrophages", "ANATOMY", 49, 60], ["plasmacytoid dendritic cells", "ANATOMY", 62, 90], ["monocyte", "ANATOMY", 92, 100], ["dendritic cells", "ANATOMY", 109, 124], ["hepatocytes", "ANATOMY", 129, 140], ["IFN-\u03bbs", "SIMPLE_CHEMICAL", 9, 15], ["macrophages", "CELL", 49, 60], ["plasmacytoid dendritic cells", "CELL", 62, 90], ["monocyte", "CELL", 92, 100], ["-derived dendritic cells", "CELL", 100, 124], ["hepatocytes", "CELL", 129, 140], ["IFN", "PROTEIN", 9, 12], ["\u03bbs", "PROTEIN", 13, 15], ["macrophages", "CELL_TYPE", 49, 60], ["plasmacytoid dendritic cells", "CELL_TYPE", 62, 90], ["monocyte-derived dendritic cells", "CELL_TYPE", 92, 124], ["hepatocytes", "CELL_TYPE", 129, 140], ["IFN", "TEST", 9, 12], ["plasmacytoid dendritic cells", "PROBLEM", 62, 90], ["monocyte", "TEST", 92, 100], ["dendritic cells", "PROBLEM", 109, 124], ["hepatocytes", "PROBLEM", 129, 140], ["macrophages", "OBSERVATION", 49, 60], ["plasmacytoid dendritic cells", "OBSERVATION", 62, 90], ["dendritic cells", "OBSERVATION", 109, 124], ["hepatocytes", "ANATOMY", 129, 140]]], ["4, 6, [32] [33] [34] The IFN-\u03bbR1 receptor is expressed on limited cell types including epithelial cells, hepatocytes, B cells and monocytes.", [["cell", "ANATOMY", 66, 70], ["epithelial cells", "ANATOMY", 87, 103], ["hepatocytes", "ANATOMY", 105, 116], ["B cells", "ANATOMY", 118, 125], ["monocytes", "ANATOMY", 130, 139], ["[32] [33] [34", "SIMPLE_CHEMICAL", 6, 19], ["IFN-\u03bbR1 receptor", "GENE_OR_GENE_PRODUCT", 25, 41], ["cell", "CELL", 66, 70], ["epithelial cells", "CELL", 87, 103], ["hepatocytes", "CELL", 105, 116], ["B cells", "CELL", 118, 125], ["monocytes", "CELL", 130, 139], ["IFN", "PROTEIN", 25, 28], ["\u03bbR1 receptor", "PROTEIN", 29, 41], ["epithelial cells", "CELL_TYPE", 87, 103], ["hepatocytes", "CELL_TYPE", 105, 116], ["B cells", "CELL_TYPE", 118, 125], ["monocytes", "CELL_TYPE", 130, 139], ["The IFN", "TEST", 21, 28], ["epithelial cells", "PROBLEM", 87, 103], ["hepatocytes", "TEST", 105, 116], ["monocytes", "TEST", 130, 139], ["limited cell", "OBSERVATION_MODIFIER", 58, 70], ["epithelial cells", "OBSERVATION", 87, 103], ["hepatocytes", "ANATOMY", 105, 116], ["B cells", "OBSERVATION", 118, 125]]], ["5, 35 There is currently no information on whether the newly discovered ILCs secrete any of the IFN-\u03bbs and whether they express IFN-\u03bbR1.", [["ILCs", "ANATOMY", 72, 76], ["ILCs", "CELL", 72, 76], ["IFN-\u03bbs", "GENE_OR_GENE_PRODUCT", 96, 102], ["IFN-\u03bbR1", "GENE_OR_GENE_PRODUCT", 128, 135], ["ILCs", "CELL_TYPE", 72, 76], ["IFN", "PROTEIN", 96, 99], ["\u03bbs", "PROTEIN", 100, 102], ["IFN", "PROTEIN", 128, 131], ["\u03bbR1", "PROTEIN", 132, 135]]], ["IFN-\u03bbs act in a paracrine and/or autocrine manner to raise an antiviral state in the infected and to-be-infected cells by reprogramming the target cell gene expression patterns.", [["cells", "ANATOMY", 113, 118], ["cell", "ANATOMY", 147, 151], ["IFN-\u03bbs", "GENE_OR_GENE_PRODUCT", 0, 6], ["cells", "CELL", 113, 118], ["cell", "CELL", 147, 151], ["IFN-\u03bbs", "PROTEIN", 0, 6], ["an antiviral state", "PROBLEM", 59, 77], ["infected cells", "PROBLEM", 104, 118], ["antiviral", "OBSERVATION", 62, 71], ["infected cells", "OBSERVATION", 104, 118], ["target cell gene expression", "OBSERVATION", 140, 167]]], ["28, 36 The IFNL SNPs would have functional roles if they can affect the diversification of innate and adaptive immune cell subsets.", [["immune cell", "ANATOMY", 111, 122], ["IFNL", "GENE_OR_GENE_PRODUCT", 11, 15], ["immune cell subsets", "CELL", 111, 130], ["IFNL SNPs", "DNA", 11, 20], ["innate and adaptive immune cell subsets", "CELL_TYPE", 91, 130], ["The IFNL SNPs", "TREATMENT", 7, 20], ["innate and adaptive immune cell subsets", "TREATMENT", 91, 130], ["immune cell subsets", "OBSERVATION", 111, 130]]], ["Diversification of ILC subsets will lead to the polarization of dendritic cells and macrophages and will eventually influence the Th1/Th2 balance by favoring either a Th1 or a Th2 response ( Figure 3 ).", [["ILC", "ANATOMY", 19, 22], ["dendritic cells", "ANATOMY", 64, 79], ["macrophages", "ANATOMY", 84, 95], ["ILC", "CANCER", 19, 22], ["dendritic cells", "CELL", 64, 79], ["macrophages", "CELL", 84, 95], ["ILC subsets", "CELL_TYPE", 19, 30], ["dendritic cells", "CELL_TYPE", 64, 79], ["macrophages", "CELL_TYPE", 84, 95], ["ILC subsets", "PROBLEM", 19, 30], ["dendritic cells", "PROBLEM", 64, 79], ["macrophages", "PROBLEM", 84, 95], ["ILC subsets", "OBSERVATION", 19, 30], ["dendritic cells", "OBSERVATION", 64, 79]]], ["37 Although there is no evidence for this belief, it is known that the IFNL SNPs do affect the expression of IFN-\u03bb3 (ref.", [["IFNL", "GENE_OR_GENE_PRODUCT", 71, 75], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 109, 115], ["IFNL SNPs", "DNA", 71, 80], ["IFN", "PROTEIN", 109, 112], ["\u03bb3", "PROTEIN", 113, 115], ["the IFNL SNPs", "PROBLEM", 67, 80], ["IFN", "TEST", 109, 112], ["no evidence for", "UNCERTAINTY", 21, 36]]], ["15 ) and that they give rise to a new IFN (IFN-\u03bb4).", [["IFN", "GENE_OR_GENE_PRODUCT", 38, 41], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 43, 49], ["IFN", "PROTEIN", 38, 41], ["IFN", "PROTEIN", 43, 46], ["\u03bb4", "PROTEIN", 47, 49], ["a new IFN (IFN", "TREATMENT", 32, 46], ["new", "OBSERVATION_MODIFIER", 34, 37]]], ["14 IFN-\u03bb1, 2 and 3 are known to deflect the Th1/Th2 balance to a Th1 predominant mode in vitro and also in vivo in humans and mice 38, 39 (reviewed in ref.", [["IFN-\u03bb1", "GENE_OR_GENE_PRODUCT", 3, 9], ["2", "GENE_OR_GENE_PRODUCT", 11, 12], ["3", "GENE_OR_GENE_PRODUCT", 17, 18], ["humans", "ORGANISM", 115, 121], ["mice", "ORGANISM", 126, 130], ["IFN", "PROTEIN", 3, 6], ["\u03bb1, 2 and 3", "PROTEIN", 7, 18], ["humans", "SPECIES", 115, 121], ["mice", "SPECIES", 126, 130], ["humans", "SPECIES", 115, 121], ["mice", "SPECIES", 126, 130], ["IFN", "TEST", 3, 6]]], ["No such studies are reported for IFN-\u03bb4.", [["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 33, 39], ["IFN", "PROTEIN", 33, 36], ["\u03bb4", "PROTEIN", 37, 39], ["such studies", "TEST", 3, 15], ["IFN", "TEST", 33, 36]]], ["One hypothesis is that different levels of IFN-\u03bb3 expression dictated by the underlying genetic polymorphisms are responsible for eliciting a Th1 or a Th2 response.", [["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 43, 49], ["IFN", "PROTEIN", 43, 46], ["\u03bb3", "PROTEIN", 47, 49], ["IFN", "TEST", 43, 46], ["the underlying genetic polymorphisms", "PROBLEM", 73, 109]]], ["37 The role played by IFN-\u03bb4 in this process is only speculative at this stage ( Figure 3 ).", [["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 22, 28], ["IFN", "PROTEIN", 22, 25], ["\u03bb4", "PROTEIN", 26, 28]]], ["How IFN-\u03bbs interact with the newly discovered ILCs is also unknown.", [["ILCs", "ANATOMY", 46, 50], ["IFN-\u03bbs", "GENE_OR_GENE_PRODUCT", 4, 10], ["ILCs", "CELL", 46, 50], ["IFN", "PROTEIN", 4, 7], ["\u03bbs", "PROTEIN", 8, 10], ["ILCs", "CELL_TYPE", 46, 50]]], ["A recent report showed that rotavirus infection in mice is controlled by IL-22 produced by ILC3s for which the presence of an intact IFN-\u03bb signaling pathway is required.", [["rotavirus infection", "DISEASE", 28, 47], ["rotavirus", "ORGANISM", 28, 37], ["mice", "ORGANISM", 51, 55], ["IL-22", "GENE_OR_GENE_PRODUCT", 73, 78], ["ILC3s", "GENE_OR_GENE_PRODUCT", 91, 96], ["IFN-\u03bb", "GENE_OR_GENE_PRODUCT", 133, 138], ["IL-22", "PROTEIN", 73, 78], ["ILC3s", "PROTEIN", 91, 96], ["IFN", "PROTEIN", 133, 136], ["\u03bb", "PROTEIN", 137, 138], ["mice", "SPECIES", 51, 55], ["rotavirus", "SPECIES", 28, 37], ["mice", "SPECIES", 51, 55], ["rotavirus infection", "PROBLEM", 28, 47], ["an intact IFN", "TREATMENT", 123, 136], ["rotavirus", "OBSERVATION_MODIFIER", 28, 37], ["infection", "OBSERVATION", 38, 47], ["intact", "OBSERVATION", 126, 132]]], ["40 An even more important question in humans will be on what role does the IFNL SNPs, and therefore IFN-\u03bb4, play in the diversification and functioning of ILCs.GENETIC ASSOCIATION OF IFNL LOCUS POLYMORPHISMS IS NOT LIMITED TO HCV INFECTIONS: INNATE IMMUNITY IS THE KEYIFN-\u03bb4 apart from being antiviral to HCV 14 is also known to inhibit other flaviviruses such as dengue virus, yellow fever virus 41 and human corona viruses.", [["ILCs", "ANATOMY", 155, 159], ["dengue virus", "DISEASE", 364, 376], ["yellow fever", "DISEASE", 378, 390], ["humans", "ORGANISM", 38, 44], ["IFNL", "GENE_OR_GENE_PRODUCT", 75, 79], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 100, 106], ["ILCs", "CELL", 155, 159], ["KEYIFN-\u03bb4", "ORGANISM", 265, 274], ["HCV 14", "ORGANISM", 305, 311], ["dengue virus", "ORGANISM", 364, 376], ["yellow fever virus 41", "ORGANISM", 378, 399], ["human", "ORGANISM", 404, 409], ["corona viruses", "ORGANISM", 410, 424], ["IFNL SNPs", "DNA", 75, 84], ["IFN", "PROTEIN", 100, 103], ["\u03bb4", "PROTEIN", 104, 106], ["ILCs", "CELL_TYPE", 155, 159], ["humans", "SPECIES", 38, 44], ["dengue virus", "SPECIES", 364, 376], ["yellow fever virus", "SPECIES", 378, 396], ["human", "SPECIES", 404, 409], ["humans", "SPECIES", 38, 44], ["HCV", "SPECIES", 305, 308], ["dengue virus", "SPECIES", 364, 376], ["yellow fever virus 41", "SPECIES", 378, 399], ["human corona viruses", "SPECIES", 404, 424], ["IFN", "TEST", 100, 103], ["HCV INFECTIONS", "PROBLEM", 226, 240], ["KEYIFN", "TEST", 265, 271], ["antiviral to HCV", "TREATMENT", 292, 308], ["other flaviviruses", "PROBLEM", 337, 355], ["dengue virus", "PROBLEM", 364, 376], ["yellow fever virus", "PROBLEM", 378, 396], ["human corona viruses", "PROBLEM", 404, 424], ["ILCs", "OBSERVATION", 155, 159], ["corona viruses", "OBSERVATION", 410, 424]]], ["30 Some of the other IFN-\u03bbs are known to be induced by several human pathogens including M. tuberculosis, 42 human papilloma virus, 43 influenza virus 44 and human metapneumovirus (also induces IFN-\u03bb4), 45 and have clear antiviral activities against some but not other viruses in mice (reviewed in ref.", [["M. tuberculosis", "DISEASE", 89, 104], ["human papilloma virus", "DISEASE", 109, 130], ["human metapneumovirus", "DISEASE", 158, 179], ["IFN-\u03bbs", "GENE_OR_GENE_PRODUCT", 21, 27], ["human", "ORGANISM", 63, 68], ["M. tuberculosis", "ORGANISM", 89, 104], ["42", "ORGANISM", 106, 108], ["human papilloma virus", "ORGANISM", 109, 130], ["43", "ORGANISM", 132, 134], ["influenza virus 44", "ORGANISM", 135, 153], ["human", "ORGANISM", 158, 163], ["metapneumovirus", "ORGANISM", 164, 179], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 194, 200], ["mice", "ORGANISM", 280, 284], ["IFN", "PROTEIN", 21, 24], ["\u03bbs", "PROTEIN", 25, 27], ["IFN", "PROTEIN", 194, 197], ["human", "SPECIES", 63, 68], ["M. tuberculosis", "SPECIES", 89, 104], ["human papilloma virus", "SPECIES", 109, 130], ["influenza virus", "SPECIES", 135, 150], ["human", "SPECIES", 158, 163], ["metapneumovirus", "SPECIES", 164, 179], ["mice", "SPECIES", 280, 284], ["human", "SPECIES", 63, 68], ["M. tuberculosis", "SPECIES", 89, 104], ["human papilloma virus", "SPECIES", 109, 130], ["human metapneumovirus", "SPECIES", 158, 179], ["mice", "SPECIES", 280, 284], ["several human pathogens", "PROBLEM", 55, 78], ["M. tuberculosis", "PROBLEM", 89, 104], ["42 human papilloma virus", "PROBLEM", 106, 130], ["influenza virus", "PROBLEM", 135, 150], ["human metapneumovirus", "PROBLEM", 158, 179], ["IFN", "TEST", 194, 197], ["clear antiviral activities", "TREATMENT", 215, 241], ["known to be", "UNCERTAINTY", 32, 43], ["tuberculosis", "OBSERVATION", 92, 104], ["papilloma virus", "OBSERVATION", 115, 130], ["antiviral", "OBSERVATION", 221, 230]]], ["In a recent finding, murine IFN-\u03bb3 but not IFN-\u03b1/IFN-\u03b2 was responsible for protecting mice against norovirus persistence in mice colon, strikingly, even in the absence of T and B lymphocytes.", [["colon", "ANATOMY", 129, 134], ["T", "ANATOMY", 171, 172], ["B lymphocytes", "ANATOMY", 177, 190], ["murine", "ORGANISM", 21, 27], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 28, 34], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 43, 48], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 49, 54], ["mice", "ORGANISM", 86, 90], ["norovirus", "ORGANISM", 99, 108], ["mice", "ORGANISM", 124, 128], ["colon", "ORGAN", 129, 134], ["T", "CELL", 171, 172], ["B lymphocytes", "CELL", 177, 190], ["IFN", "PROTEIN", 28, 31], ["\u03bb3", "PROTEIN", 32, 34], ["IFN", "PROTEIN", 43, 46], ["IFN", "PROTEIN", 49, 52], ["\u03b2", "PROTEIN", 53, 54], ["T and B lymphocytes", "CELL_TYPE", 171, 190], ["murine", "SPECIES", 21, 27], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 124, 128], ["mice", "SPECIES", 86, 90], ["norovirus", "SPECIES", 99, 108], ["mice", "SPECIES", 124, 128], ["murine IFN", "TEST", 21, 31], ["IFN", "TEST", 43, 46], ["IFN", "PROBLEM", 49, 52], ["norovirus persistence in mice colon", "PROBLEM", 99, 134], ["mice colon", "ANATOMY", 124, 134], ["lymphocytes", "ANATOMY", 179, 190]]], ["9 Similar results were seen in reovirus infections of mice colon.", [["colon", "ANATOMY", 59, 64], ["reovirus infections", "DISEASE", 31, 50], ["reovirus", "ORGANISM", 31, 39], ["mice", "ORGANISM", 54, 58], ["colon", "ORGAN", 59, 64], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 54, 58], ["reovirus infections of mice colon", "PROBLEM", 31, 64], ["infections", "OBSERVATION", 40, 50], ["colon", "ANATOMY", 59, 64]]], ["8 In conclusion, IFN-\u03bbs are potent antiviral molecules and their cross-talk with innate immune cells can potentially Figure 2 .", [["immune cells", "ANATOMY", 88, 100], ["IFN-\u03bbs", "GENE_OR_GENE_PRODUCT", 17, 23], ["innate immune cells", "CELL", 81, 100], ["IFN-\u03bbs", "PROTEIN", 17, 23], ["antiviral molecules", "PROTEIN", 35, 54], ["innate immune cells", "CELL_TYPE", 81, 100], ["IFN", "TREATMENT", 17, 20], ["potent antiviral molecules", "TREATMENT", 28, 54], ["innate immune cells", "TREATMENT", 81, 100]]], ["Immune responses to viral infections of the epithelia.", [["epithelia", "ANATOMY", 44, 53], ["viral infections", "DISEASE", 20, 36], ["epithelia", "TISSUE", 44, 53], ["viral infections of the epithelia", "PROBLEM", 20, 53], ["viral infections", "OBSERVATION", 20, 36], ["epithelia", "ANATOMY_MODIFIER", 44, 53]]], ["Resident macrophages and dendritic cells (DCs) form the first line of cellular resistance to invading viruses.", [["macrophages", "ANATOMY", 9, 20], ["dendritic cells", "ANATOMY", 25, 40], ["DCs", "ANATOMY", 42, 45], ["cellular", "ANATOMY", 70, 78], ["macrophages", "CELL", 9, 20], ["dendritic cells", "CELL", 25, 40], ["DCs", "CELL", 42, 45], ["cellular", "CELL", 70, 78], ["Resident macrophages", "CELL_TYPE", 0, 20], ["dendritic cells", "CELL_TYPE", 25, 40], ["DCs", "CELL_TYPE", 42, 45], ["dendritic cells", "PROBLEM", 25, 40], ["cellular resistance", "PROBLEM", 70, 89], ["invading viruses", "PROBLEM", 93, 109], ["macrophages", "OBSERVATION", 9, 20], ["dendritic cells", "OBSERVATION", 25, 40], ["cellular resistance", "OBSERVATION", 70, 89], ["invading viruses", "OBSERVATION", 93, 109]]], ["The newly discovered innate lymphoid cells (ILCs) 22 may have important roles due to their ability to respond to signaling molecules/alarmins secreted by the epithelial cells.", [["innate lymphoid cells", "ANATOMY", 21, 42], ["ILCs", "ANATOMY", 44, 48], ["epithelial cells", "ANATOMY", 158, 174], ["innate lymphoid cells", "CELL", 21, 42], ["ILCs) 22", "CELL", 44, 52], ["alarmins", "GENE_OR_GENE_PRODUCT", 133, 141], ["epithelial cells", "CELL", 158, 174], ["innate lymphoid cells", "CELL_TYPE", 21, 42], ["ILCs", "CELL_TYPE", 44, 48], ["signaling molecules", "PROTEIN", 113, 132], ["alarmins", "PROTEIN", 133, 141], ["epithelial cells", "CELL_TYPE", 158, 174], ["signaling molecules/alarmins secreted", "PROBLEM", 113, 150], ["innate lymphoid cells", "OBSERVATION", 21, 42], ["epithelial cells", "OBSERVATION", 158, 174]]], ["ILCs diversify and respond by secreting large amounts of effector cytokines and chemokines locally.", [["ILCs", "ANATOMY", 0, 4], ["ILCs", "CELL", 0, 4], ["ILCs", "CELL_TYPE", 0, 4], ["effector cytokines", "PROTEIN", 57, 75], ["chemokines", "PROTEIN", 80, 90], ["effector cytokines", "TREATMENT", 57, 75], ["chemokines locally", "TREATMENT", 80, 98], ["effector cytokines", "OBSERVATION", 57, 75]]], ["These effector molecules can potentially lead to the polarization of DCs and macrophages, and therefore may be critical in shaping the adaptive immunity mediated by T-helper (Th) and T-cytotoxic (Tc) cells that develop in the nearby lymphatic tissue (green lobed structure).", [["DCs", "ANATOMY", 69, 72], ["macrophages", "ANATOMY", 77, 88], ["T-cytotoxic (Tc) cells", "ANATOMY", 183, 205], ["lymphatic tissue", "ANATOMY", 233, 249], ["DCs", "CELL", 69, 72], ["macrophages", "CELL", 77, 88], ["T-helper", "CELL", 165, 173], ["Th", "CELL", 175, 177], ["T-cytotoxic (Tc) cells", "CELL", 183, 205], ["lymphatic tissue", "TISSUE", 233, 249], ["green lobed structure", "TISSUE", 251, 272], ["DCs", "CELL_TYPE", 69, 72], ["macrophages", "CELL_TYPE", 77, 88], ["T-helper (Th) and T-cytotoxic (Tc) cells", "CELL_TYPE", 165, 205], ["macrophages", "PROBLEM", 77, 88], ["T-cytotoxic (Tc) cells", "PROBLEM", 183, 205], ["nearby", "ANATOMY_MODIFIER", 226, 232], ["lymphatic tissue", "ANATOMY", 233, 249]]], ["MHC, major histocompatability complex.GENETIC ASSOCIATION OF IFNL LOCUS POLYMORPHISMS IS NOT LIMITED TO HCV INFECTIONS: INNATE IMMUNITY IS THE KEYorchestrate innate immunity against several viruses and they may be particularly important at the barrier surfaces.", [["barrier surfaces", "TISSUE", 244, 260], ["MHC", "PROTEIN", 0, 3], ["major histocompatability complex", "PROTEIN", 5, 37], ["HCV INFECTIONS", "PROBLEM", 104, 118], ["several viruses", "PROBLEM", 182, 197], ["NOT LIMITED", "UNCERTAINTY", 89, 100]]], ["IFN-\u03bbs also modulate adaptive immunity by affecting Th1/Th2 balance, tilting it to a Th1-favoring response that is required for clearing viral infections.", [["viral infections", "DISEASE", 137, 153], ["IFN-\u03bbs", "GENE_OR_GENE_PRODUCT", 0, 6], ["IFN-\u03bbs", "PROTEIN", 0, 6], ["clearing viral infections", "PROBLEM", 128, 153]]], ["The function of the newly discovered IFN-\u03bb4 in these immune processes remains to be determined.Association of IFNL locus polymorphisms with human diseasesIn cognizance of the potential that IFN-\u03bbs may hold in innate immunity, researchers across the world have got intrigued with the IFNL SNPs and have started to test them in candidate gene case-control studies in both infectious and non-infectious diseases.", [["human diseases", "DISEASE", 140, 154], ["infectious and non-infectious diseases", "DISEASE", 370, 408], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 37, 43], ["IFNL", "GENE_OR_GENE_PRODUCT", 110, 114], ["human", "ORGANISM", 140, 145], ["IFN-\u03bbs", "GENE_OR_GENE_PRODUCT", 190, 196], ["IFNL", "GENE_OR_GENE_PRODUCT", 283, 287], ["IFN", "PROTEIN", 37, 40], ["\u03bb4", "PROTEIN", 41, 43], ["IFNL locus polymorphisms", "DNA", 110, 134], ["IFN", "PROTEIN", 190, 193], ["IFNL SNPs", "DNA", 283, 292], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 140, 145], ["IFN", "TEST", 37, 40], ["IFNL locus polymorphisms", "PROBLEM", 110, 134], ["human diseases", "PROBLEM", 140, 154], ["IFN", "PROBLEM", 190, 193], ["the IFNL SNPs", "TREATMENT", 279, 292], ["non-infectious diseases", "PROBLEM", 385, 408], ["locus polymorphisms", "OBSERVATION", 115, 134], ["human diseases", "OBSERVATION", 140, 154], ["infectious", "OBSERVATION", 370, 380], ["non-infectious", "OBSERVATION", 385, 399]]], ["So far, association has been reported with nonalcoholic fatty liver disease (NAFLD), allergy and infections with several viruses.Cytomegalovirus.", [["nonalcoholic fatty liver", "ANATOMY", 43, 67], ["nonalcoholic fatty liver disease", "DISEASE", 43, 75], ["NAFLD", "DISEASE", 77, 82], ["allergy", "DISEASE", 85, 92], ["infections", "DISEASE", 97, 107], ["Cytomegalovirus", "DISEASE", 129, 144], ["liver", "ORGAN", 62, 67], ["Cytomegalovirus", "ORGANISM", 129, 144], ["nonalcoholic fatty liver disease", "PROBLEM", 43, 75], ["NAFLD)", "PROBLEM", 77, 83], ["allergy", "PROBLEM", 85, 92], ["infections", "PROBLEM", 97, 107], ["several viruses", "PROBLEM", 113, 128], ["Cytomegalovirus", "PROBLEM", 129, 144], ["nonalcoholic", "OBSERVATION_MODIFIER", 43, 55], ["fatty", "OBSERVATION", 56, 61], ["liver", "ANATOMY", 62, 67], ["disease", "OBSERVATION", 68, 75], ["infections", "OBSERVATION", 97, 107], ["several", "OBSERVATION_MODIFIER", 113, 120], ["viruses", "OBSERVATION", 121, 128]]], ["Cytomegalovirus (CMV) is a herpes virus that infects plasmacytoid dendritic cells and epithelial cells in humanscausing chronic infections and is especially a problem in immunosuppresed individuals.", [["plasmacytoid dendritic cells", "ANATOMY", 53, 81], ["epithelial cells", "ANATOMY", 86, 102], ["Cytomegalovirus (CMV)", "DISEASE", 0, 21], ["herpes virus", "DISEASE", 27, 39], ["chronic infections", "DISEASE", 120, 138], ["Cytomegalovirus", "ORGANISM", 0, 15], ["CMV", "ORGANISM", 17, 20], ["herpes virus", "ORGANISM", 27, 39], ["plasmacytoid dendritic cells", "CELL", 53, 81], ["epithelial cells", "CELL", 86, 102], ["plasmacytoid dendritic cells", "CELL_TYPE", 53, 81], ["epithelial cells", "CELL_TYPE", 86, 102], ["herpes virus", "SPECIES", 27, 39], ["CMV", "SPECIES", 17, 20], ["herpes virus", "SPECIES", 27, 39], ["Cytomegalovirus (CMV)", "PROBLEM", 0, 21], ["a herpes virus", "PROBLEM", 25, 39], ["plasmacytoid dendritic cells", "PROBLEM", 53, 81], ["epithelial cells", "PROBLEM", 86, 102], ["humanscausing chronic infections", "PROBLEM", 106, 138], ["a problem in immunosuppresed individuals", "PROBLEM", 157, 197], ["herpes virus", "OBSERVATION_MODIFIER", 27, 39], ["infects", "OBSERVATION_MODIFIER", 45, 52], ["plasmacytoid dendritic cells", "OBSERVATION", 53, 81], ["epithelial cells", "OBSERVATION", 86, 102], ["chronic", "OBSERVATION_MODIFIER", 120, 127], ["infections", "OBSERVATION", 128, 138]]], ["Egli et al. 47 tested the association of the IFNL SNP rs8099917 with CMV replication in a small number of solid organ transplant patients (n = 38) who were seronegative for CMV (but received an organ transplant from a CMVseropositive donor) and who had stopped receiving antiviral prophylaxis.", [["solid organ transplant", "ANATOMY", 106, 128], ["organ", "ANATOMY", 194, 199], ["SNP", "CHEMICAL", 50, 53], ["IFNL", "GENE_OR_GENE_PRODUCT", 45, 49], ["CMV", "ORGANISM", 69, 72], ["solid", "CANCER", 106, 111], ["organ", "ORGAN", 112, 117], ["patients", "ORGANISM", 129, 137], ["CMV", "ORGANISM", 173, 176], ["organ", "ORGAN", 194, 199], ["IFNL SNP rs8099917", "DNA", 45, 63], ["patients", "SPECIES", 129, 137], ["CMV", "SPECIES", 69, 72], ["CMV", "SPECIES", 173, 176], ["CMV replication", "TREATMENT", 69, 84], ["CMV", "PROBLEM", 173, 176], ["an organ transplant", "TREATMENT", 191, 210], ["a CMVseropositive donor)", "TREATMENT", 216, 240], ["antiviral prophylaxis", "TREATMENT", 271, 292], ["small", "OBSERVATION_MODIFIER", 90, 95], ["organ", "ANATOMY", 194, 199], ["transplant", "OBSERVATION", 200, 210]]], ["They found that the minor allele at rs8099917 (G) was associated with decreased CMV replication (P = 0.036) in a dominant model of inheritance.", [["CMV", "ORGANISM", 80, 83], ["CMV", "SPECIES", 80, 83], ["decreased CMV replication", "PROBLEM", 70, 95], ["CMV replication", "OBSERVATION", 80, 95]]], ["Further, their in vitro studies provided evidence for a beneficial effect of the minor allele against CMV replication.", [["CMV", "ORGANISM", 102, 105], ["CMV", "SPECIES", 102, 105], ["vitro studies", "TEST", 18, 31], ["the minor allele", "TREATMENT", 77, 93], ["CMV replication", "TREATMENT", 102, 117]]], ["47 A study in CMV-seropositive kidney transplant patients 48 also found that the minor allele (T) at rs12979860 had a dominant beneficial effect against CMV replication.", [["kidney", "ANATOMY", 31, 37], ["CMV", "ORGANISM", 14, 17], ["kidney", "ORGAN", 31, 37], ["patients", "ORGANISM", 49, 57], ["CMV", "ORGANISM", 153, 156], ["patients", "SPECIES", 49, 57], ["CMV", "SPECIES", 153, 156], ["A study", "TEST", 3, 10], ["CMV", "TEST", 14, 17], ["seropositive kidney transplant", "TREATMENT", 18, 48], ["CMV replication", "TREATMENT", 153, 168], ["kidney", "ANATOMY", 31, 37], ["transplant", "OBSERVATION", 38, 48]]], ["Although in another study in allogenic stem cell transplant recipients, 49 the minor allele T at rs12979860 protected recipients against CMV infection in a recessive model of inheritance.", [["stem cell", "ANATOMY", 39, 48], ["CMV infection", "DISEASE", 137, 150], ["stem cell", "CELL", 39, 48], ["recipients", "ORGANISM", 118, 128], ["CMV", "ORGANISM", 137, 140], ["CMV", "SPECIES", 137, 140], ["another study", "TEST", 12, 25], ["allogenic stem cell transplant recipients", "TREATMENT", 29, 70], ["CMV infection", "PROBLEM", 137, 150], ["a recessive model of inheritance", "PROBLEM", 154, 186], ["allogenic stem cell transplant", "OBSERVATION", 29, 59]]], ["Two more studies have also reported on the association of IFNL SNPs with CMV.", [["IFNL", "GENE_OR_GENE_PRODUCT", 58, 62], ["CMV", "ORGANISM", 73, 76], ["IFNL SNPs", "DNA", 58, 67], ["CMV", "SPECIES", 73, 76], ["Two more studies", "TEST", 0, 16], ["IFNL SNPs", "TREATMENT", 58, 67], ["CMV", "TREATMENT", 73, 76]]], ["50, 51 The first report by Bibert et al. 50 tested for the occurrence of CMV retinitis among those human immunodeficiency virus (HIV)-infected patients who were at risk of developing CMV retinitis due to low CD4 counts and CMV seropositivity.", [["CMV retinitis", "DISEASE", 73, 86], ["human immunodeficiency virus (HIV)-infected", "DISEASE", 99, 142], ["CMV retinitis", "DISEASE", 183, 196], ["CMV", "ORGANISM", 73, 76], ["human immunodeficiency virus", "ORGANISM", 99, 127], ["HIV", "ORGANISM", 129, 132], ["patients", "ORGANISM", 143, 151], ["CMV", "ORGANISM", 183, 186], ["CD4", "GENE_OR_GENE_PRODUCT", 208, 211], ["CMV", "ORGANISM", 223, 226], ["CD4", "PROTEIN", 208, 211], ["human", "SPECIES", 99, 104], ["immunodeficiency virus (HIV", "SPECIES", 105, 132], ["patients", "SPECIES", 143, 151], ["CMV", "SPECIES", 73, 76], ["human immunodeficiency virus", "SPECIES", 99, 127], ["HIV", "SPECIES", 129, 132], ["CMV", "SPECIES", 183, 186], ["CMV", "SPECIES", 223, 226], ["CMV retinitis", "PROBLEM", 73, 86], ["those human immunodeficiency virus", "PROBLEM", 93, 127], ["CMV retinitis", "PROBLEM", 183, 196], ["low CD4 counts", "PROBLEM", 204, 218], ["CMV seropositivity", "PROBLEM", 223, 241], ["CMV retinitis", "OBSERVATION", 73, 86], ["CMV retinitis", "OBSERVATION", 183, 196], ["low CD4 counts", "OBSERVATION", 204, 218]]], ["They found that carriers of two copies of the minor allele (\u0394G/\u0394G), increased the risk of getting CMV retinitis (P = 0.007) in multivariate regression models.", [["CMV retinitis", "DISEASE", 98, 111], ["CMV", "ORGANISM", 98, 101], ["minor allele", "DNA", 46, 58], ["\u0394G", "DNA", 60, 62], ["the minor allele (\u0394G/\u0394G)", "PROBLEM", 42, 66], ["CMV retinitis", "PROBLEM", 98, 111], ["CMV retinitis", "OBSERVATION", 98, 111]]], ["In the second report by Manuel et al., 51 solid organ transplant patients were tested for the association of rs368234815 with cumulative incidence of CMV replication.", [["organ", "ANATOMY", 48, 53], ["solid organ", "CANCER", 42, 53], ["patients", "ORGANISM", 65, 73], ["rs368234815", "GENE_OR_GENE_PRODUCT", 109, 120], ["CMV", "ORGANISM", 150, 153], ["patients", "SPECIES", 65, 73], ["CMV", "SPECIES", 150, 153], ["solid organ transplant", "TREATMENT", 42, 64], ["CMV replication", "TREATMENT", 150, 165], ["CMV replication", "OBSERVATION", 150, 165]]], ["The results showed that the minor allele homozygotes (\u0394G/\u0394G), only in the pre-emptive antiviral therapy group but not among those receiving antiviral prophylaxis, had higher incidence of CMV replication.", [["CMV", "ORGANISM", 187, 190], ["CMV", "SPECIES", 187, 190], ["the minor allele homozygotes", "PROBLEM", 24, 52], ["\u0394G/\u0394G", "TREATMENT", 54, 59], ["the pre-emptive antiviral therapy group", "TREATMENT", 70, 109], ["antiviral prophylaxis", "TREATMENT", 140, 161], ["CMV replication", "TREATMENT", 187, 202], ["antiviral therapy", "OBSERVATION", 86, 103], ["CMV replication", "OBSERVATION", 187, 202]]], ["These results are indeed very interesting and sound, but the paradoxical findings of the five groups in terms of the model of inheritance of IFNL SNPs raise some questions.", [["IFNL", "GENE_OR_GENE_PRODUCT", 141, 145], ["IFNL SNPs", "DNA", 141, 150]]], ["Although two groups showed that their results fit best with a recessive model of inheritance of IFNL SNPs 50,51 in affecting CMV replication/retinitis wherein minor homozygosity was non-beneficial, the other three studies show an opposite trend where the minor allele had a beneficial effect against CMV replication in both patients and cell culture experiments, involving either dominant 47, 48 or recessive models of inheritance.", [["cell culture", "ANATOMY", 337, 349], ["CMV replication/retinitis", "DISEASE", 125, 150], ["IFNL", "GENE_OR_GENE_PRODUCT", 96, 100], ["CMV", "ORGANISM", 125, 128], ["CMV", "ORGANISM", 300, 303], ["patients", "ORGANISM", 324, 332], ["cell", "CELL", 337, 341], ["IFNL SNPs 50,51", "DNA", 96, 111], ["patients", "SPECIES", 324, 332], ["CMV", "SPECIES", 125, 128], ["CMV", "SPECIES", 300, 303], ["IFNL SNPs", "TREATMENT", 96, 105], ["CMV replication", "PROBLEM", 125, 140], ["retinitis wherein minor homozygosity", "PROBLEM", 141, 177], ["the other three studies", "TEST", 198, 221], ["CMV replication", "TREATMENT", 300, 315], ["cell culture experiments", "TEST", 337, 361], ["recessive models of inheritance", "PROBLEM", 399, 430], ["CMV replication", "OBSERVATION", 125, 140], ["retinitis", "OBSERVATION", 141, 150]]], ["49 In stark contrast, a dominant model of inheritance (of the non-beneficial IFNL SNP minor allele) has consistently given the best explanation on the observed phenotypes in association studies with both spontaneous clearance and IFN-based treatment response in chronic HCV infections.", [["SNP", "CHEMICAL", 82, 85], ["HCV infections", "DISEASE", 270, 284], ["IFNL", "GENE_OR_GENE_PRODUCT", 77, 81], ["IFN", "GENE_OR_GENE_PRODUCT", 230, 233], ["HCV", "ORGANISM", 270, 273], ["non-beneficial IFNL SNP minor allele", "DNA", 62, 98], ["IFN", "PROTEIN", 230, 233], ["HCV", "SPECIES", 270, 273], ["the observed phenotypes", "PROBLEM", 147, 170], ["both spontaneous clearance", "PROBLEM", 199, 225], ["IFN-based treatment response", "TREATMENT", 230, 258], ["chronic HCV infections", "PROBLEM", 262, 284], ["chronic", "OBSERVATION_MODIFIER", 262, 269], ["HCV infections", "OBSERVATION", 270, 284]]], ["[11] [12] [13] 15 This discrepancy within the CMV studies may be partly due to statistical fluctuations owing to low sample sizes, 47, 50 and high heterogeneity among patient groups, end points and antiviral regimens that are followed in the different studies.", [["[11] [12] [13] 15", "SIMPLE_CHEMICAL", 0, 17], ["CMV", "ORGANISM", 46, 49], ["patient", "ORGANISM", 167, 174], ["patient", "SPECIES", 167, 174], ["the CMV studies", "TEST", 42, 57], ["statistical fluctuations", "PROBLEM", 79, 103], ["low sample sizes", "PROBLEM", 113, 129], ["high heterogeneity among patient groups", "PROBLEM", 142, 181], ["antiviral regimens", "TREATMENT", 198, 216], ["the different studies", "TEST", 238, 259], ["low sample sizes", "OBSERVATION_MODIFIER", 113, 129], ["antiviral regimens", "OBSERVATION", 198, 216]]], ["The discrepancy needs be resolved by well-designed replication studies to gain a proper understanding of the role of IFNL SNPs in CMV replication and disease.Cytomegalovirus.", [["Cytomegalovirus", "DISEASE", 158, 173], ["IFNL", "GENE_OR_GENE_PRODUCT", 117, 121], ["CMV", "ORGANISM", 130, 133], ["Cytomegalovirus", "ORGANISM", 158, 173], ["IFNL SNPs", "DNA", 117, 126], ["CMV", "SPECIES", 130, 133], ["IFNL SNPs", "TREATMENT", 117, 126], ["CMV replication", "TREATMENT", 130, 145], ["disease", "PROBLEM", 150, 157], ["Cytomegalovirus", "PROBLEM", 158, 173], ["CMV replication", "OBSERVATION", 130, 145]]], ["Cytomegalovirus (CMV) is a herpes virus that infects plasmacytoid dendritic cells and epithelial cells in humansHuman T-lymphotrophic virus.", [["plasmacytoid dendritic cells", "ANATOMY", 53, 81], ["epithelial cells", "ANATOMY", 86, 102], ["Cytomegalovirus (CMV)", "DISEASE", 0, 21], ["herpes virus", "DISEASE", 27, 39], ["Cytomegalovirus", "ORGANISM", 0, 15], ["CMV", "ORGANISM", 17, 20], ["herpes virus", "ORGANISM", 27, 39], ["plasmacytoid dendritic cells", "CELL", 53, 81], ["epithelial cells", "CELL", 86, 102], ["humans", "ORGANISM", 106, 112], ["Human T-lymphotrophic virus", "ORGANISM", 112, 139], ["plasmacytoid dendritic cells", "CELL_TYPE", 53, 81], ["epithelial cells", "CELL_TYPE", 86, 102], ["herpes virus", "SPECIES", 27, 39], ["humans", "SPECIES", 106, 112], ["Human", "SPECIES", 112, 117], ["T-lymphotrophic virus", "SPECIES", 118, 139], ["CMV", "SPECIES", 17, 20], ["herpes virus", "SPECIES", 27, 39], ["humans", "SPECIES", 106, 112], ["Human T-lymphotrophic virus", "SPECIES", 112, 139], ["Cytomegalovirus (CMV)", "PROBLEM", 0, 21], ["a herpes virus", "PROBLEM", 25, 39], ["plasmacytoid dendritic cells", "PROBLEM", 53, 81], ["epithelial cells", "PROBLEM", 86, 102], ["lymphotrophic virus", "PROBLEM", 120, 139], ["herpes virus", "OBSERVATION_MODIFIER", 27, 39], ["infects", "OBSERVATION_MODIFIER", 45, 52], ["plasmacytoid dendritic cells", "OBSERVATION", 53, 81], ["epithelial cells", "OBSERVATION", 86, 102]]], ["Human T-lymphotrophic virus (HTLV)-1 is an ancient retrovirus causing chronic infections in humans and is associated with adult T-cell leukemia/lymphoma.", [["adult T-cell leukemia", "ANATOMY", 122, 143], ["lymphoma", "ANATOMY", 144, 152], ["chronic infections", "DISEASE", 70, 88], ["adult T-cell leukemia/lymphoma", "DISEASE", 122, 152], ["Human T-lymphotrophic virus (HTLV)-1", "ORGANISM", 0, 36], ["retrovirus", "ORGANISM", 51, 61], ["humans", "ORGANISM", 92, 98], ["adult T-cell leukemia", "CANCER", 122, 143], ["lymphoma", "CANCER", 144, 152], ["Human", "SPECIES", 0, 5], ["T-lymphotrophic virus", "SPECIES", 6, 27], ["-1", "SPECIES", 34, 36], ["humans", "SPECIES", 92, 98], ["Human T-lymphotrophic virus", "SPECIES", 0, 27], ["HTLV)-1", "SPECIES", 29, 36], ["humans", "SPECIES", 92, 98], ["Human T-lymphotrophic virus (HTLV)", "PROBLEM", 0, 34], ["an ancient retrovirus", "PROBLEM", 40, 61], ["chronic infections in humans", "PROBLEM", 70, 98], ["adult T-cell leukemia", "PROBLEM", 122, 143], ["lymphoma", "PROBLEM", 144, 152], ["retrovirus", "OBSERVATION", 51, 61], ["causing", "UNCERTAINTY", 62, 69], ["chronic", "OBSERVATION_MODIFIER", 70, 77], ["infections", "OBSERVATION", 78, 88], ["associated with", "UNCERTAINTY", 106, 121], ["cell leukemia", "OBSERVATION", 130, 143], ["lymphoma", "OBSERVATION", 144, 152]]], ["It is also associated with inflammatory disorders such as HTLV-1associated myelopathy/tropical spastic papaparesis (HAM/TSP), HTLV-associated arthropathy and several other related disorders including rheumatoid arthritis.", [["HTLV-1associated myelopathy", "DISEASE", 58, 85], ["tropical spastic papaparesis", "DISEASE", 86, 114], ["HAM/TSP", "DISEASE", 116, 123], ["HTLV-associated arthropathy", "DISEASE", 126, 153], ["rheumatoid arthritis", "DISEASE", 200, 220], ["HTLV", "ORGANISM", 58, 62], ["HTLV-1associated myelopathy/tropical spastic papaparesis", "SPECIES", 58, 114], ["inflammatory disorders", "PROBLEM", 27, 49], ["HTLV-1associated myelopathy", "PROBLEM", 58, 85], ["tropical spastic papaparesis", "PROBLEM", 86, 114], ["HAM/TSP)", "PROBLEM", 116, 124], ["HTLV", "PROBLEM", 126, 130], ["associated arthropathy", "PROBLEM", 131, 153], ["several other related disorders", "PROBLEM", 158, 189], ["rheumatoid arthritis", "PROBLEM", 200, 220], ["also associated with", "UNCERTAINTY", 6, 26], ["inflammatory", "OBSERVATION", 27, 39], ["myelopathy", "OBSERVATION", 75, 85], ["tropical", "OBSERVATION_MODIFIER", 86, 94], ["spastic", "OBSERVATION_MODIFIER", 95, 102], ["papaparesis", "OBSERVATION", 103, 114], ["arthropathy", "OBSERVATION", 142, 153], ["rheumatoid arthritis", "OBSERVATION", 200, 220]]], ["A Spanish study reported for the first time that an IFNL SNP (rs12979860) was associated with HAM/ TSP in a small number of patients (n = 41) who had HTLV-1 proviral DNA in their blood cells.", [["blood cells", "ANATOMY", 179, 190], ["SNP", "CHEMICAL", 57, 60], ["IFNL", "GENE_OR_GENE_PRODUCT", 52, 56], ["patients", "ORGANISM", 124, 132], ["HTLV-1", "ORGANISM", 150, 156], ["DNA", "CELLULAR_COMPONENT", 166, 169], ["blood cells", "CELL", 179, 190], ["IFNL SNP", "DNA", 52, 60], ["TSP", "PROTEIN", 99, 102], ["HTLV-1 proviral DNA", "DNA", 150, 169], ["blood cells", "CELL_TYPE", 179, 190], ["patients", "SPECIES", 124, 132], ["HTLV-1", "SPECIES", 150, 156], ["A Spanish study", "TEST", 0, 15], ["HAM", "PROBLEM", 94, 97], ["TSP", "PROBLEM", 99, 102], ["HTLV", "PROBLEM", 150, 154], ["1 proviral DNA", "PROBLEM", 155, 169], ["small", "OBSERVATION_MODIFIER", 108, 113]]], ["52 They showed that the presence of the minor allele made 12/41 patients to have a sixfold higher risk (P = 0.03) of having symptoms of HAM/TSP compared with asymptomatic carriers (n = 29) in a dominant model of inheritance.", [["HAM/TSP", "DISEASE", 136, 143], ["patients", "ORGANISM", 64, 72], ["minor allele", "DNA", 40, 52], ["patients", "SPECIES", 64, 72], ["symptoms of HAM", "PROBLEM", 124, 139], ["TSP", "PROBLEM", 140, 143], ["asymptomatic carriers", "PROBLEM", 158, 179]]], ["However, proviral DNA load was a confounder in this association; covariate analysis suggested that both the SNP and proviral DNA load were linked in their association with HAM/TSP.", [["SNP", "CHEMICAL", 108, 111], ["DNA", "CELLULAR_COMPONENT", 18, 21], ["DNA", "CELLULAR_COMPONENT", 125, 128], ["TSP", "GENE_OR_GENE_PRODUCT", 176, 179], ["HAM", "PROTEIN", 172, 175], ["TSP", "PROTEIN", 176, 179], ["proviral DNA load", "PROBLEM", 9, 26], ["covariate analysis", "TEST", 65, 83], ["the SNP", "TREATMENT", 104, 111], ["proviral DNA load", "TREATMENT", 116, 133], ["TSP", "PROBLEM", 176, 179]]], ["The minor allele-carrying genotypes (CT and TT) were indeed having higher proviral DNA in their blood cells compared with the major homozygotes (P = 0.01).", [["blood cells", "ANATOMY", 96, 107], ["DNA", "CELLULAR_COMPONENT", 83, 86], ["blood cells", "CELL", 96, 107], ["proviral DNA", "DNA", 74, 86], ["blood cells", "CELL_TYPE", 96, 107], ["CT and TT)", "TEST", 37, 47], ["higher proviral DNA in their blood cells", "PROBLEM", 67, 107]]], ["The major drawback of this study seems to be the low sample number; although the strength of the study was that there was significant effect of the minor allele on proviral DNA copy number, a functional association that could be directly linked with the antiviral role of IFN-\u03bb3.", [["DNA", "CELLULAR_COMPONENT", 173, 176], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 272, 278], ["IFN", "PROTEIN", 272, 275], ["\u03bb3", "PROTEIN", 276, 278], ["this study", "TEST", 22, 32], ["the study", "TEST", 93, 102], ["the minor allele", "PROBLEM", 144, 160]]], ["It is known that the IFNL SNP minor alleles are associated with decreased expression of IFN-\u03bb3 (reviewed in ref.", [["SNP", "CHEMICAL", 26, 29], ["IFNL", "GENE_OR_GENE_PRODUCT", 21, 25], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 88, 94], ["IFNL SNP minor alleles", "DNA", 21, 43], ["IFN", "PROTEIN", 88, 91], ["\u03bb3", "PROTEIN", 92, 94], ["the IFNL SNP minor alleles", "PROBLEM", 17, 43], ["IFN", "TEST", 88, 91]]], ["15 , although an opposite effect is evident in chronic HCV infections, where the minor allele carriers have low baseline virus levels 11 ).", [["HCV infections", "DISEASE", 55, 69], ["HCV", "ORGANISM", 55, 58], ["HCV", "SPECIES", 55, 58], ["chronic HCV infections", "PROBLEM", 47, 69], ["the minor allele carriers", "PROBLEM", 77, 102], ["low baseline virus levels", "PROBLEM", 108, 133], ["chronic", "OBSERVATION_MODIFIER", 47, 54], ["HCV", "OBSERVATION", 55, 58]]], ["In a later study from Brazil, 53 both rs8099917 and rs12979860 were tested in a cohort consisting of 229 HTLV-positive subjects (93 HAM/TSP patient and 136 asymptomatic carriers).", [["HTLV-positive", "DISEASE", 105, 118], ["rs8099917", "GENE_OR_GENE_PRODUCT", 38, 47], ["HTLV", "ORGANISM", 105, 109], ["subjects", "ORGANISM", 119, 127], ["patient", "ORGANISM", 140, 147], ["patient", "SPECIES", 140, 147], ["rs8099917", "TEST", 38, 47], ["rs12979860", "TEST", 52, 62], ["HTLV", "TEST", 105, 109]]], ["The minor allele G of rs8099917 was significantly associated with HAM/TSP in both univariate and multivariate analysis with a recessive model of inheritance (P o 0.001).", [["HAM/TSP", "PROBLEM", 66, 73], ["multivariate analysis", "TEST", 97, 118], ["a recessive model of inheritance", "PROBLEM", 124, 156]]], ["In this study, the proviral DNA load as a covariate did not seem to interfere with the association of rs8099917 with HAM/TSP unlike the previous Spanish study.", [["DNA", "CELLULAR_COMPONENT", 28, 31], ["rs8099917", "GENE_OR_GENE_PRODUCT", 102, 111], ["HAM", "PROTEIN", 117, 120], ["TSP", "PROTEIN", 121, 124], ["this study", "TEST", 3, 13], ["the proviral DNA load", "PROBLEM", 15, 36], ["the previous Spanish study", "TEST", 132, 158]]], ["52 With respect to rs12979860, the minor allele T was associated with HAM/TSP only as a heterozygote in univariate analysis (P = 0.01) and weakly in multivariate analysis (P = 0.06).", [["TSP", "GENE_OR_GENE_PRODUCT", 74, 77], ["minor allele T", "DNA", 35, 49], ["TSP", "PROTEIN", 74, 77], ["HAM/TSP", "PROBLEM", 70, 77], ["a heterozygote", "PROBLEM", 86, 100], ["univariate analysis", "TEST", 104, 123], ["P", "TEST", 125, 126], ["multivariate analysis", "TEST", 149, 170], ["P", "TEST", 172, 173]]], ["However, a series of studies have also reported conflicting results to the above two reports on the association of IFNL SNPs with HTLV-1-associated diseases.", [["IFNL", "GENE_OR_GENE_PRODUCT", 115, 119], ["HTLV-1", "ORGANISM", 130, 136], ["IFNL SNPs", "DNA", 115, 124], ["HTLV-1", "SPECIES", 130, 136], ["IFNL SNPs", "PROBLEM", 115, 124], ["HTLV", "PROBLEM", 130, 134], ["associated diseases", "PROBLEM", 137, 156], ["diseases", "OBSERVATION", 148, 156]]], ["First, Sanabani et al. 54 show clearly a lack of association of IFNL SNP rs12979860 with HAM/TSP and/or adult T-cell leukemia/lymphoma.", [["adult T-cell leukemia", "ANATOMY", 104, 125], ["lymphoma", "ANATOMY", 126, 134], ["SNP", "CHEMICAL", 69, 72], ["T-cell leukemia/lymphoma", "DISEASE", 110, 134], ["IFNL", "GENE_OR_GENE_PRODUCT", 64, 68], ["TSP", "GENE_OR_GENE_PRODUCT", 93, 96], ["adult T-cell leukemia", "CANCER", 104, 125], ["lymphoma", "CANCER", 126, 134], ["IFNL", "PROTEIN", 64, 68], ["TSP", "PROTEIN", 93, 96], ["HAM/TSP", "PROBLEM", 89, 96], ["adult T-cell leukemia", "PROBLEM", 104, 125], ["lymphoma", "PROBLEM", 126, 134], ["cell leukemia", "OBSERVATION", 112, 125], ["lymphoma", "OBSERVATION", 126, 134]]], ["This Brazilian study had more number of samples (n = 112) than the Spanish study of Trevino et al. (n = 41).", [["This Brazilian study", "TEST", 0, 20], ["the Spanish study", "TEST", 63, 80]]], ["52 They also did not find any correlation of proviral DNA load with rs12979860 genotypes.", [["DNA", "CELLULAR_COMPONENT", 54, 57], ["proviral DNA load", "PROBLEM", 45, 62]]], ["Another report from Brazil with a sample size of 79 also reflected similar findings, where they found no association of rs12979860 with HAM/TSP and proviral DNA load.", [["HAM/TSP", "GENE_OR_GENE_PRODUCT", 136, 143], ["DNA", "CELLULAR_COMPONENT", 157, 160], ["TSP", "PROTEIN", 140, 143], ["a sample size", "TEST", 32, 45], ["HAM", "TEST", 136, 139], ["TSP", "PROBLEM", 140, 143], ["proviral DNA load", "PROBLEM", 148, 165]]], ["55 This study also compared 300 healthy controls with 79 HTLV-1-positive subjects and found no association with rs12979860 and HTLV-1 infection.", [["HTLV-1 infection", "DISEASE", 127, 143], ["HTLV-1", "ORGANISM", 57, 63], ["subjects", "ORGANISM", 73, 81], ["HTLV-1", "ORGANISM", 127, 133], ["HTLV-1", "SPECIES", 57, 63], ["HTLV-1", "SPECIES", 127, 133], ["This study", "TEST", 3, 13], ["HTLV", "TEST", 57, 61], ["HTLV-1 infection", "PROBLEM", 127, 143], ["infection", "OBSERVATION", 134, 143]]], ["Yet another recent study from Brazil analyzed the genotypes at rs8099917, rs12979860 and rs8103142 in 300 healthy controls and 96 HTLV-1-infected individuals, and found no association with HTLV-associated arthropathy and any of the three SNPs when tested individually.", [["HTLV-1-infected", "DISEASE", 130, 145], ["arthropathy", "DISEASE", 205, 216], ["rs8099917", "GENE_OR_GENE_PRODUCT", 63, 72], ["HTLV-1", "ORGANISM", 130, 136], ["individuals", "ORGANISM", 146, 157], ["HTLV", "ORGANISM", 189, 193], ["HTLV-1", "SPECIES", 130, 136], ["HTLV-1", "SPECIES", 130, 136], ["another recent study", "TEST", 4, 24], ["the genotypes", "TEST", 46, 59], ["rs12979860", "TEST", 74, 84], ["HTLV", "TEST", 130, 134], ["infected individuals", "PROBLEM", 137, 157], ["HTLV", "PROBLEM", 189, 193], ["associated arthropathy", "PROBLEM", 194, 216], ["no association with", "UNCERTAINTY", 169, 188], ["arthropathy", "OBSERVATION", 205, 216]]], ["56 When they carried out haplotype analysis, they found some association (P = 0.01) with HTLV-1 infection and one of the seven haplotypes (CCT) involving the three SNPs (rs8099917, rs12979860 and rs8103142); with HTLV-associated arthropathy and another haplotype (TTG; P = 0.05).", [["HTLV-1 infection", "DISEASE", 89, 105], ["HTLV-associated arthropathy", "DISEASE", 213, 240], ["HTLV-1", "ORGANISM", 89, 95], ["HTLV-1", "SPECIES", 89, 95], ["haplotype analysis", "TEST", 25, 43], ["HTLV-1 infection", "PROBLEM", 89, 105], ["CCT", "TEST", 139, 142], ["the three SNPs", "TEST", 154, 168], ["rs8099917", "TEST", 170, 179], ["rs12979860", "TEST", 181, 191], ["HTLV-associated arthropathy", "PROBLEM", 213, 240], ["another haplotype", "TEST", 245, 262], ["TTG", "TEST", 264, 267], ["P", "TEST", 269, 270], ["infection", "OBSERVATION", 96, 105], ["arthropathy", "OBSERVATION", 229, 240]]], ["They also found an association of the three SNPs individually with levels of some cytokines (such as IFN-\u03b3) and proviral DNA load (P o 0.05).", [["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 101, 106], ["DNA", "CELLULAR_COMPONENT", 121, 124], ["cytokines", "PROTEIN", 82, 91], ["IFN", "PROTEIN", 101, 104], ["the three SNPs", "PROBLEM", 34, 48], ["some cytokines", "PROBLEM", 77, 91], ["IFN", "TEST", 101, 104], ["proviral DNA load", "PROBLEM", 112, 129]]], ["56 However, no multiple testing corrections seem to have been carried out in their analysis, thus severely undermining the results.", [["multiple testing corrections", "TEST", 15, 43]]], ["56 Further, a Japanese study also failed to see any association with adult T-cell leukemia/lymphoma and rs8099917 and also with HTLV-1 and HCV mono-or co-infections.", [["adult T-cell leukemia", "ANATOMY", 69, 90], ["lymphoma", "ANATOMY", 91, 99], ["adult T-cell leukemia/lymphoma", "DISEASE", 69, 99], ["HCV mono-or co-infections", "DISEASE", 139, 164], ["adult T-cell leukemia", "CANCER", 69, 90], ["lymphoma", "CANCER", 91, 99], ["rs8099917", "GENE_OR_GENE_PRODUCT", 104, 113], ["HTLV-1", "ORGANISM", 128, 134], ["HCV", "ORGANISM", 139, 142], ["HTLV-1", "SPECIES", 128, 134], ["HCV", "SPECIES", 139, 142], ["a Japanese study", "TEST", 12, 28], ["adult T-cell leukemia", "PROBLEM", 69, 90], ["lymphoma", "PROBLEM", 91, 99], ["rs8099917", "TEST", 104, 113], ["HTLV", "TEST", 128, 132], ["HCV mono", "PROBLEM", 139, 147], ["co-infections", "PROBLEM", 151, 164], ["cell leukemia", "OBSERVATION", 77, 90], ["lymphoma", "OBSERVATION", 91, 99], ["co-infections", "OBSERVATION", 151, 164]]], ["57 Last, a study from France on 95 HTLV-1-positive subjects of Afro-Carribean lineage compared the distribution of genotypes of rs12979860 and the IFN-\u03bb4-generating SNP rs368234815, and found no association with HAM/TSP.", [["SNP", "CHEMICAL", 165, 168], ["HTLV-1", "ORGANISM", 35, 41], ["Afro-Carribean lineage", "CELL", 63, 85], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 147, 153], ["TSP", "GENE_OR_GENE_PRODUCT", 216, 219], ["IFN", "PROTEIN", 147, 150], ["\u03bb4", "PROTEIN", 151, 153], ["SNP rs368234815", "DNA", 165, 180], ["HAM", "PROTEIN", 212, 215], ["TSP", "PROTEIN", 216, 219], ["HTLV-1", "SPECIES", 35, 41], ["a study", "TEST", 9, 16], ["HTLV", "TEST", 35, 39], ["rs12979860", "TEST", 128, 138], ["the IFN", "TEST", 143, 150], ["SNP", "TEST", 165, 168], ["TSP", "PROBLEM", 216, 219], ["no association with", "UNCERTAINTY", 192, 211]]], ["58 In summary, the results so far are not entirely convincing on a true association of the IFNL SNPs with HTLV infection-related diseases.", [["HTLV infection", "DISEASE", 106, 120], ["IFNL", "GENE_OR_GENE_PRODUCT", 91, 95], ["HTLV", "ORGANISM", 106, 110], ["IFNL SNPs", "DNA", 91, 100], ["the IFNL SNPs", "PROBLEM", 87, 100], ["HTLV infection", "PROBLEM", 106, 120], ["related diseases", "PROBLEM", 121, 137], ["HTLV infection", "OBSERVATION", 106, 120]]], ["Therefore, more functional characterization of the observed association may be needed to rule out false positivity.Hepatitis B virus.If at all there is another human disease where IFNL SNPs were expected to have associations as strong as that of HCV infections, it was the case of hepatitis B virus (HBV).", [["Hepatitis B", "DISEASE", 115, 126], ["HCV infections", "DISEASE", 246, 260], ["hepatitis B", "DISEASE", 281, 292], ["Hepatitis B virus", "ORGANISM", 115, 132], ["human", "ORGANISM", 160, 165], ["IFNL", "GENE_OR_GENE_PRODUCT", 180, 184], ["HCV", "ORGANISM", 246, 249], ["hepatitis B virus", "ORGANISM", 281, 298], ["HBV", "ORGANISM", 300, 303], ["IFNL SNPs", "DNA", 180, 189], ["Hepatitis B virus", "SPECIES", 115, 132], ["human", "SPECIES", 160, 165], ["hepatitis B virus", "SPECIES", 281, 298], ["Hepatitis B virus", "SPECIES", 115, 132], ["human", "SPECIES", 160, 165], ["HCV", "SPECIES", 246, 249], ["hepatitis B virus", "SPECIES", 281, 298], ["HBV", "SPECIES", 300, 303], ["false positivity", "PROBLEM", 98, 114], ["Hepatitis B virus", "PROBLEM", 115, 132], ["another human disease", "PROBLEM", 152, 173], ["HCV infections", "PROBLEM", 246, 260], ["hepatitis B virus", "PROBLEM", 281, 298], ["false positivity", "OBSERVATION", 98, 114], ["virus", "OBSERVATION", 127, 132]]], ["This expectation is because both viruses are hepatotropic and cause chronic infections; both diseases can be effectively treated using IFN-\u03b1 even though they differ in their PAMP ligands recognized by innate immune receptors.", [["infections", "DISEASE", 76, 86], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 135, 140], ["IFN", "PROTEIN", 135, 138], ["PAMP ligands", "PROTEIN", 174, 186], ["innate immune receptors", "PROTEIN", 201, 224], ["both viruses", "PROBLEM", 28, 40], ["hepatotropic", "PROBLEM", 45, 57], ["chronic infections", "PROBLEM", 68, 86], ["both diseases", "PROBLEM", 88, 101], ["IFN", "TREATMENT", 135, 138], ["viruses", "OBSERVATION", 33, 40], ["chronic", "OBSERVATION_MODIFIER", 68, 75], ["infections", "OBSERVATION", 76, 86]]], ["59, 60 Mixed results have been obtained about the role of IFNL SNPs in both spontaneous clearance and IFN-\u03b1-induced clearance of HBV and the literature until the year 2013-2014 has been reviewed elsewhere.", [["IFN", "CHEMICAL", 102, 105], ["IFNL", "GENE_OR_GENE_PRODUCT", 58, 62], ["IFN-\u03b1-", "GENE_OR_GENE_PRODUCT", 102, 108], ["HBV", "ORGANISM", 129, 132], ["IFNL SNPs", "DNA", 58, 67], ["IFN", "PROTEIN", 102, 105], ["HBV", "SPECIES", 129, 132], ["IFNL SNPs", "TREATMENT", 58, 67], ["IFN", "TREATMENT", 102, 105], ["HBV", "PROBLEM", 129, 132]]], ["[61] [62] [63] More studies have also been conducted since then (results from 10 of them are summarized in Supplementary Table 1 ), but have largely failed to resolve the conflict.Hepatitis B virus.Two studies have also reported on a lack of association of IFNL SNPs on spontaneous as well as IFN-induced clearance of hepatitis D virus, a co-infecting satellite virus that requires HBV for replication and assembly.", [["Hepatitis B", "DISEASE", 180, 191], ["IFN", "CHEMICAL", 293, 296], ["hepatitis D", "DISEASE", 318, 329], ["Hepatitis B virus", "ORGANISM", 180, 197], ["IFNL", "GENE_OR_GENE_PRODUCT", 257, 261], ["IFN", "GENE_OR_GENE_PRODUCT", 293, 296], ["hepatitis D virus", "ORGANISM", 318, 335], ["satellite virus", "ORGANISM", 352, 367], ["HBV", "ORGANISM", 382, 385], ["IFNL SNPs", "DNA", 257, 266], ["IFN", "PROTEIN", 293, 296], ["Hepatitis B virus", "SPECIES", 180, 197], ["hepatitis D virus", "SPECIES", 318, 335], ["Hepatitis B virus", "SPECIES", 180, 197], ["hepatitis D virus", "SPECIES", 318, 335], ["HBV", "SPECIES", 382, 385], ["Hepatitis B virus", "PROBLEM", 180, 197], ["Two studies", "TEST", 198, 209], ["IFNL SNPs", "PROBLEM", 257, 266], ["IFN", "TREATMENT", 293, 296], ["hepatitis D virus", "PROBLEM", 318, 335], ["a co-infecting satellite virus", "PROBLEM", 337, 367], ["HBV", "TREATMENT", 382, 385], ["virus", "OBSERVATION", 192, 197], ["hepatitis", "OBSERVATION", 318, 327], ["satellite virus", "OBSERVATION", 352, 367]]], ["64, 65 Although consistent results were obtained across numerous studies with HCV-IFNL SNP association mainly because they had only virological end point phenotypes 15 that correlated well with serological and biochemical parameters of the infection, several drawbacks in case of HBV studies may be responsible for the inconsistent results.", [["SNP", "CHEMICAL", 87, 90], ["infection", "DISEASE", 240, 249], ["IFNL", "GENE_OR_GENE_PRODUCT", 82, 86], ["HBV", "ORGANISM", 280, 283], ["HCV", "SPECIES", 78, 81], ["HBV", "SPECIES", 280, 283], ["HCV", "PROBLEM", 78, 81], ["virological end point phenotypes", "PROBLEM", 132, 164], ["serological", "TEST", 194, 205], ["the infection", "PROBLEM", 236, 249], ["HBV studies", "TEST", 280, 291], ["infection", "OBSERVATION", 240, 249]]], ["Some of them are: presence of different HBV genotypes as mixed infections, with some genotypes (genotype D 62 ) showing better association than others; variation in treatment regimens (IFN alone or with nucleotide analogs); end point phenotypes varying from serology to viral load, to biochemical parameters without a common quantitative parameter to assess the phenotype; prolonged clinical course of the disease with fluctuating virological, serological and biochemical markers; and prevalence rates of disease differing in different ethnicities/populations, to name a few.", [["infections", "DISEASE", 63, 73], ["IFN", "CHEMICAL", 185, 188], ["nucleotide", "CHEMICAL", 203, 213], ["nucleotide", "CHEMICAL", 203, 213], ["HBV", "ORGANISM", 40, 43], ["IFN", "PROTEIN", 185, 188], ["HBV", "SPECIES", 40, 43], ["different HBV genotypes", "PROBLEM", 30, 53], ["mixed infections", "PROBLEM", 57, 73], ["some genotypes (genotype D", "PROBLEM", 80, 106], ["treatment regimens", "TREATMENT", 165, 183], ["IFN alone", "TREATMENT", 185, 194], ["nucleotide analogs", "TREATMENT", 203, 221], ["end point phenotypes", "PROBLEM", 224, 244], ["serology", "TEST", 258, 266], ["viral load", "TEST", 270, 280], ["biochemical parameters", "TEST", 285, 307], ["the phenotype", "PROBLEM", 358, 371], ["the disease", "PROBLEM", 402, 413], ["fluctuating virological, serological and biochemical markers", "PROBLEM", 419, 479], ["disease", "PROBLEM", 505, 512], ["HBV", "OBSERVATION", 40, 43], ["mixed", "OBSERVATION_MODIFIER", 57, 62], ["infections", "OBSERVATION", 63, 73]]], ["The reports that have shown an association of IFNL SNPs with HBV spontaneous or treatment-induced clearance are largely in agreement with the results from HCV studies in terms of the model of inheritance (Supplementary Table 1 ).", [["IFNL", "GENE_OR_GENE_PRODUCT", 46, 50], ["IFNL SNPs", "DNA", 46, 55], ["HBV", "SPECIES", 61, 64], ["HCV", "SPECIES", 155, 158], ["IFNL SNPs", "PROBLEM", 46, 55], ["HBV", "TREATMENT", 61, 64], ["HCV studies", "TEST", 155, 166]]], ["Although the conflicting data so far on HBV-IFNL SNP association do lead to doubts about its true positive nature, the data are also not fully supportive of the notion that the association may be false positive.", [["SNP", "CHEMICAL", 49, 52], ["HBV-IFNL", "ORGANISM", 40, 48], ["HBV", "SPECIES", 40, 43], ["HBV", "TREATMENT", 40, 43], ["false positive", "PROBLEM", 196, 210]]], ["In fact it has been argued that if properly assessed, the association between HBV disease progression and IFNL SNPs could have clinical value.", [["HBV", "ORGANISM", 78, 81], ["IFNL", "GENE_OR_GENE_PRODUCT", 106, 110], ["IFNL SNPs", "DNA", 106, 115], ["HBV", "SPECIES", 78, 81], ["HBV disease progression", "PROBLEM", 78, 101], ["IFNL SNPs", "PROBLEM", 106, 115], ["clinical value", "TEST", 127, 141]]], ["62 But it appears that the effect of the IFNL SNPs on HBV persistence and/or progression within the human host is highly variable; it may involve more complex interactions with other variables and genes than was observed in chronic HCV infections.Hepatitis B virus.Human immunodeficiency virus.", [["HCV infections", "DISEASE", 232, 246], ["Hepatitis B", "DISEASE", 247, 258], ["Human immunodeficiency virus", "DISEASE", 265, 293], ["IFNL", "GENE_OR_GENE_PRODUCT", 41, 45], ["HBV", "ORGANISM", 54, 57], ["human", "ORGANISM", 100, 105], ["Hepatitis B virus", "ORGANISM", 247, 264], ["Human immunodeficiency virus", "ORGANISM", 265, 293], ["IFNL SNPs", "DNA", 41, 50], ["human", "SPECIES", 100, 105], ["Hepatitis B virus", "SPECIES", 247, 264], ["Human", "SPECIES", 265, 270], ["immunodeficiency virus", "SPECIES", 271, 293], ["HBV", "SPECIES", 54, 57], ["human", "SPECIES", 100, 105], ["HCV", "SPECIES", 232, 235], ["Hepatitis B virus", "SPECIES", 247, 264], ["Human immunodeficiency virus", "SPECIES", 265, 293], ["the IFNL SNPs", "TREATMENT", 37, 50], ["HBV persistence", "PROBLEM", 54, 69], ["chronic HCV infections", "PROBLEM", 224, 246], ["Hepatitis B virus", "PROBLEM", 247, 264], ["Human immunodeficiency virus", "PROBLEM", 265, 293], ["chronic", "OBSERVATION_MODIFIER", 224, 231], ["HCV", "OBSERVATION", 232, 235], ["virus", "OBSERVATION", 259, 264], ["immunodeficiency virus", "OBSERVATION", 271, 293]]], ["Another important viral disease that has been tested for the influence of IFNL SNPs is acquired immunodeficiency syndrome (AIDS) caused by HIV.", [["viral disease", "DISEASE", 18, 31], ["acquired immunodeficiency syndrome", "DISEASE", 87, 121], ["AIDS", "DISEASE", 123, 127], ["IFNL", "GENE_OR_GENE_PRODUCT", 74, 78], ["HIV", "ORGANISM", 139, 142], ["IFNL SNPs", "DNA", 74, 83], ["HIV", "SPECIES", 139, 142], ["HIV", "SPECIES", 139, 142], ["Another important viral disease", "PROBLEM", 0, 31], ["IFNL SNPs", "PROBLEM", 74, 83], ["acquired immunodeficiency syndrome", "PROBLEM", 87, 121], ["AIDS", "PROBLEM", 123, 127], ["HIV", "PROBLEM", 139, 142], ["important", "UNCERTAINTY", 8, 17], ["viral disease", "OBSERVATION", 18, 31]]], ["Particularly, it was of interest to see how the IFNL SNP beneficial alleles are distributed in a unique group of HIV-infected individuals that can suppress the virus from replicating to high levels (defined as elite controllers/suppressors or natural viral suppressors) and defer the progression to AIDS (called as long-term non-progressors) without any antiretroviral therapy; and another unique group that remains HIV-seronegative despite being at high risk for infection due to intravenous drug use (highly exposed seronegative or exposed seronegative)).", [["intravenous", "ANATOMY", 481, 492], ["SNP", "CHEMICAL", 53, 56], ["HIV-infected", "DISEASE", 113, 125], ["AIDS", "DISEASE", 299, 303], ["HIV-seronegative", "DISEASE", 416, 432], ["infection", "DISEASE", 464, 473], ["IFNL", "GENE_OR_GENE_PRODUCT", 48, 52], ["HIV", "ORGANISM", 113, 116], ["individuals", "ORGANISM", 126, 137], ["HIV", "ORGANISM", 416, 419], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 481, 492], ["IFNL SNP beneficial alleles", "DNA", 48, 75], ["HIV", "SPECIES", 113, 116], ["HIV", "SPECIES", 113, 116], ["HIV", "SPECIES", 416, 419], ["HIV", "PROBLEM", 113, 116], ["infected individuals", "PROBLEM", 117, 137], ["the virus", "PROBLEM", 156, 165], ["elite controllers/suppressors", "TREATMENT", 210, 239], ["natural viral suppressors", "TREATMENT", 243, 268], ["any antiretroviral therapy", "TREATMENT", 350, 376], ["HIV", "PROBLEM", 416, 419], ["seronegative", "PROBLEM", 420, 432], ["infection", "PROBLEM", 464, 473], ["intravenous drug use", "TREATMENT", 481, 501], ["infection", "OBSERVATION", 464, 473]]], ["More interestingly, the natural viral suppressor patients have also been known to efficiently clear HCV in HCV-HIV co-infections, compared with controls in both African Americans 66 and Caucasians.", [["HCV-HIV co-infections", "DISEASE", 107, 128], ["patients", "ORGANISM", 49, 57], ["HCV", "ORGANISM", 100, 103], ["HCV-HIV", "ORGANISM", 107, 114], ["patients", "SPECIES", 49, 57], ["HCV-HIV", "SPECIES", 107, 114], ["HCV", "SPECIES", 100, 103], ["HCV", "SPECIES", 107, 110], ["HIV", "SPECIES", 111, 114], ["HCV", "PROBLEM", 100, 103], ["HCV", "PROBLEM", 107, 110], ["HIV co-infections", "PROBLEM", 111, 128], ["HCV", "OBSERVATION", 100, 103]]], ["67 A few reports have come up in this area, some showing no correlation of HIV infection/disease progression to the IFNL SNPs, whereas others see clear association.", [["HIV infection", "DISEASE", 75, 88], ["HIV", "ORGANISM", 75, 78], ["IFNL", "GENE_OR_GENE_PRODUCT", 116, 120], ["IFNL SNPs", "DNA", 116, 125], ["HIV", "SPECIES", 75, 78], ["HIV infection", "PROBLEM", 75, 88], ["disease progression", "PROBLEM", 89, 108], ["few", "OBSERVATION_MODIFIER", 5, 8], ["HIV", "OBSERVATION_MODIFIER", 75, 78], ["infection", "OBSERVATION", 79, 88]]], ["[68] [69] [70] [71] [72] [73] [74] One of the earlier reports tested the association of rs12979860 in 291 high-risk seronegative and 1221 HIV-positive subjects comprising both white and black subjects in the USA.", [["HIV-positive", "DISEASE", 138, 150], ["[68] [69] [70] [71] [72] [73] [74", "SIMPLE_CHEMICAL", 0, 33], ["rs12979860", "GENE_OR_GENE_PRODUCT", 88, 98], ["HIV", "SPECIES", 138, 141], ["HIV", "SPECIES", 138, 141], ["rs12979860", "TEST", 88, 98], ["HIV", "TEST", 138, 141], ["positive subjects", "PROBLEM", 142, 159], ["both white and black subjects in the USA", "PROBLEM", 171, 211]]], ["68 No association was evident for either HIV positivity or for disease progression within the infected subjects.", [["HIV", "ORGANISM", 41, 44], ["HIV", "SPECIES", 41, 44], ["HIV positivity", "PROBLEM", 41, 55], ["disease progression", "PROBLEM", 63, 82], ["the infected subjects", "PROBLEM", 90, 111], ["infected", "OBSERVATION_MODIFIER", 94, 102]]], ["In another study reported by Rallon et al., 69 the association of rs12979860 was tested in two different cohorts.", [["another study", "TEST", 3, 16], ["rs12979860", "TEST", 66, 76]]], ["The first comprised of 30 long-term non-progressors and 38 typical progressors to AIDS; the second included 29 exposed seronegative and 29 HIV-positive partners.", [["AIDS", "DISEASE", 82, 86], ["HIV", "ORGANISM", 139, 142], ["HIV", "SPECIES", 139, 142], ["HIV", "SPECIES", 139, 142], ["AIDS", "TEST", 82, 86], ["seronegative", "TEST", 119, 131]]], ["Thus, the study tested both HIV progression and protection, although in a small number of patients.", [["HIV", "ORGANISM", 28, 31], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["HIV", "SPECIES", 28, 31], ["the study", "TEST", 6, 15], ["protection", "TREATMENT", 48, 58], ["small", "OBSERVATION_MODIFIER", 74, 79]]], ["No significant difference in distribution of genotypes between cases and controls was evident in both cohorts, although the beneficial CC genotype was more frequent in the exposed seronegative patients compared with HIV-positive patients (62% vs 45%), suggesting that there may be a protective role for the CC genotype against HIV that was not detected in the study, likely due to inadequate power.", [["CC", "CHEMICAL", 135, 137], ["HIV-positive", "DISEASE", 216, 228], ["CC", "CHEMICAL", 307, 309], ["patients", "ORGANISM", 193, 201], ["HIV", "ORGANISM", 216, 219], ["patients", "ORGANISM", 229, 237], ["HIV", "ORGANISM", 327, 330], ["patients", "SPECIES", 193, 201], ["HIV", "SPECIES", 216, 219], ["patients", "SPECIES", 229, 237], ["HIV", "SPECIES", 327, 330], ["HIV", "SPECIES", 216, 219], ["HIV", "SPECIES", 327, 330], ["genotypes between cases and controls", "PROBLEM", 45, 81], ["the beneficial CC genotype", "PROBLEM", 120, 146], ["HIV", "TEST", 216, 219], ["HIV", "PROBLEM", 327, 330], ["the study", "TEST", 356, 365], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION_MODIFIER", 15, 25], ["distribution", "OBSERVATION_MODIFIER", 29, 41]]], ["Another study from the USA tested whether the beneficial CC genotype at rs12979860 was overrepresented in 25 African-American elite controllers/suppressors compared with HIV-infected patients with high viral loads, and found no statistically significant difference.", [["CC", "CHEMICAL", 57, 59], ["HIV-infected", "DISEASE", 170, 182], ["HIV", "ORGANISM", 170, 173], ["patients", "ORGANISM", 183, 191], ["HIV", "SPECIES", 170, 173], ["patients", "SPECIES", 183, 191], ["HIV", "SPECIES", 170, 173], ["Another study", "TEST", 0, 13], ["the USA", "TEST", 19, 26], ["the beneficial CC genotype", "PROBLEM", 42, 68], ["suppressors", "TREATMENT", 144, 155], ["HIV", "PROBLEM", 170, 173], ["high viral loads", "PROBLEM", 197, 213], ["statistically significant difference", "PROBLEM", 228, 264], ["viral loads", "OBSERVATION", 202, 213], ["no", "UNCERTAINTY", 225, 227], ["significant", "OBSERVATION_MODIFIER", 242, 253], ["difference", "OBSERVATION", 254, 264]]], ["70 Confirming this report, Sajadi et al. 71 also found that CC genotype (for rs12979860) was not significantly over-represented in 48 natural viral suppressors of African-American origin compared with HIVpositive (n = 124) and -negative controls (n = 173).Hepatitis B virus.Three reports published subsequently have seen association with rs12979860 and rs368234815, and spontaneous control of HIV and/or AIDS progression.", [["CC", "CHEMICAL", 60, 62], ["Hepatitis B", "DISEASE", 256, 267], ["AIDS", "DISEASE", 404, 408], ["CC", "GENE_OR_GENE_PRODUCT", 60, 62], ["Hepatitis B virus", "ORGANISM", 256, 273], ["Hepatitis B virus", "SPECIES", 256, 273], ["Hepatitis B virus", "SPECIES", 256, 273], ["HIV", "SPECIES", 393, 396], ["CC genotype", "TEST", 60, 71], ["rs12979860", "TEST", 77, 87], ["HIVpositive", "TEST", 201, 212], ["Hepatitis B virus", "PROBLEM", 256, 273], ["rs12979860", "TEST", 338, 348], ["HIV", "PROBLEM", 393, 396], ["AIDS progression", "PROBLEM", 404, 420], ["virus", "OBSERVATION", 268, 273]]], ["[72] [73] [74] Interestingly, all three studies were carried out on whites/Caucasians, whereas the reports that failed to see an association described above were mostly carried out on African Americans (except that by Rallon et al 69 that used white subjects) or mixed group of blacks and whites.", [["all three studies", "TEST", 30, 47], ["mixed group of blacks and whites", "PROBLEM", 263, 295]]], ["68 First, Machmach et al. 72 found an association of rs12979860 with spontaneous HIV control when tested on 53 white natural viral suppressors and 389 matched non-controllers at P = 0.02 after correcting for occurrence of HLA-B57 (human leukocyte antigen) protective alleles (which also have independent association with HIV and HCV spontaneous clearance) and gender, in multivariate analysis.", [["HLA-B57", "GENE_OR_GENE_PRODUCT", 222, 229], ["human leukocyte antigen", "GENE_OR_GENE_PRODUCT", 231, 254], ["HIV", "ORGANISM", 321, 324], ["HCV", "ORGANISM", 329, 332], ["HLA-B57 (human leukocyte antigen) protective alleles", "DNA", 222, 274], ["human", "SPECIES", 231, 236], ["HIV", "SPECIES", 321, 324], ["HIV", "SPECIES", 81, 84], ["human", "SPECIES", 231, 236], ["HIV", "SPECIES", 321, 324], ["HCV", "SPECIES", 329, 332], ["spontaneous HIV control", "TREATMENT", 69, 92], ["HLA", "TEST", 222, 225], ["human leukocyte antigen", "TEST", 231, 254], ["protective alleles", "PROBLEM", 256, 274], ["HIV", "PROBLEM", 321, 324], ["HCV spontaneous clearance", "TREATMENT", 329, 354], ["multivariate analysis", "TEST", 371, 392]]], ["Second, Machmach et al. 73 confirmed and extended their results in another report, where they found the association of rs368234815 with AIDS progression.", [["AIDS", "DISEASE", 136, 140], ["rs368234815", "GENE_OR_GENE_PRODUCT", 119, 130], ["AIDS progression", "PROBLEM", 136, 152]]], ["Last, a recent study carried out on a well-characterized Spanish white cohort of HCVseropositive men exposed to HIV infection through shared needles shows a clear association of IFN-\u03bb4-generating rs368234815 with HIV positivity.", [["HIV infection", "DISEASE", 112, 125], ["men", "ORGANISM", 97, 100], ["HIV", "ORGANISM", 112, 115], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 178, 184], ["rs368234815", "GENE_OR_GENE_PRODUCT", 196, 207], ["HIV", "ORGANISM", 213, 216], ["IFN", "PROTEIN", 178, 181], ["\u03bb4", "PROTEIN", 182, 184], ["men", "SPECIES", 97, 100], ["HIV", "SPECIES", 112, 115], ["HIV", "SPECIES", 213, 216], ["HIV", "SPECIES", 112, 115], ["HIV", "SPECIES", 213, 216], ["a recent study", "TEST", 6, 20], ["HIV infection", "PROBLEM", 112, 125], ["IFN", "TEST", 178, 181], ["HIV positivity", "PROBLEM", 213, 227], ["infection", "OBSERVATION", 116, 125], ["clear", "OBSERVATION", 157, 162]]], ["74 The study had 213 men who were HIV seropositive and 188 were highly exposed seronegative.", [["men", "ORGANISM", 21, 24], ["men", "SPECIES", 21, 24], ["HIV", "SPECIES", 34, 37], ["HIV", "SPECIES", 34, 37], ["The study", "TEST", 3, 12], ["HIV seropositive", "TEST", 34, 50]]], ["They found that the protective TT/TT genotype was overrepresented in the highly exposed seronegative group (0.49 vs 0.41; P = 0.006).", [["TT", "GENE_OR_GENE_PRODUCT", 31, 33], ["the protective TT/TT genotype", "PROBLEM", 16, 45], ["P", "TEST", 122, 123]]], ["Further, this association had no interaction with the HIV-protective CCR5 (C-C chemokine receptor type 5) deletion (P = 0.7).", [["CCR5", "GENE_OR_GENE_PRODUCT", 69, 73], ["C-C chemokine receptor type 5", "GENE_OR_GENE_PRODUCT", 75, 104], ["CCR5", "PROTEIN", 69, 73], ["C-C chemokine receptor type 5) deletion", "DNA", 75, 114], ["HIV", "SPECIES", 54, 57], ["the HIV", "TEST", 50, 57], ["protective CCR5", "TREATMENT", 58, 73], ["C-C chemokine receptor type", "TREATMENT", 75, 102], ["P", "TEST", 116, 117]]], ["Interestingly, all three studies that found an association show data that the non-beneficial minor alleles are following a recessive model of inheritance, 72-74 suggesting a common underlying functionality in the observed genetic association between the three studies.", [["non-beneficial minor alleles", "DNA", 78, 106], ["all three studies", "TEST", 15, 32], ["functionality", "OBSERVATION", 192, 205]]], ["This is however different from the dominant model of inheritance seen in HCV studies, [11] [12] [13] 15 suggesting that the two viruses may have different interactions with IFN-\u03bb-driven immune responses.", [["[11] [12] [13] 15", "CHEMICAL", 86, 103], ["[11] [12] [13] 15", "SIMPLE_CHEMICAL", 86, 103], ["IFN-\u03bb-", "GENE_OR_GENE_PRODUCT", 173, 179], ["IFN", "PROTEIN", 173, 176], ["HCV", "SPECIES", 73, 76], ["HCV studies", "TEST", 73, 84], ["the two viruses", "PROBLEM", 120, 135], ["IFN", "TREATMENT", 173, 176], ["dominant", "OBSERVATION_MODIFIER", 35, 43], ["viruses", "OBSERVATION", 128, 135]]], ["However, unlike in the case of CMV studies discussed above, [47] [48] [49] [50] [51] all three HIV studies [72] [73] [74] show that the minor alleles are non-beneficial, similar to the observations in chronic HCV infections.", [["HCV infections", "DISEASE", 209, 223], ["CMV", "ORGANISM", 31, 34], ["[47] [48] [49] [50", "SIMPLE_CHEMICAL", 60, 78], ["HCV", "ORGANISM", 209, 212], ["HCV", "SPECIES", 209, 212], ["CMV studies", "TEST", 31, 42], ["all three HIV studies", "TEST", 85, 106], ["chronic HCV infections", "PROBLEM", 201, 223], ["chronic", "OBSERVATION_MODIFIER", 201, 208], ["HCV", "OBSERVATION", 209, 212]]], ["15 In summary, it is evident that IFNL SNPs do associate with HIV replication and disease progression, even though in an ethnicity-specific manner.", [["HIV replication", "DISEASE", 62, 77], ["IFNL", "GENE_OR_GENE_PRODUCT", 34, 38], ["HIV", "ORGANISM", 62, 65], ["IFNL SNPs", "DNA", 34, 43], ["HIV", "SPECIES", 62, 65], ["IFNL SNPs", "PROBLEM", 34, 43], ["HIV replication", "PROBLEM", 62, 77], ["disease progression", "PROBLEM", 82, 101]]], ["It appears that the beneficial alleles of IFNL SNPs have protective roles in whites/Caucasians.", [["IFNL", "GENE_OR_GENE_PRODUCT", 42, 46], ["IFNL SNPs", "DNA", 42, 51], ["the beneficial alleles of IFNL SNPs", "PROBLEM", 16, 51]]], ["In African Americans, more studies with the functional IFN-\u03bb4-generating SNP rs368234815 rather than rs12979860 will reveal any true association.", [["SNP", "CHEMICAL", 73, 76], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 55, 61], ["IFN", "PROTEIN", 55, 58], ["\u03bb4", "PROTEIN", 59, 61], ["SNP rs368234815", "DNA", 73, 88]]], ["This is especially true as the two SNPs are not in strong linkage disequilibrium (LD) in this population (Figure 1b) .Hepatitis B virus.Herpes simplex virus.", [["Hepatitis B", "DISEASE", 118, 129], ["Herpes simplex virus", "DISEASE", 136, 156], ["Hepatitis B virus", "ORGANISM", 118, 135], ["Herpes simplex virus", "ORGANISM", 136, 156], ["Hepatitis B virus", "SPECIES", 118, 135], ["Herpes simplex virus", "SPECIES", 136, 156], ["Hepatitis B virus", "SPECIES", 118, 135], ["Herpes simplex virus", "SPECIES", 136, 156], ["Hepatitis B virus", "PROBLEM", 118, 135], ["Herpes simplex virus", "PROBLEM", 136, 156], ["virus", "OBSERVATION", 130, 135], ["simplex virus", "OBSERVATION", 143, 156]]], ["Herpes simplex virus resides inside the human host latently in sensory neurons, but gets reactivated due to the altered host immunity and replicates efficiently in epithelial cells causing genital or oral lesions (the latter is referred to as 'cold sores').", [["sensory neurons", "ANATOMY", 63, 78], ["epithelial cells", "ANATOMY", 164, 180], ["genital", "ANATOMY", 189, 196], ["oral lesions", "ANATOMY", 200, 212], ["Herpes simplex", "DISEASE", 0, 14], ["genital or oral lesions", "DISEASE", 189, 212], ["sores", "DISEASE", 249, 254], ["Herpes simplex virus", "ORGANISM", 0, 20], ["human", "ORGANISM", 40, 45], ["sensory neurons", "CELL", 63, 78], ["epithelial cells", "CELL", 164, 180], ["genital", "ORGANISM_SUBDIVISION", 189, 196], ["oral lesions", "PATHOLOGICAL_FORMATION", 200, 212], ["sensory neurons", "CELL_TYPE", 63, 78], ["epithelial cells", "CELL_TYPE", 164, 180], ["Herpes simplex virus", "SPECIES", 0, 20], ["human", "SPECIES", 40, 45], ["Herpes simplex virus", "SPECIES", 0, 20], ["human", "SPECIES", 40, 45], ["Herpes simplex virus", "PROBLEM", 0, 20], ["the altered host immunity", "PROBLEM", 108, 133], ["epithelial cells", "PROBLEM", 164, 180], ["genital or oral lesions", "PROBLEM", 189, 212], ["simplex virus", "OBSERVATION", 7, 20], ["human host latently", "OBSERVATION", 40, 59], ["sensory neurons", "ANATOMY", 63, 78], ["epithelial cells", "OBSERVATION", 164, 180], ["genital", "ANATOMY", 189, 196], ["oral", "ANATOMY", 200, 204], ["lesions", "OBSERVATION", 205, 212]]], ["An association of rs12979860 with the recurrence and severity of herpes simplex virus-1-induced 'cold sores' was reported from a study on a small number of individuals (n = 57).", [["herpes simplex virus-1", "CHEMICAL", 65, 87], ["sores", "DISEASE", 102, 107], ["herpes simplex virus-1", "ORGANISM", 65, 87], ["herpes simplex virus-1", "SPECIES", 65, 87], ["herpes simplex virus-1", "SPECIES", 65, 87], ["the recurrence", "PROBLEM", 34, 48], ["herpes simplex virus", "PROBLEM", 65, 85], ["'cold sores'", "PROBLEM", 96, 108], ["a study", "TEST", 127, 134]]], ["75 A recent report carried out on a large number of individuals (n = 2192 for genital herpes; n = 1511 for oral herpes) clearly found no association of rs368234815 with recurrence of genital or oral herpes episodes.", [["genital", "ANATOMY", 78, 85], ["oral", "ANATOMY", 107, 111], ["genital", "ANATOMY", 183, 190], ["oral", "ANATOMY", 194, 198], ["genital herpes", "DISEASE", 78, 92], ["oral herpes", "DISEASE", 107, 118], ["oral herpes episodes", "DISEASE", 194, 214], ["genital herpes", "ORGANISM", 78, 92], ["oral", "ORGANISM_SUBDIVISION", 107, 111], ["herpes", "ORGANISM", 112, 118], ["rs368234815", "GENE_OR_GENE_PRODUCT", 152, 163], ["genital", "ORGANISM_SUBDIVISION", 183, 190], ["oral", "ORGANISM_SUBDIVISION", 194, 198], ["herpes", "ORGANISM", 199, 205], ["genital herpes", "PROBLEM", 78, 92], ["oral herpes", "PROBLEM", 107, 118], ["genital or oral herpes episodes", "PROBLEM", 183, 214], ["genital", "ANATOMY", 183, 190], ["herpes", "OBSERVATION", 199, 205]]], ["76 Among other phenotypes, the latter report ruled out an effect of the SNP on 'frequency of recurrence' of oral herpes, it however did not rule out an effect of the SNP on severity of infection.Hepatitis B virus.Non-infectious diseases and miscellaneous conditions.", [["oral", "ANATOMY", 108, 112], ["SNP", "CHEMICAL", 72, 75], ["oral herpes", "DISEASE", 108, 119], ["SNP", "CHEMICAL", 166, 169], ["infection", "DISEASE", 185, 194], ["Hepatitis B", "DISEASE", 195, 206], ["Non-infectious diseases", "DISEASE", 213, 236], ["SNP", "CHEMICAL", 166, 169], ["oral", "ORGANISM_SUBDIVISION", 108, 112], ["herpes", "ORGANISM", 113, 119], ["Hepatitis B virus", "ORGANISM", 195, 212], ["Hepatitis B virus", "SPECIES", 195, 212], ["Hepatitis B virus", "SPECIES", 195, 212], ["the SNP", "TREATMENT", 68, 75], ["oral herpes", "PROBLEM", 108, 119], ["the SNP", "TREATMENT", 162, 169], ["infection", "PROBLEM", 185, 194], ["Hepatitis B virus", "PROBLEM", 195, 212], ["Non-infectious diseases", "PROBLEM", 213, 236], ["miscellaneous conditions", "PROBLEM", 241, 265], ["herpes", "OBSERVATION", 113, 119], ["infection", "OBSERVATION", 185, 194], ["virus", "OBSERVATION", 207, 212], ["miscellaneous conditions", "OBSERVATION", 241, 265]]], ["IFNL SNPs have also been tried as candidate gene SNPs in some noninfectious inflammatory diseases.", [["inflammatory diseases", "DISEASE", 76, 97], ["IFNL", "GENE_OR_GENE_PRODUCT", 0, 4], ["IFNL SNPs", "DNA", 0, 9], ["candidate gene SNPs", "DNA", 34, 53], ["gene SNPs", "PROBLEM", 44, 53], ["some noninfectious inflammatory diseases", "PROBLEM", 57, 97], ["some", "OBSERVATION_MODIFIER", 57, 61], ["noninfectious", "OBSERVATION_MODIFIER", 62, 75], ["inflammatory", "OBSERVATION", 76, 88]]], ["The association of IFNL SNPs with NAFLD was earlier reported by Petta et al. 77 This study with 160 subjects identified an independent association with the CC genotype at rs12979860 and the severity of lobular inflammation (CC genotype positively correlated with severity of inflammation) in a cohort of patients with NAFLD (P = o 0.001).", [["lobular", "ANATOMY", 202, 209], ["NAFLD", "DISEASE", 34, 39], ["CC", "CHEMICAL", 156, 158], ["lobular inflammation", "DISEASE", 202, 222], ["CC", "CHEMICAL", 224, 226], ["inflammation", "DISEASE", 275, 287], ["NAFLD", "DISEASE", 318, 323], ["IFNL", "GENE_OR_GENE_PRODUCT", 19, 23], ["lobular inflammation", "PATHOLOGICAL_FORMATION", 202, 222], ["patients", "ORGANISM", 304, 312], ["IFNL SNPs", "DNA", 19, 28], ["patients", "SPECIES", 304, 312], ["IFNL SNPs", "PROBLEM", 19, 28], ["NAFLD", "PROBLEM", 34, 39], ["This study", "TEST", 80, 90], ["the CC genotype", "TEST", 152, 167], ["lobular inflammation", "PROBLEM", 202, 222], ["inflammation", "PROBLEM", 275, 287], ["NAFLD", "PROBLEM", 318, 323], ["lobular", "OBSERVATION_MODIFIER", 202, 209], ["inflammation", "OBSERVATION", 210, 222], ["inflammation", "OBSERVATION", 275, 287]]], ["The study was conducted taking lead from previous reports of increased hepatic necroinflammation in HCV patients with the CC genotype at rs12979860.", [["hepatic", "ANATOMY", 71, 78], ["hepatic necroinflammation", "DISEASE", 71, 96], ["HCV", "DISEASE", 100, 103], ["CC", "CHEMICAL", 122, 124], ["hepatic", "ORGAN", 71, 78], ["HCV", "ORGANISM", 100, 103], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["HCV", "SPECIES", 100, 103], ["The study", "TEST", 0, 9], ["increased hepatic necroinflammation", "PROBLEM", 61, 96], ["the CC genotype at rs12979860", "TREATMENT", 118, 147], ["increased", "OBSERVATION_MODIFIER", 61, 70], ["hepatic", "ANATOMY", 71, 78], ["necroinflammation", "OBSERVATION", 79, 96], ["HCV", "OBSERVATION", 100, 103]]], ["78 Another report showed no such association in 195 Caucasian biopsy-confirmed NAFLD patients.", [["NAFLD", "DISEASE", 79, 84], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["Caucasian biopsy", "TEST", 52, 68]]], ["79 However, all the patients in this cohort were obese (with body mass index 430), whereas in the previous study only 40% were obese.", [["body", "ANATOMY", 61, 65], ["patients", "ORGANISM", 20, 28], ["body", "ORGANISM_SUBDIVISION", 61, 65], ["patients", "SPECIES", 20, 28], ["obese", "PROBLEM", 49, 54], ["body mass index", "TEST", 61, 76], ["the previous study", "TEST", 94, 112], ["obese", "PROBLEM", 127, 132], ["obese", "OBSERVATION", 49, 54], ["obese", "OBSERVATION", 127, 132]]], ["After the latter report, Petta et al. 80 revisited their data and indeed found an association with the IFNL SNP only with their non-obese patients (n = 94; P = 0o0.001) but not with the obese patients (n = 66; P = 0.13).", [["SNP", "CHEMICAL", 108, 111], ["non-obese", "DISEASE", 128, 137], ["obese", "DISEASE", 186, 191], ["IFNL", "GENE_OR_GENE_PRODUCT", 103, 107], ["patients", "ORGANISM", 138, 146], ["patients", "ORGANISM", 192, 200], ["IFNL SNP", "DNA", 103, 111], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 192, 200], ["the IFNL SNP", "TREATMENT", 99, 111], ["P", "TEST", 156, 157], ["P", "TEST", 210, 211]]], ["These initial doubts seem to have been resolved with a recent report by Eslam et al. 81 who worked on a relatively large number of NAFLD patients (n = 488) and confirmed the association of the CC genotype at rs12979860 with increased severity of liver inflammation and fibrosis (P = o 0.0001).", [["liver", "ANATOMY", 246, 251], ["NAFLD", "DISEASE", 131, 136], ["CC", "CHEMICAL", 193, 195], ["liver inflammation", "DISEASE", 246, 264], ["fibrosis", "DISEASE", 269, 277], ["patients", "ORGANISM", 137, 145], ["liver", "ORGAN", 246, 251], ["patients", "SPECIES", 137, 145], ["the CC genotype", "PROBLEM", 189, 204], ["liver inflammation", "PROBLEM", 246, 264], ["fibrosis", "PROBLEM", 269, 277], ["increased", "OBSERVATION_MODIFIER", 224, 233], ["severity", "OBSERVATION_MODIFIER", 234, 242], ["liver", "ANATOMY", 246, 251], ["inflammation", "OBSERVATION", 252, 264], ["fibrosis", "OBSERVATION", 269, 277]]], ["They also found a similar strong association with hepatic inflammation and fibrosis in separate cohorts of viral hepatitis C (n = 3129) and B (n = 555), strongly suggesting that even though the major allele genotype CC is beneficial against HCV and HBV, it is also responsible for excess inflammation of the liver in viral and non-viral hepatitis.", [["hepatic", "ANATOMY", 50, 57], ["liver", "ANATOMY", 308, 313], ["hepatic inflammation", "DISEASE", 50, 70], ["fibrosis", "DISEASE", 75, 83], ["viral hepatitis C", "DISEASE", 107, 124], ["CC", "CHEMICAL", 216, 218], ["inflammation of the liver", "DISEASE", 288, 313], ["viral and non-viral hepatitis", "DISEASE", 317, 346], ["hepatic", "ORGAN", 50, 57], ["viral hepatitis C", "ORGANISM", 107, 124], ["HCV", "ORGANISM", 241, 244], ["HBV", "ORGANISM", 249, 252], ["liver", "ORGAN", 308, 313], ["non-viral hepatitis", "ORGANISM", 327, 346], ["HCV", "SPECIES", 241, 244], ["HBV", "SPECIES", 249, 252], ["hepatic inflammation", "PROBLEM", 50, 70], ["fibrosis", "PROBLEM", 75, 83], ["viral hepatitis C", "PROBLEM", 107, 124], ["B (n", "TEST", 140, 144], ["the major allele genotype CC", "PROBLEM", 190, 218], ["HCV", "PROBLEM", 241, 244], ["HBV", "PROBLEM", 249, 252], ["excess inflammation of the liver", "PROBLEM", 281, 313], ["viral and non-viral hepatitis", "PROBLEM", 317, 346], ["strong", "OBSERVATION_MODIFIER", 26, 32], ["hepatic", "ANATOMY", 50, 57], ["inflammation", "OBSERVATION", 58, 70], ["fibrosis", "OBSERVATION", 75, 83], ["viral hepatitis", "OBSERVATION", 107, 122], ["inflammation", "OBSERVATION", 288, 300], ["liver", "ANATOMY", 308, 313], ["viral", "OBSERVATION", 317, 322], ["non-viral hepatitis", "OBSERVATION", 327, 346]]], ["All four studies 77-81 report on dominant models of inheritance for the minor alleles; but unlike in the context of chronic HCV infections, [11] [12] [13] the minor alleles in NAFLD are beneficial rather than being non-beneficial, as they are responsible for less severe hepatic inflammation.Hepatitis B virus.Extending the potential role for IFNL SNPs in inflammatory diseases, there is also a recent report that showed association of rs12979860 and allergy in children aged o5 years.", [["hepatic", "ANATOMY", 271, 278], ["HCV infections", "DISEASE", 124, 138], ["[11] [12] [13", "CHEMICAL", 140, 153], ["NAFLD", "DISEASE", 176, 181], ["hepatic inflammation", "DISEASE", 271, 291], ["Hepatitis B", "DISEASE", 292, 303], ["inflammatory diseases", "DISEASE", 356, 377], ["allergy", "DISEASE", 451, 458], ["[11] [12] [13]", "SIMPLE_CHEMICAL", 140, 154], ["hepatic", "ORGAN", 271, 278], ["Hepatitis B virus", "ORGANISM", 292, 309], ["IFNL", "GENE_OR_GENE_PRODUCT", 343, 347], ["children", "ORGANISM", 462, 470], ["IFNL SNPs", "DNA", 343, 352], ["Hepatitis B virus", "SPECIES", 292, 309], ["children", "SPECIES", 462, 470], ["HCV", "SPECIES", 124, 127], ["Hepatitis B virus", "SPECIES", 292, 309], ["All four studies", "TEST", 0, 16], ["the minor alleles", "PROBLEM", 68, 85], ["chronic HCV infections", "PROBLEM", 116, 138], ["the minor alleles in NAFLD", "PROBLEM", 155, 181], ["less severe hepatic inflammation", "PROBLEM", 259, 291], ["Hepatitis B virus", "PROBLEM", 292, 309], ["IFNL SNPs", "PROBLEM", 343, 352], ["inflammatory diseases", "PROBLEM", 356, 377], ["chronic", "OBSERVATION_MODIFIER", 116, 123], ["HCV", "OBSERVATION", 124, 127], ["NAFLD", "OBSERVATION", 176, 181], ["severe", "OBSERVATION_MODIFIER", 264, 270], ["hepatic", "ANATOMY", 271, 278], ["inflammation", "OBSERVATION", 279, 291], ["virus", "OBSERVATION", 304, 309], ["inflammatory", "OBSERVATION_MODIFIER", 356, 368], ["diseases", "OBSERVATION", 369, 377]]], ["82 Although the study involved a small sample size (non-allergic, n = 35; allergic cohort 1, n = 35; food allergy cohort 2, n = 30), a large effect size (odds ratio = 4.56, P = 0.004, for cohort 1) was seen wherein the non-beneficial T allele at rs12979860 was over-represented in the allergy group in a dominant model of inheritance.", [["non-allergic", "DISEASE", 52, 64], ["allergic", "DISEASE", 74, 82], ["food allergy", "DISEASE", 101, 113], ["allergy", "DISEASE", 285, 292], ["T", "GENE_OR_GENE_PRODUCT", 234, 235], ["non-beneficial T allele", "DNA", 219, 242], ["the study", "TEST", 12, 21], ["a small sample size", "PROBLEM", 31, 50], ["non-allergic", "PROBLEM", 52, 64], ["allergic cohort", "TEST", 74, 89], ["food allergy cohort", "PROBLEM", 101, 120], ["a large effect size", "PROBLEM", 133, 152], ["odds ratio", "TEST", 154, 164], ["P", "TEST", 173, 174], ["small", "OBSERVATION_MODIFIER", 33, 38], ["size", "OBSERVATION_MODIFIER", 46, 50], ["large", "OBSERVATION_MODIFIER", 135, 140], ["effect", "OBSERVATION_MODIFIER", 141, 147], ["size", "OBSERVATION_MODIFIER", 148, 152]]], ["Another interesting finding in this study was that the effect of the IFNL SNP was more pronounced in females than males.", [["SNP", "CHEMICAL", 74, 77], ["SNP", "CHEMICAL", 74, 77], ["IFNL", "GENE_OR_GENE_PRODUCT", 69, 73], ["IFNL SNP", "DNA", 69, 77], ["this study", "TEST", 31, 41], ["the IFNL SNP", "TREATMENT", 65, 77]]], ["This report suggests that the non-beneficial IFNL SNP minor allele-carrying genotypes may predispose children to an allergic phenotype by skewing the Th1/Th2 balance to a Th2 predominant one.", [["SNP", "CHEMICAL", 50, 53], ["allergic", "DISEASE", 116, 124], ["IFNL", "GENE_OR_GENE_PRODUCT", 45, 49], ["children", "ORGANISM", 101, 109], ["Th1", "GENE_OR_GENE_PRODUCT", 150, 153], ["non-beneficial IFNL SNP minor allele", "DNA", 30, 66], ["children", "SPECIES", 101, 109], ["the non-beneficial IFNL SNP", "TREATMENT", 26, 53], ["an allergic phenotype", "PROBLEM", 113, 134], ["allergic", "OBSERVATION", 116, 124]]], ["This extrapolation is also based on the findings from a recent study on mice model of allergic asthma, which showed that IFN-\u03bb2 was able to rescue mice from allergy by suppressing Th2 cytokines.", [["allergic asthma", "DISEASE", 86, 101], ["allergy", "DISEASE", 157, 164], ["mice", "ORGANISM", 72, 76], ["IFN-\u03bb2", "GENE_OR_GENE_PRODUCT", 121, 127], ["mice", "ORGANISM", 147, 151], ["IFN", "PROTEIN", 121, 124], ["Th2 cytokines", "PROTEIN", 180, 193], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 147, 151], ["a recent study", "TEST", 54, 68], ["allergic asthma", "PROBLEM", 86, 101], ["IFN", "TEST", 121, 124], ["allergy", "PROBLEM", 157, 164], ["allergic asthma", "OBSERVATION", 86, 101]]], ["39 These conclusions would also suggest a role for IFNL SNPs in immune response to respiratory viral infections, which account for disease exacerbations in conditions such as asthma.", [["respiratory viral infections", "DISEASE", 83, 111], ["asthma", "DISEASE", 175, 181], ["IFNL", "GENE_OR_GENE_PRODUCT", 51, 55], ["IFNL SNPs", "DNA", 51, 60], ["IFNL SNPs", "PROBLEM", 51, 60], ["respiratory viral infections", "PROBLEM", 83, 111], ["disease exacerbations in conditions", "PROBLEM", 131, 166], ["asthma", "PROBLEM", 175, 181], ["respiratory", "ANATOMY", 83, 94], ["viral infections", "OBSERVATION", 95, 111], ["asthma", "OBSERVATION", 175, 181]]], ["83 A study carried out on infants with respiratory syncytial virus-induced bronchiolitis shows no association of r12979860 and rs8099917 with viral load or other clinical features.", [["respiratory syncytial virus", "DISEASE", 39, 66], ["bronchiolitis", "DISEASE", 75, 88], ["infants", "ORGANISM", 26, 33], ["respiratory syncytial virus", "ORGANISM", 39, 66], ["r12979860", "GENE_OR_GENE_PRODUCT", 113, 122], ["rs8099917", "GENE_OR_GENE_PRODUCT", 127, 136], ["infants", "SPECIES", 26, 33], ["A study", "TEST", 3, 10], ["respiratory syncytial virus", "PROBLEM", 39, 66], ["bronchiolitis", "PROBLEM", 75, 88], ["viral load", "TEST", 142, 152], ["syncytial virus", "OBSERVATION", 51, 66], ["bronchiolitis", "OBSERVATION", 75, 88], ["no", "UNCERTAINTY", 95, 97]]], ["84 Interestingly, the non-beneficial TT genotype of rs12979860 was associated with early age of hospitalization in the infants (P = 0.005).", [["infants", "ORGANISM", 119, 126], ["infants", "SPECIES", 119, 126]]], ["More studies are awaited on the association of IFNL SNPs with allergy and allergy-related diseases.", [["allergy", "DISEASE", 62, 69], ["allergy", "DISEASE", 74, 81], ["IFNL", "GENE_OR_GENE_PRODUCT", 47, 51], ["IFNL SNPs", "DNA", 47, 56], ["IFNL SNPs", "PROBLEM", 47, 56], ["allergy", "PROBLEM", 62, 69], ["allergy", "PROBLEM", 74, 81], ["related diseases", "PROBLEM", 82, 98], ["diseases", "OBSERVATION", 90, 98]]], ["In the autoimmune disorder multiple sclerosis, rs8099917 and rs12979860 did not show any association with IFN-\u03b2 treatment.", [["autoimmune disorder multiple sclerosis", "DISEASE", 7, 45], ["IFN-\u03b2", "CHEMICAL", 106, 111], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 106, 111], ["IFN", "PROTEIN", 106, 109], ["\u03b2", "PROTEIN", 110, 111], ["the autoimmune disorder", "PROBLEM", 3, 26], ["multiple sclerosis", "PROBLEM", 27, 45], ["rs8099917", "TEST", 47, 56], ["rs12979860", "TEST", 61, 71], ["IFN-\u03b2 treatment", "TREATMENT", 106, 121], ["autoimmune", "OBSERVATION_MODIFIER", 7, 17], ["multiple", "OBSERVATION_MODIFIER", 27, 35], ["sclerosis", "OBSERVATION", 36, 45]]], ["85 As evidence for a potential role of IFN-\u03bbs and IFNL SNPs in adaptive immune responses, a study has linked IFNL SNPs with development of effective vaccine response against human influenza virus in immunosuppressed individuals.", [["influenza virus", "DISEASE", 180, 195], ["IFN-\u03bbs", "GENE_OR_GENE_PRODUCT", 39, 45], ["IFNL", "GENE_OR_GENE_PRODUCT", 50, 54], ["IFNL", "GENE_OR_GENE_PRODUCT", 109, 113], ["human", "ORGANISM", 174, 179], ["influenza virus", "ORGANISM", 180, 195], ["IFN-\u03bbs and IFNL SNPs", "DNA", 39, 59], ["IFNL SNPs", "DNA", 109, 118], ["human", "SPECIES", 174, 179], ["influenza virus", "SPECIES", 180, 195], ["human influenza virus", "SPECIES", 174, 195], ["IFN", "PROBLEM", 39, 42], ["IFNL SNPs", "PROBLEM", 50, 59], ["a study", "TEST", 90, 97], ["effective vaccine response", "TREATMENT", 139, 165], ["human influenza virus", "PROBLEM", 174, 195]]], ["86 The study shows that minor allele (G)-carrying individuals at rs8099917 show better vaccine responses (odds ratio = 1.99; P = 0.038) in a dominant model of inheritance, and that T cells from minor allele-carrying individuals produce more IL-4 (a Th2 cytokine).", [["T cells", "ANATOMY", 181, 188], ["T cells", "CELL", 181, 188], ["IL-4", "GENE_OR_GENE_PRODUCT", 241, 245], ["Th2", "GENE_OR_GENE_PRODUCT", 249, 252], ["T cells", "CELL_TYPE", 181, 188], ["IL-4", "PROTEIN", 241, 245], ["Th2 cytokine", "PROTEIN", 249, 261], ["The study", "TEST", 3, 12], ["minor allele (G)-carrying individuals", "PROBLEM", 24, 61], ["odds ratio", "TEST", 106, 116], ["P", "TEST", 125, 126], ["T cells", "PROBLEM", 181, 188], ["a Th2 cytokine)", "TREATMENT", 247, 262]]], ["This study also showed that recombinant IFN-\u03bb3 increased Th1 responses from human peripheral blood mononuclear cells while inhibiting Th2 responses (Th2 cytokines are needed for effective seroconversion).", [["peripheral blood mononuclear cells", "ANATOMY", 82, 116], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 40, 46], ["Th1", "GENE_OR_GENE_PRODUCT", 57, 60], ["human", "ORGANISM", 76, 81], ["peripheral blood mononuclear cells", "CELL", 82, 116], ["IFN", "PROTEIN", 40, 43], ["\u03bb3", "PROTEIN", 44, 46], ["human peripheral blood mononuclear cells", "CELL_TYPE", 76, 116], ["Th2 cytokines", "PROTEIN", 149, 162], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["This study", "TEST", 0, 10], ["recombinant IFN", "TEST", 28, 43], ["increased Th1 responses", "PROBLEM", 47, 70], ["human peripheral blood mononuclear cells", "TREATMENT", 76, 116], ["Th2 cytokines", "TREATMENT", 149, 162], ["effective seroconversion", "TREATMENT", 178, 202], ["mononuclear cells", "OBSERVATION", 99, 116]]], ["86TRANSCRIPTION STUDIES ON THE IFNL4 GENEStudies have accumulated evidence on the different transcription factors (TFs) that bind and drive transcription from all four IFNL genes.", [["TFs", "GENE_OR_GENE_PRODUCT", 115, 118], ["IFNL", "GENE_OR_GENE_PRODUCT", 168, 172], ["transcription factors", "PROTEIN", 92, 113], ["TFs", "PROTEIN", 115, 118], ["IFNL genes", "DNA", 168, 178], ["the different transcription factors", "PROBLEM", 78, 113], ["TFs)", "TREATMENT", 115, 119]]], ["Roles for several virus-inducible TFs such as NF-\u03baB (nuclear factor kappa-light-chain-enhancer of activated B cells), IFN regulatory factor-3 and IFN regulatory factor-7 have been defined for IFNL1, 2 and 3 genes, and have been reviewed elsewhere.", [["B cells", "ANATOMY", 108, 115], ["TFs", "CELL", 34, 37], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 46, 51], ["IFN regulatory factor-3", "GENE_OR_GENE_PRODUCT", 118, 141], ["IFN regulatory factor-7", "GENE_OR_GENE_PRODUCT", 146, 169], ["IFNL1", "GENE_OR_GENE_PRODUCT", 192, 197], ["2", "GENE_OR_GENE_PRODUCT", 199, 200], ["3", "GENE_OR_GENE_PRODUCT", 205, 206], ["NF-\u03baB", "PROTEIN", 46, 51], ["nuclear factor kappa-light-chain-enhancer of activated B cells", "PROTEIN", 53, 115], ["IFN regulatory factor-3", "PROTEIN", 118, 141], ["IFN regulatory factor-7", "PROTEIN", 146, 169], ["IFNL1, 2 and 3 genes", "DNA", 192, 212], ["several virus", "PROBLEM", 10, 23], ["inducible TFs", "PROBLEM", 24, 37], ["NF", "TEST", 46, 48], ["nuclear factor kappa-", "TEST", 53, 74], ["activated B cells", "PROBLEM", 98, 115], ["IFN regulatory factor", "TEST", 118, 139], ["IFN regulatory factor", "TEST", 146, 167]]], ["28, 87, 88 We recently showed that apart from these three TFs, specificity protein 1 ( a GC-rich DNA-binding TF) also has a role in driving transcription from the IFNL4 promoter in A549 cells 89 (Figure 4a) .", [["A549 cells", "ANATOMY", 181, 191], ["TFs", "CELL", 58, 61], ["specificity protein 1", "GENE_OR_GENE_PRODUCT", 63, 84], ["DNA", "CELLULAR_COMPONENT", 97, 100], ["-binding TF", "GENE_OR_GENE_PRODUCT", 100, 111], ["IFNL4", "GENE_OR_GENE_PRODUCT", 163, 168], ["A549 cells", "CELL", 181, 191], ["specificity protein 1", "PROTEIN", 63, 84], ["GC-rich DNA-binding TF", "PROTEIN", 89, 111], ["IFNL4 promoter", "DNA", 163, 177], ["A549 cells", "CELL_LINE", 181, 191], ["specificity protein", "TEST", 63, 82], ["a GC", "TEST", 87, 91], ["A549 cells", "TEST", 181, 191]]], ["A CpG island of~1.5 kb is located upstream of the IFNL3 gene and overlapping the IFNL4 gene, and also includes two of the most important IFNL SNPs rs12979860 and rs368234815.", [["CpG", "CHEMICAL", 2, 5], ["IFNL3", "GENE_OR_GENE_PRODUCT", 50, 55], ["IFNL4", "GENE_OR_GENE_PRODUCT", 81, 86], ["IFNL", "GENE_OR_GENE_PRODUCT", 137, 141], ["CpG island", "DNA", 2, 12], ["IFNL3 gene", "DNA", 50, 60], ["IFNL4 gene", "DNA", 81, 91], ["IFNL SNPs rs12979860", "DNA", 137, 157], ["rs368234815", "DNA", 162, 173], ["A CpG island", "TREATMENT", 0, 12]]], ["Epigenetic regulation of the transcriptional activity at the IFNL locus is likely to involve this CpG island and needs further exploration.", [["CpG", "CHEMICAL", 98, 101], ["IFNL", "GENE_OR_GENE_PRODUCT", 61, 65], ["IFNL locus", "DNA", 61, 71], ["this CpG island", "PROBLEM", 93, 108], ["further exploration", "TEST", 119, 138], ["transcriptional activity", "OBSERVATION", 29, 53], ["likely to involve", "UNCERTAINTY", 75, 92]]], ["90, 91 Even though IFNL4 messenger RNA (mRNA) was shown to be highly expressed from stimulated primary hepatocytes in the original report that described the discovery of IFNL4, 14 subsequent studies have not seen robust expression levels of IFNL4 gene in human samples.", [["primary hepatocytes", "ANATOMY", 95, 114], ["samples", "ANATOMY", 261, 268], ["IFNL4", "GENE_OR_GENE_PRODUCT", 19, 24], ["hepatocytes", "CELL", 103, 114], ["IFNL4", "GENE_OR_GENE_PRODUCT", 170, 175], ["IFNL4", "GENE_OR_GENE_PRODUCT", 241, 246], ["human", "ORGANISM", 255, 260], ["samples", "CANCER", 261, 268], ["IFNL4 messenger RNA", "RNA", 19, 38], ["mRNA", "RNA", 40, 44], ["primary hepatocytes", "CELL_TYPE", 95, 114], ["IFNL4", "PROTEIN", 170, 175], ["IFNL4 gene", "DNA", 241, 251], ["human", "SPECIES", 255, 260], ["human", "SPECIES", 255, 260], ["subsequent studies", "TEST", 180, 198], ["IFNL4 gene in human samples", "PROBLEM", 241, 268]]], ["For example, Amanzada and others found IFNL4 transcripts expressed at 4.3-5.6-fold lower levels than IFNL2/3 mRNA in liver biopsies of HCV-infected patients.", [["liver biopsies", "ANATOMY", 117, 131], ["HCV-infected", "DISEASE", 135, 147], ["IFNL4", "GENE_OR_GENE_PRODUCT", 39, 44], ["IFNL2/3", "GENE_OR_GENE_PRODUCT", 101, 108], ["liver biopsies", "MULTI-TISSUE_STRUCTURE", 117, 131], ["HCV", "ORGANISM", 135, 138], ["patients", "ORGANISM", 148, 156], ["IFNL4 transcripts", "RNA", 39, 56], ["IFNL2/3 mRNA", "RNA", 101, 113], ["patients", "SPECIES", 148, 156], ["HCV", "SPECIES", 135, 138], ["fold lower levels", "PROBLEM", 78, 95], ["IFNL2", "TEST", 101, 106], ["liver biopsies", "TEST", 117, 131], ["HCV", "PROBLEM", 135, 138], ["liver", "ANATOMY", 117, 122], ["biopsies", "OBSERVATION", 123, 131], ["HCV", "OBSERVATION", 135, 138], ["infected", "OBSERVATION", 139, 147]]], ["92 In another report, IFNL4 mRNA was detectable in only in 7/23 and 8/23 patient-derived peripheral blood mononuclear cells that were stimulated or not with IFN-poly(I:C), respectively.", [["7/23", "ANATOMY", 59, 63], ["peripheral blood mononuclear cells", "ANATOMY", 89, 123], ["IFNL4", "GENE_OR_GENE_PRODUCT", 22, 27], ["patient", "ORGANISM", 73, 80], ["peripheral blood mononuclear cells", "CELL", 89, 123], ["IFNL4 mRNA", "RNA", 22, 32], ["peripheral blood mononuclear cells", "CELL_TYPE", 89, 123], ["IFN", "PROTEIN", 157, 160], ["patient", "SPECIES", 73, 80], ["IFNL4 mRNA", "TEST", 22, 32], ["peripheral blood mononuclear cells", "PROBLEM", 89, 123], ["IFN", "TEST", 157, 160], ["peripheral", "ANATOMY_MODIFIER", 89, 99], ["blood", "ANATOMY", 100, 105], ["mononuclear cells", "OBSERVATION", 106, 123]]], ["93 All 23 patients carried at least one copy of the functional IFN-\u03bb4-generating allele, \u0394G.", [["patients", "ORGANISM", 10, 18], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 63, 69], ["IFN", "PROTEIN", 63, 66], ["\u03bb4", "PROTEIN", 67, 69], ["allele", "DNA", 81, 87], ["\u0394G", "DNA", 89, 91], ["patients", "SPECIES", 10, 18]]], ["In the report by Liang and colleagues also, IFNL4 transcripts were seen in only 33/70 liver biopsies from HCV-infected patients.", [["liver biopsies", "ANATOMY", 86, 100], ["HCV-infected", "DISEASE", 106, 118], ["IFNL4", "GENE_OR_GENE_PRODUCT", 44, 49], ["liver biopsies", "MULTI-TISSUE_STRUCTURE", 86, 100], ["HCV", "ORGANISM", 106, 109], ["patients", "ORGANISM", 119, 127], ["IFNL4 transcripts", "RNA", 44, 61], ["patients", "SPECIES", 119, 127], ["HCV", "SPECIES", 106, 109], ["liver biopsies", "TEST", 86, 100], ["HCV", "PROBLEM", 106, 109], ["liver", "ANATOMY", 86, 91], ["biopsies", "OBSERVATION", 92, 100], ["HCV", "OBSERVATION", 106, 109], ["infected", "OBSERVATION", 110, 118]]], ["94 Furthermore, Lu et al. 41 found that only 2% of the transcripts generated from poly(I:C)-stimulated primary hepatocytes derived from two heterozygous (TT/\u0394G at rs368234815) individuals, represented functional IFN-\u03bb4 transcripts that originated from the \u0394G allele.", [["primary hepatocytes", "ANATOMY", 103, 122], ["poly(I:C", "CHEMICAL", 82, 90], ["poly(I:C", "GENE_OR_GENE_PRODUCT", 82, 90], ["hepatocytes", "CELL", 111, 122], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 212, 218], ["\u0394G", "GENE_OR_GENE_PRODUCT", 256, 258], ["poly(I:C)-stimulated primary hepatocytes", "CELL_LINE", 82, 122], ["IFN-\u03bb4 transcripts", "RNA", 212, 230], ["\u0394G allele", "DNA", 256, 265], ["stimulated primary hepatocytes", "PROBLEM", 92, 122], ["two heterozygous (TT/\u0394G", "PROBLEM", 136, 159], ["hepatocytes", "ANATOMY", 111, 122]]], ["Similarly, they also found no expression of the full-length functional IFN-\u03bb4 mRNA transcripts from poly(I: C)-stimulated A549 cells.", [["A549 cells", "ANATOMY", 122, 132], ["poly(I: C", "CHEMICAL", 100, 109], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 71, 77], ["poly(I: C", "SIMPLE_CHEMICAL", 100, 109], ["A549 cells", "CELL", 122, 132], ["IFN-\u03bb4 mRNA transcripts", "RNA", 71, 94], ["poly(I: C)-stimulated A549 cells", "CELL_LINE", 100, 132], ["stimulated A549 cells", "PROBLEM", 111, 132], ["A549 cells", "OBSERVATION", 122, 132]]], ["It is possible that the qPCR assays utilized in these studies may be suffering from technical difficulties in dealing with several different mRNA isoforms of IFNL4 gene.", [["IFNL4", "GENE_OR_GENE_PRODUCT", 158, 163], ["mRNA isoforms", "RNA", 141, 154], ["IFNL4 gene", "DNA", 158, 168], ["the qPCR assays", "TEST", 20, 35], ["these studies", "TEST", 48, 61], ["technical difficulties", "PROBLEM", 84, 106]]], ["14 All the four studies described above have used primer sets where at least one of the primers binds to the exon/intron/exon-intron junctions (Figure 4b) .", [["exon/intron", "DNA", 109, 120], ["All the four studies", "TEST", 3, 23], ["primer sets", "TREATMENT", 50, 61], ["the primers binds", "PROBLEM", 84, 101], ["the exon/intron/exon-intron junctions", "TREATMENT", 105, 142]]], ["Using a primer set that uniquely binds to the 3\u2032-untranslated region of IFNL4 mRNA, IFN-\u03bb4 induction was seen at levels similar to that of IFN-\u03bb2/3, upon human metapneumovirus infection of A549 cells by Banos-Lara et al. 45 We used the same primer set and found similar high expression levels upon poly(I:C)/HCV RNA transfection in A549 cells.", [["A549 cells", "ANATOMY", 189, 199], ["A549 cells", "ANATOMY", 332, 342], ["metapneumovirus infection", "DISEASE", 160, 185], ["poly(I:C", "CHEMICAL", 298, 306], ["IFNL4", "GENE_OR_GENE_PRODUCT", 72, 77], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 84, 90], ["IFN-\u03bb2", "GENE_OR_GENE_PRODUCT", 139, 145], ["3", "GENE_OR_GENE_PRODUCT", 146, 147], ["human", "ORGANISM", 154, 159], ["metapneumovirus", "ORGANISM", 160, 175], ["A549 cells", "CELL", 189, 199], ["poly(I:C", "GENE_OR_GENE_PRODUCT", 298, 306], ["HCV", "ORGANISM", 308, 311], ["A549 cells", "CELL", 332, 342], ["3\u2032-untranslated region", "DNA", 46, 68], ["IFNL4 mRNA", "RNA", 72, 82], ["IFN", "PROTEIN", 84, 87], ["\u03bb4", "PROTEIN", 88, 90], ["IFN", "PROTEIN", 139, 142], ["A549 cells", "CELL_LINE", 189, 199], ["poly(I:C)/HCV RNA", "RNA", 298, 315], ["A549 cells", "CELL_LINE", 332, 342], ["human", "SPECIES", 154, 159], ["human metapneumovirus", "SPECIES", 154, 175], ["HCV", "SPECIES", 308, 311], ["a primer", "TREATMENT", 6, 14], ["IFNL4 mRNA", "PROBLEM", 72, 82], ["IFN", "TEST", 84, 87], ["IFN", "TEST", 139, 142], ["human metapneumovirus infection of A549 cells", "PROBLEM", 154, 199], ["Banos", "TEST", 203, 208], ["similar high expression levels upon poly(I:C)/HCV RNA transfection in A549 cells", "PROBLEM", 262, 342], ["metapneumovirus", "OBSERVATION", 160, 175], ["A549 cells", "OBSERVATION", 189, 199], ["A549 cells", "OBSERVATION", 332, 342]]], ["89 Two other studies have reported no such problems in amplifying IFNL4 transcripts from liver biopsies.", [["liver biopsies", "ANATOMY", 89, 103], ["IFNL4", "GENE_OR_GENE_PRODUCT", 66, 71], ["liver biopsies", "MULTI-TISSUE_STRUCTURE", 89, 103], ["IFNL4 transcripts", "RNA", 66, 83], ["Two other studies", "TEST", 3, 20], ["such problems", "PROBLEM", 38, 51], ["liver biopsies", "TEST", 89, 103], ["liver", "ANATOMY", 89, 94], ["biopsies", "OBSERVATION", 95, 103]]], ["95, 96 Although Honda et al. 96 used the allelespecific Taqman assay described earlier, 14 Konishi et al. do not provide the primer sequence information that they used in their Taqman assays.", [["primer sequence", "DNA", 125, 140]]], ["95 The inconsistency in the above reports in detection of IFNL4 transcripts (either the full-length functional IFN-\u03bb4 isoform or the other isoforms) suggests that RNA-sequencing may be the optimal approach to measure IFNL4 transcripts.", [["IFNL4", "GENE_OR_GENE_PRODUCT", 58, 63], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 111, 117], ["IFNL4", "GENE_OR_GENE_PRODUCT", 217, 222], ["IFNL4 transcripts", "RNA", 58, 75], ["IFN", "PROTEIN", 111, 114], ["\u03bb4 isoform", "PROTEIN", 115, 125], ["IFNL4 transcripts", "RNA", 217, 234], ["IFNL4 transcripts", "PROBLEM", 58, 75], ["IFN", "TEST", 111, 114]]], ["Furthermore, the pre-mRNA splicing mechanism that leads to the expression of different IFN-\u03bb4 isoforms 14 under different stimulation and cell-type conditions needs to be examined.TRANSCRIPTION STUDIES ON THE IFNL4 GENETHE RELEVANCE OF OTHER 'IFN-\u03bb3 FUNCTIONAL SNPS' AFTER THE DISCOVERY OF FUNCTIONAL IFN-\u03bb4-GENERATING SNP Till date, three functional SNPs have been identified that regulate IFNL3 gene transcription/translation (referred to as 'IFN-\u03bb3 functional SNPs' in this section).", [["cell", "ANATOMY", 138, 142], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 87, 93], ["cell", "CELL", 138, 142], ["IFNL3", "GENE_OR_GENE_PRODUCT", 391, 396], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 445, 451], ["IFN", "PROTEIN", 87, 90], ["\u03bb4 isoforms 14", "PROTEIN", 91, 105], ["IFN", "PROTEIN", 243, 246], ["IFN", "PROTEIN", 301, 304], ["IFNL3 gene", "DNA", 391, 401], ["IFN", "PROTEIN", 445, 448], ["\u03bb3 functional SNPs", "DNA", 449, 467], ["the pre-mRNA splicing mechanism", "PROBLEM", 13, 44], ["different IFN", "TREATMENT", 77, 90], ["cell-type conditions", "TREATMENT", 138, 158], ["pre-mRNA splicing", "OBSERVATION", 17, 34]]], ["Although rs28416813 is a SNP present at~37 nucleotides upstream of the start codon of IFNL3 and is known to affect downstream gene expression by differentially binding to NF-\u03baB, 97 rs4803217 was identified in the 3\u2032-untranslated region region of IFNL3 (Figure 1a ) that affects stability of the mRNA by interfering with AU-rich element decay (AMD).", [["SNP", "CHEMICAL", 25, 28], ["AMD", "DISEASE", 343, 346], ["rs28416813", "GENE_OR_GENE_PRODUCT", 9, 19], ["IFNL3", "GENE_OR_GENE_PRODUCT", 86, 91], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 171, 176], ["rs4803217", "GENE_OR_GENE_PRODUCT", 181, 190], ["IFNL3 (Figure 1", "GENE_OR_GENE_PRODUCT", 246, 261], ["rs28416813", "DNA", 9, 19], ["~37 nucleotides upstream", "DNA", 39, 63], ["start codon", "DNA", 71, 82], ["IFNL3", "DNA", 86, 91], ["NF-\u03baB", "DNA", 171, 176], ["3\u2032-untranslated region region", "DNA", 213, 242], ["IFNL3", "DNA", 246, 251], ["mRNA", "RNA", 295, 299], ["AU-rich element", "DNA", 320, 335], ["a SNP", "TEST", 23, 28], ["NF", "TEST", 171, 173]]], ["98 Both these SNPs are in high LD with each other and with rs12979860 and were predicted to be two of the four potential causal SNPs from among the HCV-GWAS hits.", [["HCV-GWAS hits", "DNA", 148, 161], ["HCV", "SPECIES", 148, 151], ["rs12979860", "TEST", 59, 69], ["causal SNPs", "PROBLEM", 121, 132], ["HCV", "OBSERVATION", 148, 151]]], ["15, 99 A recent study defines another mechanism by which rs4803217 affects the stability of RNA by remodeling its secondary structure.", [["rs4803217", "GENE_OR_GENE_PRODUCT", 57, 66], ["A recent study", "TEST", 7, 21], ["stability", "OBSERVATION_MODIFIER", 79, 88], ["secondary structure", "OBSERVATION", 114, 133]]], ["100 Furthermore, a third functional SNP is the TA repeat polymorphism rs59702201, originally reported by the Mizokami group.", [["SNP", "CHEMICAL", 36, 39], ["TA repeat polymorphism rs59702201", "DNA", 47, 80], ["the TA repeat polymorphism", "TEST", 43, 69]]], ["101 This SNP located within the proximal promoter affects transcription of IFNL3, depending on the number of repeats present.", [["SNP", "CHEMICAL", 9, 12], ["IFNL3", "GENE_OR_GENE_PRODUCT", 75, 80], ["proximal promoter", "DNA", 32, 49], ["IFNL3", "PROTEIN", 75, 80], ["This SNP", "TREATMENT", 4, 12], ["proximal", "ANATOMY_MODIFIER", 32, 40], ["promoter", "OBSERVATION_MODIFIER", 41, 49]]], ["101 Recent reports have confirmed the significance of this SNP in association studies involving chronic HCV infections.", [["SNP", "CHEMICAL", 59, 62], ["HCV infections", "DISEASE", 104, 118], ["HCV", "ORGANISM", 104, 107], ["HCV", "SPECIES", 104, 107], ["this SNP", "TREATMENT", 54, 62], ["chronic HCV infections", "PROBLEM", 96, 118], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["HCV infections", "OBSERVATION", 104, 118]]], ["[102] [103] [104] Apart from several reports that showed genotype-dependent differences in expression levels of IFN-\u03bb3 (reviewed in ref.", [["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 112, 118], ["IFN", "PROTEIN", 112, 115], ["\u03bb3", "PROTEIN", 116, 118], ["genotype-dependent differences", "PROBLEM", 57, 87], ["expression levels", "TEST", 91, 108], ["IFN", "TEST", 112, 115]]], ["94, 105 These results suggest that IFN-\u03bb3 expression levels dictated by the alleles present at the three functional SNPs may have a role in the observed phenotype in health and disease.", [["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 35, 41], ["IFN", "PROTEIN", 35, 38], ["\u03bb3", "PROTEIN", 39, 41], ["IFN", "TEST", 35, 38], ["expression levels", "TEST", 42, 59], ["disease", "PROBLEM", 177, 184]]], ["However, the discovery of the IFN-\u03bb4-generating SNP (rs368234815, referred to as 'IFN-\u03bb4 functional SNP' in this section) has overshadowed the importance of the 'IFN-\u03bb3 functional SNPs', as most of the new reports have chosen to test for the 'IFN-\u03bb4 functional SNP' rather than rs12979860, which is the tag-SNP for the 'IFN-\u03bb3 functional SNPs'.", [["SNP", "CHEMICAL", 48, 51], ["SNP", "CHEMICAL", 100, 103], ["SNP", "CHEMICAL", 261, 264], ["SNP", "CHEMICAL", 307, 310], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 30, 36], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 82, 88], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 162, 168], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 243, 249], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 320, 326], ["IFN", "PROTEIN", 30, 33], ["\u03bb4", "PROTEIN", 34, 36], ["rs368234815", "DNA", 53, 64], ["IFN", "PROTEIN", 82, 85], ["\u03bb4", "DNA", 86, 88], ["IFN-\u03bb3 functional SNPs", "DNA", 162, 184], ["IFN-\u03bb4 functional SNP", "DNA", 243, 264], ["rs12979860", "DNA", 278, 288], ["IFN-\u03bb3 functional SNPs", "DNA", 320, 342], ["functional SNP'", "TREATMENT", 89, 104], ["the 'IFN", "TREATMENT", 315, 323]]], ["15 Another SNP within the coding region of IFNL4 that leads to a non-synonymous mutation in the functional IFN-\u03bb4 protein is thought to be a better marker of association along with rs368234815, in chronic HCV infections.", [["SNP", "CHEMICAL", 11, 14], ["HCV infections", "DISEASE", 205, 219], ["IFNL4", "GENE_OR_GENE_PRODUCT", 43, 48], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 107, 113], ["rs368234815", "GENE_OR_GENE_PRODUCT", 181, 192], ["chronic HCV", "ORGANISM", 197, 208], ["IFNL4", "DNA", 43, 48], ["IFN", "PROTEIN", 107, 110], ["\u03bb4 protein", "PROTEIN", 111, 121], ["HCV", "SPECIES", 205, 208], ["Another SNP", "TREATMENT", 3, 14], ["a non-synonymous mutation", "PROBLEM", 63, 88], ["chronic HCV infections", "PROBLEM", 197, 219], ["non-synonymous mutation", "OBSERVATION", 65, 88], ["thought to be", "UNCERTAINTY", 125, 138], ["chronic", "OBSERVATION_MODIFIER", 197, 204], ["HCV", "OBSERVATION_MODIFIER", 205, 208], ["infections", "OBSERVATION", 209, 219]]], ["106 So the question arises: is the IFN-\u03bb4-generating SNP the sole functional SNP or the other SNPs regulating the expression of IFN-\u03bb3 also have independent roles?", [["SNP", "CHEMICAL", 53, 56], ["SNP", "CHEMICAL", 77, 80], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 35, 41], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 128, 134], ["IFN-\u03bb4-generating SNP", "DNA", 35, 56], ["IFN", "PROTEIN", 128, 131], ["\u03bb3", "PROTEIN", 132, 134], ["SNP the sole functional SNP", "TREATMENT", 53, 80], ["IFN", "TEST", 128, 131]]], ["The answer to this question will be difficult to obtain under in vivo conditions due to high LD between these SNPs in most populations that precludes any attempts to assess their independent effects (Figure 1b) .", [["high LD between these SNPs", "PROBLEM", 88, 114]]], ["A recent report compared the strength of association of rs4803217 and rs368234815 in IFN treatment response in HCV-infected African Americans, who have the lowest reported LD values among all ethnicities between rs368234815 and rs12979860 SNPs (Figure 1b) .", [["HCV-infected", "DISEASE", 111, 123], ["rs4803217", "GENE_OR_GENE_PRODUCT", 56, 65], ["rs368234815", "GENE_OR_GENE_PRODUCT", 70, 81], ["IFN", "GENE_OR_GENE_PRODUCT", 85, 88], ["HCV", "ORGANISM", 111, 114], ["IFN", "PROTEIN", 85, 88], ["rs12979860 SNPs", "DNA", 228, 243], ["HCV", "SPECIES", 111, 114], ["IFN treatment", "TREATMENT", 85, 98], ["HCV", "PROBLEM", 111, 114], ["LD values", "TEST", 172, 181]]], ["107 They found that rs368234815 was more strongly associated with the outcome than rs4803217.", [["rs368234815", "GENE_OR_GENE_PRODUCT", 20, 31]]], ["107 In another independent report, Lu et al. applied multivariate regression to test the independence of rs368234815 from rs4803217 in predicting response to IFN treatment in HCV patients of African-American decent.", [["IFN", "CHEMICAL", 158, 161], ["HCV", "DISEASE", 175, 178], ["rs368234815", "GENE_OR_GENE_PRODUCT", 105, 116], ["rs4803217", "GENE_OR_GENE_PRODUCT", 122, 131], ["IFN", "GENE_OR_GENE_PRODUCT", 158, 161], ["HCV", "ORGANISM", 175, 178], ["patients", "ORGANISM", 179, 187], ["IFN", "PROTEIN", 158, 161], ["patients", "SPECIES", 179, 187], ["HCV", "SPECIES", 175, 178], ["multivariate regression", "TEST", 53, 76], ["IFN treatment", "TREATMENT", 158, 171]]], ["100 They found that correcting for the effect of s368234815 on rs4803217 abolished the latter SNP's association with treatment response, whereas correcting for the effect of the latter SNP reduced the strength of association of the former SNP (from P = 0.004 to 0.065).", [["s368234815", "CHEMICAL", 49, 59], ["SNP", "CHEMICAL", 94, 97], ["SNP", "CHEMICAL", 185, 188], ["SNP", "CHEMICAL", 239, 242], ["s368234815", "CHEMICAL", 49, 59], ["SNP", "CHEMICAL", 185, 188], ["s368234815", "GENE_OR_GENE_PRODUCT", 49, 59], ["rs4803217", "GENE_OR_GENE_PRODUCT", 63, 72], ["the latter SNP", "TREATMENT", 174, 188]]], ["100 This could have resulted due to the low sample size (n = 169); nevertheless, more results are awaited to conclude that IFN-\u03bb4-generating SNP is the sole functional SNP and that the observations giving credence to the functionality of the other 'IFN-\u03bb3 functional SNPs may only be artifacts.TRANSCRIPTION STUDIES ON THE IFNL4 GENEStudies so far point to the functional IFN-\u03bb4-generating SNP rs368234815 as the prime causal variant at the human IFNL locus.", [["IFN", "CHEMICAL", 123, 126], ["SNP", "CHEMICAL", 141, 144], ["SNP", "CHEMICAL", 168, 171], ["SNP", "CHEMICAL", 390, 393], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 123, 129], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 249, 255], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 372, 378], ["human", "ORGANISM", 441, 446], ["IFNL", "GENE_OR_GENE_PRODUCT", 447, 451], ["IFN", "PROTEIN", 123, 126], ["\u03bb4", "PROTEIN", 127, 129], ["IFN-\u03bb3 functional SNPs", "DNA", 249, 271], ["IFN", "PROTEIN", 372, 375], ["\u03bb4", "PROTEIN", 376, 378], ["SNP rs368234815", "DNA", 390, 405], ["human IFNL locus", "DNA", 441, 457], ["human", "SPECIES", 441, 446], ["human", "SPECIES", 441, 446], ["the low sample size", "PROBLEM", 36, 55], ["IFN", "TEST", 123, 126], ["functional SNPs", "PROBLEM", 256, 271], ["low sample", "OBSERVATION_MODIFIER", 40, 50], ["size", "OBSERVATION_MODIFIER", 51, 55], ["may only be", "UNCERTAINTY", 272, 283], ["artifacts", "OBSERVATION", 284, 293]]], ["Therefore, a detailed investigation is needed on the function of IFN-\u03bb4 as both an antiviral cytokine in different viral diseases and as a potential player in diversification and maintenance of innate and adaptive immune cell subsets.", [["immune cell", "ANATOMY", 214, 225], ["viral diseases", "DISEASE", 115, 129], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 65, 71], ["immune cell subsets", "CELL", 214, 233], ["IFN", "PROTEIN", 65, 68], ["\u03bb4", "PROTEIN", 69, 71], ["antiviral cytokine", "PROTEIN", 83, 101], ["innate and adaptive immune cell subsets", "CELL_TYPE", 194, 233], ["a detailed investigation", "TEST", 11, 35], ["IFN", "TEST", 65, 68], ["an antiviral cytokine", "TREATMENT", 80, 101], ["different viral diseases", "PROBLEM", 105, 129], ["innate and adaptive immune cell subsets", "TREATMENT", 194, 233], ["antiviral cytokine", "OBSERVATION", 83, 101], ["viral diseases", "OBSERVATION", 115, 129], ["immune cell subsets", "OBSERVATION", 214, 233]]], ["In case of IFN treatment response in chronic HCV infections, even though the IFN-\u03bb4 -generating SNP can explain a large amount of variance in the observed phenotypes, 107 questions still remain on its role in spontaneous clearance of HCV.", [["IFN", "CHEMICAL", 11, 14], ["HCV infections", "DISEASE", 45, 59], ["SNP", "CHEMICAL", 96, 99], ["HCV", "DISEASE", 234, 237], ["IFN", "GENE_OR_GENE_PRODUCT", 11, 14], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 77, 83], ["HCV", "ORGANISM", 234, 237], ["IFN", "PROTEIN", 11, 14], ["IFN", "PROTEIN", 77, 80], ["\u03bb4", "PROTEIN", 81, 83], ["HCV", "SPECIES", 45, 48], ["HCV", "SPECIES", 234, 237], ["IFN treatment", "TREATMENT", 11, 24], ["chronic HCV infections", "PROBLEM", 37, 59], ["the IFN", "TEST", 73, 80], ["SNP", "TREATMENT", 96, 99], ["a large amount of variance in the observed phenotypes", "PROBLEM", 112, 165], ["HCV", "PROBLEM", 234, 237], ["chronic", "OBSERVATION_MODIFIER", 37, 44], ["HCV", "OBSERVATION", 45, 48], ["large", "OBSERVATION_MODIFIER", 114, 119], ["amount", "OBSERVATION_MODIFIER", 120, 126]]], ["It is known that expression of functional IFN-\u03bb4 is associated with high levels of IFN-stimulated gene (ISG) expression in non-responders who further fail to upregulate their ISG expression upon IFN-\u03b1 treatment.", [["IFN-\u03b1", "CHEMICAL", 195, 200], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 42, 48], ["IFN-stimulated gene", "GENE_OR_GENE_PRODUCT", 83, 102], ["ISG", "GENE_OR_GENE_PRODUCT", 104, 107], ["ISG", "GENE_OR_GENE_PRODUCT", 175, 178], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 195, 200], ["IFN", "PROTEIN", 42, 45], ["\u03bb4", "PROTEIN", 46, 48], ["IFN", "PROTEIN", 83, 86], ["ISG", "DNA", 104, 107], ["IFN", "PROTEIN", 195, 198], ["IFN-\u03b1 treatment", "TREATMENT", 195, 210]]], ["15 However, such an elegant explanation is lacking in the case of spontaneous clearance of HCV ( Figure 5 ).", [["HCV", "DISEASE", 91, 94], ["HCV", "ORGANISM", 91, 94], ["HCV", "SPECIES", 91, 94], ["HCV", "PROBLEM", 91, 94]]], ["Although the majority of studies on spontaneous HCV clearance are with rs12979860 and not rs368234815, the fact that these two SNPs are in high LD in most populations 14 allows us to extrapolate the results.", [["HCV", "ORGANISM", 48, 51], ["HCV", "SPECIES", 48, 51], ["spontaneous HCV clearance", "TEST", 36, 61], ["rs12979860", "TEST", 71, 81]]], ["So, how does the expression of a functional IFN-\u03bb4 in patients who get an acute HCV infection will lead them to become chronically infected?", [["HCV infection", "DISEASE", 80, 93], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 44, 50], ["patients", "ORGANISM", 54, 62], ["HCV", "ORGANISM", 80, 83], ["IFN", "PROTEIN", 44, 47], ["\u03bb4", "PROTEIN", 48, 50], ["patients", "SPECIES", 54, 62], ["HCV", "SPECIES", 80, 83], ["an acute HCV infection", "PROBLEM", 71, 93], ["chronically infected", "PROBLEM", 119, 139], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["HCV", "OBSERVATION", 80, 83], ["chronically", "OBSERVATION_MODIFIER", 119, 130], ["infected", "OBSERVATION", 131, 139]]], ["One explanation could be that similar to the IFN treatment nonresponders group, the subjects expressing functional IFN-\u03bb4 also have higher baseline levels of ISGs, which do not get further upregulated upon acute HCV infection.", [["IFN", "CHEMICAL", 45, 48], ["HCV infection", "DISEASE", 212, 225], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 115, 121], ["ISGs", "GENE_OR_GENE_PRODUCT", 158, 162], ["HCV", "ORGANISM", 212, 215], ["IFN", "PROTEIN", 45, 48], ["IFN", "PROTEIN", 115, 118], ["\u03bb4", "PROTEIN", 119, 121], ["ISGs", "PROTEIN", 158, 162], ["HCV", "SPECIES", 212, 215], ["the IFN treatment nonresponders group", "TREATMENT", 41, 78], ["higher baseline levels of ISGs", "PROBLEM", 132, 162], ["acute HCV infection", "PROBLEM", 206, 225], ["acute", "OBSERVATION_MODIFIER", 206, 211], ["HCV", "OBSERVATION_MODIFIER", 212, 215], ["infection", "OBSERVATION", 216, 225]]], ["Having a higher basal innate immune response may have helped those populations with higher frequency of the functional IFN-\u03bb4-generating allele in dealing with prevalent viral infections.", [["viral infections", "DISEASE", 170, 186], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 119, 125], ["IFN", "PROTEIN", 119, 122], ["\u03bb4", "PROTEIN", 123, 125], ["a higher basal innate immune response", "PROBLEM", 7, 44], ["prevalent viral infections", "PROBLEM", 160, 186], ["infections", "OBSERVATION", 176, 186]]], ["Higher baseline levels of ISGs in people who can express a functional IFN-\u03bb4 may be offering protection against excess inflammation of the liver in hepatitis of non-viral origin such as NAFLD.", [["liver", "ANATOMY", 139, 144], ["inflammation of the liver", "DISEASE", 119, 144], ["hepatitis", "DISEASE", 148, 157], ["NAFLD", "DISEASE", 186, 191], ["people", "ORGANISM", 34, 40], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 70, 76], ["liver", "ORGAN", 139, 144], ["ISGs", "PROTEIN", 26, 30], ["IFN", "PROTEIN", 70, 73], ["\u03bb4", "PROTEIN", 74, 76], ["people", "SPECIES", 34, 40], ["excess inflammation of the liver", "PROBLEM", 112, 144], ["NAFLD", "PROBLEM", 186, 191], ["inflammation", "OBSERVATION", 119, 131], ["liver", "ANATOMY", 139, 144], ["hepatitis", "OBSERVATION", 148, 157], ["NAFLD", "OBSERVATION", 186, 191]]], ["[78] [79] [80] [81] However, as is evident from studies on spontaneous and treatment-induced clearance of HCV, such a pre-emptive state may become nonbeneficial in dealing with hepatitis of viral origin.", [["HCV", "DISEASE", 106, 109], ["hepatitis", "DISEASE", 177, 186], ["[78] [79] [80] [81", "SIMPLE_CHEMICAL", 0, 18], ["HCV", "ORGANISM", 106, 109], ["HCV", "SPECIES", 106, 109], ["treatment", "TREATMENT", 75, 84], ["HCV", "PROBLEM", 106, 109], ["hepatitis of viral origin", "PROBLEM", 177, 202], ["HCV", "OBSERVATION", 106, 109], ["viral origin", "OBSERVATION", 190, 202]]], ["Further, there may be other conditions that we do not yet know in which expression of a functional IFN-\u03bb4 may be beneficial.", [["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 99, 105], ["IFN", "PROTEIN", 99, 102], ["\u03bb4", "PROTEIN", 103, 105], ["a functional IFN", "TEST", 86, 102]]], ["Therefore, an epidemiological investigation to assess basal ISG expression levels, in humans both in health and disease, and their correlation with expression of IFN-\u03bb4, is needed.", [["ISG", "GENE_OR_GENE_PRODUCT", 60, 63], ["humans", "ORGANISM", 86, 92], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 162, 168], ["IFN", "PROTEIN", 162, 165], ["\u03bb4", "PROTEIN", 166, 168], ["humans", "SPECIES", 86, 92], ["humans", "SPECIES", 86, 92], ["an epidemiological investigation", "TEST", 11, 43], ["basal ISG expression levels", "PROBLEM", 54, 81], ["disease", "PROBLEM", 112, 119], ["IFN", "TEST", 162, 165], ["ISG expression", "OBSERVATION", 60, 74]]], ["Further, studies are also needed to examine why hepatic IFN-\u03bb3 levels are lower in the beneficial allele/genotype-carrying individuals during chronic HCV infection and how this phenomenon is reversed once treatment is initiated (Figure 5c ; ref.", [["hepatic", "ANATOMY", 48, 55], ["HCV infection", "DISEASE", 150, 163], ["hepatic", "ORGAN", 48, 55], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 56, 62], ["individuals", "ORGANISM", 123, 134], ["HCV", "ORGANISM", 150, 153], ["IFN", "PROTEIN", 56, 59], ["allele", "DNA", 98, 104], ["HCV", "SPECIES", 150, 153], ["Further, studies", "TEST", 0, 16], ["hepatic IFN-\u03bb3 levels", "TEST", 48, 69], ["chronic HCV infection", "PROBLEM", 142, 163], ["treatment", "TREATMENT", 205, 214], ["hepatic", "ANATOMY", 48, 55], ["chronic", "OBSERVATION_MODIFIER", 142, 149], ["HCV", "OBSERVATION_MODIFIER", 150, 153], ["infection", "OBSERVATION", 154, 163]]], ["94) .TRANSCRIPTION STUDIES ON THE IFNL4 GENEAlthough IFN-\u03bb1, 2 and 3 are known to associate with a Th1 response, 38, 39, 86 no information is available in this regard for IFN-\u03bb4.", [["IFN-\u03bb1", "GENE_OR_GENE_PRODUCT", 53, 59], ["2", "GENE_OR_GENE_PRODUCT", 61, 62], ["3", "GENE_OR_GENE_PRODUCT", 67, 68], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 171, 177], ["IFN", "PROTEIN", 53, 56], ["\u03bb1, 2 and 3", "PROTEIN", 57, 68], ["IFN", "PROTEIN", 171, 174], ["\u03bb4", "PROTEIN", 175, 177], ["TRANSCRIPTION STUDIES", "TEST", 5, 26], ["IFN", "TEST", 53, 56], ["a Th1 response", "TEST", 97, 111], ["IFN", "TEST", 171, 174]]], ["If the hypothesis that higher levels of IFN-\u03bb3 expression (due to presence of major alleles) will lead to a Th1 predominant response is to be believed, then by extrapolation, IFN-\u03bb4 should promote Th2 responses (Figure 3 ; as 'IFN-\u03bb3 functional SNPs' and 'IFN-\u03bb4 functional SNP' are in strong LD and the minor allele will give rise to IFN-\u03bb4).", [["SNP", "CHEMICAL", 274, 277], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 40, 46], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 175, 181], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 227, 233], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 256, 262], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 335, 341], ["IFN", "PROTEIN", 40, 43], ["\u03bb3", "PROTEIN", 44, 46], ["IFN", "PROTEIN", 175, 178], ["\u03bb4", "PROTEIN", 179, 181], ["IFN", "PROTEIN", 227, 230], ["IFN-\u03bb4", "DNA", 256, 262], ["IFN", "PROTEIN", 335, 338], ["IFN", "TEST", 40, 43], ["functional SNP'", "TREATMENT", 263, 278], ["IFN", "TEST", 335, 338]]], ["This explanation is difficult to reconcile with the observations that IFN-\u03bb4, except for being a poorly secreted IFN, requires the same dimeric receptor for signaling and can stimulate not only similar set of ISGs but also at similar levels when compared with IFN-\u03bb3.", [["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 70, 76], ["IFN", "GENE_OR_GENE_PRODUCT", 113, 116], ["ISGs", "GENE_OR_GENE_PRODUCT", 209, 213], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 260, 266], ["IFN", "PROTEIN", 70, 73], ["\u03bb4", "PROTEIN", 74, 76], ["IFN", "PROTEIN", 113, 116], ["dimeric receptor", "PROTEIN", 136, 152], ["ISGs", "PROTEIN", 209, 213], ["IFN", "PROTEIN", 260, 263], ["\u03bb3", "PROTEIN", 264, 266], ["IFN", "TEST", 70, 73], ["a poorly secreted IFN", "PROBLEM", 95, 116], ["IFN", "TEST", 260, 263], ["ISGs", "OBSERVATION", 209, 213]]], ["14, 30, 36 Besides, both IFN-\u03bb4 and IFN-\u03bb3 have similar antiviral potencies in vitro.", [["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 25, 31], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 36, 42], ["IFN", "PROTEIN", 25, 28], ["IFN", "PROTEIN", 36, 39], ["\u03bb3", "PROTEIN", 40, 42], ["IFN", "TEST", 25, 28], ["IFN", "TEST", 36, 39], ["similar antiviral potencies", "TREATMENT", 48, 75], ["antiviral potencies", "OBSERVATION", 56, 75]]], ["14,41 Therefore, expression of IFN-\u03bb4 and its associated ISGs in a subset of individuals carrying minor alleles is less likely to favor a completely opposite phenotype to that seen in those carrying major alleles that induce higher levels of IFN-\u03bb3 expression.CONCLUSIONSHuman IFNL SNPs came to the limelight after genetic studies showed their relevance in chronic HCV infections in the year 2009.", [["HCV infections", "DISEASE", 365, 379], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 31, 37], ["ISGs", "GENE_OR_GENE_PRODUCT", 57, 61], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 242, 248], ["IFNL", "GENE_OR_GENE_PRODUCT", 277, 281], ["IFN", "PROTEIN", 31, 34], ["\u03bb4", "PROTEIN", 35, 37], ["ISGs", "DNA", 57, 61], ["IFN", "PROTEIN", 242, 245], ["\u03bb3", "PROTEIN", 246, 248], ["IFNL SNPs", "DNA", 277, 286], ["HCV", "SPECIES", 365, 368], ["IFN", "TEST", 31, 34], ["genetic studies", "TEST", 315, 330], ["chronic HCV infections", "PROBLEM", 357, 379], ["chronic", "OBSERVATION_MODIFIER", 357, 364], ["HCV", "OBSERVATION", 365, 368]]], ["Since then, case-control studies in humans have been reported involving IFNL SNPs and several other viral diseases, NAFLD, allergy and even in vaccine responses.", [["viral diseases", "DISEASE", 100, 114], ["NAFLD", "DISEASE", 116, 121], ["allergy", "DISEASE", 123, 130], ["humans", "ORGANISM", 36, 42], ["IFNL", "GENE_OR_GENE_PRODUCT", 72, 76], ["IFNL SNPs", "DNA", 72, 81], ["humans", "SPECIES", 36, 42], ["humans", "SPECIES", 36, 42], ["IFNL SNPs", "PROBLEM", 72, 81], ["several other viral diseases", "PROBLEM", 86, 114], ["NAFLD", "PROBLEM", 116, 121], ["allergy", "PROBLEM", 123, 130], ["viral diseases", "OBSERVATION", 100, 114]]], ["Although it appears that the associations are well replicated (such as in NAFLD and AIDS) and strong in some diseases (such as in pediatric allergy), conflicting reports weaken the association in some (such as those involving HTLV and HBV), whereas further studies are needed in others (such as those involving CMV and herpes simplex virus) to clear discrepancies.", [["NAFLD", "DISEASE", 74, 79], ["AIDS", "DISEASE", 84, 88], ["allergy", "DISEASE", 140, 147], ["CMV and herpes simplex virus", "DISEASE", 311, 339], ["HTLV", "ORGANISM", 226, 230], ["HBV", "ORGANISM", 235, 238], ["CMV", "ORGANISM", 311, 314], ["herpes simplex virus", "ORGANISM", 319, 339], ["herpes simplex virus", "SPECIES", 319, 339], ["HTLV", "SPECIES", 226, 230], ["HBV", "SPECIES", 235, 238], ["CMV", "SPECIES", 311, 314], ["herpes simplex virus", "SPECIES", 319, 339], ["some diseases", "PROBLEM", 104, 117], ["HTLV", "PROBLEM", 226, 230], ["HBV", "PROBLEM", 235, 238], ["further studies", "TEST", 249, 264], ["CMV", "PROBLEM", 311, 314], ["herpes simplex virus", "PROBLEM", 319, 339], ["some", "OBSERVATION_MODIFIER", 104, 108], ["diseases", "OBSERVATION", 109, 117]]], ["The IFNL-\u03bbs may have critical roles in shaping innate and adaptive immunity in general and in viral infections in particular.", [["viral infections", "DISEASE", 94, 110], ["IFNL-\u03bbs", "GENE_OR_GENE_PRODUCT", 4, 11], ["IFNL", "PROTEIN", 4, 8], ["\u03bbs", "PROTEIN", 9, 11], ["viral infections", "PROBLEM", 94, 110], ["viral infections", "OBSERVATION", 94, 110]]], ["However, unlike their effect in HCV infections, the IFNL SNPs may involve interactions with variables other than just standard end point phenotypes in many of the reported diseases/ conditions.", [["HCV infections", "DISEASE", 32, 46], ["HCV", "ORGANISM", 32, 35], ["IFNL", "GENE_OR_GENE_PRODUCT", 52, 56], ["IFNL SNPs", "DNA", 52, 61], ["HCV", "SPECIES", 32, 35], ["HCV infections", "PROBLEM", 32, 46], ["the IFNL SNPs", "TREATMENT", 48, 61], ["the reported diseases/ conditions", "PROBLEM", 159, 192], ["effect", "OBSERVATION_MODIFIER", 22, 28], ["HCV", "OBSERVATION_MODIFIER", 32, 35], ["infections", "OBSERVATION", 36, 46]]], ["Therefore, future studies should aim at dissecting these interactions to arrive at meaningful results.", [["future studies", "TEST", 11, 25]]], ["Well-designed replication studies and functional studies to strengthen the genetic association results are required to arrive at firm conclusions.", [["replication studies", "TEST", 14, 33], ["functional studies", "TEST", 38, 56]]], ["Importantly, IFN-\u03bb4 has emerged as the key causal link to the genetic associations, but many questions remain on its functional role in the diversification and shaping of innate and adaptive immune responses in viral infections and other inflammatory conditions.", [["viral infections", "DISEASE", 211, 227], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 13, 19], ["IFN", "PROTEIN", 13, 16], ["\u03bb4", "PROTEIN", 17, 19], ["viral infections", "PROBLEM", 211, 227], ["other inflammatory conditions", "PROBLEM", 232, 261], ["viral infections", "OBSERVATION", 211, 227], ["inflammatory", "OBSERVATION_MODIFIER", 238, 250]]], ["14) and therefore are expected to express IFN-\u03bb4.", [["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 42, 48], ["IFN", "PROTEIN", 42, 45], ["\u03bb4", "PROTEIN", 46, 48], ["IFN", "TEST", 42, 45]]], ["94 A recent study has documented that type III IFNs including IFN-\u03bb2/3 and IFN-\u03bb4 expression levels correlate with ISG expression in the liver of patients undergoing anti-HCV therapy.", [["liver", "ANATOMY", 137, 142], ["type III IFNs", "GENE_OR_GENE_PRODUCT", 38, 51], ["IFN-\u03bb2/3", "GENE_OR_GENE_PRODUCT", 62, 70], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 75, 81], ["ISG", "GENE_OR_GENE_PRODUCT", 115, 118], ["liver", "ORGAN", 137, 142], ["patients", "ORGANISM", 146, 154], ["type III IFNs", "PROTEIN", 38, 51], ["IFN", "PROTEIN", 62, 65], ["IFN", "PROTEIN", 75, 78], ["\u03bb4", "PROTEIN", 79, 81], ["patients", "SPECIES", 146, 154], ["A recent study", "TEST", 3, 17], ["type III IFNs", "PROBLEM", 38, 51], ["IFN", "TEST", 62, 65], ["IFN", "TEST", 75, 78], ["expression levels", "TEST", 82, 99], ["ISG expression in the liver", "PROBLEM", 115, 142], ["anti-HCV therapy", "TREATMENT", 166, 182], ["type III", "OBSERVATION_MODIFIER", 38, 46], ["IFNs", "OBSERVATION_MODIFIER", 47, 51], ["ISG expression", "OBSERVATION", 115, 129], ["liver", "ANATOMY", 137, 142], ["anti-HCV therapy", "OBSERVATION", 166, 182]]], ["94 The IFN-\u03bb2/3 and IFN-\u03bb4 levels and their associated ISG levels are higher in the liver of patients who will eventually not respond to the therapy 94 compared with those who will respond, suggesting that an unknown effect inhibits the expression of IFN-\u03bb3 in the latter group of patients (shown as an ellipse in c).", [["liver", "ANATOMY", 84, 89], ["IFN-\u03bb2/3", "GENE_OR_GENE_PRODUCT", 7, 15], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 20, 26], ["ISG", "GENE_OR_GENE_PRODUCT", 55, 58], ["liver", "ORGAN", 84, 89], ["patients", "ORGANISM", 93, 101], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 251, 257], ["patients", "ORGANISM", 281, 289], ["IFN", "PROTEIN", 7, 10], ["\u03bb2/3", "PROTEIN", 11, 15], ["IFN", "PROTEIN", 20, 23], ["\u03bb4", "PROTEIN", 24, 26], ["IFN", "PROTEIN", 251, 254], ["\u03bb3", "PROTEIN", 255, 257], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 281, 289], ["The IFN", "TEST", 3, 10], ["IFN", "TEST", 20, 23], ["ISG levels", "TEST", 55, 65], ["the therapy", "TREATMENT", 137, 148], ["liver", "ANATOMY", 84, 89]]], ["It seems that IFN-\u03b1-ribavirin treatment induces the expression of IFN-\u03bb3 once treatment begins (depicted as a circle in c) preferably in those patients who will eventually respond to the treatment 94 (These patients have lower frequency of the functional IFN-\u03bb4-generating alleles 14 and hence are shown without IFN-\u03bb4 expression (c)).", [["IFN", "CHEMICAL", 14, 17], ["ribavirin", "CHEMICAL", 20, 29], ["ribavirin", "CHEMICAL", 20, 29], ["IFN-\u03b1-", "GENE_OR_GENE_PRODUCT", 14, 20], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 66, 72], ["patients", "ORGANISM", 143, 151], ["patients", "ORGANISM", 207, 215], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 255, 261], ["IFN-\u03bb4", "GENE_OR_GENE_PRODUCT", 312, 318], ["IFN", "PROTEIN", 14, 17], ["IFN", "PROTEIN", 66, 69], ["\u03bb3", "PROTEIN", 70, 72], ["IFN", "PROTEIN", 255, 258], ["\u03bb4", "PROTEIN", 259, 261], ["alleles 14", "DNA", 273, 283], ["IFN", "PROTEIN", 312, 315], ["\u03bb4", "PROTEIN", 316, 318], ["patients", "SPECIES", 143, 151], ["patients", "SPECIES", 207, 215], ["IFN", "TREATMENT", 14, 17], ["ribavirin treatment", "TREATMENT", 20, 39], ["IFN", "TREATMENT", 66, 69], ["the treatment", "TREATMENT", 183, 196]]], ["This induction is further dependent on whether the patients carry beneficial alleles at rs12979860.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59]]], ["The patients who have the beneficial alleles show higher increase in their hepatic IFN-\u03bb3 levels than those who do not, once treatment is initiated.", [["hepatic", "ANATOMY", 75, 82], ["patients", "ORGANISM", 4, 12], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 83, 89], ["IFN", "PROTEIN", 83, 86], ["\u03bb3", "PROTEIN", 87, 89], ["patients", "SPECIES", 4, 12], ["the beneficial alleles", "PROBLEM", 22, 44], ["treatment", "TREATMENT", 125, 134], ["higher", "OBSERVATION_MODIFIER", 50, 56], ["increase", "OBSERVATION_MODIFIER", 57, 65], ["hepatic", "ANATOMY", 75, 82]]], ["94 A previous report also had seen similar changes in serum IFN-\u03bb3 levels.", [["serum", "ANATOMY", 54, 59], ["serum", "ORGANISM_SUBSTANCE", 54, 59], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 60, 66], ["IFN", "PROTEIN", 60, 63], ["serum IFN", "TEST", 54, 63]]], ["109 The ISG levels are shown in correlation with IFN-\u03bb3 expression.", [["ISG", "GENE_OR_GENE_PRODUCT", 8, 11], ["IFN-\u03bb3", "GENE_OR_GENE_PRODUCT", 49, 55], ["IFN", "PROTEIN", 49, 52], ["\u03bb3", "PROTEIN", 53, 55], ["The ISG levels", "TEST", 4, 18], ["IFN", "TEST", 49, 52]]]], "PMC7108083": [["METHODSInformation on all confirmed cases of SARS in Hong Kong was obtained from the Centre for Health Protection, Department of Health, in Hong Kong, including date of symptom onset, occupation, and residential address.", [["SARS", "DISEASE", 45, 49], ["SARS", "PROBLEM", 45, 49]]], ["Subjects were divided into 3 groups according to their proximity to the common source of SARS coronavirus present in the Amoy Gardens: (1) Amoy Gardens residents, (2) residents in the surrounding residential buildings (North: Lee Kee Building, Wang Kwong Building, Jade Field Gardens [Ka Lai Mansion, Ka Yin Mansion, Ka Yan Mansion], Tak Bo Gardens; East: Choi Ha Estate; South: Upper Ngau Tau Kok Estate, Lok Wah Estate; West: Lower Ngau Tau Kok Estate, Telford Gardens), and (3) residents elsewhere in Kwun Tong (KT) District, 1 of 18 districts of Hong Kong, where the Amoy Gardens was located.", [["SARS coronavirus", "DISEASE", 89, 105], ["Subjects", "ORGANISM", 0, 8], ["SARS coronavirus", "SPECIES", 89, 105], ["SARS coronavirus", "PROBLEM", 89, 105]]], ["Epidemic curves were produced for each group and compared.", [["Epidemic curves", "PROBLEM", 0, 15]]], ["The spatial distribution of all cases in Amoy Gardens and surrounding residential buildings was located on a map, focusing on cases with symptom onset during the period 24\u201329 March 2003, that is, 5\u201310 days after the index patient visited a unit in Block E of Amoy Gardens on March 19 and used the toilet there [2].", [["patient", "ORGANISM", 222, 229], ["patient", "SPECIES", 222, 229], ["symptom", "PROBLEM", 137, 144], ["spatial", "OBSERVATION_MODIFIER", 4, 11], ["distribution", "OBSERVATION_MODIFIER", 12, 24]]], ["The index patient was receiving renal dialysis in the Prince of Wales Hospital during the largest nosocomial outbreak [3], had diarrhea, and was subsequently found to have very high viral load.RESULTSThe temporal distributions of dates of symptom onset for cases in the 3 groups during the period 20 March to 10 April 2003 are depicted in Figure 1.", [["renal", "ANATOMY", 32, 37], ["diarrhea", "DISEASE", 127, 135], ["patient", "ORGANISM", 10, 17], ["renal", "ORGAN", 32, 37], ["patient", "SPECIES", 10, 17], ["renal dialysis", "TREATMENT", 32, 46], ["diarrhea", "PROBLEM", 127, 135], ["very high viral load", "PROBLEM", 172, 192], ["symptom", "PROBLEM", 239, 246], ["index", "OBSERVATION_MODIFIER", 4, 9], ["renal", "ANATOMY", 32, 37], ["dialysis", "OBSERVATION", 38, 46], ["viral load", "OBSERVATION", 182, 192]]], ["The peak of the epidemic curve for Amoy Gardens residents occurred on 24\u201325 March 2003.", [["peak", "OBSERVATION_MODIFIER", 4, 8]]], ["The numbers of cases in the surrounding buildings were much smaller, but a small peak could be seen on 25 March 2003.", [["a small peak", "PROBLEM", 73, 85], ["numbers", "OBSERVATION_MODIFIER", 4, 11], ["much", "OBSERVATION_MODIFIER", 55, 59], ["smaller", "OBSERVATION_MODIFIER", 60, 67], ["small", "OBSERVATION_MODIFIER", 75, 80], ["peak", "OBSERVATION", 81, 85]]], ["In contrast, no peaks of the epidemic curve among residents elsewhere in KT District were noted, and the number of cases was small.", [["the epidemic curve", "PROBLEM", 25, 43], ["no", "UNCERTAINTY", 13, 15], ["peaks", "OBSERVATION_MODIFIER", 16, 21], ["small", "OBSERVATION_MODIFIER", 125, 130]]], ["The proportion of cases with symptom onset during the period 24\u201329 March was 76.4% (253/331), 55.3% (57/103), and 16.2% (16/99), respectively, for Amoy Gardens residents, residents in the surrounding residential buildings, and residents elsewhere in KT District.", [["symptom onset", "PROBLEM", 29, 42]]]], "PMC7223626": [["IntroductionAcetylcholinesterase (AChE) inhibitors are chemical compounds which considered being among the most therapeutic tools for many neurodegenerative disorders such as Alzheimer\u2019s disease (AD), glaucoma, Parkinson\u2019s disease, myasthenia gravies, and Down syndrome.", [["glaucoma", "ANATOMY", 201, 209], ["neurodegenerative disorders", "DISEASE", 139, 166], ["Alzheimer\u2019s disease", "DISEASE", 175, 194], ["AD", "DISEASE", 196, 198], ["glaucoma", "DISEASE", 201, 209], ["Parkinson\u2019s disease", "DISEASE", 211, 230], ["myasthenia gravies", "DISEASE", 232, 250], ["Down syndrome", "DISEASE", 256, 269], ["Acetylcholinesterase", "GENE_OR_GENE_PRODUCT", 12, 32], ["AChE", "GENE_OR_GENE_PRODUCT", 34, 38], ["AChE", "PROTEIN", 34, 38], ["IntroductionAcetylcholinesterase (AChE) inhibitors", "TREATMENT", 0, 50], ["chemical compounds", "TREATMENT", 55, 73], ["many neurodegenerative disorders", "PROBLEM", 134, 166], ["Alzheimer\u2019s disease", "PROBLEM", 175, 194], ["glaucoma", "PROBLEM", 201, 209], ["Parkinson\u2019s disease", "PROBLEM", 211, 230], ["myasthenia gravies", "PROBLEM", 232, 250], ["Down syndrome", "PROBLEM", 256, 269], ["neurodegenerative", "OBSERVATION", 139, 156], ["glaucoma", "OBSERVATION", 201, 209], ["Parkinson\u2019s", "OBSERVATION", 211, 222], ["myasthenia", "OBSERVATION", 232, 242], ["Down syndrome", "OBSERVATION", 256, 269]]], ["AChE inhibitors belong to many classes such as carbamate derivatives which participate in the action mechanism of insecticidal drugs, while those belonging to parathion and malathion play a significant role in nerve gases (Erdogan Orhan et al. 2011).IntroductionAD is a serious neurodegenerative disease, mostly targeting people above 65 years of age (Mohamed and Rao 2011).", [["nerve", "ANATOMY", 210, 215], ["carbamate", "CHEMICAL", 47, 56], ["parathion", "CHEMICAL", 159, 168], ["malathion", "CHEMICAL", 173, 182], ["neurodegenerative disease", "DISEASE", 278, 303], ["carbamate", "CHEMICAL", 47, 56], ["parathion", "CHEMICAL", 159, 168], ["malathion", "CHEMICAL", 173, 182], ["AChE", "GENE_OR_GENE_PRODUCT", 0, 4], ["carbamate derivatives", "SIMPLE_CHEMICAL", 47, 68], ["parathion", "SIMPLE_CHEMICAL", 159, 168], ["malathion", "SIMPLE_CHEMICAL", 173, 182], ["people", "ORGANISM", 322, 328], ["people", "SPECIES", 322, 328], ["AChE inhibitors", "TREATMENT", 0, 15], ["carbamate derivatives", "TREATMENT", 47, 68], ["insecticidal drugs", "TREATMENT", 114, 132], ["a serious neurodegenerative disease", "PROBLEM", 268, 303], ["nerve", "ANATOMY", 210, 215], ["serious", "OBSERVATION_MODIFIER", 270, 277], ["neurodegenerative", "OBSERVATION_MODIFIER", 278, 295], ["disease", "OBSERVATION", 296, 303]]], ["AD patients are suffering mainly from sequential memory loss and deficiency of their cognitive functions (Khairallah and Kassem 2011).", [["AD", "DISEASE", 0, 2], ["memory loss", "DISEASE", 49, 60], ["deficiency of their cognitive functions", "DISEASE", 65, 104], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["sequential memory loss", "PROBLEM", 38, 60], ["deficiency of their cognitive functions", "PROBLEM", 65, 104], ["memory loss", "OBSERVATION", 49, 60]]], ["AD threatens the public health and society as the epidemiological data indicated that the number of people affected with AD worldwide by 2050 is expected to increase, predicting that, every 33 s, there will be one new AD case (Prince et al. 2013; Alzheimer\u2019s Association 2017).IntroductionAbout 5% of the people above 65 years and more than 20% above 80 years are subjected to the risk of AD.", [["AD", "DISEASE", 0, 2], ["AD", "DISEASE", 121, 123], ["AD", "DISEASE", 218, 220], ["AD", "DISEASE", 389, 391], ["people", "ORGANISM", 100, 106], ["people", "ORGANISM", 305, 311], ["people", "SPECIES", 100, 106], ["people", "SPECIES", 305, 311], ["AD", "PROBLEM", 389, 391]]], ["After cardiovascular diseases and cancer, AD is considered to be the third main reason of death in the developing countries.", [["cardiovascular", "ANATOMY", 6, 20], ["cancer", "ANATOMY", 34, 40], ["cardiovascular diseases", "DISEASE", 6, 29], ["cancer", "DISEASE", 34, 40], ["AD", "DISEASE", 42, 44], ["death", "DISEASE", 90, 95], ["cancer", "CANCER", 34, 40], ["cardiovascular diseases", "PROBLEM", 6, 29], ["cancer", "PROBLEM", 34, 40], ["death", "PROBLEM", 90, 95], ["diseases", "OBSERVATION", 21, 29], ["cancer", "OBSERVATION", 34, 40]]], ["Pathogenesis of AD is complex and includes genetic and environmental factors (Williams et al. 2011).IntroductionThis disorder is characterized by the progressive irreversible loss of neurons in specific brain areas, mainly the hippocampus, accumulation of \u03b2-amyloid protein (A\u03b2) plaques and neurofibrillary tangles (NFTs) in brain tissues, hyper-phosphorylation of Tau protein in neurons, and collapsing of cognitive functions leading to death (Khairallah and Kassem 2011; Mohamed and Rao 2011).IntroductionSurprisingly, oxidative stress and the formation of reactive oxygen species (ROS) are considered to be the main causes of this disease (Behl and Moosmann 2002).", [["neurons", "ANATOMY", 183, 190], ["brain areas", "ANATOMY", 203, 214], ["hippocampus", "ANATOMY", 227, 238], ["brain tissues", "ANATOMY", 325, 338], ["neurons", "ANATOMY", 380, 387], ["AD", "DISEASE", 16, 18], ["loss of neurons", "DISEASE", 175, 190], ["death", "DISEASE", 438, 443], ["oxygen", "CHEMICAL", 568, 574], ["ROS", "CHEMICAL", 584, 587], ["oxygen", "CHEMICAL", 568, 574], ["neurons", "CELL", 183, 190], ["brain areas", "MULTI-TISSUE_STRUCTURE", 203, 214], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 227, 238], ["\u03b2-amyloid protein", "GENE_OR_GENE_PRODUCT", 256, 273], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 275, 277], ["neurofibrillary tangles", "GENE_OR_GENE_PRODUCT", 291, 314], ["NFTs", "SIMPLE_CHEMICAL", 316, 320], ["brain tissues", "TISSUE", 325, 338], ["Tau", "GENE_OR_GENE_PRODUCT", 365, 368], ["neurons", "CELL", 380, 387], ["reactive oxygen species", "SIMPLE_CHEMICAL", 559, 582], ["ROS", "SIMPLE_CHEMICAL", 584, 587], ["\u03b2-amyloid protein", "PROTEIN", 256, 273], ["A\u03b2", "PROTEIN", 275, 277], ["Tau protein", "PROTEIN", 365, 376], ["AD", "PROBLEM", 16, 18], ["This disorder", "PROBLEM", 112, 125], ["the progressive irreversible loss of neurons in specific brain areas", "PROBLEM", 146, 214], ["\u03b2-amyloid protein (A\u03b2) plaques", "PROBLEM", 256, 286], ["neurofibrillary tangles (NFTs) in brain tissues", "PROBLEM", 291, 338], ["hyper-phosphorylation of Tau protein in neurons", "PROBLEM", 340, 387], ["collapsing of cognitive functions", "PROBLEM", 393, 426], ["death", "PROBLEM", 438, 443], ["oxidative stress", "PROBLEM", 521, 537], ["reactive oxygen species", "PROBLEM", 559, 582], ["this disease", "PROBLEM", 629, 641], ["progressive", "OBSERVATION_MODIFIER", 150, 161], ["irreversible", "OBSERVATION_MODIFIER", 162, 174], ["loss", "OBSERVATION", 175, 179], ["neurons", "ANATOMY_MODIFIER", 183, 190], ["brain", "ANATOMY", 203, 208], ["areas", "ANATOMY_MODIFIER", 209, 214], ["hippocampus", "ANATOMY", 227, 238], ["accumulation", "OBSERVATION_MODIFIER", 240, 252], ["\u03b2-amyloid protein", "OBSERVATION", 256, 273], ["plaques", "OBSERVATION", 279, 286], ["neurofibrillary tangles", "OBSERVATION", 291, 314], ["brain tissues", "ANATOMY", 325, 338], ["hyper", "OBSERVATION_MODIFIER", 340, 345], ["neurons", "ANATOMY", 380, 387], ["oxidative stress", "OBSERVATION", 521, 537], ["reactive", "OBSERVATION_MODIFIER", 559, 567], ["oxygen species", "OBSERVATION", 568, 582]]], ["As AD is a multi-factorial disease, many therapeutic approaches were suggested for its treatment.", [["AD", "DISEASE", 3, 5], ["a multi-factorial disease", "PROBLEM", 9, 34], ["many therapeutic approaches", "TREATMENT", 36, 63], ["its treatment", "TREATMENT", 83, 96], ["multi-factorial", "OBSERVATION_MODIFIER", 11, 26], ["disease", "OBSERVATION", 27, 34]]], ["Therapeutic approaches were then classified into two main effective routes, cholinergic and non-cholinergic.", [["non-cholinergic", "CELL", 92, 107], ["Therapeutic approaches", "TREATMENT", 0, 22]]], ["In patients with AD, the disorder in the cholinergic neurotransmission is causing a decline in the neurotransmitter acetylcholine (ACh) (Konrath et al. 2013).IntroductionAs a result, acetylcholinesterase (AChE) inhibitors could rebalance the level of acetylcholine by inhibiting the AChE activity.", [["AD", "DISEASE", 17, 19], ["disorder", "DISEASE", 25, 33], ["acetylcholine", "CHEMICAL", 116, 129], ["ACh", "CHEMICAL", 131, 134], ["acetylcholine", "CHEMICAL", 251, 264], ["acetylcholine", "CHEMICAL", 116, 129], ["ACh", "CHEMICAL", 131, 134], ["acetylcholine", "CHEMICAL", 251, 264], ["patients", "ORGANISM", 3, 11], ["acetylcholine", "SIMPLE_CHEMICAL", 116, 129], ["ACh", "SIMPLE_CHEMICAL", 131, 134], ["acetylcholinesterase", "SIMPLE_CHEMICAL", 183, 203], ["AChE", "GENE_OR_GENE_PRODUCT", 205, 209], ["acetylcholine", "SIMPLE_CHEMICAL", 251, 264], ["AChE", "GENE_OR_GENE_PRODUCT", 283, 287], ["AChE", "PROTEIN", 205, 209], ["AChE", "PROTEIN", 283, 287], ["patients", "SPECIES", 3, 11], ["AD", "PROBLEM", 17, 19], ["the disorder", "PROBLEM", 21, 33], ["a decline", "PROBLEM", 82, 91], ["acetylcholinesterase (AChE) inhibitors", "TREATMENT", 183, 221], ["acetylcholine", "TREATMENT", 251, 264]]], ["Consequently, acetylcholine could be accumulated in the synaptic cleft (Su et al. 2017).", [["synaptic cleft", "ANATOMY", 56, 70], ["acetylcholine", "CHEMICAL", 14, 27], ["acetylcholine", "CHEMICAL", 14, 27], ["acetylcholine", "SIMPLE_CHEMICAL", 14, 27], ["acetylcholine", "TREATMENT", 14, 27], ["synaptic cleft", "OBSERVATION", 56, 70]]], ["This route is called cholinergic approach and considered as the major symptomatic treatment for AD.IntroductionAnother treatment approach depends on preventing the accumulation of \u03b2-amyloid peptide (A\u03b2).", [["AD", "DISEASE", 96, 98], ["\u03b2-amyloid peptide", "CHEMICAL", 180, 197], ["\u03b2-amyloid peptide", "CHEMICAL", 180, 197], ["\u03b2-amyloid peptide", "GENE_OR_GENE_PRODUCT", 180, 197], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 199, 201], ["cholinergic approach", "TREATMENT", 21, 41], ["the major symptomatic treatment", "TREATMENT", 60, 91], ["AD", "PROBLEM", 96, 98], ["IntroductionAnother treatment approach", "TREATMENT", 99, 137], ["\u03b2-amyloid peptide", "TREATMENT", 180, 197]]], ["Thus, any compound, able to reduce or prevent the aggregation of A\u03b2 between neurons, could be a potential anti-AD drug candidate which can reduce the disease progression (Jiang et al. 2003).", [["neurons", "ANATOMY", 76, 83], ["A\u03b2", "GENE_OR_GENE_PRODUCT", 65, 67], ["neurons", "CELL", 76, 83], ["anti-AD", "CANCER", 106, 113], ["A\u03b2", "PROTEIN", 65, 67], ["the aggregation of A\u03b2 between neurons", "PROBLEM", 46, 83], ["the disease progression", "PROBLEM", 146, 169]]], ["Other suggested approaches included many compounds and routes such as antioxidants, vitamins, anti-hypertensive drugs, selective phosphodiesterase inhibitors, non-steroidal anti-inflammatory drugs, transition metal chelators, inhibitory drugs of Tau proteins hyper-phosphorylation and intracellular NFT accumulation, use of brain-derived neurotropic factor (BDNF), stem cell therapy, and hormonal therapy (Dey et al. 2017).", [["intracellular", "ANATOMY", 285, 298], ["brain", "ANATOMY", 324, 329], ["stem cell", "ANATOMY", 365, 374], ["vitamins", "CHEMICAL", 84, 92], ["transition metal", "CHEMICAL", 198, 214], ["vitamins", "SIMPLE_CHEMICAL", 84, 92], ["non-steroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 159, 196], ["transition metal chelators", "SIMPLE_CHEMICAL", 198, 224], ["Tau", "GENE_OR_GENE_PRODUCT", 246, 249], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 285, 298], ["NFT", "SIMPLE_CHEMICAL", 299, 302], ["brain-derived neurotropic factor", "GENE_OR_GENE_PRODUCT", 324, 356], ["BDNF", "GENE_OR_GENE_PRODUCT", 358, 362], ["stem cell", "CELL", 365, 374], ["Tau proteins", "PROTEIN", 246, 258], ["brain-derived neurotropic factor", "PROTEIN", 324, 356], ["BDNF", "PROTEIN", 358, 362], ["antioxidants", "TREATMENT", 70, 82], ["vitamins", "TREATMENT", 84, 92], ["anti-hypertensive drugs", "TREATMENT", 94, 117], ["selective phosphodiesterase inhibitors", "TREATMENT", 119, 157], ["non-steroidal anti-inflammatory drugs", "TREATMENT", 159, 196], ["transition metal chelators", "TREATMENT", 198, 224], ["inhibitory drugs", "TREATMENT", 226, 242], ["Tau proteins hyper-phosphorylation", "TREATMENT", 246, 280], ["intracellular NFT accumulation", "PROBLEM", 285, 315], ["brain-derived neurotropic factor (BDNF)", "TREATMENT", 324, 363], ["stem cell therapy", "TREATMENT", 365, 382], ["hormonal therapy", "TREATMENT", 388, 404], ["intracellular NFT accumulation", "OBSERVATION", 285, 315], ["brain", "ANATOMY", 324, 329], ["stem cell therapy", "OBSERVATION", 365, 382]]], ["Additionally, stimulatory therapies such as physical exercise, cognitive training, socialization, and music have been reported.", [["stimulatory therapies", "TREATMENT", 14, 35], ["cognitive training", "TREATMENT", 63, 81]]], ["Moreover, nutritional supplements, medicinal plants, phyto-chemicals, minerals, and omega-3 fatty acids have been also tested (Wollen 2010).IntroductionAChE inhibitors can be obtained either by chemical synthesis or by extraction from natural plants and microorganisms.", [["omega-3 fatty acids", "CHEMICAL", 84, 103], ["omega-3 fatty acids", "CHEMICAL", 84, 103], ["phyto-chemicals", "SIMPLE_CHEMICAL", 53, 68], ["minerals", "SIMPLE_CHEMICAL", 70, 78], ["omega-3 fatty acids", "SIMPLE_CHEMICAL", 84, 103], ["nutritional supplements", "TREATMENT", 10, 33], ["medicinal plants", "TREATMENT", 35, 51], ["phyto-chemicals", "TREATMENT", 53, 68], ["minerals", "TREATMENT", 70, 78], ["omega-3 fatty acids", "TREATMENT", 84, 103], ["IntroductionAChE inhibitors", "TREATMENT", 140, 167], ["microorganisms", "PROBLEM", 254, 268]]], ["Microbial production of AChE inhibitors is gaining a lot of attention due to its advantages over both phyto-extraction and chemical synthesis.", [["AChE", "GENE_OR_GENE_PRODUCT", 24, 28], ["Microbial production of AChE inhibitors", "TREATMENT", 0, 39], ["both phyto-extraction", "TREATMENT", 97, 118], ["chemical synthesis", "TREATMENT", 123, 141], ["chemical synthesis", "OBSERVATION", 123, 141]]], ["On the one hand, extraction processes are limited by lacking of natural plant resources due to their excessive harvesting, and chemical synthesis is threatening the environment by pollution and hazardous materials (Wang et al. 2015b).IntroductionOn the other hand, marked-available AChE inhibitors derived from plants and chemical synthesis showed many disadvantages such as low bioavailability and other abdominal side effects (Erdogan Orhan et al. 2011).", [["abdominal", "ANATOMY", 405, 414], ["AChE", "GENE_OR_GENE_PRODUCT", 282, 286], ["abdominal", "ORGANISM_SUBDIVISION", 405, 414], ["their excessive harvesting", "TREATMENT", 95, 121], ["AChE inhibitors", "TREATMENT", 282, 297], ["chemical synthesis", "TEST", 322, 340], ["many disadvantages", "PROBLEM", 348, 366], ["low bioavailability", "PROBLEM", 375, 394], ["other abdominal side effects", "PROBLEM", 399, 427], ["excessive", "OBSERVATION_MODIFIER", 101, 110], ["harvesting", "OBSERVATION", 111, 121], ["abdominal", "ANATOMY", 405, 414]]], ["Thus, exploring other alternatives of AChE inhibitors derived from microbial sources with different niches is a must.IntroductionHuperzine A (HupA) is a Lycopodium alkaloid, which can be naturally extracted from the traditional Chinese medicinal plant, Huperzia serrata.", [["Huperzine A", "CHEMICAL", 129, 140], ["HupA", "CHEMICAL", 142, 146], ["Lycopodium alkaloid", "CHEMICAL", 153, 172], ["Huperzine A", "CHEMICAL", 129, 140], ["HupA", "CHEMICAL", 142, 146], ["Lycopodium alkaloid", "CHEMICAL", 153, 172], ["AChE", "GENE_OR_GENE_PRODUCT", 38, 42], ["Huperzine A", "SIMPLE_CHEMICAL", 129, 140], ["HupA", "SIMPLE_CHEMICAL", 142, 146], ["Lycopodium alkaloid", "SIMPLE_CHEMICAL", 153, 172], ["Huperzia serrata", "ORGANISM", 253, 269], ["Huperzia serrata", "SPECIES", 253, 269], ["Huperzia serrata", "SPECIES", 253, 269], ["AChE inhibitors", "TREATMENT", 38, 53], ["a Lycopodium alkaloid", "PROBLEM", 151, 172], ["Lycopodium alkaloid", "OBSERVATION", 153, 172]]], ["HupA has attracted intense attention after discovering its activity as an effective cholinesterase inhibitor (Ishiuchi et al. 2013).", [["HupA", "CHEMICAL", 0, 4], ["HupA", "GENE_OR_GENE_PRODUCT", 0, 4], ["cholinesterase", "SIMPLE_CHEMICAL", 84, 98], ["HupA", "PROTEIN", 0, 4], ["HupA", "TREATMENT", 0, 4], ["an effective cholinesterase inhibitor", "TREATMENT", 71, 108], ["intense", "OBSERVATION_MODIFIER", 19, 26]]], ["Compared with the well-known and commercially available AChE inhibitors, HupA is a more effective reversible inhibitor.IntroductionAdditionally, it can effectively penetrate the blood\u2013brain barrier and showed better oral bioavailability and longer inhibitory effect (Wang et al. 2006).", [["blood\u2013brain", "ANATOMY", 178, 189], ["oral", "ANATOMY", 216, 220], ["HupA", "CHEMICAL", 73, 77], ["HupA", "CHEMICAL", 73, 77], ["AChE", "GENE_OR_GENE_PRODUCT", 56, 60], ["HupA", "SIMPLE_CHEMICAL", 73, 77], ["blood\u2013brain barrier", "TISSUE", 178, 197], ["oral", "ORGANISM_SUBDIVISION", 216, 220], ["AChE inhibitors", "TREATMENT", 56, 71], ["HupA", "TREATMENT", 73, 77], ["a more effective reversible inhibitor", "PROBLEM", 81, 118]]], ["Consequently, since 1996, HupA appeared in the Chinese drug market in a form of tablets named Shuangyiping for symptomatic treatment of AD, while in the USA and Europe, HupA is present as a dietary supplement (H. serrata powder in a capsule format) for limiting further memory disorders (Ma and Gang 2008).IntroductionThis review collects a variety of soil, marine, and endophytic microorganisms which considered promising producers of anti-AD drugs that showed in vitro anti-AChE activity.", [["HupA", "CHEMICAL", 26, 30], ["Shuangyiping", "CHEMICAL", 94, 106], ["AD", "DISEASE", 136, 138], ["HupA", "CHEMICAL", 169, 173], ["memory disorders", "DISEASE", 270, 286], ["HupA", "SIMPLE_CHEMICAL", 26, 30], ["Shuangyiping", "SIMPLE_CHEMICAL", 94, 106], ["HupA", "SIMPLE_CHEMICAL", 169, 173], ["anti-AD", "SIMPLE_CHEMICAL", 436, 443], ["anti-AChE", "CANCER", 471, 480], ["anti-AChE", "PROTEIN", 471, 480], ["H. serrata", "SPECIES", 210, 220], ["H. serrata", "SPECIES", 210, 220], ["tablets", "TREATMENT", 80, 87], ["symptomatic treatment", "TREATMENT", 111, 132], ["AD", "PROBLEM", 136, 138], ["a dietary supplement (H. serrata powder", "TREATMENT", 188, 227], ["further memory disorders", "PROBLEM", 262, 286], ["endophytic microorganisms", "PROBLEM", 370, 395], ["anti-AD drugs", "TREATMENT", 436, 449]]], ["In addition, it summarizes recent reports on the production, extraction, and detection methodologies of the most effective anti-AD drug candidate HupA with the established and recommended enhancement strategies for scaling up the microbial production of AChE inhibitors, to open the way towards the large-scale production.", [["HupA", "CHEMICAL", 146, 150], ["anti-AD", "SIMPLE_CHEMICAL", 123, 130], ["HupA", "SIMPLE_CHEMICAL", 146, 150], ["AChE", "GENE_OR_GENE_PRODUCT", 254, 258], ["extraction", "TREATMENT", 61, 71], ["enhancement strategies", "TREATMENT", 188, 210], ["AChE inhibitors", "TREATMENT", 254, 269], ["large", "OBSERVATION_MODIFIER", 299, 304]]], ["Moreover, incorporation of these active compounds with nano-structured drug delivery systems to increase their selectivity and reactivity will be also discussed.The approved AChE inhibitors for treating AD ::: Acetylcholinesterase and AChE inhibitorsMany drugs have been approved by the US Food and Drug Administration (FDA) for symptomatic treatment of AD patients.", [["AD", "DISEASE", 203, 205], ["AD", "DISEASE", 354, 356], ["AChE", "SIMPLE_CHEMICAL", 174, 178], ["Acetylcholinesterase", "GENE_OR_GENE_PRODUCT", 210, 230], ["AChE", "GENE_OR_GENE_PRODUCT", 235, 239], ["patients", "ORGANISM", 357, 365], ["Acetylcholinesterase", "PROTEIN", 210, 230], ["patients", "SPECIES", 357, 365], ["these active compounds", "PROBLEM", 27, 49], ["nano-structured drug delivery systems", "TREATMENT", 55, 92], ["The approved AChE inhibitors", "TREATMENT", 161, 189], ["Acetylcholinesterase", "TREATMENT", 210, 230], ["AChE inhibitors", "TREATMENT", 235, 250], ["symptomatic treatment of AD patients", "TREATMENT", 329, 365], ["active", "OBSERVATION_MODIFIER", 33, 39]]], ["Most of these drugs are AChE inhibitors.", [["AChE", "GENE_OR_GENE_PRODUCT", 24, 28], ["these drugs", "TREATMENT", 8, 19], ["AChE inhibitors", "TREATMENT", 24, 39]]], ["For example, Tacrine was approved in 1993, but it was withdrawn from market in 2012 because of its hepato-toxicity which affected more than 29% of patients.", [["Tacrine", "CHEMICAL", 13, 20], ["hepato-toxicity", "DISEASE", 99, 114], ["Tacrine", "CHEMICAL", 13, 20], ["Tacrine", "SIMPLE_CHEMICAL", 13, 20], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["Tacrine", "TREATMENT", 13, 20], ["its hepato-toxicity", "PROBLEM", 95, 114]]], ["In addition, Donepezil was approved in 1996 as a reversible AChE inhibitor and a fully synthetic compound with good inhibitory effect and low toxic effects than Tacrine.", [["Donepezil", "CHEMICAL", 13, 22], ["Tacrine", "CHEMICAL", 161, 168], ["Donepezil", "CHEMICAL", 13, 22], ["Tacrine", "CHEMICAL", 161, 168], ["Donepezil", "SIMPLE_CHEMICAL", 13, 22], ["AChE", "GENE_OR_GENE_PRODUCT", 60, 64], ["Tacrine", "SIMPLE_CHEMICAL", 161, 168], ["Donepezil", "TREATMENT", 13, 22], ["a reversible AChE inhibitor", "TREATMENT", 47, 74], ["low toxic effects", "PROBLEM", 138, 155], ["Tacrine", "TREATMENT", 161, 168], ["low toxic", "OBSERVATION_MODIFIER", 138, 147]]], ["Moreover, galantamine was approved in 2001 as a natural alkaloid extracted from Galanthus nivalis L. and related plants in Amaryllidaceae family (Heinrich and Teoh 2004; Marco and Carreiras 2006).", [["galantamine", "CHEMICAL", 10, 21], ["galantamine", "CHEMICAL", 10, 21], ["galantamine", "SIMPLE_CHEMICAL", 10, 21], ["Galanthus nivalis L.", "ORGANISM", 80, 100], ["Amaryllidaceae", "ORGANISM", 123, 137], ["Galanthus nivalis L.", "SPECIES", 80, 100], ["Galanthus nivalis L.", "SPECIES", 80, 100], ["galantamine", "TREATMENT", 10, 21], ["a natural alkaloid", "TREATMENT", 46, 64]]], ["More and above, Rivastigmine which is a semi-synthetic derivative of physostigmine, was approved in 2000.", [["Rivastigmine", "CHEMICAL", 16, 28], ["physostigmine", "CHEMICAL", 69, 82], ["Rivastigmine", "CHEMICAL", 16, 28], ["physostigmine", "CHEMICAL", 69, 82], ["Rivastigmine", "SIMPLE_CHEMICAL", 16, 28], ["physostigmine", "SIMPLE_CHEMICAL", 69, 82], ["Rivastigmine", "TREATMENT", 16, 28], ["a semi-synthetic derivative of physostigmine", "TREATMENT", 38, 82]]], ["Although it did not show liver toxicity like Tacrine, it showed other side effects such as nausea and vomiting (Zhao et al. 2004).Microbial production of AChE inhibitors ::: Acetylcholinesterase and AChE inhibitorsPlants represent the main significant source of AChE inhibitors.", [["liver", "ANATOMY", 25, 30], ["liver toxicity", "DISEASE", 25, 39], ["Tacrine", "CHEMICAL", 45, 52], ["nausea", "DISEASE", 91, 97], ["vomiting", "DISEASE", 102, 110], ["Tacrine", "CHEMICAL", 45, 52], ["liver", "ORGAN", 25, 30], ["Tacrine", "SIMPLE_CHEMICAL", 45, 52], ["AChE", "GENE_OR_GENE_PRODUCT", 154, 158], ["Acetylcholinesterase", "GENE_OR_GENE_PRODUCT", 174, 194], ["AChE", "GENE_OR_GENE_PRODUCT", 199, 203], ["AChE", "GENE_OR_GENE_PRODUCT", 262, 266], ["Acetylcholinesterase", "PROTEIN", 174, 194], ["liver toxicity", "PROBLEM", 25, 39], ["Tacrine", "TREATMENT", 45, 52], ["other side effects", "PROBLEM", 64, 82], ["nausea", "PROBLEM", 91, 97], ["vomiting", "PROBLEM", 102, 110], ["Acetylcholinesterase", "TREATMENT", 174, 194], ["AChE inhibitors", "TREATMENT", 199, 214], ["AChE inhibitors", "TREATMENT", 262, 277], ["liver", "ANATOMY", 25, 30], ["toxicity", "OBSERVATION", 31, 39], ["AChE inhibitors", "OBSERVATION", 262, 277]]], ["However, few researches reported the ability of some microorganisms to produce similar inhibitors (Pandey et al. 2014).", [["some microorganisms", "PROBLEM", 48, 67], ["few", "OBSERVATION_MODIFIER", 9, 12]]], ["Searching for natural, cost-effective, and sustainable source of effective AChE inhibitors became an attractive scope for many researchers.", [["AChE", "GENE_OR_GENE_PRODUCT", 75, 79], ["effective AChE inhibitors", "TREATMENT", 65, 90]]], ["Hence, great efforts have been dedicated for investigating the production of AChE inhibitors by microbial strains isolated from soil and marine environments, and unusual sources such as plant-associated microbes known as endophytes (Singh et al. 2012).", [["AChE", "GENE_OR_GENE_PRODUCT", 77, 81], ["AChE inhibitors", "TREATMENT", 77, 92], ["microbial strains", "PROBLEM", 96, 113]]], ["Table 1 summarizes most-recent reported data on the microbial anti-AChE activity and the identified microbial AChE inhibitors by various microorganisms from different niches.Endophytic fungi as new sources for\u00a0AChE inhibitors ::: Acetylcholinesterase and AChE inhibitorsEndophytic fungi are mutualistic microorganisms, occupy the internal tissues of healthy plants through certain life stages or throughout their whole life, without leading to any significant disease symptoms on the host (Strobel 2003; Ismaiel et al. 2017).", [["tissues", "ANATOMY", 339, 346], ["AChE", "GENE_OR_GENE_PRODUCT", 110, 114], ["AChE", "GENE_OR_GENE_PRODUCT", 210, 214], ["Acetylcholinesterase", "GENE_OR_GENE_PRODUCT", 230, 250], ["AChE", "GENE_OR_GENE_PRODUCT", 255, 259], ["tissues", "TISSUE", 339, 346], ["the microbial anti-AChE activity", "TREATMENT", 48, 80], ["microbial AChE inhibitors", "TREATMENT", 100, 125], ["various microorganisms", "PROBLEM", 129, 151], ["Endophytic fungi", "PROBLEM", 174, 190], ["AChE inhibitors", "TREATMENT", 210, 225], ["Acetylcholinesterase", "TREATMENT", 230, 250], ["AChE inhibitors", "TREATMENT", 255, 270], ["Endophytic fungi", "TEST", 270, 286], ["mutualistic microorganisms", "PROBLEM", 291, 317], ["any significant disease symptoms", "PROBLEM", 444, 476], ["microbial AChE", "OBSERVATION", 100, 114], ["internal tissues", "ANATOMY", 330, 346], ["healthy plants", "OBSERVATION", 350, 364], ["significant", "OBSERVATION_MODIFIER", 448, 459], ["disease", "OBSERVATION", 460, 467]]], ["They are known to provide a plethora of fitness benefits to the host as previously reported endophytes are biologically active and can efficiently enhance the growth of their host, and promote host resistance to diseases-causing phyto-pathogens and environmental stress (Aly et al. 2011).Endophytic fungi as new sources for\u00a0AChE inhibitors ::: Acetylcholinesterase and AChE inhibitorsInterestingly, they can also produce identical or similar bioactive substances as host plants (Strobel 2003).", [["phyto-pathogens", "DISEASE", 229, 244], ["AChE", "GENE_OR_GENE_PRODUCT", 324, 328], ["Acetylcholinesterase", "GENE_OR_GENE_PRODUCT", 344, 364], ["AChE", "GENE_OR_GENE_PRODUCT", 369, 373], ["phyto-pathogens", "PROBLEM", 229, 244], ["environmental stress", "PROBLEM", 249, 269], ["Endophytic fungi", "PROBLEM", 288, 304], ["AChE inhibitors", "TREATMENT", 324, 339], ["Acetylcholinesterase", "TREATMENT", 344, 364], ["AChE inhibitors", "TREATMENT", 369, 384], ["host resistance", "OBSERVATION", 193, 208], ["bioactive substances", "OBSERVATION", 442, 462]]], ["After Stierle et al. (1993) reported the discovery of an endophytic fungus, Taxomyces andreanae, which can produce the anticancer-active substance, paclitaxel, the endophytic fungi producing pharmaceutically active compounds have gained significant consideration worldwide.Endophytic fungi as new sources for\u00a0AChE inhibitors ::: Acetylcholinesterase and AChE inhibitorsThe hypothesis of horizontal gene transfer has revealed the capability of endophytes to produce the same active compounds which produced by host plants.", [["anticancer", "ANATOMY", 119, 129], ["paclitaxel", "CHEMICAL", 148, 158], ["paclitaxel", "CHEMICAL", 148, 158], ["Taxomyces andreanae", "ORGANISM", 76, 95], ["anticancer", "CANCER", 119, 129], ["paclitaxel", "SIMPLE_CHEMICAL", 148, 158], ["AChE", "GENE_OR_GENE_PRODUCT", 309, 313], ["Acetylcholinesterase", "GENE_OR_GENE_PRODUCT", 329, 349], ["AChE", "GENE_OR_GENE_PRODUCT", 354, 358], ["Acetylcholinesterase", "PROTEIN", 329, 349], ["Taxomyces andreanae", "SPECIES", 76, 95], ["Taxomyces andreanae", "SPECIES", 76, 95], ["an endophytic fungus", "PROBLEM", 54, 74], ["Taxomyces andreanae", "TREATMENT", 76, 95], ["paclitaxel", "TREATMENT", 148, 158], ["the endophytic fungi", "PROBLEM", 160, 180], ["pharmaceutically active compounds", "PROBLEM", 191, 224], ["Endophytic fungi", "PROBLEM", 273, 289], ["AChE inhibitors", "TREATMENT", 309, 324], ["Acetylcholinesterase", "TREATMENT", 329, 349], ["AChE inhibitors", "TREATMENT", 354, 369], ["endophytic fungus", "OBSERVATION", 57, 74], ["active", "OBSERVATION_MODIFIER", 474, 480], ["compounds", "OBSERVATION", 481, 490]]], ["Moreover, they could produce some novel medicines against some incurable diseases (Strobel 2003; Strobe and Daisy 2003; Staniek et al. 2008).", [["some incurable diseases", "PROBLEM", 58, 81], ["incurable", "OBSERVATION_MODIFIER", 63, 72]]], ["However, the unmanaged harvesting of plant resources for extracting AChE inhibitors would lead to their depletion.", [["AChE", "GENE_OR_GENE_PRODUCT", 68, 72], ["plant resources", "TREATMENT", 37, 52], ["extracting AChE inhibitors", "TREATMENT", 57, 83], ["their depletion", "PROBLEM", 98, 113], ["unmanaged", "OBSERVATION_MODIFIER", 13, 22], ["depletion", "OBSERVATION", 104, 113]]], ["For protecting these resources, the capability of producing similar AChE inhibitors by endophytes of medicinal plants has been widely investigated.", [["AChE", "GENE_OR_GENE_PRODUCT", 68, 72], ["similar AChE inhibitors", "TREATMENT", 60, 83], ["medicinal plants", "TREATMENT", 101, 117], ["medicinal plants", "OBSERVATION", 101, 117]]], ["Endophytic fungi proved their efficiency as valuable, novel, and alternate resources with good AChE inhibitory activity (Wang et al. 2015b; Ali et al. 2016).Endophytic fungi as new sources for\u00a0AChE inhibitors ::: Acetylcholinesterase and AChE inhibitorsEndophytic fungi with good anti-AChE activity are presented in Table 1.", [["AChE", "GENE_OR_GENE_PRODUCT", 95, 99], ["AChE", "GENE_OR_GENE_PRODUCT", 193, 197], ["Acetylcholinesterase", "GENE_OR_GENE_PRODUCT", 213, 233], ["AChE", "GENE_OR_GENE_PRODUCT", 238, 242], ["AChE", "PROTEIN", 95, 99], ["anti-AChE", "PROTEIN", 280, 289], ["Endophytic fungi", "PROBLEM", 0, 16], ["Endophytic fungi", "PROBLEM", 157, 173], ["AChE inhibitors", "TREATMENT", 193, 208], ["Acetylcholinesterase", "TREATMENT", 213, 233], ["AChE inhibitors", "TREATMENT", 238, 253], ["Endophytic fungi", "TEST", 253, 269]]], ["Recovery of endophytic fungi from healthy plant tissues led to a massive argument whether these entophytes are plant pathogen or not.", [["tissues", "ANATOMY", 48, 55], ["plant tissues", "TISSUE", 42, 55], ["entophytes", "CANCER", 96, 106], ["endophytic fungi", "PROBLEM", 12, 28], ["healthy plant tissues", "PROBLEM", 34, 55], ["these entophytes", "PROBLEM", 90, 106], ["plant pathogen", "PROBLEM", 111, 125], ["endophytic fungi", "OBSERVATION", 12, 28], ["massive", "OBSERVATION_MODIFIER", 65, 72]]], ["According to Chen et al. (2010) and Mohinudeen et al. (2019), endophytic fungi may appear at two phases, non-pathogenic and pathogenic.", [["endophytic fungi", "TEST", 62, 78], ["non-pathogenic", "PROBLEM", 105, 119], ["pathogenic", "PROBLEM", 124, 134], ["non-pathogenic", "OBSERVATION_MODIFIER", 105, 119], ["pathogenic", "OBSERVATION_MODIFIER", 124, 134]]], ["Many non-pathogenic endophytes are dormant pathogens and may become pathogenic under certain environmental stress conditions or after plant aging.", [["Many non-pathogenic endophytes", "PROBLEM", 0, 30], ["dormant pathogens", "PROBLEM", 35, 52], ["pathogenic", "PROBLEM", 68, 78], ["non-pathogenic", "OBSERVATION_MODIFIER", 5, 19], ["endophytes", "OBSERVATION", 20, 30]]], ["Other possible reason may be attributed to the nature of host species as endophytes can be useful and growth stimulating to certain host species while they can be pathogenic to other plants.Biosynthesis of HupA: related genes and enzymes ::: HupA identity and structural elucidationDistribution of gene functions and biochemical pathways in Colletotrichum gloeosporioides (HupA-producing fungus) was based on the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) assignments, particularly in the categories of molecular function and metabolism (Zhang et al. 2015b).", [["HupA", "CHEMICAL", 206, 210], ["HupA", "CHEMICAL", 373, 377], ["HupA", "GENE_OR_GENE_PRODUCT", 206, 210], ["Colletotrichum gloeosporioides", "ORGANISM", 341, 371], ["HupA-producing fungus", "ORGANISM", 373, 394], ["HupA", "PROTEIN", 206, 210], ["enzymes", "PROTEIN", 230, 237], ["Colletotrichum gloeosporioides", "SPECIES", 341, 371], ["Colletotrichum gloeosporioides", "SPECIES", 341, 371], ["host species", "PROBLEM", 57, 69], ["endophytes", "PROBLEM", 73, 83], ["HupA identity", "TEST", 242, 255], ["structural elucidationDistribution of gene functions", "PROBLEM", 260, 312], ["Colletotrichum gloeosporioides", "PROBLEM", 341, 371], ["fungus", "PROBLEM", 388, 394], ["host species", "OBSERVATION", 57, 69], ["structural elucidationDistribution", "OBSERVATION", 260, 294], ["gene functions", "OBSERVATION", 298, 312], ["Colletotrichum gloeosporioides", "OBSERVATION", 341, 371]]], ["These annotations provide valuable resources for the investigation of gene functions, and cellular structures and processes in C. gloeosporioides.Biosynthesis of HupA: related genes and enzymes ::: HupA identity and structural elucidationAmong the 308 metabolic pathways (annotated by KEGG), three pathways were involved in alkaloid biosynthesis: lysine biosynthesis, biotin metabolism, and (tropane, piperidine, and pyridine) alkaloid biosynthesis.", [["cellular structures", "ANATOMY", 90, 109], ["HupA", "CHEMICAL", 162, 166], ["lysine", "CHEMICAL", 347, 353], ["biotin", "CHEMICAL", 368, 374], ["tropane", "CHEMICAL", 392, 399], ["piperidine", "CHEMICAL", 401, 411], ["pyridine", "CHEMICAL", 417, 425], ["lysine", "CHEMICAL", 347, 353], ["biotin", "CHEMICAL", 368, 374], ["tropane", "CHEMICAL", 392, 399], ["piperidine", "CHEMICAL", 401, 411], ["pyridine", "CHEMICAL", 417, 425], ["cellular", "CELL", 90, 98], ["C. gloeosporioides", "ORGANISM", 127, 145], ["HupA", "GENE_OR_GENE_PRODUCT", 162, 166], ["alkaloid", "SIMPLE_CHEMICAL", 324, 332], ["lysine", "SIMPLE_CHEMICAL", 347, 353], ["biotin", "SIMPLE_CHEMICAL", 368, 374], ["tropane", "SIMPLE_CHEMICAL", 392, 399], ["piperidine", "SIMPLE_CHEMICAL", 401, 411], ["pyridine) alkaloid", "SIMPLE_CHEMICAL", 417, 435], ["HupA", "PROTEIN", 162, 166], ["enzymes", "PROTEIN", 186, 193], ["C. gloeosporioides", "SPECIES", 127, 145], ["C. gloeosporioides", "SPECIES", 127, 145], ["the investigation", "TEST", 49, 66], ["gene functions", "PROBLEM", 70, 84], ["HupA identity", "TEST", 198, 211], ["alkaloid biosynthesis", "TREATMENT", 324, 345], ["lysine biosynthesis", "TREATMENT", 347, 366], ["biotin metabolism", "TREATMENT", 368, 385], ["tropane", "TREATMENT", 392, 399], ["piperidine", "TREATMENT", 401, 411], ["pyridine", "TREATMENT", 417, 425], ["alkaloid biosynthesis", "TREATMENT", 427, 448]]], ["A total of 30 unigenes in this library showed similarities to the non-characterized enzymes that might be associated with the biosynthesis of HupA (Table 3).Biosynthesis of HupA: related genes and enzymes ::: HupA identity and structural elucidationBased on these three pathways and more literature survey (Luo et al. 2010; Choi et al. 2012; Liu et al. 2012), a more detailed biosynthetic pathway was deduced as shown in Fig. 2 with related enzymes and genes as shown in Table 3.", [["HupA", "CHEMICAL", 173, 177], ["HupA (Table 3", "GENE_OR_GENE_PRODUCT", 142, 155], ["HupA", "GENE_OR_GENE_PRODUCT", 173, 177], ["non-characterized enzymes", "PROTEIN", 66, 91], ["HupA", "PROTEIN", 142, 146], ["HupA", "PROTEIN", 173, 177], ["enzymes", "PROTEIN", 197, 204], ["enzymes", "PROTEIN", 441, 448], ["this library", "TEST", 26, 38], ["the non-characterized enzymes", "TEST", 62, 91], ["related enzymes", "TEST", 433, 448]]], ["The discovery of new transcripts will further facilitate the elucidation of the biosynthetic mechanisms of HupA at the molecular level in C. gloeosporioides (Zhang et al. 2015a, b, c, d).HupA production and supply problems ::: HupA identity and structural elucidationThere is a serious problem obstructing the large-scale production of this highly effective drug as Huperziaceae plant species specially, Huperzia serrata which are the major source of HupA, give low extracted yield and their vegetative cycle is very long (Ma and Gang 2008).", [["HupA", "CHEMICAL", 107, 111], ["HupA", "CHEMICAL", 187, 191], ["HupA", "CHEMICAL", 451, 455], ["HupA", "GENE_OR_GENE_PRODUCT", 107, 111], ["C. gloeosporioides", "ORGANISM", 138, 156], ["HupA", "SIMPLE_CHEMICAL", 187, 191], ["Huperziaceae", "ORGANISM", 366, 378], ["Huperzia serrata", "ORGANISM", 404, 420], ["HupA", "GENE_OR_GENE_PRODUCT", 451, 455], ["HupA", "PROTEIN", 107, 111], ["C. gloeosporioides", "SPECIES", 138, 156], ["Huperzia serrata", "SPECIES", 404, 420], ["C. gloeosporioides", "SPECIES", 138, 156], ["Huperzia serrata", "SPECIES", 404, 420], ["HupA", "TREATMENT", 107, 111], ["a serious problem", "PROBLEM", 276, 293], ["Huperziaceae plant species", "TREATMENT", 366, 392], ["low extracted yield", "PROBLEM", 462, 481], ["new", "OBSERVATION_MODIFIER", 17, 20], ["serious", "OBSERVATION_MODIFIER", 278, 285], ["large", "OBSERVATION_MODIFIER", 310, 315], ["-scale", "OBSERVATION_MODIFIER", 315, 321]]], ["It means that these plants are not considered to be effective source for HupA production at the commercial scale.", [["HupA", "CHEMICAL", 73, 77], ["HupA", "SIMPLE_CHEMICAL", 73, 77], ["HupA production", "PROBLEM", 73, 88], ["not considered", "UNCERTAINTY", 31, 45]]], ["As a result, researchers tried to find other methods to produce HupA such as in vitro plant tissue cultivation and chemical synthesis.", [["tissue", "ANATOMY", 92, 98], ["HupA", "CHEMICAL", 64, 68], ["HupA", "SIMPLE_CHEMICAL", 64, 68], ["tissue", "TISSUE", 92, 98], ["HupA", "TREATMENT", 64, 68], ["vitro plant tissue cultivation", "TREATMENT", 80, 110], ["chemical synthesis", "TREATMENT", 115, 133], ["plant tissue", "OBSERVATION", 86, 98], ["chemical synthesis", "OBSERVATION", 115, 133]]], ["Tissue culturing was not considered as a successful technique for HupA production at a large scale (Ma and Gang 2008; Ishiuchi et al. 2013).", [["Tissue", "ANATOMY", 0, 6], ["HupA", "CHEMICAL", 66, 70], ["Tissue", "TISSUE", 0, 6], ["HupA", "SIMPLE_CHEMICAL", 66, 70], ["Tissue culturing", "TEST", 0, 16], ["HupA production", "PROBLEM", 66, 81]]], ["Although HupA was totally synthesized from (R)-pulegone (Ding et al. 2012), the chemical synthesis of HupA showed some limitations such as complex interactions, continual pollution, and expensive processes (Koshiba et al. 2009).", [["HupA", "CHEMICAL", 9, 13], ["HupA", "CHEMICAL", 102, 106], ["(R)-pulegone", "CHEMICAL", 43, 55], ["HupA", "CHEMICAL", 102, 106], ["HupA", "SIMPLE_CHEMICAL", 9, 13], ["(R)-pulegone", "SIMPLE_CHEMICAL", 43, 55], ["HupA", "SIMPLE_CHEMICAL", 102, 106], ["the chemical synthesis of HupA", "TEST", 76, 106]]], ["As these trials have not achieved satisfactory results to be applied at a large industrial scale, the discovery of HupA-producing endophytic fungi from the tissues of Huperziaceae plant species provides an alternative solution.HupA production and supply problems ::: HupA identity and structural elucidationAlthough the production of HupA drug from endophytes would reduce the price of traditional drugs and effectively protect the ecological environment, only a small number of endophytic fungi that produce HupA were reported.", [["tissues", "ANATOMY", 156, 163], ["HupA", "CHEMICAL", 115, 119], ["HupA", "CHEMICAL", 227, 231], ["HupA", "CHEMICAL", 334, 338], ["HupA", "CHEMICAL", 509, 513], ["HupA", "CHEMICAL", 334, 338], ["HupA", "GENE_OR_GENE_PRODUCT", 115, 119], ["tissues", "TISSUE", 156, 163], ["HupA", "SIMPLE_CHEMICAL", 227, 231], ["HupA", "SIMPLE_CHEMICAL", 334, 338], ["HupA", "GENE_OR_GENE_PRODUCT", 509, 513], ["HupA", "PROTEIN", 115, 119], ["HupA", "PROTEIN", 509, 513], ["a large industrial scale", "TREATMENT", 72, 96], ["HupA", "TREATMENT", 115, 119], ["endophytic fungi", "PROBLEM", 130, 146], ["Huperziaceae plant species", "TREATMENT", 167, 193], ["an alternative solution", "TREATMENT", 203, 226], ["HupA drug", "TREATMENT", 334, 343], ["traditional drugs", "TREATMENT", 386, 403], ["endophytic fungi", "PROBLEM", 479, 495], ["endophytic fungi", "OBSERVATION", 130, 146], ["small", "OBSERVATION_MODIFIER", 463, 468], ["endophytic fungi", "OBSERVATION", 479, 495]]], ["Li et al. (2007) reported the recovery of HupA-producing endophytic fungal species from tissues of Huperzia serrata.", [["tissues", "ANATOMY", 88, 95], ["HupA", "CHEMICAL", 42, 46], ["HupA", "GENE_OR_GENE_PRODUCT", 42, 46], ["tissues", "TISSUE", 88, 95], ["Huperzia serrata", "ORGANISM", 99, 115], ["HupA", "PROTEIN", 42, 46], ["Huperzia serrata", "SPECIES", 99, 115], ["Huperzia serrata", "SPECIES", 99, 115], ["HupA", "TEST", 42, 46], ["endophytic fungal species", "PROBLEM", 57, 82], ["endophytic fungal species", "OBSERVATION", 57, 82]]], ["This finding stimulated many researchers to isolate and screen many endophytic fungi from Huperzia serrata and other related plants such as Phlegmariurus, and this research interest is still increasing till today.", [["Huperzia serrata", "ORGANISM", 90, 106], ["Huperzia serrata", "SPECIES", 90, 106], ["Huperzia serrata", "SPECIES", 90, 106], ["many endophytic fungi", "PROBLEM", 63, 84], ["Huperzia serrata", "PROBLEM", 90, 106], ["endophytic fungi", "OBSERVATION", 68, 84]]], ["The reported HupA-producing endophytes with varying HupA yield are highlighted in Table 4.HupA extraction and detection from endophytic fungal culture ::: Isolation of endophytic fungi from Huperziaceae plant speciesHupA is an intracellular metabolite of endophytic fungi and is mainly extracted from the fungal biomass.", [["intracellular", "ANATOMY", 227, 240], ["HupA", "CHEMICAL", 13, 17], ["HupA", "CHEMICAL", 52, 56], ["HupA", "CHEMICAL", 90, 94], ["HupA", "CHEMICAL", 216, 220], ["HupA", "SIMPLE_CHEMICAL", 13, 17], ["HupA", "SIMPLE_CHEMICAL", 52, 56], ["HupA", "SIMPLE_CHEMICAL", 90, 94], ["Huperziaceae plant species", "ORGANISM", 190, 216], ["HupA", "SIMPLE_CHEMICAL", 216, 220], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 227, 240], ["HupA", "PROTEIN", 13, 17], ["HupA", "PROTEIN", 52, 56], ["HupA extraction", "TREATMENT", 90, 105], ["endophytic fungal culture", "TEST", 125, 150], ["endophytic fungi", "PROBLEM", 168, 184], ["endophytic fungi", "PROBLEM", 255, 271], ["the fungal biomass", "PROBLEM", 301, 319], ["endophytes", "OBSERVATION", 28, 38], ["endophytic fungi", "OBSERVATION", 168, 184], ["speciesHupA", "OBSERVATION", 209, 220], ["intracellular", "OBSERVATION_MODIFIER", 227, 240], ["metabolite", "OBSERVATION_MODIFIER", 241, 251], ["endophytic fungi", "OBSERVATION", 255, 271], ["fungal biomass", "OBSERVATION", 305, 319]]], ["Thus, the HupA extraction method depends primarily on some sequenced steps of biomass grinding, acidic soaking, and ultrasonication in order to weaken the fungal cell walls and facilitate the extraction of the targeted intracellular metabolite (Pinu et al. 2017).HupA extraction and detection from endophytic fungal culture ::: Isolation of endophytic fungi from Huperziaceae plant speciesAs HupA is an alkaloid compound by nature, it could be extracted by the conventional acid-water method.", [["cell walls", "ANATOMY", 162, 172], ["intracellular", "ANATOMY", 219, 232], ["HupA", "CHEMICAL", 263, 267], ["HupA", "CHEMICAL", 392, 396], ["HupA", "SIMPLE_CHEMICAL", 10, 14], ["cell", "CELL", 162, 166], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 219, 232], ["HupA", "SIMPLE_CHEMICAL", 263, 267], ["Huperziaceae", "ORGANISM", 363, 375], ["HupA", "SIMPLE_CHEMICAL", 392, 396], ["the HupA extraction method", "TREATMENT", 6, 32], ["biomass grinding", "PROBLEM", 78, 94], ["acidic soaking", "TREATMENT", 96, 110], ["ultrasonication", "TREATMENT", 116, 131], ["the fungal cell walls", "PROBLEM", 151, 172], ["the extraction", "TREATMENT", 188, 202], ["HupA extraction", "TREATMENT", 263, 278], ["endophytic fungal culture", "TEST", 298, 323], ["endophytic fungi", "PROBLEM", 341, 357], ["Huperziaceae plant species", "PROBLEM", 363, 389], ["the conventional acid-water method", "TREATMENT", 457, 491], ["fungal cell walls", "OBSERVATION", 155, 172], ["endophytic fungi", "OBSERVATION", 341, 357], ["alkaloid compound", "OBSERVATION", 403, 420]]], ["However, Weigang et al. (2013) and Ting et al. (2015) studied the significant extraction factors and determined the optimum levels for maximizing the HupA extracted yield from H. serrata using Box-Behnken factorial design.", [["H. serrata", "ORGANISM", 176, 186], ["H. serrata", "SPECIES", 176, 186], ["H. serrata", "SPECIES", 176, 186], ["the significant extraction factors", "PROBLEM", 62, 96], ["the optimum levels", "TEST", 112, 130]]], ["Currently, there are no reported extraction optimization studies for maximizing the extraction of HupA from fungal biomass and the different extraction conditions have been reported and summarized in Table 5.HupA extraction and detection from endophytic fungal culture ::: Isolation of endophytic fungi from Huperziaceae plant speciesJu et al. (2009) used 2% tartaric acid on the fungal dried biomass followed by ultrasonic extraction for 2 h.", [["HupA", "CHEMICAL", 98, 102], ["HupA", "CHEMICAL", 208, 212], ["tartaric acid", "CHEMICAL", 359, 372], ["tartaric acid", "CHEMICAL", 359, 372], ["HupA", "SIMPLE_CHEMICAL", 98, 102], ["HupA", "SIMPLE_CHEMICAL", 208, 212], ["tartaric acid", "SIMPLE_CHEMICAL", 359, 372], ["optimization studies", "TEST", 44, 64], ["the extraction", "TREATMENT", 80, 94], ["HupA", "TREATMENT", 98, 102], ["fungal biomass", "PROBLEM", 108, 122], ["the different extraction", "TREATMENT", 127, 151], ["HupA extraction", "TREATMENT", 208, 223], ["endophytic fungal culture", "TEST", 243, 268], ["endophytic fungi", "PROBLEM", 286, 302], ["2% tartaric acid", "TREATMENT", 356, 372], ["the fungal dried biomass", "TREATMENT", 376, 400], ["ultrasonic extraction", "TREATMENT", 413, 434], ["no", "UNCERTAINTY", 21, 23], ["fungal biomass", "OBSERVATION", 108, 122], ["endophytic fungi", "OBSERVATION", 286, 302]]], ["Then, high-speed centrifugation at 10.000 rpm for 10 min; finally, supernatant was screened for HupA.", [["supernatant", "ANATOMY", 67, 78], ["HupA", "CHEMICAL", 96, 100], ["HupA", "SIMPLE_CHEMICAL", 96, 100], ["HupA", "PROTEIN", 96, 100], ["high-speed centrifugation", "TREATMENT", 6, 31]]], ["Wang et al. (2011a) and Dong et al. (2014) exposed the collected cells to sonication with immersion in 95% ethanol overnight, then the extract was concentrated under reduced pressure.HupA extraction and detection from endophytic fungal culture ::: Isolation of endophytic fungi from Huperziaceae plant speciesOther reports soaked the dried cells (1 g) overnight in 50 mL of 0.5\u20131.5% (v/v) hydrochloric acid (Zhao et al. 2013; Shu et al. 2014;Han et al. 2015; Zaki et al. 2019) or 2% tartaric acid (Zhang et al. 2015a), then cells were disrupted by ultrasonication for 40 min.", [["cells", "ANATOMY", 65, 70], ["extract", "ANATOMY", 135, 142], ["cells", "ANATOMY", 340, 345], ["cells", "ANATOMY", 524, 529], ["ethanol", "CHEMICAL", 107, 114], ["HupA", "CHEMICAL", 183, 187], ["Huperziaceae", "CHEMICAL", 283, 295], ["hydrochloric acid", "CHEMICAL", 389, 406], ["tartaric acid", "CHEMICAL", 483, 496], ["ethanol", "CHEMICAL", 107, 114], ["hydrochloric acid", "CHEMICAL", 389, 406], ["tartaric acid", "CHEMICAL", 483, 496], ["cells", "CELL", 65, 70], ["ethanol", "SIMPLE_CHEMICAL", 107, 114], ["HupA", "SIMPLE_CHEMICAL", 183, 187], ["Huperziaceae", "ORGANISM", 283, 295], ["cells", "CELL", 340, 345], ["v/v) hydrochloric acid", "SIMPLE_CHEMICAL", 384, 406], ["tartaric acid", "SIMPLE_CHEMICAL", 483, 496], ["cells", "CELL", 524, 529], ["dried cells", "CELL_TYPE", 334, 345], ["immersion", "TREATMENT", 90, 99], ["HupA extraction", "TREATMENT", 183, 198], ["endophytic fungal culture", "TEST", 218, 243], ["endophytic fungi", "PROBLEM", 261, 277], ["Huperziaceae plant speciesOther", "TREATMENT", 283, 314], ["the dried cells", "TREATMENT", 330, 345], ["hydrochloric acid", "TREATMENT", 389, 406], ["2% tartaric acid", "TREATMENT", 480, 496], ["reduced pressure", "OBSERVATION", 166, 182], ["endophytic fungi", "OBSERVATION", 261, 277]]], ["After that, ammonia solution was used to alkalize the water phase (pH 9); thus, alkaloids containing HupA left the water phase and transferred to the chloroform layer upon vigorous shaking.HupA extraction and detection from endophytic fungal culture ::: Isolation of endophytic fungi from Huperziaceae plant speciesAfter that, the chloroform extract was evaporated, and the obtained residue was dissolved in methanol.", [["ammonia", "CHEMICAL", 12, 19], ["HupA", "CHEMICAL", 101, 105], ["HupA", "CHEMICAL", 189, 193], ["chloroform extract", "CHEMICAL", 331, 349], ["ammonia", "CHEMICAL", 12, 19], ["HupA", "CHEMICAL", 101, 105], ["chloroform", "CHEMICAL", 150, 160], ["chloroform", "CHEMICAL", 331, 341], ["methanol", "CHEMICAL", 408, 416], ["ammonia", "SIMPLE_CHEMICAL", 12, 19], ["alkaloids", "SIMPLE_CHEMICAL", 80, 89], ["HupA", "SIMPLE_CHEMICAL", 101, 105], ["HupA", "SIMPLE_CHEMICAL", 189, 193], ["chloroform", "SIMPLE_CHEMICAL", 331, 341], ["methanol", "SIMPLE_CHEMICAL", 408, 416], ["ammonia solution", "TREATMENT", 12, 28], ["pH", "TEST", 67, 69], ["alkaloids", "TREATMENT", 80, 89], ["vigorous shaking", "PROBLEM", 172, 188], ["HupA extraction", "TREATMENT", 189, 204], ["endophytic fungal culture", "TEST", 224, 249], ["endophytic fungi", "PROBLEM", 267, 283], ["Huperziaceae plant species", "PROBLEM", 289, 315], ["the chloroform extract", "TREATMENT", 327, 349], ["methanol", "TREATMENT", 408, 416], ["water phase", "OBSERVATION_MODIFIER", 115, 126], ["vigorous", "OBSERVATION_MODIFIER", 172, 180], ["shaking", "OBSERVATION", 181, 188], ["endophytic fungi", "OBSERVATION", 267, 283], ["plant species", "OBSERVATION", 302, 315]]], ["Zhu et al. (2010) and Cruz-Miranda et al. (2019) applied sequential extraction; the dried cells underwent extraction with 75% ethanol for 30 min in a 40 \u00b0C ultrasonic bath.", [["cells", "ANATOMY", 90, 95], ["ethanol", "CHEMICAL", 126, 133], ["ethanol", "CHEMICAL", 126, 133], ["cells", "CELL", 90, 95], ["ethanol", "SIMPLE_CHEMICAL", 126, 133], ["sequential extraction", "TREATMENT", 57, 78], ["the dried cells", "TREATMENT", 80, 95], ["extraction", "TREATMENT", 106, 116], ["a 40 \u00b0C ultrasonic bath", "TREATMENT", 148, 171]]], ["Then, alcoholic extracts were allowed to evaporate under reduced pressure.", [["extracts", "ANATOMY", 16, 24], ["extracts", "ORGANISM_SUBSTANCE", 16, 24], ["alcoholic extracts", "TREATMENT", 6, 24], ["pressure", "OBSERVATION_MODIFIER", 65, 73]]], ["After that, 2.5% hydrochloric acid was added to dissolve any dried residues.", [["hydrochloric acid", "CHEMICAL", 17, 34], ["hydrochloric acid", "CHEMICAL", 17, 34], ["hydrochloric acid", "SIMPLE_CHEMICAL", 17, 34], ["2.5% hydrochloric acid", "TREATMENT", 12, 34], ["any dried residues", "PROBLEM", 57, 75]]], ["Then, ammonia solution was added followed by chloroform extraction and evaporation.", [["ammonia", "CHEMICAL", 6, 13], ["ammonia", "CHEMICAL", 6, 13], ["chloroform", "CHEMICAL", 45, 55], ["ammonia", "SIMPLE_CHEMICAL", 6, 13], ["chloroform", "SIMPLE_CHEMICAL", 45, 55], ["ammonia solution", "TREATMENT", 6, 22], ["chloroform extraction", "TREATMENT", 45, 66], ["evaporation", "TREATMENT", 71, 82]]], ["Finally, the obtained dried residues were dissolved in 1 ml solvent (mostly methanol) for HupA identification.HupA extraction and detection from endophytic fungal culture ::: Isolation of endophytic fungi from Huperziaceae plant speciesHupA in an alkaloid extract from the endophytic fungi could be mainly identified and quantified by using spectroscopic and chromatographic analyses such as thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), and mass spectrometry (MS) analyses.", [["HupA", "CHEMICAL", 90, 94], ["HupA", "CHEMICAL", 110, 114], ["HupA", "CHEMICAL", 236, 240], ["alkaloid extract", "CHEMICAL", 247, 263], ["methanol", "CHEMICAL", 76, 84], ["methanol", "SIMPLE_CHEMICAL", 76, 84], ["HupA", "SIMPLE_CHEMICAL", 90, 94], ["HupA", "SIMPLE_CHEMICAL", 110, 114], ["Huperziaceae", "ORGANISM", 210, 222], ["HupA", "SIMPLE_CHEMICAL", 236, 240], ["dried residues", "PROBLEM", 22, 36], ["HupA identification", "TEST", 90, 109], ["HupA extraction", "TREATMENT", 110, 125], ["endophytic fungal culture", "TEST", 145, 170], ["endophytic fungi", "PROBLEM", 188, 204], ["Huperziaceae plant speciesHupA", "TREATMENT", 210, 240], ["an alkaloid extract", "TREATMENT", 244, 263], ["the endophytic fungi", "PROBLEM", 269, 289], ["spectroscopic and chromatographic analyses", "TEST", 341, 383], ["thin-layer chromatography", "TEST", 392, 417], ["TLC", "TEST", 419, 422], ["HPLC", "TEST", 465, 469], ["mass spectrometry (MS) analyses", "PROBLEM", 476, 507], ["endophytic fungi", "OBSERVATION", 188, 204], ["species", "OBSERVATION_MODIFIER", 229, 236], ["HupA", "OBSERVATION_MODIFIER", 236, 240], ["alkaloid extract", "OBSERVATION", 247, 263], ["endophytic fungi", "OBSERVATION", 273, 289]]], ["Each analysis conditions and the composition of tested mobile phases were reviewed in Table 5 as the following: the preliminary identification step for HupA is application of TLC analysis, where the extracted HupA and standard samples were loaded on silica gel-coated plates with developing run reagent that differed from one report to another (Table 5), as it was composed of acetone: chloroform: isopropanol (4:4:2 v/v/v) (Wang et al. 2011a, b; Han et al. 2015), acetone: chloroform: isopropanol: ammonia (4:4:2:0.12) (Zhu et al. 2010; Zaki et al. 2019); acetone: chloroform: isopropanol: ammonia (4:4:1.5:0.15); acetic acid:1-Butanol:water (3:3:2); 1-Butanol: isopropanol: water (10:5:4); 1-Butanol: isopropanol: acetic acid: water (7:5:2:4); chloroform: acetone: methanol (65:35:5) (Zhu et al. 2010).HupA extraction and detection from endophytic fungal culture ::: Isolation of endophytic fungi from Huperziaceae plant speciesThen, HupA spot was visualized using UV-fluorescence at 254 nm (Su and Yang 2015) or by spraying 3% (w/v) potassium permanganate as a chromogenic reagent forming yellow spots containing HupA compound against a violet background (Zhu et al. 2010).", [["samples", "ANATOMY", 227, 234], ["HupA", "CHEMICAL", 152, 156], ["HupA", "CHEMICAL", 209, 213], ["silica gel", "CHEMICAL", 250, 260], ["acetone: chloroform", "CHEMICAL", 377, 396], ["isopropanol", "CHEMICAL", 398, 409], ["acetone: chloroform", "CHEMICAL", 465, 484], ["isopropanol", "CHEMICAL", 486, 497], ["ammonia", "CHEMICAL", 499, 506], ["4:4:2:0.12", "CHEMICAL", 508, 518], ["acetone: chloroform: isopropanol", "CHEMICAL", 557, 589], ["ammonia", "CHEMICAL", 591, 598], ["acetic acid", "CHEMICAL", 615, 626], ["1-Butanol", "CHEMICAL", 627, 636], ["1-Butanol: isopropanol", "CHEMICAL", 652, 674], ["1-Butanol: isopropanol: acetic acid", "CHEMICAL", 692, 727], ["chloroform: acetone: methanol", "CHEMICAL", 746, 775], ["HupA", "CHEMICAL", 804, 808], ["potassium permanganate", "CHEMICAL", 1036, 1058], ["HupA compound", "CHEMICAL", 1116, 1129], ["silica gel", "CHEMICAL", 250, 260], ["acetone", "CHEMICAL", 377, 384], ["chloroform", "CHEMICAL", 386, 396], ["isopropanol", "CHEMICAL", 398, 409], ["acetone", "CHEMICAL", 465, 472], ["chloroform", "CHEMICAL", 474, 484], ["isopropanol", "CHEMICAL", 486, 497], ["ammonia", "CHEMICAL", 499, 506], ["acetone", "CHEMICAL", 557, 564], ["chloroform", "CHEMICAL", 566, 576], ["isopropanol", "CHEMICAL", 578, 589], ["ammonia", "CHEMICAL", 591, 598], ["acetic acid", "CHEMICAL", 615, 626], ["1-Butanol", "CHEMICAL", 627, 636], ["1-Butanol", "CHEMICAL", 652, 661], ["isopropanol", "CHEMICAL", 663, 674], ["1-Butanol", "CHEMICAL", 692, 701], ["isopropanol", "CHEMICAL", 703, 714], ["acetic acid", "CHEMICAL", 716, 727], ["chloroform", "CHEMICAL", 746, 756], ["acetone", "CHEMICAL", 758, 765], ["methanol", "CHEMICAL", 767, 775], ["potassium permanganate", "CHEMICAL", 1036, 1058], ["HupA", "CHEMICAL", 1116, 1120], ["HupA", "SIMPLE_CHEMICAL", 152, 156], ["HupA", "SIMPLE_CHEMICAL", 209, 213], ["silica", "SIMPLE_CHEMICAL", 250, 256], ["acetone", "SIMPLE_CHEMICAL", 377, 384], ["chloroform", "SIMPLE_CHEMICAL", 386, 396], ["isopropanol", "SIMPLE_CHEMICAL", 398, 409], ["acetone", "SIMPLE_CHEMICAL", 465, 472], ["chloroform", "SIMPLE_CHEMICAL", 474, 484], ["isopropanol", "SIMPLE_CHEMICAL", 486, 497], ["ammonia", "SIMPLE_CHEMICAL", 499, 506], ["4:4:2:0.12", "SIMPLE_CHEMICAL", 508, 518], ["acetone", "SIMPLE_CHEMICAL", 557, 564], ["chloroform", "SIMPLE_CHEMICAL", 566, 576], ["isopropanol", "SIMPLE_CHEMICAL", 578, 589], ["ammonia", "SIMPLE_CHEMICAL", 591, 598], ["4:4:1.5:0.15)", "SIMPLE_CHEMICAL", 600, 613], ["acetic acid", "SIMPLE_CHEMICAL", 615, 626], ["1-Butanol", "SIMPLE_CHEMICAL", 627, 636], ["water", "SIMPLE_CHEMICAL", 637, 642], ["3:3:2", "SIMPLE_CHEMICAL", 644, 649], ["1-Butanol", "SIMPLE_CHEMICAL", 652, 661], ["isopropanol", "SIMPLE_CHEMICAL", 663, 674], ["water", "SIMPLE_CHEMICAL", 676, 681], ["1-Butanol", "SIMPLE_CHEMICAL", 692, 701], ["isopropanol: acetic acid", "SIMPLE_CHEMICAL", 703, 727], ["water", "SIMPLE_CHEMICAL", 729, 734], ["7:5:2:4", "SIMPLE_CHEMICAL", 736, 743], ["chloroform", "SIMPLE_CHEMICAL", 746, 756], ["acetone", "SIMPLE_CHEMICAL", 758, 765], ["methanol", "SIMPLE_CHEMICAL", 767, 775], ["HupA", "SIMPLE_CHEMICAL", 804, 808], ["potassium permanganate", "SIMPLE_CHEMICAL", 1036, 1058], ["HupA compound", "SIMPLE_CHEMICAL", 1116, 1129], ["Each analysis conditions", "TEST", 0, 24], ["TLC analysis", "TEST", 175, 187], ["the extracted HupA", "TREATMENT", 195, 213], ["standard samples", "TREATMENT", 218, 234], ["silica gel-coated plates", "TREATMENT", 250, 274], ["isopropanol", "TREATMENT", 398, 409], ["ammonia", "TREATMENT", 591, 598], ["acetic acid", "TREATMENT", 615, 626], ["acetic acid", "TREATMENT", 716, 727], ["HupA extraction", "TREATMENT", 804, 819], ["endophytic fungal culture", "TEST", 839, 864], ["endophytic fungi", "PROBLEM", 882, 898], ["Huperziaceae plant species", "PROBLEM", 904, 930], ["HupA spot", "TEST", 936, 945], ["potassium permanganate", "TREATMENT", 1036, 1058], ["a chromogenic reagent", "TREATMENT", 1062, 1083], ["yellow spots", "PROBLEM", 1092, 1104], ["HupA", "TREATMENT", 1116, 1120], ["endophytic fungi", "OBSERVATION", 882, 898], ["plant species", "OBSERVATION", 917, 930]]], ["HupA extracted from the positive producing strains recorded the closest migration rate to the standard HupA with a retention factor (RF) between 0.70 and 0.73 (Zhu et al. 2010).HupA extraction and detection from endophytic fungal culture ::: Isolation of endophytic fungi from Huperziaceae plant speciesSubsequent characterization and quantification of HupA were performed using different HPLC methodologies as shown in Table 5.", [["HupA", "CHEMICAL", 0, 4], ["HupA", "CHEMICAL", 177, 181], ["HupA", "GENE_OR_GENE_PRODUCT", 0, 4], ["HupA", "SIMPLE_CHEMICAL", 177, 181], ["Huperziaceae", "ORGANISM", 277, 289], ["HupA", "SIMPLE_CHEMICAL", 353, 357], ["HupA", "PROTEIN", 0, 4], ["HupA", "PROTEIN", 103, 107], ["HupA", "PROTEIN", 353, 357], ["the positive producing strains", "PROBLEM", 20, 50], ["HupA extraction", "TREATMENT", 177, 192], ["endophytic fungal culture", "TEST", 212, 237], ["endophytic fungi", "PROBLEM", 255, 271], ["Huperziaceae plant species", "PROBLEM", 277, 303], ["quantification of HupA", "TEST", 335, 357], ["different HPLC methodologies", "TREATMENT", 379, 407], ["endophytic fungi", "OBSERVATION", 255, 271]]], ["The extracted HupA content can be quantified using a standard curve that was created by analyzing the concentration range of HupA standard sample, and represented by \u03bcg/g dcw (dried mycelia).HupA extraction and detection from endophytic fungal culture ::: Isolation of endophytic fungi from Huperziaceae plant speciesLi et al. (2007) used HPLC with a mobile phase of acetonitrile: 0.02 M KH2P04 (10:90), flow rate 1 ml/min, 20 \u03bcl injected sample, column temperature (25 \u00b0C), and detecting wavelength of 310 nm, while HPLC mobile phase of methanol: 0.8% ammonium acetate solution (33: 67, p H 6.0), flow rate: 1 ml/min, column temperature: 25 \u00b0C, detection wavelength: 310 nm, and the injection volume: 20 \u03bcL was reported by Ju et al. (2009).HupA extraction and detection from endophytic fungal culture ::: Isolation of endophytic fungi from Huperziaceae plant speciesAdditionally, Zhou et al. (2009) used a run solvent of 10% acetonitrile, 35 \u00b0C column temperature, and 308 nm detecting wavelength.", [["mycelia", "ANATOMY", 182, 189], ["sample", "ANATOMY", 439, 445], ["HupA", "CHEMICAL", 14, 18], ["HupA", "CHEMICAL", 191, 195], ["ammonium acetate", "CHEMICAL", 553, 569], ["HupA", "CHEMICAL", 741, 745], ["acetonitrile", "CHEMICAL", 926, 938], ["acetonitrile", "CHEMICAL", 367, 379], ["KH2P04", "CHEMICAL", 388, 394], ["methanol", "CHEMICAL", 538, 546], ["ammonium acetate", "CHEMICAL", 553, 569], ["acetonitrile", "CHEMICAL", 926, 938], ["HupA", "SIMPLE_CHEMICAL", 14, 18], ["HupA", "SIMPLE_CHEMICAL", 125, 129], ["HupA", "SIMPLE_CHEMICAL", 191, 195], ["acetonitrile", "SIMPLE_CHEMICAL", 367, 379], ["methanol", "SIMPLE_CHEMICAL", 538, 546], ["ammonium acetate", "SIMPLE_CHEMICAL", 553, 569], ["HupA", "SIMPLE_CHEMICAL", 741, 745], ["Huperziaceae", "ORGANISM", 841, 853], ["acetonitrile", "SIMPLE_CHEMICAL", 926, 938], ["HupA", "PROTEIN", 14, 18], ["a standard curve", "TREATMENT", 51, 67], ["HupA extraction", "TREATMENT", 191, 206], ["endophytic fungal culture", "TEST", 226, 251], ["endophytic fungi", "PROBLEM", 269, 285], ["Huperziaceae plant species", "PROBLEM", 291, 317], ["flow rate", "TEST", 404, 413], ["column temperature", "TEST", 447, 465], ["HPLC", "TEST", 517, 521], ["methanol", "TEST", 538, 546], ["% ammonium acetate solution", "TREATMENT", 551, 578], ["flow rate", "TEST", 598, 607], ["column temperature", "TEST", 619, 637], ["the injection volume", "TEST", 680, 700], ["HupA extraction", "TREATMENT", 741, 756], ["endophytic fungal culture", "TEST", 776, 801], ["endophytic fungi", "PROBLEM", 819, 835], ["Huperziaceae plant species", "PROBLEM", 841, 867], ["a run solvent", "TREATMENT", 905, 918], ["10% acetonitrile", "TREATMENT", 922, 938], ["HupA content", "OBSERVATION", 14, 26], ["endophytic fungi", "OBSERVATION", 269, 285], ["plant species", "OBSERVATION", 304, 317], ["endophytic fungi", "OBSERVATION", 819, 835]]], ["Other reports (Zhu et al. 2010; Wang et al. 2011a; Zaki et al. 2019) performed HPLC with a mobile phase of methanol: water (85: 15), 1.0 mL/min as flow rate, 25 \u00b0C column temperature, 10 \u03bcL injected volume, and 310 nm detecting wavelength.HupA extraction and detection from endophytic fungal culture ::: Isolation of endophytic fungi from Huperziaceae plant speciesAlso, a mobile phase composed of ammonium acetate (80 mM, or 0.1 M, pH 6.0): methanol (7: 3 or 6: 4 or 36: 64 v/v) was also tested (Zhao et al. 2013; Dong et al. 2014; Su and Yang 2015).", [["HupA", "CHEMICAL", 239, 243], ["ammonium acetate", "CHEMICAL", 398, 414], ["methanol", "CHEMICAL", 442, 450], ["methanol", "CHEMICAL", 107, 115], ["ammonium acetate", "CHEMICAL", 398, 414], ["methanol", "CHEMICAL", 442, 450], ["methanol", "SIMPLE_CHEMICAL", 107, 115], ["HupA", "SIMPLE_CHEMICAL", 239, 243], ["ammonium acetate", "SIMPLE_CHEMICAL", 398, 414], ["methanol", "SIMPLE_CHEMICAL", 442, 450], ["flow rate", "TEST", 147, 156], ["HupA extraction", "TREATMENT", 239, 254], ["endophytic fungal culture", "TEST", 274, 299], ["endophytic fungi", "PROBLEM", 317, 333], ["Huperziaceae plant species", "PROBLEM", 339, 365], ["ammonium acetate", "TREATMENT", 398, 414], ["pH", "TEST", 433, 435], ["endophytic fungi", "OBSERVATION", 317, 333], ["plant species", "OBSERVATION", 352, 365]]], ["In addition, Han et al. (2015) applied a mobile phase of methanol: 0.1% formic acid (75: 25 v/v).", [["methanol", "CHEMICAL", 57, 65], ["formic acid", "CHEMICAL", 72, 83], ["methanol", "CHEMICAL", 57, 65], ["formic acid", "CHEMICAL", 72, 83], ["methanol", "SIMPLE_CHEMICAL", 57, 65], ["formic acid", "SIMPLE_CHEMICAL", 72, 83], ["a mobile phase of methanol", "TREATMENT", 39, 65]]], ["Different mobile phases of acetonitrile: water (acidified with 0.0125% trifluoro-acetic acid) (15: 85 v/v) were also investigated (Cruz-Miranda et al. 2019).HupA extraction and detection from endophytic fungal culture ::: Isolation of endophytic fungi from Huperziaceae plant speciesConfirmatory analyses combining both liquid chromatography (LC) and mass analysis by mass spectrometry (MS) using LC/MS and UPLC/MS analyses were also performed, where the alkaloid extract underwent chromatographic separation using a suitable run solvent as methanoic acid (0.1%): acetonitrile (9: 1 v/v) at a flow rate of 1.0 mL/min (Su and Yang 2015), 10 mM ammonium acetate (pH 3.5) and methanol with 5: 56: 56% gradient elution (T: 0: 20: 30 min) (Shu et al. 2014), methanol: 0.2% aqueous formic acid (50: 50 v/v), flow rate of 0.15 mL/min, 308 nm as a detecting wavelength, and 5 \u03bcL injected volume (Zhang et al. 2015a), and acetonitrile: 0.025% formic acid 15: 85 v/v, 0.25 mL/ min as a flow rate (Cruz-Miranda et al. 2019), then the elute of the chromatography was subjected to MS analysis.Improvement strategies for enhancing the production of microbial AChE inhibitors ::: Isolation of endophytic fungi from Huperziaceae plant speciesTill now, there are no commercial products of AChE inhibitors depending on the microbial fermentation processes.", [["acetonitrile", "CHEMICAL", 27, 39], ["trifluoro-acetic acid", "CHEMICAL", 71, 92], ["HupA", "CHEMICAL", 157, 161], ["methanoic acid", "CHEMICAL", 541, 555], ["acetonitrile", "CHEMICAL", 564, 576], ["ammonium acetate", "CHEMICAL", 643, 659], ["formic acid", "CHEMICAL", 776, 787], ["acetonitrile", "CHEMICAL", 913, 925], ["formic acid", "CHEMICAL", 934, 945], ["acetonitrile", "CHEMICAL", 27, 39], ["trifluoro-acetic acid", "CHEMICAL", 71, 92], ["methanoic acid", "CHEMICAL", 541, 555], ["acetonitrile", "CHEMICAL", 564, 576], ["ammonium acetate", "CHEMICAL", 643, 659], ["methanol", "CHEMICAL", 673, 681], ["methanol", "CHEMICAL", 753, 761], ["formic acid", "CHEMICAL", 776, 787], ["acetonitrile", "CHEMICAL", 913, 925], ["formic acid", "CHEMICAL", 934, 945], ["acetonitrile", "SIMPLE_CHEMICAL", 27, 39], ["water", "SIMPLE_CHEMICAL", 41, 46], ["trifluoro-acetic acid", "SIMPLE_CHEMICAL", 71, 92], ["HupA", "SIMPLE_CHEMICAL", 157, 161], ["methanoic acid", "SIMPLE_CHEMICAL", 541, 555], ["acetonitrile", "SIMPLE_CHEMICAL", 564, 576], ["ammonium acetate", "SIMPLE_CHEMICAL", 643, 659], ["methanol", "SIMPLE_CHEMICAL", 673, 681], ["methanol", "SIMPLE_CHEMICAL", 753, 761], ["aqueous formic acid", "SIMPLE_CHEMICAL", 768, 787], ["acetonitrile", "SIMPLE_CHEMICAL", 913, 925], ["formic acid", "SIMPLE_CHEMICAL", 934, 945], ["AChE", "GENE_OR_GENE_PRODUCT", 1145, 1149], ["AChE", "GENE_OR_GENE_PRODUCT", 1272, 1276], ["water (acidified", "TREATMENT", 41, 57], ["HupA extraction", "TREATMENT", 157, 172], ["endophytic fungal culture", "TEST", 192, 217], ["endophytic fungi", "PROBLEM", 235, 251], ["Huperziaceae plant species", "PROBLEM", 257, 283], ["Confirmatory analyses", "TEST", 283, 304], ["both liquid chromatography", "TEST", 315, 341], ["mass analysis", "TEST", 351, 364], ["mass spectrometry", "TEST", 368, 385], ["MS", "TEST", 387, 389], ["LC/MS", "TEST", 397, 402], ["UPLC/MS analyses", "TEST", 407, 423], ["the alkaloid extract", "TREATMENT", 451, 471], ["chromatographic separation", "TREATMENT", 482, 508], ["a suitable run solvent", "TREATMENT", 515, 537], ["methanoic acid", "TREATMENT", 541, 555], ["acetonitrile", "TREATMENT", 564, 576], ["a flow rate", "TREATMENT", 591, 602], ["10 mM ammonium acetate", "TREATMENT", 637, 659], ["pH", "TEST", 661, 663], ["flow rate", "TEST", 802, 811], ["acetonitrile", "TREATMENT", 913, 925], ["a flow rate", "TEST", 974, 985], ["the chromatography", "TEST", 1032, 1050], ["MS analysis", "TEST", 1068, 1079], ["endophytic fungi", "PROBLEM", 1178, 1194], ["Huperziaceae plant species", "PROBLEM", 1200, 1226], ["commercial products", "TREATMENT", 1249, 1268], ["AChE inhibitors", "TREATMENT", 1272, 1287], ["endophytic fungi", "OBSERVATION", 235, 251], ["endophytic fungi", "OBSERVATION", 1178, 1194], ["plant species", "OBSERVATION", 1213, 1226]]], ["Hence, enhancement of microbial strains for large-scale production through process optimization and irradiation-assisted strain improvement will lead to a cost-effective fermentation.Improvement strategies for enhancing the production of microbial AChE inhibitors ::: Isolation of endophytic fungi from Huperziaceae plant speciesIn any microbial fermentation process, optimization of process variables such as medium designing is considered to be one of the most important and critical scopes.", [["AChE", "GENE_OR_GENE_PRODUCT", 248, 252], ["microbial strains", "PROBLEM", 22, 39], ["large-scale production", "TREATMENT", 44, 66], ["process optimization", "TREATMENT", 75, 95], ["irradiation", "TREATMENT", 100, 111], ["a cost-effective fermentation", "TREATMENT", 153, 182], ["endophytic fungi", "PROBLEM", 281, 297], ["Huperziaceae plant species", "PROBLEM", 303, 329], ["enhancement", "OBSERVATION_MODIFIER", 7, 18], ["microbial strains", "OBSERVATION", 22, 39], ["large", "OBSERVATION_MODIFIER", 44, 49], ["-scale", "OBSERVATION_MODIFIER", 49, 55], ["endophytic fungi", "OBSERVATION", 281, 297], ["plant species", "OBSERVATION", 316, 329], ["microbial fermentation", "OBSERVATION", 336, 358]]], ["The constituents of fermentation medium have a significant impact on microbial growth and productivity.", [["fermentation medium", "PROBLEM", 20, 39], ["microbial growth", "PROBLEM", 69, 85], ["fermentation medium", "OBSERVATION", 20, 39], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["microbial growth", "OBSERVATION_MODIFIER", 69, 85]]], ["Additionally, for the production of valuable compounds, medium components such as nitrogen, carbon, and phosphate sources have a large impact on the cost of overall process and the feasibility of product separation (Singh et al. 2017).Improvement strategies for enhancing the production of microbial AChE inhibitors ::: Isolation of endophytic fungi from Huperziaceae plant speciesMoreover, chemical elicitors that enhance the production process can greatly affect the process cost.", [["nitrogen", "CHEMICAL", 82, 90], ["carbon", "CHEMICAL", 92, 98], ["phosphate", "CHEMICAL", 104, 113], ["nitrogen", "CHEMICAL", 82, 90], ["carbon", "CHEMICAL", 92, 98], ["phosphate", "CHEMICAL", 104, 113], ["nitrogen", "SIMPLE_CHEMICAL", 82, 90], ["carbon", "SIMPLE_CHEMICAL", 92, 98], ["phosphate", "SIMPLE_CHEMICAL", 104, 113], ["AChE", "GENE_OR_GENE_PRODUCT", 300, 304], ["valuable compounds", "PROBLEM", 36, 54], ["medium components", "PROBLEM", 56, 73], ["nitrogen, carbon, and phosphate sources", "PROBLEM", 82, 121], ["endophytic fungi", "PROBLEM", 333, 349], ["Huperziaceae plant species", "TREATMENT", 355, 381], ["chemical elicitors", "TREATMENT", 391, 409], ["the production process", "PROBLEM", 423, 445], ["large", "OBSERVATION_MODIFIER", 129, 134], ["impact", "OBSERVATION_MODIFIER", 135, 141], ["endophytic fungi", "OBSERVATION", 333, 349]]], ["The ideal method for designing the optimum fermentation medium could be started by studying the optimum physical fermentation conditions and may end with optimizing medium components.", [["the optimum fermentation medium", "TREATMENT", 31, 62]]], ["There are few reports explaining the optimization of medium components and fermentation condition for maximizing HupA yield from endophytes (Li et al. 2007; Zhao et al. 2013; Fangfang et al. 2015).Improvement strategies for enhancing the production of microbial AChE inhibitors ::: Isolation of endophytic fungi from Huperziaceae plant speciesCurrently, multi-factorial statistical designs including response surface methodology could be used for the optimization of fermentation medium components.", [["HupA", "CHEMICAL", 113, 117], ["Li", "CHEMICAL", 141, 143], ["HupA", "SIMPLE_CHEMICAL", 113, 117], ["AChE", "GENE_OR_GENE_PRODUCT", 262, 266], ["HupA", "PROTEIN", 113, 117], ["fermentation condition", "PROBLEM", 75, 97], ["endophytic fungi", "PROBLEM", 295, 311], ["Huperziaceae plant species", "PROBLEM", 317, 343], ["multi-factorial statistical designs", "PROBLEM", 354, 389], ["response surface methodology", "TREATMENT", 400, 428], ["fermentation medium components", "TREATMENT", 467, 497], ["few", "OBSERVATION_MODIFIER", 10, 13], ["endophytic fungi", "OBSERVATION", 295, 311], ["plant species", "OBSERVATION", 330, 343]]], ["Recently, Zaki et al. (2019) used both Plackett\u2013Burman and central composite models for optimizing the fermentation conditions and medium composition resulting in 40.8% enhancement of HupA production by the endophytic fungus Alternaria brassicae AGF041.Improvement strategies for enhancing the production of microbial AChE inhibitors ::: Isolation of endophytic fungi from Huperziaceae plant speciesRelated studies that employed factorial designs for optimizing the production of valuable microbial secondary metabolites were also reported.", [["HupA", "CHEMICAL", 184, 188], ["HupA", "SIMPLE_CHEMICAL", 184, 188], ["Alternaria brassicae", "ORGANISM", 225, 245], ["AGF041", "ORGANISM", 246, 252], ["AChE", "GENE_OR_GENE_PRODUCT", 318, 322], ["Alternaria brassicae", "SPECIES", 225, 245], ["Alternaria brassicae", "SPECIES", 225, 245], ["both Plackett\u2013Burman", "TREATMENT", 34, 54], ["central composite models", "TREATMENT", 59, 83], ["the fermentation conditions", "TREATMENT", 99, 126], ["HupA production", "PROBLEM", 184, 199], ["the endophytic fungus", "PROBLEM", 203, 224], ["endophytic fungi", "PROBLEM", 351, 367], ["Huperziaceae plant species", "PROBLEM", 373, 399], ["endophytic fungus", "OBSERVATION", 207, 224], ["endophytic fungi", "OBSERVATION", 351, 367], ["plant species", "OBSERVATION", 386, 399]]], ["Abdel-Fattah et al. (2007) used this strategy for determining the optimum fermentation conditions required for maximum fungal cyclosporin A production.", [["cyclosporin A", "CHEMICAL", 126, 139], ["cyclosporin A", "CHEMICAL", 126, 139], ["cyclosporin A", "SIMPLE_CHEMICAL", 126, 139], ["this strategy", "TREATMENT", 32, 45], ["the optimum fermentation conditions", "TREATMENT", 62, 97], ["maximum fungal cyclosporin", "TREATMENT", 111, 137], ["fungal cyclosporin", "OBSERVATION", 119, 137]]], ["Additionally, Xu et al. (2006), Garyali et al. (2014), and El-Sayed et al. (2019d) applied response surface methodology for maximizing the production of the anticancer drug taxol by endophytic fungi.Improvement strategies for enhancing the production of microbial AChE inhibitors ::: Isolation of endophytic fungi from Huperziaceae plant speciesStrain improvement through irradiation mutagenesis for hyper-production of industrial products is of critical importance as the improved mutants can show more desirable properties, and give relatively higher productivity with lower cost (Parekh et al. 2000).Improvement strategies for enhancing the production of microbial AChE inhibitors ::: Isolation of endophytic fungi from Huperziaceae plant speciesSubjecting the microbial cells to radiation leads to physiological, chemical, and metabolic differences as radiation imposes an extra stress to cells disturbing their organization (Unluturk 2017).", [["anticancer", "ANATOMY", 157, 167], ["cells", "ANATOMY", 774, 779], ["cells", "ANATOMY", 893, 898], ["taxol", "CHEMICAL", 173, 178], ["taxol", "CHEMICAL", 173, 178], ["anticancer", "CANCER", 157, 167], ["taxol", "SIMPLE_CHEMICAL", 173, 178], ["AChE", "GENE_OR_GENE_PRODUCT", 264, 268], ["Huperziaceae", "ORGANISM", 319, 331], ["AChE", "GENE_OR_GENE_PRODUCT", 668, 672], ["Huperziaceae", "ORGANISM", 723, 735], ["microbial cells", "CELL", 764, 779], ["cells", "CELL", 893, 898], ["microbial cells", "CELL_TYPE", 764, 779], ["the anticancer drug taxol", "TREATMENT", 153, 178], ["endophytic fungi", "PROBLEM", 297, 313], ["Huperziaceae plant species", "TREATMENT", 319, 345], ["irradiation mutagenesis", "TREATMENT", 372, 395], ["hyper", "PROBLEM", 400, 405], ["industrial products", "TREATMENT", 420, 439], ["endophytic fungi", "PROBLEM", 701, 717], ["Huperziaceae plant species", "TREATMENT", 723, 749], ["an extra stress to cells", "PROBLEM", 874, 898], ["endophytic fungi", "OBSERVATION", 182, 198], ["endophytic fungi", "OBSERVATION", 297, 313], ["higher", "OBSERVATION_MODIFIER", 546, 552], ["productivity", "OBSERVATION_MODIFIER", 553, 565], ["endophytic fungi", "OBSERVATION", 701, 717], ["plant species", "OBSERVATION", 736, 749], ["microbial cells", "OBSERVATION", 764, 779]]], ["Microbial strain mutation can be achieved by exposing the microbial cells to chemical or physical agents (such as UV. and gamma-rays) which is called mutagens.", [["cells", "ANATOMY", 68, 73], ["gamma-rays", "CHEMICAL", 122, 132], ["cells", "CELL", 68, 73], ["microbial cells", "CELL_TYPE", 58, 73], ["Microbial strain mutation", "PROBLEM", 0, 25], ["physical agents", "TREATMENT", 89, 104]]], ["As a result, the genetic materials of the subjected cells would be affected resulting in a strain modification.", [["cells", "ANATOMY", 52, 57], ["cells", "CELL", 52, 57], ["the subjected cells", "PROBLEM", 38, 57], ["a strain modification", "TREATMENT", 89, 110]]], ["UV. radiation is a non-ionizing radiation of a moderate effect, and considered as a first choice mutagenic agent (Irum and Anjum 2012).Improvement strategies for enhancing the production of microbial AChE inhibitors ::: Isolation of endophytic fungi from Huperziaceae plant speciesIrradiation of microbial cell by UV. rays results in pyrimidine dimerization and DNA cross linking (Parekh et al. 2000), while irradiation by the highly energetic ionizing radiation such as gamma-rays causes mutations through DNA breakage in the single or double strands, nucleotide deletion, or structural modification and cross linking in the DNA-protein (Cadet et al. 1999).Improvement strategies for enhancing the production of microbial AChE inhibitors ::: Isolation of endophytic fungi from Huperziaceae plant speciesXiao-qion et al. (2015) applied UV irradiation mutagenesis of protoplast of HupA-producing endophytic fungal strain NX9 resulting in 16.7 times production increase.", [["cell", "ANATOMY", 306, 310], ["protoplast", "ANATOMY", 866, 876], ["pyrimidine", "CHEMICAL", 334, 344], ["gamma-rays", "CHEMICAL", 471, 481], ["nucleotide", "CHEMICAL", 553, 563], ["HupA", "CHEMICAL", 880, 884], ["pyrimidine", "CHEMICAL", 334, 344], ["nucleotide", "CHEMICAL", 553, 563], ["AChE", "GENE_OR_GENE_PRODUCT", 200, 204], ["microbial cell", "CELL", 296, 310], ["pyrimidine", "SIMPLE_CHEMICAL", 334, 344], ["DNA", "CELLULAR_COMPONENT", 362, 365], ["DNA", "CELLULAR_COMPONENT", 507, 510], ["DNA", "CELLULAR_COMPONENT", 626, 629], ["AChE", "GENE_OR_GENE_PRODUCT", 723, 727], ["Huperziaceae", "ORGANISM", 778, 790], ["HupA", "GENE_OR_GENE_PRODUCT", 880, 884], ["gamma", "PROTEIN", 471, 476], ["DNA-protein", "PROTEIN", 626, 637], ["radiation", "TREATMENT", 4, 13], ["a non-ionizing radiation", "TREATMENT", 17, 41], ["endophytic fungi", "PROBLEM", 233, 249], ["Huperziaceae plant species", "PROBLEM", 255, 281], ["pyrimidine dimerization", "TEST", 334, 357], ["irradiation", "TREATMENT", 408, 419], ["energetic ionizing radiation", "TREATMENT", 434, 462], ["gamma-rays", "TREATMENT", 471, 481], ["mutations", "PROBLEM", 489, 498], ["DNA breakage", "PROBLEM", 507, 519], ["the single or double strands", "PROBLEM", 523, 551], ["nucleotide deletion", "PROBLEM", 553, 572], ["structural modification", "PROBLEM", 577, 600], ["endophytic fungi", "PROBLEM", 756, 772], ["Huperziaceae plant speciesXiao", "TREATMENT", 778, 808], ["UV irradiation mutagenesis", "TREATMENT", 836, 862], ["protoplast of HupA", "TREATMENT", 866, 884], ["endophytic fungal strain", "PROBLEM", 895, 919], ["non-ionizing radiation", "OBSERVATION_MODIFIER", 19, 41], ["moderate effect", "OBSERVATION_MODIFIER", 47, 62], ["endophytic fungi", "OBSERVATION", 233, 249], ["plant species", "OBSERVATION", 268, 281], ["microbial cell", "OBSERVATION", 296, 310], ["endophytic fungi", "OBSERVATION", 756, 772], ["endophytic", "OBSERVATION_MODIFIER", 895, 905], ["fungal strain", "OBSERVATION", 906, 919], ["16.7 times", "OBSERVATION_MODIFIER", 937, 947]]], ["In literature, UV. and gamma-rays were employed for improvement of fungal strains and overproduction of different pharmaceutical products such as mycophenolic acid by irradiated Penicillium roqueforti AG101 and LG109 strains (Ismaiel et al. 2014, 2015; El-Sayed et al. 2019c), paclitaxel by UV-irradiated Fusarium mairie (Xu et al. 2006), taxol by UV. and gamma-irradiated Aspergillus fumigates and Alternaria tenuissima (El-Sayed et al. 2019d), and the cardiac glycoside digoxin by gamma-irradiated Epicoccum nigrum (El-Sayed et al. 2019a).Nanotechnology and AChE-inhibitor HupA drug delivery ::: Isolation of endophytic fungi from Huperziaceae plant speciesVarious nano-materials possess exceptional physical, chemical, and physiological characteristics allowing them to be perfect candidates for many applications (Maksoud et al. 2018, 2019; Pal et al. 2018; Thirugnanasambandan et al. 2018; Asiya et al. 2020; Elkodous et al. 2019c; Govindasamy et al. 2019; Pal et al. 2019; Jeevanandam et al. 2020).", [["cardiac", "ANATOMY", 454, 461], ["mycophenolic acid", "CHEMICAL", 146, 163], ["paclitaxel", "CHEMICAL", 277, 287], ["UV", "CHEMICAL", 291, 293], ["taxol", "CHEMICAL", 339, 344], ["digoxin", "CHEMICAL", 472, 479], ["HupA", "CHEMICAL", 575, 579], ["mycophenolic acid", "CHEMICAL", 146, 163], ["paclitaxel", "CHEMICAL", 277, 287], ["taxol", "CHEMICAL", 339, 344], ["digoxin", "CHEMICAL", 472, 479], ["mycophenolic acid", "SIMPLE_CHEMICAL", 146, 163], ["Penicillium roqueforti", "ORGANISM", 178, 200], ["AG101", "ORGANISM", 201, 206], ["LG109", "ORGANISM", 211, 216], ["paclitaxel", "SIMPLE_CHEMICAL", 277, 287], ["taxol", "SIMPLE_CHEMICAL", 339, 344], ["Aspergillus fumigates", "ORGANISM", 373, 394], ["Alternaria tenuissima", "ORGANISM", 399, 420], ["cardiac", "ORGAN", 454, 461], ["digoxin", "SIMPLE_CHEMICAL", 472, 479], ["Epicoccum nigrum", "ORGANISM", 500, 516], ["AChE", "GENE_OR_GENE_PRODUCT", 560, 564], ["HupA", "SIMPLE_CHEMICAL", 575, 579], ["gamma", "PROTEIN", 23, 28], ["Penicillium roqueforti", "SPECIES", 178, 200], ["Alternaria tenuissima", "SPECIES", 399, 420], ["Epicoccum nigrum", "SPECIES", 500, 516], ["Penicillium roqueforti", "SPECIES", 178, 200], ["Fusarium mairie", "SPECIES", 305, 320], ["Aspergillus fumigates", "SPECIES", 373, 394], ["Alternaria tenuissima (El-Sayed et al. 2019d", "SPECIES", 399, 443], ["Epicoccum nigrum (El-Sayed et al. 2019a", "SPECIES", 500, 539], ["gamma-rays", "TREATMENT", 23, 33], ["fungal strains", "PROBLEM", 67, 81], ["different pharmaceutical products", "TREATMENT", 104, 137], ["mycophenolic acid", "TREATMENT", 146, 163], ["paclitaxel", "TREATMENT", 277, 287], ["taxol", "TREATMENT", 339, 344], ["gamma-irradiated Aspergillus fumigates", "PROBLEM", 356, 394], ["Alternaria tenuissima", "PROBLEM", 399, 420], ["the cardiac glycoside digoxin", "TREATMENT", 450, 479], ["endophytic fungi", "PROBLEM", 611, 627], ["Huperziaceae plant species", "PROBLEM", 633, 659], ["Various nano-materials", "TREATMENT", 659, 681], ["UV", "OBSERVATION", 15, 17], ["fungal strains", "OBSERVATION", 67, 81], ["Penicillium roqueforti", "OBSERVATION", 178, 200], ["Aspergillus fumigates", "OBSERVATION", 373, 394], ["cardiac", "ANATOMY", 454, 461], ["endophytic fungi", "OBSERVATION", 611, 627], ["plant species", "OBSERVATION", 646, 659]]], ["Biomedical applications of nano-materials have gained significant consideration from numerous researchers across the past decade because of the important role they can perform in improving the public health (Elkodous et al. 2019a, b, d, e; El-Batal et al. 2019; Wong et al. 2019; Abdelhakim et al. 2020; Elkhenany et al. 2020; El-Sayed et al. 2020a, b).Nanotechnology and AChE-inhibitor HupA drug delivery ::: Isolation of endophytic fungi from Huperziaceae plant speciesNanotechnology advances through nano-material-based drug delivery systems have opened the way for better treatment of AD (Fonseca-Santos et al. 2015; Ansari et al. 2017; Wen et al. 2017).", [["HupA", "CHEMICAL", 387, 391], ["AD", "DISEASE", 589, 591], ["AChE", "GENE_OR_GENE_PRODUCT", 372, 376], ["HupA", "SIMPLE_CHEMICAL", 387, 391], ["nano-materials", "TREATMENT", 27, 41], ["endophytic fungi", "PROBLEM", 423, 439], ["Huperziaceae plant species", "TREATMENT", 445, 471], ["nano-material-based drug delivery systems", "TREATMENT", 503, 544], ["AD", "PROBLEM", 589, 591], ["endophytic fungi", "OBSERVATION", 423, 439]]], ["Designed nano-carriers can effectively cross the blood\u2013brain barrier (Costantino et al. 2005; Mahajan et al. 2010; Guarnieri et al. 2014; Gao 2016).", [["blood\u2013brain", "ANATOMY", 49, 60], ["nano-carriers", "SIMPLE_CHEMICAL", 9, 22], ["blood\u2013brain barrier", "TISSUE", 49, 68]]], ["Thus, concentration of drugs in the target neural cells will be significantly increased with respect to the traditional methods of treatment without nano-carriers (Wen et al. 2017).", [["neural cells", "ANATOMY", 43, 55], ["neural cells", "CELL", 43, 55], ["target neural cells", "CELL_TYPE", 36, 55], ["drugs", "TREATMENT", 23, 28], ["the target neural cells", "TREATMENT", 32, 55], ["treatment", "TREATMENT", 131, 140], ["nano-carriers", "TREATMENT", 149, 162], ["neural cells", "OBSERVATION", 43, 55]]], ["This superior activity of nano-carriers can be attributed to their tiny size and their ability to be bounded with specific moieties for better selectivity and permeability (Peer et al. 2007;Arruebo et al. 2009;Tiwari et al. 2011).Nanotechnology and AChE-inhibitor HupA drug delivery ::: Isolation of endophytic fungi from Huperziaceae plant speciesHupA can be delivered effectively to the brain through many nano-carriers such as polymeric nanoparticles (PNPs), lipid nanoparticles (LNPs), liposomes, nano-emulsions, and micro-emulsions as presented in Fig. 3.Lipid nanoparticles ::: Polymeric nanoparticlesUnlike PNPs, LNPs are dispersions possessing the same advantages of PNPs with relatively smaller size and better control of drug release, targeting, and higher stability against drug degradation (Patel et al. 2013).", [["brain", "ANATOMY", 389, 394], ["HupA", "CHEMICAL", 264, 268], ["HupA", "CHEMICAL", 348, 352], ["nanoparticles", "CHEMICAL", 594, 607], ["AChE", "GENE_OR_GENE_PRODUCT", 249, 253], ["HupA", "SIMPLE_CHEMICAL", 264, 268], ["Huperziaceae", "ORGANISM", 322, 334], ["HupA", "SIMPLE_CHEMICAL", 348, 352], ["brain", "ORGAN", 389, 394], ["polymeric nanoparticles", "SIMPLE_CHEMICAL", 430, 453], ["PNPs", "SIMPLE_CHEMICAL", 455, 459], ["lipid nanoparticles", "SIMPLE_CHEMICAL", 462, 481], ["LNPs", "SIMPLE_CHEMICAL", 483, 487], ["liposomes", "SIMPLE_CHEMICAL", 490, 499], ["nano-emulsions", "SIMPLE_CHEMICAL", 501, 515], ["micro-emulsions", "SIMPLE_CHEMICAL", 521, 536], ["Lipid nanoparticles", "SIMPLE_CHEMICAL", 560, 579], ["PNPs", "SIMPLE_CHEMICAL", 614, 618], ["LNPs", "SIMPLE_CHEMICAL", 620, 624], ["PNPs", "SIMPLE_CHEMICAL", 675, 679], ["endophytic fungi", "PROBLEM", 300, 316], ["Huperziaceae plant speciesHupA", "TREATMENT", 322, 352], ["many nano-carriers", "TREATMENT", 403, 421], ["polymeric nanoparticles (PNPs)", "TREATMENT", 430, 460], ["lipid nanoparticles (LNPs)", "TREATMENT", 462, 488], ["liposomes", "TREATMENT", 490, 499], ["nano-emulsions", "TREATMENT", 501, 515], ["micro-emulsions", "PROBLEM", 521, 536], ["Polymeric nanoparticles", "TREATMENT", 584, 607], ["PNPs", "TREATMENT", 675, 679], ["drug degradation", "PROBLEM", 785, 801], ["tiny", "OBSERVATION_MODIFIER", 67, 71], ["size", "OBSERVATION_MODIFIER", 72, 76], ["endophytic fungi", "OBSERVATION", 300, 316], ["brain", "ANATOMY", 389, 394], ["nano-emulsions", "OBSERVATION", 501, 515], ["nanoparticles", "OBSERVATION", 594, 607], ["smaller", "OBSERVATION_MODIFIER", 696, 703], ["size", "OBSERVATION_MODIFIER", 704, 708], ["higher stability", "OBSERVATION_MODIFIER", 760, 776]]], ["LNPs comprise two main types: solid-lipid NPs (SLNPs) and nano-structured lipid carriers (NLCs) (Wissing et al. 2004; Naseri et al. 2015).", [["LNPs", "SIMPLE_CHEMICAL", 0, 4], ["solid-lipid NPs", "SIMPLE_CHEMICAL", 30, 45], ["SLNPs", "SIMPLE_CHEMICAL", 47, 52], ["nano-structured lipid carriers", "SIMPLE_CHEMICAL", 58, 88], ["solid-lipid NPs", "TREATMENT", 30, 45], ["nano-structured lipid carriers", "TREATMENT", 58, 88], ["lipid NPs", "OBSERVATION", 36, 45]]], ["The main difference between the two types is that SLNPs have lipid core which stay solid at body temperature while NLCs contain a mixture of solid and liquid lipids (Gastaldi et al. 2014).Lipid nanoparticles ::: Polymeric nanoparticlesSLNPs were developed in 1991 providing a promising drug delivery potential with respect to other colloidal vectors like PNPs, liposomes, and emulsions; they were particularly designed for the transfer of a lipophilic composite (Freitas and M\u00fcller 1999).", [["body", "ANATOMY", 92, 96], ["NLCs", "ANATOMY", 115, 119], ["SLNPs", "SIMPLE_CHEMICAL", 50, 55], ["body", "ORGANISM_SUBDIVISION", 92, 96], ["NLCs", "SIMPLE_CHEMICAL", 115, 119], ["solid", "SIMPLE_CHEMICAL", 141, 146], ["Lipid nanoparticles", "SIMPLE_CHEMICAL", 188, 207], ["Polymeric nanoparticlesSLNPs", "SIMPLE_CHEMICAL", 212, 240], ["PNPs", "SIMPLE_CHEMICAL", 355, 359], ["liposomes", "SIMPLE_CHEMICAL", 361, 370], ["NLCs", "CELL_TYPE", 115, 119], ["lipid core", "TREATMENT", 61, 71], ["a mixture of solid and liquid lipids", "TREATMENT", 128, 164], ["Lipid nanoparticles", "TREATMENT", 188, 207], ["Polymeric nanoparticlesSLNPs", "TREATMENT", 212, 240], ["a promising drug delivery", "TREATMENT", 274, 299], ["other colloidal vectors", "TREATMENT", 326, 349], ["main", "OBSERVATION_MODIFIER", 4, 8], ["difference", "OBSERVATION_MODIFIER", 9, 19], ["two types", "OBSERVATION_MODIFIER", 32, 41]]], ["The principal advantages of SLNPs are their higher selectivity, biocompatibility, absence of organic solvents during preparation, and improved drug release.", [["SLNPs", "SIMPLE_CHEMICAL", 28, 33], ["SLNPs", "TREATMENT", 28, 33], ["organic solvents", "TREATMENT", 93, 109], ["higher selectivity", "OBSERVATION_MODIFIER", 44, 62], ["organic solvents", "OBSERVATION", 93, 109]]], ["However, they exhibited some restrictions such as fixed drug packing space and drug removal capacity throughout the storage process (poor drug loading efficiency) (Mukherjee et al. 2009).", [["fixed drug packing space", "TREATMENT", 50, 74], ["drug removal capacity", "TREATMENT", 79, 100], ["the storage process", "TREATMENT", 112, 131], ["poor drug loading efficiency", "TREATMENT", 133, 161], ["drug packing", "OBSERVATION", 56, 68]]], ["To overcome limitations of SLNPs, NLCs were developed and received considerable investigations (M\u00fcller et al. 2002).", [["SLNPs", "SIMPLE_CHEMICAL", 27, 32], ["NLCs", "SIMPLE_CHEMICAL", 34, 38], ["NLCs", "CELL_TYPE", 34, 38], ["SLNPs", "TREATMENT", 27, 32], ["NLCs", "TREATMENT", 34, 38], ["considerable investigations", "TEST", 67, 94]]], ["NLCs were extensively employed for HupA delivery due to their unique solid-liquid lipid matrix as displayed in Fig. 4.Lipid nanoparticles ::: Polymeric nanoparticlesNLCs are generated by mixing solid lipids with spatially inconsistent liquid lipids under controlled conditions which are directed to nanostructures with increased drug conjugation and discharge features (Souto et al. 2004).", [["NLCs", "ANATOMY", 0, 4], ["HupA", "CHEMICAL", 35, 39], ["NLCs", "SIMPLE_CHEMICAL", 0, 4], ["HupA", "SIMPLE_CHEMICAL", 35, 39], ["Lipid nanoparticles", "SIMPLE_CHEMICAL", 118, 137], ["Polymeric nanoparticlesNLCs", "SIMPLE_CHEMICAL", 142, 169], ["solid lipids", "SIMPLE_CHEMICAL", 194, 206], ["NLCs", "CELL_TYPE", 0, 4], ["HupA delivery", "TREATMENT", 35, 48], ["their unique solid-liquid lipid matrix", "TREATMENT", 56, 94], ["Lipid nanoparticles", "TREATMENT", 118, 137], ["Polymeric nanoparticlesNLCs", "TREATMENT", 142, 169], ["mixing solid lipids", "TREATMENT", 187, 206], ["spatially inconsistent liquid lipids", "TREATMENT", 212, 248], ["increased drug conjugation", "PROBLEM", 319, 345], ["liquid lipids", "OBSERVATION", 235, 248], ["increased", "OBSERVATION_MODIFIER", 319, 328], ["drug conjugation", "OBSERVATION", 329, 345]]], ["HupA-loaded NLCs were effectively synthesized by a tailored method of melt ultrasonication followed by high pressure homogenization (Yang et al. 2010).Lipid nanoparticles ::: Polymeric nanoparticlesThe DSC results revealed that HupA matrix that overloaded with NLCs possessed poor crystal arrangement.", [["NLCs", "ANATOMY", 12, 16], ["HupA", "CHEMICAL", 0, 4], ["nanoparticles", "CHEMICAL", 185, 198], ["NLCs", "CHEMICAL", 261, 265], ["HupA", "CHEMICAL", 0, 4], ["HupA", "SIMPLE_CHEMICAL", 0, 4], ["NLCs", "SIMPLE_CHEMICAL", 12, 16], ["Lipid nanoparticles", "SIMPLE_CHEMICAL", 151, 170], ["NLCs", "SIMPLE_CHEMICAL", 261, 265], ["HupA-loaded NLCs", "CELL_LINE", 0, 16], ["NLCs", "PROTEIN", 261, 265], ["HupA-loaded NLCs", "TREATMENT", 0, 16], ["melt ultrasonication", "TREATMENT", 70, 90], ["high pressure homogenization", "TREATMENT", 103, 131], ["Polymeric nanoparticles", "TREATMENT", 175, 198], ["The DSC", "TEST", 198, 205], ["HupA matrix", "PROBLEM", 228, 239], ["NLCs", "TREATMENT", 261, 265], ["nanoparticles", "OBSERVATION", 185, 198], ["overloaded", "OBSERVATION", 245, 255], ["poor crystal", "OBSERVATION", 276, 288]]], ["As a result, a lot of imperfections can be generated leading to gaps hindering drug loading.", [["a lot of imperfections", "PROBLEM", 13, 35], ["drug loading", "TREATMENT", 79, 91]]], ["In vitro study showed an early rupture followed by an extended release (Yang et al. 2010).", [["vitro study", "TEST", 3, 14], ["an early rupture", "PROBLEM", 22, 38], ["early", "OBSERVATION_MODIFIER", 25, 30], ["rupture", "OBSERVATION", 31, 38]]], ["In addition, Patel et al. (2013) performed in vitro and in vivo comparative study to test the delivery of HupA; they used micro-emulsion template method to prepare SLNPs, NLCs, and micro-emulsions for the treatment of AD.", [["HupA", "CHEMICAL", 106, 110], ["AD", "DISEASE", 218, 220], ["HupA", "CHEMICAL", 106, 110], ["HupA", "SIMPLE_CHEMICAL", 106, 110], ["SLNPs", "SIMPLE_CHEMICAL", 164, 169], ["NLCs", "SIMPLE_CHEMICAL", 171, 175], ["micro-emulsions", "SIMPLE_CHEMICAL", 181, 196], ["comparative study", "TEST", 64, 81], ["the delivery of HupA", "TREATMENT", 90, 110], ["micro-emulsion template method", "TREATMENT", 122, 152], ["SLNPs", "TREATMENT", 164, 169], ["NLCs", "TREATMENT", 171, 175], ["micro-emulsions", "TREATMENT", 181, 196], ["AD", "PROBLEM", 218, 220]]], ["Their results showed the significant ability of micro-emulsions followed by SLNPs and then NLCs to deliver HupA after 24 h of treatment.", [["SLNPs", "CHEMICAL", 76, 81], ["HupA", "CHEMICAL", 107, 111], ["micro-emulsions", "SIMPLE_CHEMICAL", 48, 63], ["SLNPs", "SIMPLE_CHEMICAL", 76, 81], ["NLCs", "SIMPLE_CHEMICAL", 91, 95], ["HupA", "SIMPLE_CHEMICAL", 107, 111], ["HupA", "PROTEIN", 107, 111], ["HupA", "TREATMENT", 107, 111], ["treatment", "TREATMENT", 126, 135], ["significant", "OBSERVATION_MODIFIER", 25, 36]]], ["Moreover, mice groups treated with these HupA-loaded nano-carriers showed significant developments in cognitive abilities with respect to the control group.Lipid nanoparticles ::: Polymeric nanoparticlesRecently, a complex of HupA-loaded muco-adhesive and polylactide-co-glycoside (PLGA-NPs) with external adjustment by lactoferrin-conjugated N-trimethylated chitosan (Lf-TMC NPs) was generated for effective intranasal distribution of HupA to the brain for potential Alzheimer\u2019s disorder therapy (Sheng et al. 2015; Meng et al. 2018).Lipid nanoparticles ::: Polymeric nanoparticlesUnfortunately, NLCs have some limitations as the drug loading into them is controlled by many parameters such as lipid type, lipid character, production method, and surfactants used in production (Qian et al. 2013; Kathe et al. 2014; Lauterbach and M\u00fcller-Goymann 2015).Liposomes ::: Polymeric nanoparticlesLiposomes are 50\u2013100 \u03bcm spherical vesicles, composed of phospholipid-bilayer enclosing inner core (Wright and Huang 1989; Schroeder et al. 2009).", [["brain", "ANATOMY", 448, 453], ["vesicles", "ANATOMY", 923, 931], ["inner core", "ANATOMY", 976, 986], ["HupA", "CHEMICAL", 41, 45], ["nanoparticles", "CHEMICAL", 190, 203], ["HupA", "CHEMICAL", 226, 230], ["polylactide-co-glycoside", "CHEMICAL", 256, 280], ["PLGA-NPs", "CHEMICAL", 282, 290], ["N-trimethylated chitosan", "CHEMICAL", 343, 367], ["Lf-TMC NPs", "CHEMICAL", 369, 379], ["HupA", "CHEMICAL", 436, 440], ["Alzheimer\u2019s disorder", "DISEASE", 468, 488], ["nanoparticles", "CHEMICAL", 569, 582], ["HupA", "CHEMICAL", 226, 230], ["polylactide-co-glycoside", "CHEMICAL", 256, 280], ["PLGA", "CHEMICAL", 282, 286], ["mice", "ORGANISM", 10, 14], ["HupA", "GENE_OR_GENE_PRODUCT", 41, 45], ["Lipid nanoparticles", "SIMPLE_CHEMICAL", 156, 175], ["HupA", "SIMPLE_CHEMICAL", 226, 230], ["muco-adhesive", "SIMPLE_CHEMICAL", 238, 251], ["polylactide-co-glycoside", "SIMPLE_CHEMICAL", 256, 280], ["PLGA-NPs", "SIMPLE_CHEMICAL", 282, 290], ["lactoferrin-conjugated N-trimethylated chitosan", "SIMPLE_CHEMICAL", 320, 367], ["Lf-TMC NPs", "SIMPLE_CHEMICAL", 369, 379], ["HupA", "SIMPLE_CHEMICAL", 436, 440], ["brain", "ORGAN", 448, 453], ["Lipid nanoparticles", "SIMPLE_CHEMICAL", 535, 554], ["NLCs", "SIMPLE_CHEMICAL", 597, 601], ["lipid", "SIMPLE_CHEMICAL", 707, 712], ["Liposomes", "SIMPLE_CHEMICAL", 852, 861], ["Polymeric nanoparticlesLiposomes", "SIMPLE_CHEMICAL", 866, 898], ["phospholipid", "SIMPLE_CHEMICAL", 945, 957], ["HupA", "PROTEIN", 41, 45], ["HupA", "PROTEIN", 226, 230], ["lactoferrin", "PROTEIN", 320, 331], ["HupA", "PROTEIN", 436, 440], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 10, 14], ["these HupA", "TREATMENT", 35, 45], ["nano-carriers", "TREATMENT", 53, 66], ["Polymeric nanoparticles", "TREATMENT", 180, 203], ["HupA-loaded muco-adhesive", "TREATMENT", 226, 251], ["polylactide", "TREATMENT", 256, 267], ["glycoside (PLGA-NPs", "TREATMENT", 271, 290], ["external adjustment", "TREATMENT", 297, 316], ["lactoferrin-conjugated N-trimethylated chitosan (Lf-TMC NPs", "TREATMENT", 320, 379], ["potential Alzheimer\u2019s disorder therapy", "TREATMENT", 458, 496], ["Lipid nanoparticles", "TREATMENT", 535, 554], ["Polymeric nanoparticles", "TREATMENT", 559, 582], ["NLCs", "TREATMENT", 597, 601], ["the drug loading", "TREATMENT", 627, 643], ["production method", "TREATMENT", 724, 741], ["surfactants", "TREATMENT", 747, 758], ["Liposomes", "TEST", 852, 861], ["Polymeric nanoparticlesLiposomes", "TREATMENT", 866, 898], ["nanoparticles", "OBSERVATION", 190, 203], ["brain", "ANATOMY", 448, 453], ["Alzheimer", "OBSERVATION", 468, 477], ["nanoparticles", "OBSERVATION", 569, 582]]], ["They are highly biocompatible and non-toxic (He et al. 2019).", [["biocompatible", "OBSERVATION_MODIFIER", 16, 29], ["non-toxic", "OBSERVATION_MODIFIER", 34, 43]]], ["In addition, they have the ability to encapsulate both hydrophilic and hydrophobic drugs and they exhibit superior protection ability of encapsulated drugs against enzymatic degradation (Bruch et al. 2019;Mirab et al. 2019).", [["hydrophilic and hydrophobic drugs", "TREATMENT", 55, 88], ["encapsulated drugs", "TREATMENT", 137, 155], ["enzymatic degradation", "PROBLEM", 164, 185]]], ["However, they showed phospholipid-type dependent stability; the charge of phospholipids affects their stability (Wen et al. 2017).Nano-emulsion and micro-emulsions ::: Polymeric nanoparticlesOil-in-water nano-emulsions are cloudy and surfactant-stabilized heterogeneous drug delivery systems; they are composed of oil droplets (10\u2013100 nm) dispersed in water or other aqueous solutions (Hort et al. 2019; Karami et al. 2019).", [["oil droplets", "ANATOMY", 314, 326], ["nanoparticles", "CHEMICAL", 178, 191], ["phospholipid", "SIMPLE_CHEMICAL", 21, 33], ["phospholipids", "SIMPLE_CHEMICAL", 74, 87], ["Nano-emulsion", "SIMPLE_CHEMICAL", 130, 143], ["micro-emulsions", "SIMPLE_CHEMICAL", 148, 163], ["Oil", "SIMPLE_CHEMICAL", 191, 194], ["surfactant", "SIMPLE_CHEMICAL", 234, 244], ["phospholipid-type dependent stability", "PROBLEM", 21, 58], ["the charge of phospholipids", "TREATMENT", 60, 87], ["Polymeric nanoparticles", "TREATMENT", 168, 191], ["Oil", "TREATMENT", 191, 194], ["water nano-emulsions", "TREATMENT", 198, 218], ["surfactant", "TREATMENT", 234, 244], ["heterogeneous drug delivery systems", "TREATMENT", 256, 291], ["oil droplets", "TREATMENT", 314, 326], ["type dependent", "OBSERVATION_MODIFIER", 34, 48], ["stability", "OBSERVATION_MODIFIER", 49, 58], ["nanoparticles", "OBSERVATION", 178, 191], ["cloudy", "OBSERVATION", 223, 229]]], ["On the other hand, nano-emulsions can be effectively used to encapsulate HupA with high protection against degradation and can be produced at the large scale (Jiang et al. 2019).", [["HupA", "CHEMICAL", 73, 77], ["HupA", "CHEMICAL", 73, 77], ["nano-emulsions", "SIMPLE_CHEMICAL", 19, 33], ["HupA", "SIMPLE_CHEMICAL", 73, 77], ["nano-emulsions", "TREATMENT", 19, 33], ["HupA", "TREATMENT", 73, 77]]], ["Jiang et al. (2019) reported a new nano-emulsion-based system loaded with Lactoferrin for enhanced targeted drug delivery via intranasal administration.", [["Lactoferrin", "GENE_OR_GENE_PRODUCT", 74, 85], ["Lactoferrin", "PROTEIN", 74, 85], ["Lactoferrin", "TREATMENT", 74, 85], ["enhanced targeted drug delivery", "TREATMENT", 90, 121], ["intranasal administration", "TREATMENT", 126, 151]]], ["Their results showed the successful targeting of hCMEC/D3 cells, and their system is non-toxic and was highly stable up to 6 months (Jiang et al. 2019).Nano-emulsion and micro-emulsions ::: Polymeric nanoparticlesHowever, nano-emulsions have some limitations such as instability phase separation and non-controlled release (Basha et al. 2019).", [["hCMEC/D3 cells", "ANATOMY", 49, 63], ["nanoparticles", "CHEMICAL", 200, 213], ["hCMEC/D3 cells", "CELL", 49, 63], ["Nano-emulsion", "SIMPLE_CHEMICAL", 152, 165], ["micro-emulsions", "SIMPLE_CHEMICAL", 170, 185], ["nano-emulsions", "SIMPLE_CHEMICAL", 222, 236], ["hCMEC/D3 cells", "CELL_LINE", 49, 63], ["hCMEC/D3 cells", "TREATMENT", 49, 63], ["Polymeric nanoparticles", "TREATMENT", 190, 213], ["nano-emulsions", "PROBLEM", 222, 236], ["instability phase separation", "PROBLEM", 267, 295], ["D3 cells", "OBSERVATION", 55, 63], ["non-toxic", "OBSERVATION_MODIFIER", 85, 94], ["stable", "OBSERVATION_MODIFIER", 110, 116], ["nanoparticles", "OBSERVATION", 200, 213], ["nano-emulsions", "OBSERVATION", 222, 236]]], ["On the other hand, micro-emulsions are clear and transparent systems composed of water, oil, and amphiphile which is a stable liquid solution (Poh et al. 2019).", [["micro-emulsions", "SIMPLE_CHEMICAL", 19, 34], ["water", "SIMPLE_CHEMICAL", 81, 86], ["oil", "ORGANISM_SUBSTANCE", 88, 91], ["amphiphile", "TREATMENT", 97, 107], ["a stable liquid solution", "TREATMENT", 117, 141], ["clear", "OBSERVATION", 39, 44], ["stable", "OBSERVATION_MODIFIER", 119, 125]]], ["The advantages of micro-emulsions over nano-emulsions are their thermodynamic stability and cost-effectiveness as they do not need too much energy (Kumar and Pravallika 2019).", [["micro-emulsions", "SIMPLE_CHEMICAL", 18, 33], ["nano-emulsions", "SIMPLE_CHEMICAL", 39, 53], ["micro-emulsions over nano-emulsions", "PROBLEM", 18, 53], ["thermodynamic stability", "OBSERVATION", 64, 87]]], ["But, micro-emulsions need large amounts of emulsifiers (Doering 2019).Nano-emulsion and micro-emulsions ::: Polymeric nanoparticlesAll and above, the chemical structure of HupA (as a secondary metabolite of microbial synthesis), with its important functional groups like C=O and N\u2013H (Jiang et al. 2003), both O and N contain lone pair of electrons suggesting its capability for metal ions reduction, subsequent fabrication of different NPs that would be incorporated and/or conjugated with the reducing agent, and as a stabilizing agent that could prevent the precipitation and aggregation of metal NPs (Mosallam et al. 2018; El-Sayyad et al. 2019).", [["nanoparticles", "CHEMICAL", 118, 131], ["HupA", "CHEMICAL", 172, 176], ["HupA", "CHEMICAL", 172, 176], ["C=O", "CHEMICAL", 271, 274], ["N\u2013H", "CHEMICAL", 279, 282], ["O", "CHEMICAL", 309, 310], ["N", "CHEMICAL", 315, 316], ["Nano-emulsion", "SIMPLE_CHEMICAL", 70, 83], ["micro-emulsions", "SIMPLE_CHEMICAL", 88, 103], ["HupA", "SIMPLE_CHEMICAL", 172, 176], ["C=O", "SIMPLE_CHEMICAL", 271, 274], ["N\u2013H", "SIMPLE_CHEMICAL", 279, 282], ["metal ions", "SIMPLE_CHEMICAL", 378, 388], ["NPs", "SIMPLE_CHEMICAL", 436, 439], ["metal NPs", "SIMPLE_CHEMICAL", 593, 602], ["Polymeric nanoparticles", "TREATMENT", 108, 131], ["HupA", "TREATMENT", 172, 176], ["microbial synthesis", "TREATMENT", 207, 226], ["metal ions reduction", "TREATMENT", 378, 398], ["subsequent fabrication of different NPs", "TREATMENT", 400, 439], ["the reducing agent", "TREATMENT", 490, 508], ["a stabilizing agent", "TREATMENT", 517, 536], ["the precipitation", "PROBLEM", 556, 573], ["metal NPs", "TREATMENT", 593, 602], ["large", "OBSERVATION_MODIFIER", 26, 31], ["amounts", "OBSERVATION_MODIFIER", 32, 39], ["nanoparticles", "OBSERVATION", 118, 131]]], ["Finally, some comparative and survey studies reporting the incorporation of HupA with different nano-structured compounds are listed in Table 6.Conclusion and future approachingThe wide applications of the AChE inhibitors especially in AD treatment as there is a continuous increase in the number of AD patients, and the feasibility of AChE inhibitors production by microbial fermentation approach make it necessary to do excessive research efforts to discover more novel microbial AChE inhibitors.", [["HupA", "CHEMICAL", 76, 80], ["AD", "DISEASE", 236, 238], ["AD", "DISEASE", 300, 302], ["HupA", "SIMPLE_CHEMICAL", 76, 80], ["AChE", "GENE_OR_GENE_PRODUCT", 206, 210], ["patients", "ORGANISM", 303, 311], ["AChE", "GENE_OR_GENE_PRODUCT", 336, 340], ["AChE", "GENE_OR_GENE_PRODUCT", 482, 486], ["patients", "SPECIES", 303, 311], ["survey studies", "TEST", 30, 44], ["HupA", "TREATMENT", 76, 80], ["different nano-structured compounds", "TREATMENT", 86, 121], ["the AChE inhibitors", "TREATMENT", 202, 221], ["AD treatment", "TREATMENT", 236, 248], ["AChE inhibitors production", "TREATMENT", 336, 362], ["microbial fermentation approach", "TREATMENT", 366, 397], ["novel microbial AChE inhibitors", "TREATMENT", 466, 497], ["wide", "OBSERVATION_MODIFIER", 181, 185], ["continuous", "OBSERVATION_MODIFIER", 263, 273], ["increase", "OBSERVATION_MODIFIER", 274, 282]]], ["In addition, more microbial strain enhancement protocols are needed to be applied.", [["more microbial strain enhancement protocols", "TREATMENT", 13, 56]]], ["As a recommendation, besides the conventional submerged fermentation (SMF), solid-state fermentation (SSF) may be a promising alternative for the production of AChE inhibitors.", [["AChE", "GENE_OR_GENE_PRODUCT", 160, 164], ["AChE inhibitors", "TREATMENT", 160, 175]]], ["Over the years, SSF proved to be a promising system for the production of many valuable products.", [["SSF", "TREATMENT", 16, 19]]], ["SSF has many advantages over the conventional SMF including resistance of microorganisms to catabolic repression, low-cost production process, production of metabolites at higher ,yields and the potentiality of applying agro-industrial wastes as nutritional rich substrates (El-Sayed et al. 2019c, 2020c).Conclusion and future approachingAdditionally, the technique of microbial immobilization would be very potential and promising for enhancing the microbial manufacturing of AChE inhibitors, and achieving a continual or a semi continual manufacturing process.", [["AChE", "GENE_OR_GENE_PRODUCT", 477, 481], ["the conventional SMF", "TREATMENT", 29, 49], ["microorganisms", "PROBLEM", 74, 88], ["catabolic repression", "PROBLEM", 92, 112], ["low-cost production process", "PROBLEM", 114, 141], ["production of metabolites", "PROBLEM", 143, 168], ["agro-industrial wastes", "TREATMENT", 220, 242], ["microbial immobilization", "TREATMENT", 369, 393], ["AChE inhibitors", "TREATMENT", 477, 492], ["a semi continual manufacturing process", "PROBLEM", 523, 561], ["low", "OBSERVATION_MODIFIER", 114, 117]]], ["This technique is effective for providing a time-consuming production process, and successive fermentation cycles with product extracting and purifying feasibility (Ismaiel et al. 2015; El-Sayed et al. 2019b, 2020d).", [["This technique", "TREATMENT", 0, 14], ["successive fermentation cycles", "TREATMENT", 83, 113]]], ["After the prospective achieving of these steps, it could be possible to transfer the microbial production of AChE inhibitors from an improved lab scale to the promising large-scale industrial production.", [["AChE", "GENE_OR_GENE_PRODUCT", 109, 113], ["AChE inhibitors", "TREATMENT", 109, 124], ["large", "OBSERVATION_MODIFIER", 169, 174], ["-scale", "OBSERVATION_MODIFIER", 174, 180], ["industrial production", "OBSERVATION", 181, 202]]]], "137cc22345cbb003187b65fa71d57dfe2ac80eda": [["COVID-19 and the Urology Match: Perspectives and a Call to ActionOn March 11, 2020 the World Health Organization declared COVID-19, the disease caused by the novel coronavirus SARS-Cov-2, a global pandemic.", [["SARS", "DISEASE", 176, 180], ["coronavirus", "SPECIES", 164, 175], ["COVID", "TEST", 122, 127], ["the disease", "PROBLEM", 132, 143], ["the novel coronavirus SARS", "PROBLEM", 154, 180], ["Cov", "TEST", 181, 184], ["a global pandemic", "PROBLEM", 188, 205], ["global", "OBSERVATION_MODIFIER", 190, 196], ["pandemic", "OBSERVATION", 197, 205]]], ["1 As COVID-19 continues to spread, governments have imposed increasingly aggressive measures including travel bans and even statewide shelters-in-place.", [["COVID-19", "CHEMICAL", 5, 13], ["COVID", "TEST", 5, 10], ["aggressive measures", "TREATMENT", 73, 92]]], ["1 These actions have demonstrated benefits in reducing the spread of the virus and minimizing the impact that cases have on local health care systems.", [["the virus", "PROBLEM", 69, 78]]], ["1 However, in the wake of these changes, medical student education has been brought to a standstill.COVID-19 and the Urology Match: Perspectives and a Call to ActionFor third-year medical students, spring is a critical period for making final decisions on their future medical specialty, often relying on home urology rotations to confirm final decisions.", [["COVID", "TEST", 100, 105], ["home urology rotations", "TREATMENT", 305, 327]]], ["Spring is also when visiting student learning opportunities (VSLO or away rotations) are organized and a plan is created for completing required licensing examinations, notably the United States Medical Licensing Examination (USMLE) Step 2 Clinical Knowledge (CK) and Clinical Skills (CS).COVID-19 and the Urology Match: Perspectives and a Call to ActionUrology is a unique field in that many students will have no or minimal experience in the specialty during core rotations, with students relying heavily on home sub-internships and VSLO for exposure and confirmation that urology is their desired field.", [["VSLO", "CHEMICAL", 535, 539], ["licensing examinations", "TEST", 145, 167]]], ["However, a large number of academic urology departments across the nation have appropriately either suspended or canceled medical student rotations as well as away rotations while uncertainty regarding the trajectory of the COVID-19 pandemic looms.", [["large", "OBSERVATION_MODIFIER", 11, 16], ["number", "OBSERVATION_MODIFIER", 17, 23]]], ["Elective rotations in urology are essential for recruitment as only 5% of medical schools have a mandatory urology rotation.", [["Elective rotations", "TREATMENT", 0, 18], ["a mandatory urology rotation", "TREATMENT", 95, 123]]], ["Away rotations serve as a critical component of medical student evaluation and function in addition to providing a rich educational experience.", [["medical student evaluation", "TEST", 48, 74]]], ["3 The loss of this experience limits an applicant's ability to evaluate diverse working environments (academic vs clinical focus, traditional vs mentorship model, 5 vs 6-year training, Veteran Affairs exposure, small vs large hospital footprint), and precludes opportunities to demonstrate a strong work ethic, amicability and cohesiveness with existing residents and faculty.", [["small vs large hospital footprint", "PROBLEM", 211, 244], ["loss", "OBSERVATION_MODIFIER", 6, 10], ["small", "OBSERVATION_MODIFIER", 211, 216]]], ["As such, another potential consequence of limited VSLO in the 2021 match cycle is a geographical clustering of applicants matching in regions near where students attended medical school.COVID-19 and the Urology Match: Perspectives and a Call to ActionStudies have found that letters of recommendation (LORs) are among the most essential components of the urology residency application.", [["VSLO", "DISEASE", 50, 54], ["VSLO", "CANCER", 50, 54]]], ["Furthermore, if students are unable to complete home clinical rotations prior to application deadlines, LOR writers may be unable to comment on a student's clinical and interpersonal aptitude which is an essential data point to any program director.COVID-19 and the Urology Match: Perspectives and a Call to ActionWith restrictions on VSLO and a resulting decrease in LOR opportunities, there is a loss of subjective measures that can be incorporated into the applicant evaluation process.", [["interpersonal aptitude", "TEST", 169, 191], ["COVID", "TEST", 249, 254], ["the applicant evaluation", "TEST", 456, 480], ["decrease", "OBSERVATION_MODIFIER", 356, 364]]], ["As such, there may be an increasing push among applicants to replace the loss of subjective measures with an additional objective measure, such as the USMLECOVID-19 and the Urology Match: Perspectives and a Call to ActionStep 2 CK exam.", [["subjective measures", "TREATMENT", 81, 100], ["the USMLECOVID", "TEST", 147, 161], ["ActionStep 2 CK exam", "TEST", 215, 235], ["increasing", "OBSERVATION_MODIFIER", 25, 35]]], ["Given the National Board of Medical Examiner's recent decision to eliminate 3digit scoring of USMLE Step 1, it is likely that there will be greater emphasis placed on USMLECOVID-19 and the Urology Match: Perspectives and a Call to ActionStep 2 CK.", [["CK", "GENE_OR_GENE_PRODUCT", 244, 246], ["CK", "PROTEIN", 244, 246], ["USMLECOVID", "TEST", 167, 177]]], ["This decision may be apropos given findings that Step 2 CK, rather than Step 1, is an independent predictor of excellent performance as a urology resident.", [["CK", "GENE_OR_GENE_PRODUCT", 56, 58], ["CK", "PROTEIN", 56, 58], ["Step 2 CK", "TEST", 49, 58]]], ["An important first step may require delaying the date at which urology match applications open and, therefore, modifying interview dates to maximize student opportunities to complete a urology rotation at their home institution as well as at least 1 away rotation.", [["a urology rotation", "TREATMENT", 183, 201]]], ["Urology stands unique among all specialties in that we control our own match, giving us the ability to be agile and adjust to this once-in-a-lifetime event.COVID-19 and the Urology Match: Perspectives and a Call to ActionMoreover, it may be worthwhile to foster greater adoption of a standardized letter template with consistent metrics and language such as the one designed by Penson cited by Filippou et al 6 to better evaluate applicants on a more level playing field.", [["COVID", "TEST", 156, 161], ["a standardized letter template", "TREATMENT", 282, 312]]], ["Finally, if letter writers are unable to comment on clinical and interpersonal aptitude, perhaps recommending students submit a letter from another surgical clerkship in which their clinical interactions were observed may be an appropriate surrogate.COVID-19 and the Urology Match: Perspectives and a Call to ActionIf away rotations are completed this year, it is also important that programs prioritize applicants without home urology programs to allow them the opportunity to gain exposure to the field and acquire vital LORs.", [["home urology programs", "TREATMENT", 423, 444]]], ["Those without a home urology program may be disproportionately affected by a loss of VSLO, and loss of this group of prospective applicants may perpetuate the ongoing decline in the urology applicant pool.", [["VSLO", "DISEASE", 85, 89], ["a home urology program", "TREATMENT", 14, 36], ["a loss of VSLO", "PROBLEM", 75, 89], ["the ongoing decline", "PROBLEM", 155, 174]]], ["Just as COVID-19 has caused an increased reliance on online means of connecting with colleagues and patients, there should be a push for improved online open access urology resources that appeal to medical students.COVID-19 and the Urology Match: Perspectives and a Call to ActionFinally, medical students are encouraged to take advantage of whatever time was set aside for away rotations (but may no longer be able to capitalize on) to bolster other elements of their application, including finalizing research activities, studying for Step 2 CK and engaging in urology educational activities (ie remote grand rounds).COVID-19 and the Urology Match: Perspectives and a Call to ActionUltimately the COVID-19 pandemic will create challenges for the upcoming urology match.", [["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["an increased reliance", "PROBLEM", 28, 49], ["Step 2 CK", "TEST", 537, 546], ["COVID", "TEST", 619, 624], ["increased", "OBSERVATION_MODIFIER", 31, 40]]], ["However, the time to make changes is now, and consider moving back the application process and setting clear application requirements for the upcoming urology match to encourage and not dissuade applicants from pursuing a career in urology.COVID-19 and the Urology Match: Perspectives and a Call to ActionAndrew T. Gabrielson, Taylor P. Kohn and Marisa M. Clifton*", [["the application process", "TREATMENT", 67, 90], ["COVID", "TEST", 240, 245]]]], "ac8ea2b6afdbbf50e057615cb945200774eb95a5": [["MinION (23,390 reads) sequencing with Geneious mapper using default parameters.", [["MinION", "DNA", 0, 6], ["Geneious mapper", "DNA", 38, 53], ["MinION", "TEST", 0, 6], ["default parameters", "TEST", 60, 78]]], ["The four genome sizes ranged from 29,486 to 29,898 bp with GC contents of 36.6 to 37.9% (Table 1) .", [["The four genome sizes", "TEST", 0, 21], ["bp", "TEST", 51, 53], ["GC contents", "TEST", 59, 70], ["four", "OBSERVATION_MODIFIER", 4, 8], ["genome", "OBSERVATION_MODIFIER", 9, 15], ["sizes", "OBSERVATION_MODIFIER", 16, 21]]], ["Multiple sequence alignment was performed with MAFFT with default parameters (3) .", [["Multiple sequence alignment", "TEST", 0, 27]]], ["Phylogenetic analysis was conducted with FastTree 2.1.11 (4) implemented in Geneious with default parameters using whole genomes available at GISAID (www.gisaid.org), including six other previously deposited Malaysian strains (EPI_ISL_416829, EPI_ISL_416866, EPI_ISL_416884, EPI_ISL_416885, EPI_ISL_416886, and EPI_ISL_416907).", [["Phylogenetic analysis", "TEST", 0, 21], ["FastTree", "TEST", 41, 49], ["EPI_ISL_", "TEST", 275, 283], ["EPI", "TEST", 311, 314]]]], "PMC7264595": [["Author Roles(1) Research Project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript: A. Writing of the First Draft, B. Review and Critique.Author RolesC.G.G.: 1A, 1B, 1C, 2A, 2C, 3A, 3BAuthor RolesG.T.S.: 1A, 1B, 1C, 2A, 2B, 2C, 3BAuthor RolesS.L.: 1A, 1B, 2A, 2B, 2C, 3BFinancial disclosures of all authors (for the preceding 12 months)C.G.G. reports funding to Rush University Medical Center from the National Institutes of Health, Department of Defense, and Michael J. Fox Foundation for research conducted by Dr. Goetz.", [["RolesG", "PROTEIN", 278, 284], ["1C", "TEST", 299, 301]]], ["During the reporting time, Dr. Goetz directed the Rush Parkinson's Disease Research Center supported by the Parkinson's Foundation and some of these funds supported Dr. Goetz's salary as well as his research efforts.", [["Parkinson's Disease", "DISEASE", 55, 74], ["Parkinson", "DISEASE", 108, 117]]], ["He also reports a presidential stipend from the International Parkinson and Movement Disorder Society paid to Rush University Medical Center as part of Dr. Goetz's salary, faculty stipends from the International Parkinson and Movement Disorder Society and the American Academy of Neurology, and guest professorship honorarium provided by NorthShore University Health System.", [["Parkinson and Movement Disorder", "DISEASE", 62, 93], ["Parkinson and Movement Disorder", "DISEASE", 212, 243], ["Movement Disorder", "PROBLEM", 76, 93]]], ["G.T.S. reports consulting and advisory board membership with honoraria from Acadia, Pharmaceuticals, Adamas Pharmaceuticals, Inc., Biogen, Inc., Ceregene, Inc., CHDI Management, Inc., Cleveland Clinic Foundation, Ingenix Pharmaceutical Services (i3 Research), MedGenesis Therapeutix, Inc., Neurocrine Biosciences, Inc., Pfizer, Inc., Tools\u20104\u2010Patients, Ultragenyx, Inc., and the Sunshine Care Foundation; grants and research from the National Institutes of Health, Department of Defense, Michael J. Fox Foundation for Parkinson's Research, Dystonia Coalition, CHDI, Cleveland Clinic Foundation, International Parkinson and Movement Disorder Society, and CBD Solutions; and honoraria from the International Parkinson and Movement Disorder Society, American Academy of Neurology, Michael J. Fox Foundation for Parkinson's Research, US Food and Drug Administration, National Institutes of Health, and Alzheimer's Association; and a salary from Rush University Medical Center.", [["Parkinson's Research", "DISEASE", 517, 537], ["Dystonia", "DISEASE", 539, 547], ["Parkinson and Movement Disorder", "DISEASE", 608, 639], ["Parkinson and Movement Disorder", "DISEASE", 705, 736], ["Parkinson's Research", "DISEASE", 807, 827], ["Alzheimer", "DISEASE", 897, 906], ["honoraria", "ORGANISM", 61, 70], ["Patients", "SPECIES", 342, 350], ["Adamas Pharmaceuticals", "TREATMENT", 101, 123], ["Biogen", "TREATMENT", 131, 137], ["CHDI Management", "TREATMENT", 161, 176], ["Parkinson's Research", "PROBLEM", 517, 537], ["Dystonia", "PROBLEM", 539, 547], ["International Parkinson and Movement Disorder", "PROBLEM", 594, 639], ["CBD Solutions", "TREATMENT", 653, 666], ["CBD", "ANATOMY", 653, 656]]]], "f8aade8fd2bca2d96e4f74c47afff94f335ad169": [["What can we expect from first-generation COVID-19 vaccines?A first generation of COVID-19 vaccines is expected to gain approval as soon as the end of 2020 or early 2021.", [["COVID-19", "CHEMICAL", 41, 49], ["first-generation COVID-19 vaccines", "TREATMENT", 24, 58], ["COVID-19 vaccines", "TREATMENT", 81, 98]]], ["A popular assumption is that these vaccines will provide population immunity that can reduce transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and lead to a resumption of pre-COVID-19 \"normalcy\".", [["acute respiratory syndrome coronavirus", "DISEASE", 116, 154], ["SARS-CoV-2", "ORGANISM", 158, 168], ["severe acute respiratory syndrome coronavirus", "SPECIES", 109, 154], ["SARS-CoV-2", "SPECIES", 158, 168], ["these vaccines", "TREATMENT", 29, 43], ["population immunity", "TREATMENT", 57, 76], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 109, 154], ["CoV", "TEST", 163, 166], ["pre-COVID", "TEST", 198, 207], ["severe", "OBSERVATION_MODIFIER", 109, 115], ["acute", "OBSERVATION_MODIFIER", 116, 121], ["respiratory syndrome", "OBSERVATION", 122, 142]]], ["Given an initial reproduction number of around 2\u00b72, 1 which has since been revised to as high as about 4, and taking into account overdispersion of infections, 2 perhaps about 25-50% of the population would have to be immune to the virus to achieve suppression of community transmission.", [["infections", "DISEASE", 148, 158], ["infections", "PROBLEM", 148, 158], ["the virus", "PROBLEM", 228, 237], ["infections", "OBSERVATION", 148, 158]]], ["[1] [2] [3] Multiple COVID-19 vaccines are currently in phase 3 trials with efficacy assessed as prevention of virologically confirmed disease.", [["[1] [2] [3", "SIMPLE_CHEMICAL", 0, 10], ["Multiple COVID-19 vaccines", "TREATMENT", 12, 38], ["efficacy", "TREATMENT", 76, 84], ["virologically", "PROBLEM", 111, 124], ["disease", "PROBLEM", 135, 142]]], ["4 WHO recommends that successful vaccines should show disease risk reduction of at least 50%, with 95% CI that true vaccine efficacy exceeds 30%.", [["successful vaccines", "TREATMENT", 22, 41], ["disease risk reduction", "PROBLEM", 54, 76]]], ["5 However, the impact of these COVID-19 vaccines on infection and thus transmission is not being assessed.", [["infection", "DISEASE", 52, 61], ["these COVID-19 vaccines", "TREATMENT", 25, 48], ["infection", "PROBLEM", 52, 61], ["infection", "OBSERVATION", 52, 61]]], ["Even if vaccines were able to confer protection from disease, they might not reduce transmission similarly.What can we expect from first-generation COVID-19 vaccines?Challenge studies in vaccinated primates showed reductions in pathology, symptoms, and viral load in the lower respiratory tract, 6,7 but failed to elicit sterilising immunity in the upper airways.", [["lower respiratory tract", "ANATOMY", 271, 294], ["upper airways", "ANATOMY", 349, 362], ["COVID-19", "CHEMICAL", 148, 156], ["primates", "ORGANISM", 198, 206], ["lower", "ORGANISM_SUBDIVISION", 271, 276], ["respiratory tract", "ORGANISM_SUBDIVISION", 277, 294], ["upper airways", "MULTI-TISSUE_STRUCTURE", 349, 362], ["vaccines", "TREATMENT", 8, 16], ["disease", "PROBLEM", 53, 60], ["first-generation COVID-19 vaccines", "TREATMENT", 131, 165], ["Challenge studies", "TEST", 166, 183], ["reductions in pathology", "PROBLEM", 214, 237], ["symptoms", "PROBLEM", 239, 247], ["viral load in the lower respiratory tract", "PROBLEM", 253, 294], ["disease", "OBSERVATION", 53, 60], ["reductions", "OBSERVATION_MODIFIER", 214, 224], ["viral load", "OBSERVATION", 253, 263], ["lower", "ANATOMY_MODIFIER", 271, 276], ["respiratory tract", "ANATOMY", 277, 294], ["upper", "ANATOMY_MODIFIER", 349, 354], ["airways", "ANATOMY", 355, 362]]], ["Sterilising immunity in the upper airways has been claimed for one vaccine, but peer-reviewed publication of these data are awaited.", [["upper airways", "ANATOMY", 28, 41], ["upper airways", "MULTI-TISSUE_STRUCTURE", 28, 41], ["these data", "TEST", 109, 119], ["upper", "ANATOMY_MODIFIER", 28, 33], ["airways", "ANATOMY", 34, 41]]], ["8 There have been reports of virologically confirmed SARS-CoV-2 re-infection of previously infected individuals, but the extent of such re-infection is unclear.", [["SARS-CoV-2", "ORGANISM", 53, 63], ["individuals", "ORGANISM", 100, 111], ["SARS-CoV", "SPECIES", 53, 61], ["virologically", "PROBLEM", 29, 42], ["SARS", "PROBLEM", 53, 57], ["CoV", "PROBLEM", 58, 61], ["previously infected individuals", "PROBLEM", 80, 111], ["such re-infection", "PROBLEM", 131, 148], ["SARS", "OBSERVATION", 53, 57], ["infected", "OBSERVATION_MODIFIER", 91, 99], ["re-infection", "OBSERVATION", 136, 148]]], ["9 Whether re-infection is associated with secondary spread is unknown.What can we expect from first-generation COVID-19 vaccines?The immunological correlates of protection from SARS-CoV-2 infection and COVID-19 have yet to be elucidated.", [["SARS", "DISEASE", 177, 181], ["infection", "DISEASE", 188, 197], ["COVID-19", "CHEMICAL", 111, 119], ["SARS-CoV-2", "ORGANISM", 177, 187], ["COVID-19", "GENE_OR_GENE_PRODUCT", 202, 210], ["CoV-2", "SPECIES", 182, 187], ["SARS-CoV-2", "SPECIES", 177, 187], ["re-infection", "PROBLEM", 10, 22], ["secondary spread", "PROBLEM", 42, 58], ["first-generation COVID-19 vaccines", "TREATMENT", 94, 128], ["SARS", "PROBLEM", 177, 181], ["CoV-2 infection", "PROBLEM", 182, 197], ["COVID", "TEST", 202, 207], ["re-infection", "OBSERVATION", 10, 22], ["associated with", "UNCERTAINTY", 26, 41], ["secondary spread", "OBSERVATION", 42, 58]]], ["Pre-existing neutralising antibody seemed to have afforded protection against re-infection in people on board a fishing vessel where there was an outbreak of SARS-CoV-2 with a high infection attack rate.", [["vessel", "ANATOMY", 120, 126], ["SARS", "DISEASE", 158, 162], ["infection", "DISEASE", 181, 190], ["people", "ORGANISM", 94, 100], ["vessel", "MULTI-TISSUE_STRUCTURE", 120, 126], ["SARS-CoV-2", "ORGANISM", 158, 168], ["neutralising antibody", "PROTEIN", 13, 34], ["people", "SPECIES", 94, 100], ["SARS-CoV", "SPECIES", 158, 166], ["Pre-existing neutralising antibody", "PROBLEM", 0, 34], ["re-infection", "PROBLEM", 78, 90], ["SARS", "PROBLEM", 158, 162], ["CoV", "TEST", 163, 166], ["a high infection attack rate", "PROBLEM", 174, 202], ["neutralising antibody", "OBSERVATION", 13, 34], ["re-infection", "OBSERVATION", 78, 90], ["vessel", "ANATOMY", 120, 126], ["outbreak", "OBSERVATION_MODIFIER", 146, 154], ["high", "OBSERVATION_MODIFIER", 176, 180], ["infection", "OBSERVATION", 181, 190]]], ["10 In animal models, passive antibody transfer protected against COVID-19, 11, 12 whereas neutralising antibody correlated with protection after inoculation.", [["neutralising antibody", "PROTEIN", 90, 111], ["passive antibody transfer", "TREATMENT", 21, 46], ["COVID", "TEST", 65, 70], ["neutralising antibody", "TEST", 90, 111], ["inoculation", "PROBLEM", 145, 156]]], ["13 However, the roles of mucosal immunity, other biological antibody activities (eg, antibody-dependent cellular cytotoxicity), and T cells in protection conferred by natural infection or passive immunisation are unclear.What can we expect from first-generation COVID-19 vaccines?The prevalence and duration of neutralising antibody responses after natural infection remain to be defined by gold-standard neutralisation assays that use live virus rather than pseudotype neutralising assays or nonfunctional ELISA assays.", [["mucosal", "ANATOMY", 25, 32], ["cellular", "ANATOMY", 104, 112], ["T cells", "ANATOMY", 132, 139], ["infection", "DISEASE", 175, 184], ["natural infection", "DISEASE", 349, 366], ["COVID-19", "CHEMICAL", 262, 270], ["mucosal", "MULTI-TISSUE_STRUCTURE", 25, 32], ["cellular", "CELL", 104, 112], ["T cells", "CELL", 132, 139], ["T cells", "CELL_TYPE", 132, 139], ["neutralising antibody", "PROTEIN", 311, 332], ["mucosal immunity", "TEST", 25, 41], ["other biological antibody activities", "TEST", 43, 79], ["eg", "TEST", 81, 83], ["antibody", "TEST", 85, 93], ["dependent cellular cytotoxicity", "PROBLEM", 94, 125], ["T cells in protection", "TREATMENT", 132, 153], ["natural infection", "PROBLEM", 167, 184], ["passive immunisation", "TREATMENT", 188, 208], ["first-generation COVID-19 vaccines", "TREATMENT", 245, 279], ["neutralising antibody responses", "TREATMENT", 311, 342], ["natural infection", "PROBLEM", 349, 366], ["gold-standard neutralisation assays", "TREATMENT", 391, 426], ["live virus", "PROBLEM", 436, 446], ["pseudotype neutralising assays", "PROBLEM", 459, 489], ["nonfunctional ELISA assays", "PROBLEM", 493, 519], ["mucosal", "ANATOMY", 25, 32], ["infection", "OBSERVATION", 175, 184], ["infection", "OBSERVATION", 357, 366]]], ["14 The duration of protection against re-infection with seasonal human coronaviruses might last for less than a year.", [["human", "ORGANISM", 65, 70], ["human", "SPECIES", 65, 70], ["human coronaviruses", "SPECIES", 65, 84], ["protection", "TREATMENT", 19, 29], ["re-infection", "PROBLEM", 38, 50], ["seasonal human coronaviruses", "PROBLEM", 56, 84]]], ["15 Middle East respiratory syndrome coronavirus (MERS-CoV) re-infection occurs in dromedary camels, the natural host of that virus.", [["respiratory syndrome coronavirus", "DISEASE", 15, 47], ["MERS-CoV) re-infection", "DISEASE", 49, 71], ["15", "ORGANISM", 0, 2], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 3, 47], ["MERS-CoV", "ORGANISM", 49, 57], ["Middle East respiratory syndrome coronavirus", "SPECIES", 3, 47], ["MERS-CoV", "SPECIES", 49, 57], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 3, 47], ["re-infection", "PROBLEM", 59, 71], ["dromedary camels", "PROBLEM", 82, 98], ["that virus", "PROBLEM", 120, 130], ["Middle", "ANATOMY_MODIFIER", 3, 9], ["respiratory syndrome coronavirus", "OBSERVATION", 15, 47]]], ["16 Whether re-infected camels are as infectious as those with primary infections is not known.", [["primary infections", "DISEASE", 62, 80], ["camels", "ORGANISM", 23, 29], ["re-infected camels", "PROBLEM", 11, 29], ["infectious", "PROBLEM", 37, 47], ["primary infections", "PROBLEM", 62, 80]]], ["The observation that MERS-CoV is enzootic in dromedary populations despite high (>90%) seroprevalence in juvenile and adult camels implies that virus transmission may not be functionally interrupted by previous infection.", [["infection", "DISEASE", 211, 220], ["MERS-CoV", "ORGANISM", 21, 29], ["adult camels", "ORGANISM", 118, 130], ["MERS-CoV", "SPECIES", 21, 29], ["The observation", "TEST", 0, 15], ["CoV", "PROBLEM", 26, 29], ["enzootic in dromedary populations", "PROBLEM", 33, 66], ["virus transmission", "PROBLEM", 144, 162], ["previous infection", "PROBLEM", 202, 220], ["enzootic", "OBSERVATION_MODIFIER", 33, 41], ["high", "OBSERVATION_MODIFIER", 75, 79], ["virus", "OBSERVATION", 144, 149], ["may not be", "UNCERTAINTY", 163, 173], ["infection", "OBSERVATION", 211, 220]]], ["Also relevant is how influenza vaccines can reduce disease transmission, 17 whereas inactivated polio vaccines are effective at protecting from disease but have less effect on reduction of faecal shedding of poliomyelitis virus 18 and thus possibly on transmission.What can we expect from first-generation COVID-19 vaccines?These observations suggest that we cannot assume COVID-19 vaccines, even if shown to be effective in reducing severity of disease, will reduce virus transmission to a comparable degree.", [["faecal", "ANATOMY", 189, 195], ["poliomyelitis", "DISEASE", 208, 221], ["COVID-19", "CHEMICAL", 306, 314], ["faecal", "ORGANISM_SUBSTANCE", 189, 195], ["poliomyelitis virus 18", "ORGANISM", 208, 230], ["poliomyelitis virus", "SPECIES", 208, 227], ["influenza vaccines", "TREATMENT", 21, 39], ["disease transmission", "PROBLEM", 51, 71], ["polio vaccines", "TREATMENT", 96, 110], ["disease", "PROBLEM", 144, 151], ["faecal shedding", "PROBLEM", 189, 204], ["poliomyelitis virus", "PROBLEM", 208, 227], ["first-generation COVID-19 vaccines", "TREATMENT", 289, 323], ["COVID-19 vaccines", "TREATMENT", 373, 390], ["disease", "PROBLEM", 446, 453], ["virus transmission", "TREATMENT", 467, 485], ["less effect", "OBSERVATION_MODIFIER", 161, 172], ["poliomyelitis", "OBSERVATION", 208, 221], ["disease", "OBSERVATION", 446, 453]]], ["The notion that COVID-19vaccine-induced population immunity will allow a return to pre-COVID-19 \"normalcy\" might be based on illusory assumptions.What can we expect from first-generation COVID-19 vaccines?Another important consideration is COVID-19 vaccine allocation strategy.", [["COVID-19vaccine", "CHEMICAL", 16, 31], ["COVID-19", "CHEMICAL", 187, 195], ["COVID-19vaccine", "GENE_OR_GENE_PRODUCT", 16, 31], ["COVID", "TEST", 16, 21], ["pre-COVID", "TEST", 83, 92], ["first-generation COVID-19 vaccines", "TREATMENT", 170, 204], ["COVID-19 vaccine allocation strategy", "TREATMENT", 240, 276]]], ["First principles would preferentially allocate vaccine supplies to people at high risk of severe morbidity and mortality.", [["people", "ORGANISM", 67, 73], ["people", "SPECIES", 67, 73], ["severe morbidity", "PROBLEM", 90, 106], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["morbidity", "OBSERVATION", 97, 106]]], ["Preliminary modelinformed analyses support this theoretical inference.", [["Preliminary modelinformed analyses", "TEST", 0, 34]]], ["19 However, vaccine allocation perspectives in addition to utilitarian considerations are important.", [["vaccine allocation perspectives", "TREATMENT", 12, 43]]], ["The US National Academy of Medicine's Preliminary Framework for Equitable Allocation of COVID-19 Vaccines identified other foundational criteria, such as equal regard, mitigation of health inequities, fairness, and transparency, that should also determine vaccine allocation.", [["COVID-19 Vaccines", "TREATMENT", 88, 105]]], ["20 Alongside the risks of severe morbidity and mortality and of disease transmission, this framework stipulates two additional criteria for equitable vaccine allocation-namely, risks of acquiring infection and of negative societal impact.", [["infection", "DISEASE", 196, 205], ["severe morbidity", "PROBLEM", 26, 42], ["disease transmission", "PROBLEM", 64, 84], ["equitable vaccine allocation", "TREATMENT", 140, 168], ["acquiring infection", "PROBLEM", 186, 205], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["morbidity", "OBSERVATION", 33, 42], ["infection", "OBSERVATION", 196, 205]]], ["20 Front-line health-care and essential workers, such as school teachers, belong in both these latter groups.What can we expect from first-generation COVID-19 vaccines?Policy makers must be vigilant of the possible impact of vaccine hesitancy.", [["COVID-19", "CHEMICAL", 150, 158], ["first-generation COVID-19 vaccines", "TREATMENT", 133, 167], ["vaccine hesitancy", "PROBLEM", 225, 242]]], ["The potential disruption of a proportion of people declining vaccine uptake could be substantial.", [["people", "ORGANISM", 44, 50], ["people", "SPECIES", 44, 50], ["people declining vaccine uptake", "PROBLEM", 44, 75], ["could be", "UNCERTAINTY", 76, 84], ["substantial", "OBSERVATION_MODIFIER", 85, 96]]], ["The likely heterogeneity of such abreactions to vaccination roll-outs between countries and across partisan divides within nations should not be underestimated.", [["such abreactions", "PROBLEM", 28, 44], ["vaccination roll", "TREATMENT", 48, 64], ["likely", "UNCERTAINTY", 4, 10], ["heterogeneity", "OBSERVATION_MODIFIER", 11, 24], ["should not be", "UNCERTAINTY", 131, 144]]], ["Finally, if international travel were to fully recommence, vaccine allocation to different countries with varying means of access will require careful deliberation, based on moral grounds and because no country will be truly protected from COVID-19 until virtually the entire world is.", [["vaccine allocation", "TREATMENT", 59, 77], ["careful deliberation", "TREATMENT", 143, 163]]], ["22 Notwithstanding these caveats, COVID-19 vaccines are needed, even if they have minimal impact on transmission and despite the challenges of vaccine allocation.", [["COVID-19 vaccines", "TREATMENT", 34, 51], ["vaccine allocation", "TREATMENT", 143, 161], ["minimal", "OBSERVATION_MODIFIER", 82, 89]]], ["If so, strategies for how we use such vaccines would have to be based on other considerations.", [["such vaccines", "TREATMENT", 33, 46]]], ["Will vaccines that protect healthy young adults also protect groups vulnerable to severe disease such as older adults and those with comorbidities?", [["adults", "ORGANISM", 41, 47], ["vaccines", "TREATMENT", 5, 13], ["severe disease", "PROBLEM", 82, 96], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["disease", "OBSERVATION", 89, 96]]], ["Influenza vaccines are less effective in older populations than in younger populations, partly due to immune senescence, 23 which might similarly affect COVID-19 vaccines.", [["Influenza", "DISEASE", 0, 9], ["Influenza vaccines", "TREATMENT", 0, 18], ["immune senescence", "PROBLEM", 102, 119], ["COVID", "TEST", 153, 158], ["less effective", "OBSERVATION_MODIFIER", 23, 37]]], ["However, the so-called original antigenic sin in influenza vaccines that arises from sequential infections by or vaccinations with antigenically closely related strains 24 is not relevant to coronaviruses.", [["influenza", "DISEASE", 49, 58], ["infections", "DISEASE", 96, 106], ["influenza", "ORGANISM", 49, 58], ["coronaviruses", "ORGANISM", 191, 204], ["original antigenic sin in influenza vaccines", "TREATMENT", 23, 67], ["sequential infections", "PROBLEM", 85, 106], ["vaccinations", "TREATMENT", 113, 125], ["coronaviruses", "PROBLEM", 191, 204]]], ["If COVID-19 vaccines have acceptable effectiveness in reducing morbidity and mortality in high-risk groups, they would have an important role, irrespective of impact on transmission and population immunity.", [["COVID", "TEST", 3, 8], ["vaccines", "TREATMENT", 12, 20], ["reducing morbidity", "PROBLEM", 54, 72]]], ["If high-risk populations can be shielded by vaccination, COVID-19 control measures could be recalibrated.", [["high-risk populations", "PROBLEM", 3, 24], ["COVID-19 control measures", "TREATMENT", 57, 82]]], ["Crucially, it will be important to communicate to policy makers and the general public that first-generation vaccines are only one tool in the overall public health response to COVID-19 and unlikely to be the ultimate solution that many expect.What can we expect from first-generation COVID-19 vaccines?We declare no competing interests.", [["COVID-19", "CHEMICAL", 285, 293], ["first-generation vaccines", "TREATMENT", 92, 117], ["COVID", "TEST", 177, 182], ["first-generation COVID-19 vaccines", "TREATMENT", 268, 302]]]], "60f1445b5e867f960e1a6cd99db51a965a2e9006": [["Background public health in the pre and the post antibiotic eras", [["the post antibiotic eras", "TREATMENT", 40, 64]]]], "PMC7511155": [["We collected biospecimens from 192 children, under age22 years, who presented to the urgent care clinics or were hospitalized for concerns for SARS-CoV-2 infection or multisystem inflammatory disorder in children (MIS-C).", [["biospecimens", "ANATOMY", 13, 25], ["SARS-CoV-2 infection", "DISEASE", 143, 163], ["multisystem inflammatory disorder", "DISEASE", 167, 200], ["children", "ORGANISM", 35, 43], ["CoV-2", "ORGANISM", 148, 153], ["children", "ORGANISM", 204, 212], ["children", "SPECIES", 35, 43], ["CoV-", "SPECIES", 148, 152], ["children", "SPECIES", 204, 212], ["SARS-CoV-2", "SPECIES", 143, 153], ["SARS", "PROBLEM", 143, 147], ["CoV", "PROBLEM", 148, 151], ["2 infection", "PROBLEM", 152, 163], ["multisystem inflammatory disorder", "PROBLEM", 167, 200], ["multisystem", "OBSERVATION_MODIFIER", 167, 178], ["inflammatory", "OBSERVATION_MODIFIER", 179, 191]]], ["We showed that children have high viral loads in day 1-2 of illness as compared with adults with severe disease with >7 days of symptoms.", [["illness", "DISEASE", 60, 67], ["children", "ORGANISM", 15, 23], ["children", "SPECIES", 15, 23], ["high viral loads", "PROBLEM", 29, 45], ["illness", "PROBLEM", 60, 67], ["severe disease", "PROBLEM", 97, 111], ["symptoms", "PROBLEM", 128, 136], ["viral loads", "OBSERVATION", 34, 45], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["disease", "OBSERVATION", 104, 111]]], ["Although we did not observe viral load differences between children and adults when stratified by time (perhaps because of a small sample size of adults in this cohort with <7 days of symptoms), Heald-Sargent et al showed that children under 5 years of age had significantly higher SARS-CoV-2 viral loads compared to adults >18 years of age2.", [["children", "ORGANISM", 59, 67], ["children", "ORGANISM", 227, 235], ["children", "SPECIES", 59, 67], ["children", "SPECIES", 227, 235], ["symptoms", "PROBLEM", 184, 192], ["significantly higher SARS", "PROBLEM", 261, 286], ["CoV", "TEST", 287, 290]]], ["We also showed that, in children, viral load decreases over time, as has been shown in infected adults3.", [["children", "ORGANISM", 24, 32], ["children", "SPECIES", 24, 32], ["viral load", "PROBLEM", 34, 44], ["viral load", "OBSERVATION", 34, 44], ["infected", "OBSERVATION", 87, 95]]], ["We did not collect data on mask-usage by these children.", [["children", "ORGANISM", 47, 55], ["children", "SPECIES", 47, 55], ["mask", "TREATMENT", 27, 31]]], ["However, the samples were collected from April-June 2020, when schools and businesses were shut down.", [["samples", "ANATOMY", 13, 20], ["the samples", "TEST", 9, 20]]], ["Children were mostly at home during this time period, so mask use was likely low.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["However, most non-essential workers were also likely at home during this time period, so it would be difficult to compare mask-usage between adults and children.", [["children", "ORGANISM", 152, 160], ["children", "SPECIES", 152, 160]]], ["Universally, recommendations now include wearing a mask to mitigate the spread of infection.", [["infection", "DISEASE", 82, 91], ["a mask", "TREATMENT", 49, 55], ["infection", "PROBLEM", 82, 91], ["infection", "OBSERVATION", 82, 91]]], ["To compare viral load of mask wearers vs non-mask wearers going forward poses logistical and ethical challenges.", [["viral load of mask wearers", "TREATMENT", 11, 37], ["non-mask wearers", "TREATMENT", 41, 57], ["ethical challenges", "TREATMENT", 93, 111]]], ["The hypothesis suggesting that wearing a mask provides anti-viral benefit in addition to providing a physical barrier to the virus is compelling, but our study design did not include data on mask-usage and, therefore, we cannot dispute nor confirm this hypothesis.", [["a mask", "TREATMENT", 39, 45], ["anti-viral benefit", "TREATMENT", 55, 73], ["a physical barrier", "TREATMENT", 99, 117], ["our study", "TEST", 150, 159], ["mask", "TREATMENT", 191, 195]]]]}